{"3e49c389d2d4bb5e34dac0ba12e3be783ca9165f": [["ObjetivoComparar la actividad del Servicio de Urolog\u00eda de un Hospital Universitario Portugu\u00e9s durante el estado de alarma y el per\u00edodo equivalente del a\u00f1o anterior.", [["anterior", "ANATOMY_MODIFIER", 155, 163]]], ["El per\u00edodo (COVID versus sin-COVID) no mostr\u00f3 una asociaci\u00f3n significativa con la cirug\u00eda.Conclusi\u00f3nNuestro departamento experiment\u00f3 una reducci\u00f3n importante en la actividad.", [["mostr\u00f3 una asociaci\u00f3n", "PROBLEM", 39, 60]]], ["Tambi\u00e9n observamos una reducci\u00f3n de las causas urgentes para acudir a los servicios de urgencias considerados menos graves.", [["menos graves", "PROBLEM", 110, 122]]], ["We compared the number of elective consultations and diagnostic urologic examinations, number and type of elective surgeries, as well as patients' demographic characteristics and main causes of presentation to Urology Emergency Department (ED) during the two mentioned periods Materials and Methods Data from 691 patients coming to emergency department were collected from institutional clinical software from March 18 th 2020 to May 2 nd 2020 -and from the same period the previous year.", [["patients", "ORGANISM", 137, 145], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 313, 321], ["diagnostic urologic examinations", "TEST", 53, 85], ["elective surgeries", "TREATMENT", 106, 124]]], ["Data collected were age, sex, day of the presentation to Emergency Department, referral from other hospitals, triage color, reason of admission, diagnosis of discharge, and the need for emergency surgery or hospitalization.", [["emergency surgery", "TREATMENT", 186, 203], ["hospitalization", "TREATMENT", 207, 222]]], ["In order to identify associations between demographic and clinical variables with having been submitted to an emergency surgery (outcome), logistic regression models were applied.ResultsMultivariable analysis showed an association of sex with being submitted to surgery, 65.6% decrease in the odds for the male gender.", [["an emergency surgery", "TREATMENT", 107, 127], ["logistic regression models", "TREATMENT", 139, 165], ["ResultsMultivariable analysis", "TEST", 179, 208], ["surgery", "TREATMENT", 262, 269]]], ["The period (COVID versus non-COVID) did not show a significant association with surgery.ConclusionOur department experienced an noticeable activity reduction.", [["surgery", "TREATMENT", 80, 87], ["an noticeable activity reduction", "TREATMENT", 125, 157], ["surgery", "OBSERVATION", 80, 87], ["activity reduction", "OBSERVATION", 139, 157]]], ["We also observe a reduction in urgent causes to attend the ED considered less serious.", [["reduction", "OBSERVATION_MODIFIER", 18, 27]]], ["The percentage of cases requiring emergency surgery and hospitalization was higher during COVID-period.ConclusionKeyWords: COVID-19; Emergency Department; Tertiary Hospital; Urology;Introducci\u00f3nEl brote de la enfermedad del coronavirus 2019 (COVID-19) causada por el s\u00edndrome respiratorio agudo grave-coronavirus 2 (SARS-CoV-2)(1) se ha propagado a nivel mundial y fue declarado pandemia mundial por la Organizaci\u00f3n Mundial de la Salud el 11 de marzo de 2020 (2) .", [["emergency surgery", "TREATMENT", 34, 51], ["hospitalization", "TREATMENT", 56, 71], ["COVID", "TEST", 242, 247], ["respiratorio", "TEST", 276, 288], ["coronavirus", "PROBLEM", 301, 312], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["Tras propagarse en la regi\u00f3n de Hubei, en China, el SARS-CoV-2 lleg\u00f3 a muchos otros pa\u00edses.Introducci\u00f3nPortugal tuvo los primeros casos reportados el 2 de marzo de 2020, causando la declaraci\u00f3n de estado de alarma por parte del Gobierno varios d\u00edas despu\u00e9s, el 18 de marzo.", [["CoV", "TEST", 57, 60]]], ["Debido al aumento de casos, el estado de alarma se renov\u00f3 desde el 2 de abril hasta el 2 de mayo.Introducci\u00f3nEl Centro Hospitalario Universitario de Lisboa Central (CHULC) fue identificado como uno de los centros de referencia de COVID-19, donde algunas de las Unidades de Cuidados Intensivos existentes se dedicaron exclusivamente a pacientes con este virus.", [["a pacientes con este virus", "TREATMENT", 332, 358]]], ["Tambi\u00e9n se crearon algunas salas nuevas para la hospitalizaci\u00f3n de pacientes menos graves de COVID-19.Introducci\u00f3nUno de los objetivos de este estudio fue comparar la actividad del Departamento de Urolog\u00eda de un Hospital Universitario Portugu\u00e9s CHULC durante el estado de alarma y el per\u00edodo J o u r n a l P r e -p r o o f 3 equivalente del a\u00f1o anterior.", [["CHULC durante el estado de alarma y el per\u00edodo J o u r n a l P r e -p r o o f 3 equivalente", "SPECIES", 245, 336], ["Tambi\u00e9n", "TREATMENT", 0, 7], ["a l P", "TEST", 302, 307], ["anterior", "ANATOMY_MODIFIER", 345, 353]]], ["En el grupo 1 incluimos: disuria, hematuria y retenci\u00f3n urinaria; en el grupo 2: dolor abdominal y lumbar; y en el grupo 3: dolor Page 4 of 16 J o u r n a l P r e -p r o o f 4 de pene, dolor testicular, y otros, donde consideramos otras causas menores de ingreso como prurito genital, afecciones dermatol\u00f3gicas, entre otras causas aisladas.", [["hematuria", "DISEASE", 34, 43], ["disuria", "PROBLEM", 25, 32], ["hematuria", "PROBLEM", 34, 43], ["dolor", "TEST", 185, 190], ["testicular", "TEST", 191, 201], ["y otros", "TEST", 203, 210], ["donde", "TEST", 212, 217], ["consideramos", "TEST", 218, 230], ["hematuria", "OBSERVATION", 34, 43], ["abdominal", "ANATOMY", 87, 96], ["lumbar", "ANATOMY", 99, 105], ["testicular", "ANATOMY", 191, 201]]], ["En cuanto al diagn\u00f3stico al alta, los clasificamos en cuatro grupos.", [["En cuanto al diagn\u00f3stico al alta", "TREATMENT", 0, 32], ["los clasificamos en cuatro grupos", "TREATMENT", 34, 67]]], ["En el grupo 1 consideramos: traumatismo testicular, estenosis uretral, hidrocele y orquiepididimitis; en el grupo 2: prostatitis, infecci\u00f3n urinaria no complicada, hiperplasia benigna de pr\u00f3stata y vejiga hipoactiva; en el grupo 3: hidronefrosis con lesi\u00f3n renal aguda, pielonefritis, pionefrosis, c\u00e1ncer de pr\u00f3stata y tumor de ri\u00f1\u00f3n; y en el grupo 4: c\u00f3lico renal, desconocido, otros y tumor vesical.Materiales y m\u00e9todosEn lo que respecta a las derivaciones hospitalarias, las dividimos en tres grupos, a saber, el grupo 0: no derivado de otros hospitales; el grupo 1: Barreiro, Garc\u00eda Orta, Set\u00fabal; el grupo 2: Beja; \u00c9vora; Litoral Alentejano, Portalegre; y el grupo 3: Vila Franca de Xira, Hospitales Privados, Santar\u00e9m y otros.Materiales y m\u00e9todosLas variables continuas se expresaron como mediana y rango intercuartil (RIC: P25-P75) y las variables categ\u00f3ricas como frecuencias (porcentajes).", [["testicular", "ANATOMY", 40, 50], ["renal", "ANATOMY", 359, 364], ["tumor", "ANATOMY", 387, 392], ["estenosis uretral, hidrocele y orquiepididimitis", "DISEASE", 52, 100], ["prostatitis", "DISEASE", 117, 128], ["renal aguda", "DISEASE", 257, 268], ["tumor", "DISEASE", 319, 324], ["tumor", "DISEASE", 387, 392], ["tumor vesical", "CANCER", 387, 400], ["traumatismo testicular", "PROBLEM", 28, 50], ["prostatitis", "PROBLEM", 117, 128], ["infecci\u00f3n urinaria", "PROBLEM", 130, 148], ["complicada", "PROBLEM", 152, 162], ["hiperplasia", "PROBLEM", 164, 175], ["hidronefrosis", "PROBLEM", 232, 245], ["renal aguda", "PROBLEM", 257, 268], ["pielonefritis", "PROBLEM", 270, 283], ["pionefrosis", "PROBLEM", 285, 296], ["desconocido", "TREATMENT", 366, 377], ["Vila Franca de Xira", "TREATMENT", 673, 692], ["Hospitales Privados", "TREATMENT", 694, 713], ["testicular", "ANATOMY", 40, 50], ["prostatitis", "OBSERVATION", 117, 128], ["renal", "ANATOMY", 257, 262], ["renal", "ANATOMY", 359, 364], ["vesical", "ANATOMY", 393, 400]]], ["En el an\u00e1lisis univariante, se consideraron todas las variables que alcanzaron un valor p \u2264 0,25 para el modelo multivariante.", [["para el modelo multivariante", "TREATMENT", 97, 125]]], ["Los odds ratio (OR) brutos y ajustados se estimaron con los correspondientes intervalos de confianza del 95%.", [["Los odds ratio", "TEST", 0, 14]]], ["Sin embargo, considerando los porcentajes correspondientes al n\u00famero total de pruebas diagn\u00f3sticas complementarias previamente reportadas para cada a\u00f1o, hubo un aumento en las biopsias de pr\u00f3stata (13,1% vs. 9,2%, p=0,221), extracci\u00f3n de stent (15,9% vs. 6,6%, p=0,001) y reemplazo de cat\u00e9ter de nefrostom\u00eda (4,7% vs. 1,4%, p=0,042), y una considerable reducci\u00f3n en las cistoscopias (33,6% vs. 62,6%, p<0,001) y las uroflujometr\u00edas (1,9% vs. 30.0%, p<0.001).Materiales y m\u00e9todosIgualmente, en el mismo per\u00edodo se redujo el n\u00famero total de cirug\u00edas electivas del 77,6% En lo que respecta a los tres grupos de causas de ingreso (Tabla 1), no hubo diferencias significativas entre los dos per\u00edodos (p=0,229).", [["extracci\u00f3n de stent", "TREATMENT", 224, 243], ["p", "TEST", 261, 262], ["p", "TEST", 324, 325], ["y una", "TEST", 334, 339], ["p", "TEST", 401, 402], ["y las uroflujometr\u00edas", "TEST", 410, 431], ["p", "TEST", 449, 450], ["stent", "OBSERVATION", 238, 243]]], ["Sin embargo, hubo diferencias en cuanto al diagn\u00f3stico al alta, con casi un tercio (31,1%) correspondiente al grupo con causas mas graves (grupo 3), que incluye hidronefrosis con lesi\u00f3n renal aguda, pielonefritis, pionefrosis, c\u00e1ncer de pr\u00f3stata y tumor renal, comparado con el 14,7% del a\u00f1o pasado (p<0,001).", [["renal aguda", "DISEASE", 186, 197], ["tumor", "DISEASE", 248, 253], ["hubo diferencias en cuanto al diagn\u00f3stico al alta, con casi un tercio", "TREATMENT", 13, 82], ["al grupo con causas mas graves", "PROBLEM", 107, 137], ["hidronefrosis", "PROBLEM", 161, 174], ["renal aguda", "PROBLEM", 186, 197], ["pielonefritis", "PROBLEM", 199, 212], ["pionefrosis", "PROBLEM", 214, 225], ["comparado con el", "TEST", 261, 277], ["renal", "ANATOMY", 186, 191], ["renal", "ANATOMY", 254, 259]]], ["Hubo una disminuci\u00f3n de aproximadamente el 50% en el c\u00f3lico renal y en las infecciones del tracto urinario (ITU) no complicadas en el periodo COVID (14,1% vs. 7,8%) y (9,2% vs. 4,3%) respectivamente, pero hubo un aumento 7 considerable de hidronefrosis con lesi\u00f3n renal aguda (4,1% vs. 8,6%) y pionefrosis (5,3% vs.10,9%) (Tabla 3).Durante el per\u00edodo analizado en 2019, el porcentaje de pacientes que requiri\u00f3 cirug\u00eda de urgencia y hospitalizaci\u00f3n fue del 11,8% y el 15,2%, respectivamente.", [["renal aguda", "DISEASE", 264, 275], ["pionefrosis", "DISEASE", 294, 305], ["una disminuci\u00f3n de aproximadamente el", "TREATMENT", 5, 42], ["en el c\u00f3lico renal y en las infecciones", "TREATMENT", 47, 86], ["complicadas", "PROBLEM", 116, 127], ["COVID", "TEST", 142, 147], ["respectivamente", "TEST", 183, 198], ["renal aguda", "PROBLEM", 264, 275], ["y pionefrosis", "PROBLEM", 292, 305], ["renal", "ANATOMY", 60, 65], ["renal", "ANATOMY", 264, 269]]], ["Los resultados del an\u00e1lisis multivariante mostraron una asociaci\u00f3n entre el sexo con el hecho de ser sometido a una cirug\u00eda, con una disminuci\u00f3n del 65,6% en las probabilidades para el sexo masculino (OR = 0,34; IC del 95%: 0,17-0,70; p=0,003).10,9%) (Tabla 3).Adem\u00e1s, en los pacientes derivados de otros hospitales, las probabilidades de cirug\u00eda aumentaron en diez veces (OR = 10,57; IC del 95%: 5,52-20,26; p<0,001), y la pertenencia al grupo de diagn\u00f3stico 3 se asocia con un aumento de nueve veces de estas probabilidades cuando se compara con los pacientes del grupo de diagn\u00f3stico 1, 2 o 4 (OR = 9,85; IC del 95%: 5,06-19,17; p<0,001).", [["multivariante", "TEST", 28, 41], ["IC del", "TEST", 212, 218], ["IC del", "TEST", 385, 391], ["IC del", "TEST", 608, 614]]], ["En cuanto a los motivos de las consultas, los pacientes con dolor de espalda o con dolor abdominal (grupo 2) tuvieron casi cuatro veces m\u00e1s posibilidades de ser sometidos a una intervenci\u00f3n quir\u00fargica en comparaci\u00f3n con los dem\u00e1s grupos de motivo de consulta (OR = 3,60; IC del 95%: 1,84-7,05; p<0,001).10,9%) (Tabla 3).El per\u00edodo (COVID versus periodo sin COVID) no mostr\u00f3 una asociaci\u00f3n significativa con la cirug\u00eda (OR = 1,04; IC del 95%: 0,54-2,02; p = 0,905).Discusi\u00f3nLa pandemia del COVID 19 dio lugar a una crisis de emergencia sanitaria internacional, lo que oblig\u00f3 a dar una respuesta r\u00e1pida y espec\u00edfica a la enfermedad, aparentemente dejando en suspenso otras \u00e1reas de asistencia, reducidas a procedimientos m\u00ednimos y urgentes (4).", [["dolor abdominal", "DISEASE", 83, 98], ["IC del", "TEST", 430, 436], ["a una crisis", "PROBLEM", 508, 520], ["abdominal", "ANATOMY", 89, 98]]], ["Se desconocen las consecuencias de esta opci\u00f3n estrat\u00e9gica sobre la salud de los pacientes.Discusi\u00f3nPage 8 of 16 J o u r n a l P r e -p r o o f 8 Como era de esperar, el Servicio de Urolog\u00eda experiment\u00f3 una reducci\u00f3n notable de las cirug\u00edas electivas y las pruebas diagnosticas, as\u00ed como del n\u00famero de pacientes que acudieron al Servicio de Urgencias de Urolog\u00eda, como ya han informado otros estudios (5, 6) .Discusi\u00f3nTodos los procedimientos quir\u00fargicos programados y las pruebas complementarias se han ido reduciendo progresivamente en nuestra instituci\u00f3n durante la crisis.", [["a l P r e -p", "TREATMENT", 123, 135], ["ido reduciendo progresivamente", "TREATMENT", 504, 534]]], ["En el per\u00edodo analizado en nuestro estudio, hubo una reducci\u00f3n de las admisiones globales al SU en el CHULC (-9370), y el SU de Urolog\u00eda no fue una excepci\u00f3n (-177).", [["En el per\u00edodo analizado en nuestro estudio, hubo una reducci\u00f3n de las admisiones globales al SU en el CHULC (-9370), y el SU de Urolog\u00eda no fue una excepci\u00f3n (-177", "SPECIES", 0, 163], ["fue una excepci\u00f3n", "TEST", 140, 157]]], ["En los casos en que se requer\u00eda la presencia del paciente, se programaba una cita presencial.Discusi\u00f3nAdem\u00e1s, en nuestra muestra hemos podido observar una reducci\u00f3n de los motivos urgentes para acudir a los SU considerados menos graves, como la ITU no complicada o el c\u00f3lico renal, como tambi\u00e9n se\u00f1alaron Madanelo et al (5) .", [["renal", "ANATOMY", 275, 280]]], ["Probablemente, una proporci\u00f3n significativa de esta reducci\u00f3n se debe al hecho de que algunos de los pacientes con condiciones leves y no urgentes no acud\u00edan al servicio de urgencias debido al miedo por la pandemia.", [["la pandemia", "PROBLEM", 203, 214]]], ["Adem\u00e1s, el porcentaje de casos que requirieron cirug\u00eda de urgencia y hospitalizaci\u00f3n, como la pionefrosis o la hidronefrosis con lesi\u00f3n renal aguda, fue mayor durante el per\u00edodo COVID.Discusi\u00f3nEn este contexto, existe una opini\u00f3n compartida en Portugal de que el acceso a los servicios de urgencias puede ser con frecuencia mal utilizado por los pacientes, que se aprovechan de la atenci\u00f3n 24 horas para consultar por afecciones que no son urgentes y que podr\u00edan ser tratadasDeclaraciones Aprobaci\u00f3n \u00e9tica y consentimiento de participaci\u00f3nEl manuscrito fue aprobado por el Comit\u00e9 de \u00c9tica del Centro Hospitalar de Lisboa Central.", [["renal", "ANATOMY", 136, 141]]], ["La pandemia del COVID es un gran problema sanitario y nuestro estudio tiene un impacto en la salud p\u00fablica.No procedeDisponibilidad de datos y materiales \uf0b7 Los conjuntos de datos generados y/o analizados durante el presente estudio no est\u00e1n a disposici\u00f3n del p\u00fablico debido a la informaci\u00f3n del Hospital Privado, pero se pueden obtener del autor correspondiente previa solicitud razonable.", [["previa solicitud razonable", "PROBLEM", 362, 388]]]], "941f606a35d7e89dfe084eccfba952df31baf3b9": [["IntroductionSince the first case of coronavirus disease was detected, the virus has spread rapidly and swept most countries worldwide.", [["coronavirus disease", "DISEASE", 36, 55], ["coronavirus", "ORGANISM", 36, 47], ["coronavirus", "SPECIES", 36, 47], ["coronavirus disease", "PROBLEM", 36, 55], ["the virus", "PROBLEM", 70, 79], ["coronavirus disease", "OBSERVATION", 36, 55]]], ["Currently, there is no effective antiviral therapy or immune-based treatments for COVID-19, especially for asymptomatic or mild patient, who are recommended for self-cured under home quarantine.", [["patient", "ORGANISM", 128, 135], ["patient", "SPECIES", 128, 135], ["effective antiviral therapy", "TREATMENT", 23, 50], ["immune-based treatments", "TREATMENT", 54, 77], ["COVID", "TEST", 82, 87], ["no", "UNCERTAINTY", 20, 22], ["effective", "OBSERVATION_MODIFIER", 23, 32], ["antiviral therapy", "OBSERVATION", 33, 50]]], ["However, the severe cases were rapidly increased from the progression of the mild cases one week after the onset and develop into respiratory failure and acute respiratory distress syndrome (ARDS) on the basis of pneumonia 1 .", [["respiratory", "ANATOMY", 130, 141], ["respiratory", "ANATOMY", 160, 171], ["respiratory failure", "DISEASE", 130, 149], ["acute respiratory distress syndrome", "DISEASE", 154, 189], ["ARDS", "DISEASE", 191, 195], ["pneumonia", "DISEASE", 213, 222], ["the severe cases", "PROBLEM", 9, 25], ["respiratory failure", "PROBLEM", 130, 149], ["acute respiratory distress syndrome", "PROBLEM", 154, 189], ["ARDS", "PROBLEM", 191, 195], ["pneumonia", "PROBLEM", 213, 222], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["cases", "OBSERVATION", 20, 25], ["rapidly", "OBSERVATION_MODIFIER", 31, 38], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["mild", "OBSERVATION_MODIFIER", 77, 81], ["respiratory failure", "OBSERVATION", 130, 149], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["respiratory distress", "OBSERVATION", 160, 180], ["pneumonia", "OBSERVATION", 213, 222]]], ["Therefore, the urgent challenge is to prevent the transition of COVID-19 from mild to severe.", [["COVID", "TEST", 64, 69], ["mild to severe", "PROBLEM", 78, 92], ["mild", "OBSERVATION_MODIFIER", 78, 82], ["severe", "OBSERVATION_MODIFIER", 86, 92]]], ["In China, oxygen therapy has been widely used and strongly recommended for patients in hospitals and cabin hospitals, however, for the asymptomatic or mild COVID-19, has not been given sufficient considerations in the present therapeutic guidelines.", [["oxygen", "CHEMICAL", 10, 16], ["oxygen", "CHEMICAL", 10, 16], ["oxygen", "SIMPLE_CHEMICAL", 10, 16], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["oxygen therapy", "TREATMENT", 10, 24], ["the asymptomatic or mild COVID", "PROBLEM", 131, 161], ["oxygen therapy", "OBSERVATION", 10, 24]]], ["Through reviewing relevant literature and combining the characteristics of COVID-19, we propose that nocturnal oxygen therapy can be administrated for patients diagnosed with COVID-19 regardless of hypoxia and may be helpful to prevent the disease progression by inhibiting the rapid replication of the virus and improving the body's antiviral ability.Oxygen-rich environment may disrupt the virus replicationViruses rely on the host cell's infrastructure and metabolism to complete their life cycle.", [["body", "ANATOMY", 327, 331], ["cell", "ANATOMY", 434, 438], ["oxygen", "CHEMICAL", 111, 117], ["hypoxia", "DISEASE", 198, 205], ["Oxygen", "CHEMICAL", 352, 358], ["oxygen", "CHEMICAL", 111, 117], ["COVID-19", "CHEMICAL", 175, 183], ["Oxygen", "CHEMICAL", 352, 358], ["oxygen", "SIMPLE_CHEMICAL", 111, 117], ["patients", "ORGANISM", 151, 159], ["body", "ORGANISM_SUBDIVISION", 327, 331], ["Oxygen", "SIMPLE_CHEMICAL", 352, 358], ["host cell", "CELL", 429, 438], ["patients", "SPECIES", 151, 159], ["COVID", "TEST", 75, 80], ["nocturnal oxygen therapy", "TREATMENT", 101, 125], ["COVID", "TEST", 175, 180], ["hypoxia", "PROBLEM", 198, 205], ["the disease progression", "PROBLEM", 236, 259], ["the virus", "PROBLEM", 299, 308], ["Oxygen", "TREATMENT", 352, 358], ["the virus replicationViruses", "TREATMENT", 388, 416]]], ["Many viruses can reprogramme host cellular metabolism for their replication.", [["cellular", "ANATOMY", 34, 42], ["cellular", "CELL", 34, 42], ["Many viruses", "PROBLEM", 0, 12], ["viruses", "OBSERVATION", 5, 12], ["cellular metabolism", "OBSERVATION", 34, 53]]], ["For instance, it has been shown that adenoviral, cytomegalovirus, vaccinia virus, and Kaposi's sarcoma-associated herpesvirus (KSHV) decreases oxidative phosphorylation and induces glycolysis, which provides a large carbon source for the synthesis of nucleotides and amino acids needed to replicate the virus [2] [3] [4] [5] .", [["adenoviral, cytomegalovirus, vaccinia virus", "DISEASE", 37, 80], ["Kaposi's sarcoma", "DISEASE", 86, 102], ["amino acids", "CHEMICAL", 267, 278], ["carbon", "CHEMICAL", 216, 222], ["nucleotides", "CHEMICAL", 251, 262], ["amino acids", "CHEMICAL", 267, 278], ["adenoviral", "ORGANISM", 37, 47], ["cytomegalovirus", "ORGANISM", 49, 64], ["vaccinia virus", "ORGANISM", 66, 80], ["Kaposi's sarcoma-associated herpesvirus", "ORGANISM", 86, 125], ["KSHV", "ORGANISM", 127, 131], ["amino acids", "AMINO_ACID", 267, 278], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 309, 324], ["Kaposi's sarcoma-associated herpesvirus", "SPECIES", 86, 125], ["vaccinia virus", "SPECIES", 66, 80], ["Kaposi's sarcoma-associated herpesvirus", "SPECIES", 86, 125], ["KSHV", "SPECIES", 127, 131], ["adenoviral, cytomegalovirus, vaccinia virus", "PROBLEM", 37, 80], ["Kaposi's sarcoma", "PROBLEM", 86, 102], ["associated herpesvirus (KSHV", "PROBLEM", 103, 131], ["oxidative phosphorylation", "TREATMENT", 143, 168], ["a large carbon source", "TREATMENT", 208, 229], ["the synthesis of nucleotides", "TREATMENT", 234, 262], ["amino acids", "TREATMENT", 267, 278], ["cytomegalovirus", "OBSERVATION", 49, 64]]], ["The mechanisms of viral activation of the glycolysis are sophisticated.", [["viral activation of the glycolysis", "PROBLEM", 18, 52], ["viral activation", "OBSERVATION", 18, 34]]], ["Some investigations have found that hepatitis B virus\uff0cH1N1 virus\uff0cvaccinia virus, and human papillomavirus can stabilize hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) from degradation under normoxic condition 4,6-8 .", [["hepatitis B", "DISEASE", 36, 47], ["human papillomavirus", "DISEASE", 85, 105], ["hypoxia", "DISEASE", 120, 127], ["hepatitis B virus", "ORGANISM", 36, 53], ["H1N1 virus\uff0cvaccinia virus", "ORGANISM", 54, 79], ["human", "ORGANISM", 85, 90], ["papillomavirus", "ORGANISM", 91, 105], ["hypoxia-inducible factor 1\u03b1", "GENE_OR_GENE_PRODUCT", 120, 147], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 149, 155], ["hypoxia-inducible factor 1\u03b1", "PROTEIN", 120, 147], ["HIF-1\u03b1", "PROTEIN", 149, 155], ["hepatitis B virus", "SPECIES", 36, 53], ["H1N1 virus\uff0cvaccinia virus", "SPECIES", 54, 79], ["human", "SPECIES", 85, 90], ["papillomavirus", "SPECIES", 91, 105], ["hepatitis B virus", "SPECIES", 36, 53], ["H1N1 virus\uff0cvaccinia virus", "SPECIES", 54, 79], ["human papillomavirus", "SPECIES", 85, 105], ["Some investigations", "TEST", 0, 19], ["hepatitis B virus", "PROBLEM", 36, 53], ["H1N1 virus\uff0cvaccinia virus", "PROBLEM", 54, 79], ["human papillomavirus", "PROBLEM", 85, 105], ["hypoxia", "PROBLEM", 120, 127], ["inducible factor", "PROBLEM", 128, 144], ["HIF", "TEST", 149, 152], ["degradation under normoxic condition", "PROBLEM", 162, 198], ["normoxic condition", "OBSERVATION", 180, 198]]], ["It is well-known that HIF-1\u03b1 is a transcriptional activator of cellular metabolic state by hypoxia and stabilizing HIF-1\u03b1 induces metabolic transformation from mitochondrial biogenesis to glycolysis.", [["cellular", "ANATOMY", 63, 71], ["mitochondrial", "ANATOMY", 160, 173], ["hypoxia", "DISEASE", 91, 98], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 22, 28], ["cellular", "CELL", 63, 71], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 115, 121], ["mitochondrial", "CELLULAR_COMPONENT", 160, 173], ["HIF-1\u03b1", "PROTEIN", 22, 28], ["HIF-1\u03b1", "PROTEIN", 115, 121], ["hypoxia", "PROBLEM", 91, 98], ["metabolic transformation", "PROBLEM", 130, 154], ["mitochondrial biogenesis to glycolysis", "PROBLEM", 160, 198], ["metabolic state", "OBSERVATION", 72, 87], ["hypoxia", "OBSERVATION", 91, 98], ["metabolic transformation", "OBSERVATION", 130, 154], ["mitochondrial biogenesis", "OBSERVATION", 160, 184]]], ["Furthermore, evidence also revealed that hypoxia could enhance human B19 erythrovirus gene expression and hepatitis c virus replication 9, 10 .", [["hypoxia", "DISEASE", 41, 48], ["hepatitis", "DISEASE", 106, 115], ["human", "ORGANISM", 63, 68], ["B19", "ORGANISM", 69, 72], ["erythrovirus", "GENE_OR_GENE_PRODUCT", 73, 85], ["hepatitis c virus", "ORGANISM", 106, 123], ["human B19 erythrovirus gene", "DNA", 63, 90], ["human", "SPECIES", 63, 68], ["human B19 erythrovirus", "SPECIES", 63, 85], ["hepatitis c virus", "SPECIES", 106, 123], ["hypoxia", "PROBLEM", 41, 48], ["human B19 erythrovirus gene expression", "PROBLEM", 63, 101], ["hepatitis c virus replication", "TREATMENT", 106, 135], ["hypoxia", "OBSERVATION", 41, 48]]], ["These results indicate that HIF-1\u03b1 may play a pivotal role in promoting virus replication.", [["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 28, 34], ["HIF-1\u03b1", "PROTEIN", 28, 34], ["promoting virus replication", "TREATMENT", 62, 89]]], ["From the analysis of clinical data, the development of COVID-19 is a process of gradual hypoxia, which is more conducive to virus replication.", [["COVID-19", "CHEMICAL", 55, 63], ["hypoxia", "DISEASE", 88, 95], ["COVID-19", "GENE_OR_GENE_PRODUCT", 55, 63], ["COVID-19", "DNA", 55, 63], ["clinical data", "TEST", 21, 34], ["COVID", "TEST", 55, 60], ["gradual hypoxia", "PROBLEM", 80, 95], ["virus replication", "TREATMENT", 124, 141], ["gradual", "OBSERVATION_MODIFIER", 80, 87], ["hypoxia", "OBSERVATION", 88, 95]]], ["However, HIF-1\u03b1 activity is suppressed by hydroxylate two proline residues within HIF-1\u03b1 under sufficient oxygen (O2) conditions 11 .", [["proline", "CHEMICAL", 58, 65], ["oxygen", "CHEMICAL", 106, 112], ["O2", "CHEMICAL", 114, 116], ["proline", "CHEMICAL", 58, 65], ["oxygen", "CHEMICAL", 106, 112], ["O2", "CHEMICAL", 114, 116], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 9, 15], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 82, 88], ["oxygen", "SIMPLE_CHEMICAL", 106, 112], ["O2", "SIMPLE_CHEMICAL", 114, 116], ["HIF-1\u03b1", "PROTEIN", 9, 15], ["HIF-1\u03b1", "PROTEIN", 82, 88], ["HIF", "TEST", 9, 12], ["hydroxylate two proline residues", "TREATMENT", 42, 74], ["sufficient oxygen (O2", "TREATMENT", 95, 116]]], ["Although there is no direct evidence that oxygen supplementation could reduce the HIF-1\u03b1 expression in virus-infected cells, researchers have reported that HIF-1\u03b1 expression in the kidney significantly decreased after exposure to high oxygen concentrations in vivo 12 .", [["cells", "ANATOMY", 118, 123], ["kidney", "ANATOMY", 181, 187], ["oxygen", "CHEMICAL", 42, 48], ["oxygen", "CHEMICAL", 235, 241], ["oxygen", "CHEMICAL", 42, 48], ["oxygen", "CHEMICAL", 235, 241], ["oxygen", "SIMPLE_CHEMICAL", 42, 48], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 82, 88], ["cells", "CELL", 118, 123], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 156, 162], ["kidney", "ORGAN", 181, 187], ["oxygen", "SIMPLE_CHEMICAL", 235, 241], ["HIF-1\u03b1", "PROTEIN", 82, 88], ["virus-infected cells", "CELL_TYPE", 103, 123], ["HIF-1\u03b1", "PROTEIN", 156, 162], ["oxygen supplementation", "TREATMENT", 42, 64], ["the HIF", "TEST", 78, 85], ["expression in virus", "PROBLEM", 89, 108], ["infected cells", "PROBLEM", 109, 123], ["expression in the kidney", "PROBLEM", 163, 187], ["high oxygen concentrations", "TREATMENT", 230, 256], ["no direct evidence", "UNCERTAINTY", 18, 36], ["oxygen supplementation", "OBSERVATION", 42, 64], ["infected cells", "OBSERVATION", 109, 123], ["kidney", "ANATOMY", 181, 187], ["significantly", "OBSERVATION_MODIFIER", 188, 201], ["decreased", "OBSERVATION_MODIFIER", 202, 211], ["high oxygen", "OBSERVATION", 230, 241]]], ["A recent study also showed that hyperoxic breathing of 60% O2 markedly down-regulated HIF-1\u03b1 expression in tumor cells and inhibited tumor growth compared with breathing of 20% O2 13 .", [["tumor cells", "ANATOMY", 107, 118], ["tumor", "ANATOMY", 133, 138], ["O2", "CHEMICAL", 59, 61], ["tumor", "DISEASE", 107, 112], ["tumor", "DISEASE", 133, 138], ["O2 13", "CHEMICAL", 177, 182], ["O2", "CHEMICAL", 59, 61], ["O2", "CHEMICAL", 177, 179], ["O2", "SIMPLE_CHEMICAL", 59, 61], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 86, 92], ["tumor cells", "CELL", 107, 118], ["tumor", "CANCER", 133, 138], ["HIF-1\u03b1", "PROTEIN", 86, 92], ["tumor cells", "CELL_TYPE", 107, 118], ["A recent study", "TEST", 0, 14], ["hyperoxic breathing", "PROBLEM", 32, 51], ["O2", "TEST", 59, 61], ["tumor cells", "PROBLEM", 107, 118], ["inhibited tumor growth", "PROBLEM", 123, 145], ["breathing", "TEST", 160, 169], ["20% O2", "TREATMENT", 173, 179], ["hyperoxic breathing", "OBSERVATION", 32, 51], ["tumor cells", "OBSERVATION", 107, 118], ["tumor", "OBSERVATION", 133, 138]]], ["Thus, we speculated that early appropriate oxygen therapy for COVID-19 patients is expected to disrupt the virus replication by decreasing HIF-1\u03b1.Oxygen supplementation can improve antiviral immune responseThe median time of COVID-19 patients from the initial symptom to dyspnea was 5.0 days 14 , which may be associated with cytokine storm and resulted in multi-organ damage or failure.", [["multi-organ", "ANATOMY", 357, 368], ["oxygen", "CHEMICAL", 43, 49], ["Oxygen", "CHEMICAL", 146, 152], ["dyspnea", "DISEASE", 271, 278], ["multi-organ damage", "DISEASE", 357, 375], ["oxygen", "CHEMICAL", 43, 49], ["Oxygen", "CHEMICAL", 146, 152], ["oxygen", "SIMPLE_CHEMICAL", 43, 49], ["patients", "ORGANISM", 71, 79], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 139, 145], ["Oxygen", "SIMPLE_CHEMICAL", 146, 152], ["patients", "ORGANISM", 234, 242], ["multi-organ", "ORGAN", 357, 368], ["HIF-1\u03b1", "PROTEIN", 139, 145], ["cytokine", "PROTEIN", 326, 334], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 234, 242], ["early appropriate oxygen therapy", "TREATMENT", 25, 57], ["COVID", "TEST", 62, 67], ["the virus replication", "TREATMENT", 103, 124], ["Oxygen supplementation", "TREATMENT", 146, 168], ["antiviral immune response", "TREATMENT", 181, 206], ["COVID", "TEST", 225, 230], ["the initial symptom", "PROBLEM", 248, 267], ["dyspnea", "PROBLEM", 271, 278], ["cytokine storm", "PROBLEM", 326, 340], ["multi-organ damage", "PROBLEM", 357, 375], ["failure", "PROBLEM", 379, 386], ["oxygen therapy", "OBSERVATION", 43, 57], ["may be associated with", "UNCERTAINTY", 303, 325], ["cytokine storm", "OBSERVATION", 326, 340], ["multi-organ", "ANATOMY", 357, 368], ["damage", "OBSERVATION", 369, 375], ["failure", "OBSERVATION", 379, 386]]], ["Early robust virus replication disrupts the immune response and contributes to the subsequent inflammatory storm, while the mechanism has not been fully elucidated.", [["Early robust virus replication", "PROBLEM", 0, 30], ["the subsequent inflammatory storm", "PROBLEM", 79, 112], ["robust", "OBSERVATION_MODIFIER", 6, 12], ["virus", "OBSERVATION", 13, 18], ["inflammatory storm", "OBSERVATION", 94, 112]]], ["For virus infection, host factors initiate an immune response against the virus.Oxygen supplementation can improve antiviral immune responseA major component of our innate immunity is the type I interferon (IFN-I) response.", [["infection", "DISEASE", 10, 19], ["Oxygen", "CHEMICAL", 80, 86], ["Oxygen", "CHEMICAL", 80, 86], ["Oxygen", "SIMPLE_CHEMICAL", 80, 86], ["type I interferon", "GENE_OR_GENE_PRODUCT", 188, 205], ["IFN-I", "GENE_OR_GENE_PRODUCT", 207, 212], ["host factors", "PROTEIN", 21, 33], ["IFN", "PROTEIN", 207, 210], ["virus infection", "PROBLEM", 4, 19], ["host factors", "PROBLEM", 21, 33], ["the virus", "PROBLEM", 70, 79], ["Oxygen supplementation", "TREATMENT", 80, 102], ["antiviral immune response", "TREATMENT", 115, 140], ["the type I interferon", "TREATMENT", 184, 205], ["infection", "OBSERVATION", 10, 19], ["major", "OBSERVATION_MODIFIER", 142, 147], ["component", "OBSERVATION_MODIFIER", 148, 157]]], ["IFN-I can activate transcription factors and induce expression of IFN-stimulated genes 15 , thus promoting host cells to fight against the virus infection.", [["cells", "ANATOMY", 112, 117], ["infection", "DISEASE", 145, 154], ["IFN-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN-stimulated genes 15", "GENE_OR_GENE_PRODUCT", 66, 89], ["host cells", "CELL", 107, 117], ["IFN-I", "PROTEIN", 0, 5], ["transcription factors", "PROTEIN", 19, 40], ["IFN-stimulated genes 15", "DNA", 66, 89], ["host cells", "CELL_TYPE", 107, 117], ["transcription factors", "TREATMENT", 19, 40], ["IFN-stimulated genes", "TREATMENT", 66, 86], ["the virus infection", "PROBLEM", 135, 154]]], ["However, SARS-CoV, which similar to SARS-CoV-2, has been proved to inhibit the production of IFN-I in cell and animal models 16 .", [["cell", "ANATOMY", 102, 106], ["SARS", "DISEASE", 9, 13], ["SARS-CoV", "ORGANISM", 9, 17], ["SARS-CoV-2", "ORGANISM", 36, 46], ["IFN-I", "GENE_OR_GENE_PRODUCT", 93, 98], ["cell", "CELL", 102, 106], ["IFN-I", "PROTEIN", 93, 98], ["SARS-CoV", "SPECIES", 9, 17], ["SARS-CoV", "SPECIES", 36, 44], ["SARS-CoV", "PROBLEM", 9, 17], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44], ["CoV", "ANATOMY", 14, 17]]], ["Therefore, it is imperative to understand the mechanism of the virus to overcome the interferon response in order to take corresponding measures.Oxygen supplementation can improve antiviral immune responseRecently, researchers have demonstrated that lactate derived from glycolysis is the first metabolite directly combined with mitochondrial antiviral-signaling (MAVS), and the lactate aggregation due to glycolysis or by increased LDH may be a potential mechanism for the virus to inhibit IFN production 17 .", [["mitochondrial", "ANATOMY", 329, 342], ["Oxygen", "CHEMICAL", 145, 151], ["lactate", "CHEMICAL", 250, 257], ["lactate", "CHEMICAL", 379, 386], ["LDH", "CHEMICAL", 433, 436], ["Oxygen", "CHEMICAL", 145, 151], ["lactate", "CHEMICAL", 250, 257], ["lactate", "CHEMICAL", 379, 386], ["Oxygen", "SIMPLE_CHEMICAL", 145, 151], ["lactate", "SIMPLE_CHEMICAL", 250, 257], ["mitochondrial", "CELLULAR_COMPONENT", 329, 342], ["MAVS", "GENE_OR_GENE_PRODUCT", 364, 368], ["lactate", "SIMPLE_CHEMICAL", 379, 386], ["LDH", "GENE_OR_GENE_PRODUCT", 433, 436], ["IFN", "GENE_OR_GENE_PRODUCT", 491, 494], ["interferon", "PROTEIN", 85, 95], ["MAVS", "PROTEIN", 364, 368], ["LDH", "PROTEIN", 433, 436], ["IFN", "PROTEIN", 491, 494], ["the virus", "PROBLEM", 59, 68], ["the interferon response", "TREATMENT", 81, 104], ["Oxygen supplementation", "TREATMENT", 145, 167], ["lactate", "TEST", 250, 257], ["mitochondrial antiviral-signaling (MAVS)", "PROBLEM", 329, 369], ["the lactate aggregation", "PROBLEM", 375, 398], ["glycolysis", "PROBLEM", 406, 416], ["increased LDH", "PROBLEM", 423, 436], ["the virus", "PROBLEM", 470, 479], ["increased", "OBSERVATION_MODIFIER", 423, 432], ["LDH", "OBSERVATION", 433, 436]]], ["It is worth noting that clinical studies have shown that elevated LDH or lactate levels have been detected in some patients with viral infection, especially those with poor prognosis 18, 19 .", [["lactate", "CHEMICAL", 73, 80], ["viral infection", "DISEASE", 129, 144], ["lactate", "CHEMICAL", 73, 80], ["LDH", "GENE_OR_GENE_PRODUCT", 66, 69], ["lactate", "SIMPLE_CHEMICAL", 73, 80], ["patients", "ORGANISM", 115, 123], ["LDH", "PROTEIN", 66, 69], ["patients", "SPECIES", 115, 123], ["clinical studies", "TEST", 24, 40], ["elevated LDH", "PROBLEM", 57, 69], ["lactate levels", "TEST", 73, 87], ["viral infection", "PROBLEM", 129, 144], ["elevated", "OBSERVATION_MODIFIER", 57, 65], ["LDH", "OBSERVATION", 66, 69], ["viral", "OBSERVATION_MODIFIER", 129, 134], ["infection", "OBSERVATION", 135, 144]]], ["According to clinical data from patients infected with SARS-CoV-2 in Wuhan, China, LDH increased in 29/40 (73%), of which ICU care12/13 (92%) and No ICU care 17/27 (63%) 20 .", [["SARS", "DISEASE", 55, 59], ["patients", "ORGANISM", 32, 40], ["SARS-CoV-2", "ORGANISM", 55, 65], ["LDH", "GENE_OR_GENE_PRODUCT", 83, 86], ["patients", "SPECIES", 32, 40], ["SARS-CoV", "SPECIES", 55, 63], ["SARS", "PROBLEM", 55, 59], ["CoV", "TEST", 60, 63], ["LDH", "TEST", 83, 86]]], ["Thus, inhibiting glycolysis and reducing lactate production are expected to activate antiviral immunity in the early stage of virus infection.", [["lactate", "CHEMICAL", 41, 48], ["infection", "DISEASE", 132, 141], ["lactate", "CHEMICAL", 41, 48], ["lactate", "SIMPLE_CHEMICAL", 41, 48], ["inhibiting glycolysis", "PROBLEM", 6, 27], ["reducing lactate production", "PROBLEM", 32, 59], ["antiviral immunity", "TREATMENT", 85, 103], ["virus infection", "PROBLEM", 126, 141], ["virus infection", "OBSERVATION", 126, 141]]], ["As mentioned above, oxygen can affect the activation of HIF-1\u03b1 and reduce glycolysis.", [["oxygen", "CHEMICAL", 20, 26], ["oxygen", "CHEMICAL", 20, 26], ["oxygen", "SIMPLE_CHEMICAL", 20, 26], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 56, 62], ["HIF-1\u03b1", "PROTEIN", 56, 62], ["oxygen", "TREATMENT", 20, 26], ["HIF", "TEST", 56, 59]]], ["In addition, oxygen could also reduce the accumulation of lactate by accelerating its degradation.", [["oxygen", "CHEMICAL", 13, 19], ["lactate", "CHEMICAL", 58, 65], ["oxygen", "CHEMICAL", 13, 19], ["lactate", "CHEMICAL", 58, 65], ["oxygen", "SIMPLE_CHEMICAL", 13, 19], ["lactate", "SIMPLE_CHEMICAL", 58, 65], ["oxygen", "TREATMENT", 13, 19], ["the accumulation of lactate", "PROBLEM", 38, 65], ["accumulation", "OBSERVATION_MODIFIER", 42, 54]]], ["Therefore, early appropriate oxygen therapy for COVID-19 patients is expected to be beneficial to release interferon and activate antiviral immune response.J o u r n a l P r e -p r o o fImmune cells such as CD8 + effector T cells and natural killer cells (NK) are believed to play a crucial role in antiviral immunity.", [["fImmune cells", "ANATOMY", 185, 198], ["CD8 + effector T cells", "ANATOMY", 207, 229], ["natural killer cells", "ANATOMY", 234, 254], ["NK", "ANATOMY", 256, 258], ["oxygen", "CHEMICAL", 29, 35], ["oxygen", "CHEMICAL", 29, 35], ["oxygen", "SIMPLE_CHEMICAL", 29, 35], ["patients", "ORGANISM", 57, 65], ["cells", "CELL", 193, 198], ["CD8", "GENE_OR_GENE_PRODUCT", 207, 210], ["natural killer cells", "CELL", 234, 254], ["NK", "CELL", 256, 258], ["interferon", "PROTEIN", 106, 116], ["CD8", "PROTEIN", 207, 210], ["effector T cells", "CELL_TYPE", 213, 229], ["natural killer cells", "CELL_TYPE", 234, 254], ["NK", "CELL_TYPE", 256, 258], ["patients", "SPECIES", 57, 65], ["early appropriate oxygen therapy", "TREATMENT", 11, 43], ["COVID", "TREATMENT", 48, 53], ["interferon", "TREATMENT", 106, 116], ["activate antiviral immune response", "TREATMENT", 121, 155], ["a l P r e -p r o o fImmune cells", "TEST", 166, 198], ["CD8", "TEST", 207, 210], ["antiviral immunity", "TREATMENT", 299, 317], ["oxygen therapy", "OBSERVATION", 29, 43], ["killer cells", "OBSERVATION", 242, 254], ["antiviral immunity", "OBSERVATION", 299, 317]]], ["However, the proportion of immune cells in the blood of most patients infected with SARS-CoV-2 is decreased.", [["immune cells", "ANATOMY", 27, 39], ["blood", "ANATOMY", 47, 52], ["SARS", "DISEASE", 84, 88], ["immune cells", "CELL", 27, 39], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["patients", "ORGANISM", 61, 69], ["SARS-CoV-2", "ORGANISM", 84, 94], ["immune cells", "CELL_TYPE", 27, 39], ["patients", "SPECIES", 61, 69], ["SARS-CoV", "SPECIES", 84, 92], ["immune cells", "PROBLEM", 27, 39], ["the blood", "TEST", 43, 52], ["SARS", "PROBLEM", 84, 88], ["CoV", "TEST", 89, 92], ["immune cells", "OBSERVATION", 27, 39], ["blood", "ANATOMY", 47, 52], ["infected", "OBSERVATION", 70, 78], ["decreased", "OBSERVATION_MODIFIER", 98, 107]]], ["Recently, researchers have detected the peripheral blood lymphocyte subsets in patients with COVID-19 and found that the reduction rate of CD4+T, CD8+T and NK cells were 60.16%, 68.3% and 36.59% respectively 21 , which greatly weaken the body resistance to virus.", [["peripheral blood lymphocyte", "ANATOMY", 40, 67], ["CD4+T", "ANATOMY", 139, 144], ["CD8+T", "ANATOMY", 146, 151], ["NK cells", "ANATOMY", 156, 164], ["body", "ANATOMY", 238, 242], ["peripheral blood lymphocyte", "CELL", 40, 67], ["patients", "ORGANISM", 79, 87], ["COVID-19", "CELL", 93, 101], ["CD4+T", "GENE_OR_GENE_PRODUCT", 139, 144], ["CD8", "GENE_OR_GENE_PRODUCT", 146, 149], ["body", "ORGANISM_SUBDIVISION", 238, 242], ["peripheral blood lymphocyte subsets", "CELL_TYPE", 40, 75], ["CD4", "PROTEIN", 139, 142], ["CD8", "PROTEIN", 146, 149], ["T and NK cells", "CELL_TYPE", 150, 164], ["patients", "SPECIES", 79, 87], ["the peripheral blood lymphocyte subsets", "PROBLEM", 36, 75], ["COVID", "TEST", 93, 98], ["the reduction rate", "TEST", 117, 135], ["CD4+T", "TEST", 139, 144], ["CD8", "TEST", 146, 149], ["NK cells", "TEST", 156, 164], ["the body resistance to virus", "PROBLEM", 234, 262], ["peripheral", "ANATOMY_MODIFIER", 40, 50], ["blood", "ANATOMY", 51, 56], ["lymphocyte subsets", "OBSERVATION", 57, 75], ["body resistance", "OBSERVATION", 238, 253]]], ["Until now, no specific strategy has been recommended to improve the body immunity to deal with the early COVID-19.J o u r n a l P r e -p r o o fConcurrently, therapeutic effect of oxygen therapy in severe cases prompted us to the impact of oxygen on immune system.", [["body", "ANATOMY", 68, 72], ["immune system", "ANATOMY", 250, 263], ["oxygen", "CHEMICAL", 180, 186], ["oxygen", "CHEMICAL", 240, 246], ["oxygen", "CHEMICAL", 180, 186], ["oxygen", "CHEMICAL", 240, 246], ["body", "ORGANISM_SUBDIVISION", 68, 72], ["oxygen", "SIMPLE_CHEMICAL", 180, 186], ["oxygen", "SIMPLE_CHEMICAL", 240, 246], ["immune system", "ANATOMICAL_SYSTEM", 250, 263], ["oxygen therapy", "TREATMENT", 180, 194], ["severe cases", "PROBLEM", 198, 210], ["oxygen on immune system", "TREATMENT", 240, 263], ["oxygen therapy", "OBSERVATION", 180, 194]]], ["Functional T cell exhaustion has been demonstrated in patients with COVID-19, especially in severe cases, which is associated with higher levels of PD-1 22 .", [["T cell", "ANATOMY", 11, 17], ["T cell", "CELL", 11, 17], ["patients", "ORGANISM", 54, 62], ["PD-1 22", "GENE_OR_GENE_PRODUCT", 148, 155], ["patients", "SPECIES", 54, 62], ["Functional T cell exhaustion", "PROBLEM", 0, 28], ["COVID", "TEST", 68, 73], ["severe cases", "PROBLEM", 92, 104], ["PD", "TEST", 148, 150], ["T cell exhaustion", "OBSERVATION", 11, 28], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["cases", "OBSERVATION", 99, 104]]], ["PD-1 was considered as a marker of T cell exhaustion and previous studies have confirmed that blocking PD-1 / PD-L1 can restore T cell function and accelerate virus clearance 23 .", [["T cell", "ANATOMY", 35, 41], ["T cell", "ANATOMY", 128, 134], ["PD-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["T cell", "CELL", 35, 41], ["PD-1", "GENE_OR_GENE_PRODUCT", 103, 107], ["PD-L1", "GENE_OR_GENE_PRODUCT", 110, 115], ["T cell", "CELL", 128, 134], ["PD-L1", "DNA", 110, 115], ["PD", "TEST", 0, 2], ["T cell exhaustion", "PROBLEM", 35, 52], ["previous studies", "TEST", 57, 73], ["blocking PD", "TEST", 94, 105], ["PD", "PROBLEM", 110, 112], ["accelerate virus clearance", "PROBLEM", 148, 174], ["cell exhaustion", "OBSERVATION", 37, 52], ["L1", "ANATOMY", 113, 115], ["cell", "OBSERVATION", 130, 134]]], ["Recently, researchers have found that PD-L1 expression can be controlled by HIF-1\u03b1 both in mouse myeloid-derived suppressor cells and in sepsis model.", [["myeloid-derived suppressor cells", "ANATOMY", 97, 129], ["sepsis", "DISEASE", 137, 143], ["PD-L1", "GENE_OR_GENE_PRODUCT", 38, 43], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 76, 82], ["mouse", "ORGANISM", 91, 96], ["myeloid-derived suppressor cells", "CELL", 97, 129], ["L1", "DNA", 41, 43], ["HIF-1\u03b1", "PROTEIN", 76, 82], ["mouse myeloid-derived suppressor cells", "CELL_TYPE", 91, 129], ["mouse", "SPECIES", 91, 96], ["mouse", "SPECIES", 91, 96], ["PD-L1 expression", "PROBLEM", 38, 54], ["suppressor cells", "TREATMENT", 113, 129], ["sepsis model", "PROBLEM", 137, 149], ["L1", "ANATOMY", 41, 43], ["myeloid", "ANATOMY", 97, 104], ["suppressor cells", "OBSERVATION", 113, 129], ["sepsis model", "OBSERVATION", 137, 149]]], ["Silencing HIF-1a has been shown to reduce the expression of PD-L1 in monocytes and restore T cell proliferation 24, 25 .J o u r n a l P r e -p r o o fIt is noteworthy that our previous analysis suggested that sufficient oxygen could reduce the HIF-1\u03b1 expression\uff0cand respiratory hyperoxia has also been proved to reverse immunosuppression by decreasing PD-L1 expression levels in cancer mouse model 26 .", [["monocytes", "ANATOMY", 69, 78], ["T cell", "ANATOMY", 91, 97], ["cancer", "ANATOMY", 379, 385], ["oxygen", "CHEMICAL", 220, 226], ["hyperoxia", "CHEMICAL", 278, 287], ["cancer", "DISEASE", 379, 385], ["oxygen", "CHEMICAL", 220, 226], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 10, 16], ["PD-L1", "GENE_OR_GENE_PRODUCT", 60, 65], ["monocytes", "CELL", 69, 78], ["T cell", "CELL", 91, 97], ["oxygen", "SIMPLE_CHEMICAL", 220, 226], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 244, 250], ["PD-L1", "GENE_OR_GENE_PRODUCT", 352, 357], ["cancer", "CANCER", 379, 385], ["mouse", "ORGANISM", 386, 391], ["HIF-1a", "PROTEIN", 10, 16], ["PD-L1", "PROTEIN", 60, 65], ["monocytes", "CELL_TYPE", 69, 78], ["HIF-1\u03b1", "PROTEIN", 244, 250], ["mouse", "SPECIES", 386, 391], ["mouse", "SPECIES", 386, 391], ["PD", "TEST", 60, 62], ["restore T cell proliferation", "TREATMENT", 83, 111], ["the HIF", "TEST", 240, 247], ["respiratory hyperoxia", "PROBLEM", 266, 287], ["immunosuppression", "TREATMENT", 320, 337], ["decreasing PD", "PROBLEM", 341, 354], ["cancer mouse model", "TEST", 379, 397], ["L1", "ANATOMY", 63, 65], ["monocytes", "ANATOMY", 69, 78], ["respiratory hyperoxia", "OBSERVATION", 266, 287]]], ["Moreover, Kondala R. Atkuri et al reported that T cell proliferation was significantly higher at atmospheric oxygen levels (20% oxygen) than at physiological oxygen levels (5% or 10% oxygen) when lymphocytes were cultured in vitro in response to external stimuli 27 .", [["T cell", "ANATOMY", 48, 54], ["lymphocytes", "ANATOMY", 196, 207], ["oxygen", "CHEMICAL", 109, 115], ["oxygen", "CHEMICAL", 128, 134], ["oxygen", "CHEMICAL", 158, 164], ["oxygen", "CHEMICAL", 183, 189], ["oxygen", "CHEMICAL", 109, 115], ["oxygen", "CHEMICAL", 128, 134], ["oxygen", "CHEMICAL", 158, 164], ["oxygen", "CHEMICAL", 183, 189], ["T cell", "CELL", 48, 54], ["oxygen", "SIMPLE_CHEMICAL", 109, 115], ["oxygen", "SIMPLE_CHEMICAL", 128, 134], ["oxygen", "SIMPLE_CHEMICAL", 158, 164], ["oxygen", "SIMPLE_CHEMICAL", 183, 189], ["lymphocytes", "CELL", 196, 207], ["lymphocytes", "CELL_TYPE", 196, 207], ["T cell proliferation", "PROBLEM", 48, 68], ["atmospheric oxygen levels", "TEST", 97, 122], ["20% oxygen", "TREATMENT", 124, 134], ["physiological oxygen levels", "TEST", 144, 171], ["10% oxygen", "TREATMENT", 179, 189], ["lymphocytes", "PROBLEM", 196, 207], ["external stimuli", "TEST", 246, 262], ["cell proliferation", "OBSERVATION", 50, 68], ["higher", "OBSERVATION_MODIFIER", 87, 93]]], ["A recent study revealed that breathing 60% oxygen increased activities of T and NK cells, and decreased immunosuppressive molecules in a murine lung cancer model 28 .", [["T", "ANATOMY", 74, 75], ["NK cells", "ANATOMY", 80, 88], ["lung cancer", "ANATOMY", 144, 155], ["oxygen", "CHEMICAL", 43, 49], ["lung cancer", "DISEASE", 144, 155], ["oxygen", "CHEMICAL", 43, 49], ["oxygen", "SIMPLE_CHEMICAL", 43, 49], ["T", "CELL", 74, 75], ["NK cells", "CELL", 80, 88], ["murine", "ORGANISM", 137, 143], ["lung cancer", "CANCER", 144, 155], ["T and NK cells", "CELL_TYPE", 74, 88], ["immunosuppressive molecules", "PROTEIN", 104, 131], ["murine", "SPECIES", 137, 143], ["A recent study", "TEST", 0, 14], ["breathing 60% oxygen increased activities of T and NK cells", "PROBLEM", 29, 88], ["decreased immunosuppressive molecules", "TREATMENT", 94, 131], ["a murine lung cancer model", "TREATMENT", 135, 161], ["decreased", "OBSERVATION_MODIFIER", 94, 103], ["immunosuppressive molecules", "OBSERVATION", 104, 131], ["lung", "ANATOMY", 144, 148], ["cancer", "OBSERVATION", 149, 155]]], ["Some researchers also demonstrated that lymphocytes had higher proliferation efficiency in the condition of rich-oxygen compared with hypoxia 29, 30 .", [["lymphocytes", "ANATOMY", 40, 51], ["oxygen", "CHEMICAL", 113, 119], ["hypoxia", "DISEASE", 134, 141], ["oxygen", "CHEMICAL", 113, 119], ["lymphocytes", "CELL", 40, 51], ["oxygen", "SIMPLE_CHEMICAL", 113, 119], ["lymphocytes", "CELL_TYPE", 40, 51], ["lymphocytes", "PROBLEM", 40, 51], ["higher proliferation efficiency", "PROBLEM", 56, 87], ["oxygen", "TREATMENT", 113, 119], ["hypoxia", "PROBLEM", 134, 141], ["higher", "OBSERVATION_MODIFIER", 56, 62], ["proliferation efficiency", "OBSERVATION", 63, 87], ["oxygen", "OBSERVATION_MODIFIER", 113, 119]]], ["Accordingly, it is tempting to speculate that sufficient oxygen may improve J o u r n a l P r e -p r o o f the antiviral ability of patients with early COVID-19 by increasing the abundance and activities of immune cells.Early oxygen intervention may reduce the up-regulated expression of ACE2 caused by hypoxiaACE2 is a cell membrane-associated enzyme belongs to renin-angiotensin system and expressed much higher in kidney and heart than that in lung based on the date of previous report.", [["immune cells", "ANATOMY", 207, 219], ["cell membrane", "ANATOMY", 320, 333], ["kidney", "ANATOMY", 417, 423], ["heart", "ANATOMY", 428, 433], ["lung", "ANATOMY", 447, 451], ["oxygen", "CHEMICAL", 57, 63], ["COVID-19", "CHEMICAL", 152, 160], ["oxygen", "CHEMICAL", 226, 232], ["hypoxiaACE2", "CHEMICAL", 303, 314], ["angiotensin", "CHEMICAL", 369, 380], ["oxygen", "CHEMICAL", 57, 63], ["COVID-19", "CHEMICAL", 152, 160], ["oxygen", "CHEMICAL", 226, 232], ["oxygen", "SIMPLE_CHEMICAL", 57, 63], ["patients", "ORGANISM", 132, 140], ["immune cells", "CELL", 207, 219], ["oxygen", "SIMPLE_CHEMICAL", 226, 232], ["ACE2", "GENE_OR_GENE_PRODUCT", 288, 292], ["hypoxiaACE2", "GENE_OR_GENE_PRODUCT", 303, 314], ["cell membrane", "CELLULAR_COMPONENT", 320, 333], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 363, 380], ["kidney", "ORGAN", 417, 423], ["heart", "ORGAN", 428, 433], ["lung", "ORGAN", 447, 451], ["immune cells", "CELL_TYPE", 207, 219], ["ACE2", "PROTEIN", 288, 292], ["hypoxiaACE2", "PROTEIN", 303, 314], ["renin", "PROTEIN", 363, 368], ["patients", "SPECIES", 132, 140], ["early COVID", "TEST", 146, 157], ["immune cells", "PROBLEM", 207, 219], ["Early oxygen intervention", "TREATMENT", 220, 245], ["ACE2", "PROBLEM", 288, 292], ["a cell membrane", "PROBLEM", 318, 333], ["renin", "TEST", 363, 368], ["angiotensin system", "TEST", 369, 387], ["immune cells", "OBSERVATION", 207, 219], ["kidney", "ANATOMY", 417, 423], ["heart", "ANATOMY", 428, 433], ["lung", "ANATOMY", 447, 451]]], ["It have been confirmed that SARS-CoV-2 uses ACE2, the same cell entry receptor of SARS-CoV, to enter the target cell 31 .", [["cell", "ANATOMY", 59, 63], ["cell", "ANATOMY", 112, 116], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["cell", "CELL", 59, 63], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["cell 31", "CELL", 112, 119], ["ACE2", "PROTEIN", 44, 48], ["cell entry receptor", "PROTEIN", 59, 78], ["SARS-CoV", "PROTEIN", 82, 90], ["SARS-CoV", "SPECIES", 28, 36], ["SARS-CoV", "SPECIES", 82, 90], ["SARS", "TEST", 28, 32], ["ACE2", "TREATMENT", 44, 48]]], ["Thus, previous researches on SARS-CoV may be helpful to understand the COVID-19.", [["SARS", "DISEASE", 29, 33], ["SARS-CoV", "ORGANISM", 29, 37], ["COVID-19", "DNA", 71, 79], ["SARS-CoV", "SPECIES", 29, 37], ["the COVID", "TEST", 67, 76]]], ["One study showed that SARS-CoV genome was found in the heart of 35% of the patients (7 of 20), demonstrating that heart attack was associated with earlier death 32 .", [["heart", "ANATOMY", 55, 60], ["heart", "ANATOMY", 114, 119], ["SARS", "DISEASE", 22, 26], ["heart attack", "DISEASE", 114, 126], ["death", "DISEASE", 155, 160], ["SARS-CoV", "ORGANISM", 22, 30], ["heart", "ORGAN", 55, 60], ["patients", "ORGANISM", 75, 83], ["heart", "ORGAN", 114, 119], ["SARS-CoV genome", "DNA", 22, 37], ["patients", "SPECIES", 75, 83], ["SARS-CoV", "SPECIES", 22, 30], ["One study", "TEST", 0, 9], ["SARS", "PROBLEM", 22, 26], ["CoV genome", "PROBLEM", 27, 37], ["heart attack", "PROBLEM", 114, 126], ["earlier death", "PROBLEM", 147, 160], ["SARS", "OBSERVATION", 22, 26], ["CoV genome", "OBSERVATION", 27, 37], ["heart", "ANATOMY", 55, 60], ["heart", "ANATOMY", 114, 119], ["attack", "OBSERVATION", 120, 126]]], ["The study on renal function of patients with SARS-CoV also indicated that acute renal impairment caused by SARS-CoV was related to a high mortality 33 36 .", [["renal", "ANATOMY", 13, 18], ["renal", "ANATOMY", 80, 85], ["SARS", "DISEASE", 45, 49], ["acute renal impairment", "DISEASE", 74, 96], ["SARS", "DISEASE", 107, 111], ["renal", "ORGAN", 13, 18], ["patients", "ORGANISM", 31, 39], ["SARS-CoV", "ORGANISM", 45, 53], ["renal", "ORGAN", 80, 85], ["SARS-CoV", "ORGANISM", 107, 115], ["patients", "SPECIES", 31, 39], ["SARS-CoV", "SPECIES", 45, 53], ["SARS-CoV", "SPECIES", 107, 115], ["The study", "TEST", 0, 9], ["SARS", "PROBLEM", 45, 49], ["acute renal impairment", "PROBLEM", 74, 96], ["SARS", "PROBLEM", 107, 111], ["CoV", "PROBLEM", 112, 115], ["renal", "ANATOMY", 13, 18], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["renal", "ANATOMY", 80, 85], ["impairment", "OBSERVATION", 86, 96]]], ["In pulmonary vascular smooth muscle cells, hypoxia was also shown to up-regulate ACE2 expression 37 .", [["pulmonary vascular smooth muscle cells", "ANATOMY", 3, 41], ["hypoxia", "DISEASE", 43, 50], ["pulmonary vascular smooth muscle cells", "CELL", 3, 41], ["ACE2", "GENE_OR_GENE_PRODUCT", 81, 85], ["pulmonary vascular smooth muscle cells", "CELL_TYPE", 3, 41], ["ACE2", "PROTEIN", 81, 85], ["hypoxia", "PROBLEM", 43, 50], ["pulmonary", "ANATOMY_MODIFIER", 3, 12], ["vascular smooth", "ANATOMY", 13, 28], ["muscle cells", "OBSERVATION", 29, 41], ["hypoxia", "OBSERVATION", 43, 50]]], ["Unfortunately, researchers 38 have found that SARS-CoV infection significantly enhanced the expression of hypoxia upregulated 1gene as early as 6 h, and patient with novel coronavirus pneumonia has already appeared anoxia in the early stage.", [["SARS", "DISEASE", 46, 50], ["infection", "DISEASE", 55, 64], ["hypoxia", "DISEASE", 106, 113], ["coronavirus pneumonia", "DISEASE", 172, 193], ["SARS-CoV", "ORGANISM", 46, 54], ["1gene", "GENE_OR_GENE_PRODUCT", 126, 131], ["patient", "ORGANISM", 153, 160], ["coronavirus", "ORGANISM", 172, 183], ["1gene", "PROTEIN", 126, 131], ["patient", "SPECIES", 153, 160], ["SARS-CoV", "SPECIES", 46, 54], ["SARS", "PROBLEM", 46, 50], ["CoV infection", "PROBLEM", 51, 64], ["hypoxia", "PROBLEM", 106, 113], ["novel coronavirus pneumonia", "PROBLEM", 166, 193], ["anoxia", "PROBLEM", 215, 221], ["CoV", "OBSERVATION_MODIFIER", 51, 54], ["infection", "OBSERVATION", 55, 64], ["hypoxia upregulated", "OBSERVATION", 106, 125], ["coronavirus", "OBSERVATION_MODIFIER", 172, 183], ["pneumonia", "OBSERVATION", 184, 193], ["anoxia", "OBSERVATION_MODIFIER", 215, 221], ["early stage", "OBSERVATION_MODIFIER", 229, 240]]], ["However, the symptoms of dyspnoeic do not appear until late in the disease course, which probably due to the hypoxia with accompanying hypocapnia 39 .", [["dyspnoeic", "DISEASE", 25, 34], ["hypoxia", "DISEASE", 109, 116], ["hypocapnia", "DISEASE", 135, 145], ["the symptoms", "PROBLEM", 9, 21], ["dyspnoeic", "PROBLEM", 25, 34], ["the hypoxia", "PROBLEM", 105, 116], ["accompanying hypocapnia", "PROBLEM", 122, 145], ["probably due to", "UNCERTAINTY", 89, 104], ["hypoxia", "OBSERVATION", 109, 116], ["hypocapnia", "OBSERVATION", 135, 145]]], ["Thus, management of hypoxia in the early stages is expected to delay the progression of COVID-19.", [["hypoxia", "DISEASE", 20, 27], ["COVID", "DISEASE", 88, 93], ["COVID-19", "CHEMICAL", 88, 96], ["management", "TREATMENT", 6, 16], ["hypoxia", "PROBLEM", 20, 27], ["COVID", "TEST", 88, 93], ["hypoxia", "OBSERVATION", 20, 27]]], ["Oxygen J o u r n a l P r e -p r o o f supplementation could increase partial pressure of O2 in arterial blood by driving pressure for O2 and improve tissue oxygenation 40 , which has been proved to improve function in the ischemic myocardium 41 .Early oxygen intervention may reduce the up-regulated expression of ACE2 caused by hypoxiaOxygen therapy has also been reported to reduce renal vascular resistance and increases blood flow in patients with hypoxaemia 42 .", [["arterial blood", "ANATOMY", 95, 109], ["tissue", "ANATOMY", 149, 155], ["myocardium", "ANATOMY", 231, 241], ["renal vascular", "ANATOMY", 384, 398], ["blood", "ANATOMY", 424, 429], ["O2", "CHEMICAL", 89, 91], ["O2", "CHEMICAL", 134, 136], ["oxygen", "CHEMICAL", 252, 258], ["hypoxiaOxygen", "CHEMICAL", 329, 342], ["hypoxaemia", "DISEASE", 452, 462], ["Oxygen", "CHEMICAL", 0, 6], ["r o o f", "CHEMICAL", 30, 37], ["O2", "CHEMICAL", 89, 91], ["O2", "CHEMICAL", 134, 136], ["oxygen", "CHEMICAL", 252, 258], ["hypoxiaOxygen", "CHEMICAL", 329, 342], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["O2", "SIMPLE_CHEMICAL", 89, 91], ["arterial", "ORGANISM_SUBSTANCE", 95, 103], ["blood", "ORGANISM_SUBSTANCE", 104, 109], ["O2", "SIMPLE_CHEMICAL", 134, 136], ["tissue", "TISSUE", 149, 155], ["myocardium", "ORGAN", 231, 241], ["oxygen", "SIMPLE_CHEMICAL", 252, 258], ["ACE2", "GENE_OR_GENE_PRODUCT", 314, 318], ["hypoxiaOxygen", "SIMPLE_CHEMICAL", 329, 342], ["renal vascular", "MULTI-TISSUE_STRUCTURE", 384, 398], ["blood", "ORGANISM_SUBSTANCE", 424, 429], ["patients", "ORGANISM", 438, 446], ["ACE2", "PROTEIN", 314, 318], ["patients", "SPECIES", 438, 446], ["Oxygen J", "TREATMENT", 0, 8], ["a l P r e -p r o o f supplementation", "TREATMENT", 17, 53], ["partial pressure of O2", "TREATMENT", 69, 91], ["arterial blood", "TEST", 95, 109], ["O2", "TREATMENT", 134, 136], ["tissue oxygenation", "TEST", 149, 167], ["the ischemic myocardium", "PROBLEM", 218, 241], ["Early oxygen intervention", "TREATMENT", 246, 271], ["ACE2", "PROBLEM", 314, 318], ["hypoxiaOxygen therapy", "TREATMENT", 329, 350], ["renal vascular resistance", "PROBLEM", 384, 409], ["blood flow", "TEST", 424, 434], ["hypoxaemia", "PROBLEM", 452, 462], ["partial", "OBSERVATION_MODIFIER", 69, 76], ["pressure", "OBSERVATION_MODIFIER", 77, 85], ["ischemic myocardium", "ANATOMY", 222, 241], ["oxygen intervention", "OBSERVATION", 252, 271], ["renal", "ANATOMY_MODIFIER", 384, 389], ["vascular", "ANATOMY", 390, 398], ["resistance", "OBSERVATION", 399, 409], ["flow", "OBSERVATION_MODIFIER", 430, 434]]], ["Therefore, early appropriate oxygen therapy for COVID-19 patients may reduce the invasion of virus by increasing O2 content of blood against the up-regulated expression of ACE2 in tissues and organs caused by hypoxia.Nocturnal oxygen therapy may delay the progression of COVID-19Since cytokine storm is currently considered to be the primary cause of acute exacerbation of COVID-19, early intervention should be taken to inhibit or reduce the excessive production of inflammatory cytokine.Nocturnal oxygen therapy may delay the progression of COVID-19The production of cytokine in human whole blood shows diurnal rhythmicity.", [["blood", "ANATOMY", 127, 132], ["tissues", "ANATOMY", 180, 187], ["organs", "ANATOMY", 192, 198], ["whole blood", "ANATOMY", 587, 598], ["oxygen", "CHEMICAL", 29, 35], ["O2", "CHEMICAL", 113, 115], ["hypoxia", "DISEASE", 209, 216], ["oxygen", "CHEMICAL", 227, 233], ["COVID", "DISEASE", 271, 276], ["oxygen", "CHEMICAL", 499, 505], ["COVID", "DISEASE", 543, 548], ["oxygen", "CHEMICAL", 29, 35], ["O2", "CHEMICAL", 113, 115], ["oxygen", "CHEMICAL", 227, 233], ["COVID-19", "CHEMICAL", 373, 381], ["oxygen", "CHEMICAL", 499, 505], ["COVID-19", "CHEMICAL", 543, 551], ["oxygen", "SIMPLE_CHEMICAL", 29, 35], ["patients", "ORGANISM", 57, 65], ["O2", "SIMPLE_CHEMICAL", 113, 115], ["blood", "ORGANISM_SUBSTANCE", 127, 132], ["ACE2", "GENE_OR_GENE_PRODUCT", 172, 176], ["tissues", "TISSUE", 180, 187], ["organs", "ORGAN", 192, 198], ["oxygen", "SIMPLE_CHEMICAL", 227, 233], ["COVID-19Since", "GENE_OR_GENE_PRODUCT", 271, 284], ["oxygen", "SIMPLE_CHEMICAL", 499, 505], ["human", "ORGANISM", 581, 586], ["blood", "ORGANISM_SUBSTANCE", 593, 598], ["ACE2", "PROTEIN", 172, 176], ["cytokine", "PROTEIN", 285, 293], ["inflammatory cytokine", "PROTEIN", 467, 488], ["cytokine", "PROTEIN", 569, 577], ["patients", "SPECIES", 57, 65], ["human", "SPECIES", 581, 586], ["human", "SPECIES", 581, 586], ["early appropriate oxygen therapy", "TREATMENT", 11, 43], ["COVID", "TREATMENT", 48, 53], ["the invasion of virus", "PROBLEM", 77, 98], ["increasing O2 content of blood", "PROBLEM", 102, 132], ["ACE2 in tissues", "PROBLEM", 172, 187], ["hypoxia", "PROBLEM", 209, 216], ["Nocturnal oxygen therapy", "TREATMENT", 217, 241], ["COVID", "TEST", 271, 276], ["cytokine storm", "PROBLEM", 285, 299], ["acute exacerbation of COVID", "PROBLEM", 351, 378], ["early intervention", "TREATMENT", 383, 401], ["inflammatory cytokine", "PROBLEM", 467, 488], ["Nocturnal oxygen therapy", "TREATMENT", 489, 513], ["COVID", "TEST", 543, 548], ["cytokine in human whole blood", "TEST", 569, 598], ["diurnal rhythmicity", "PROBLEM", 605, 624], ["oxygen therapy", "OBSERVATION", 29, 43], ["invasion", "OBSERVATION", 81, 89], ["hypoxia", "OBSERVATION", 209, 216], ["oxygen therapy", "OBSERVATION", 227, 241], ["acute", "OBSERVATION_MODIFIER", 351, 356], ["exacerbation", "OBSERVATION", 357, 369], ["excessive", "OBSERVATION_MODIFIER", 443, 452], ["inflammatory cytokine", "OBSERVATION", 467, 488], ["oxygen therapy", "OBSERVATION", 499, 513], ["diurnal rhythmicity", "OBSERVATION", 605, 624]]], ["The production of pro-inflammatory cytokines including IFN-\u03b3, TNF-a, IL-1 and IL-12 peak at night and early morning when plasma cortisol is lowest 43 .", [["plasma", "ANATOMY", 121, 127], ["cortisol", "CHEMICAL", 128, 136], ["cortisol", "CHEMICAL", 128, 136], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 55, 60], ["TNF-a", "GENE_OR_GENE_PRODUCT", 62, 67], ["IL-1", "GENE_OR_GENE_PRODUCT", 69, 73], ["IL-12", "GENE_OR_GENE_PRODUCT", 78, 83], ["plasma", "ORGANISM_SUBSTANCE", 121, 127], ["cortisol", "SIMPLE_CHEMICAL", 128, 136], ["pro-inflammatory cytokines", "PROTEIN", 18, 44], ["IFN", "PROTEIN", 55, 58], ["TNF", "PROTEIN", 62, 65], ["pro-inflammatory cytokines", "TEST", 18, 44], ["IFN", "TEST", 55, 58], ["TNF", "TEST", 62, 65], ["IL", "TEST", 69, 71], ["IL", "TEST", 78, 80], ["plasma cortisol", "TEST", 121, 136], ["pro-inflammatory cytokines", "OBSERVATION", 18, 44]]], ["Evidence has shown whole blood stimulation with LPS in vitro, at night and early in the morning displayed increased cytokine and chemokine levels in samples from healthy volunteers compared to the daylight 44 .", [["blood", "ANATOMY", 25, 30], ["samples", "ANATOMY", 149, 156], ["LPS", "CHEMICAL", 48, 51], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["LPS", "SIMPLE_CHEMICAL", 48, 51], ["volunteers", "ORGANISM", 170, 180], ["cytokine", "PROTEIN", 116, 124], ["chemokine", "PROTEIN", 129, 138], ["whole blood stimulation", "TREATMENT", 19, 42], ["LPS", "TREATMENT", 48, 51], ["increased cytokine", "PROBLEM", 106, 124], ["chemokine levels", "TEST", 129, 145], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["cytokine", "OBSERVATION", 116, 124]]], ["A subsequent study during a human in vivo has also confirmed this 45 .", [["human", "ORGANISM", 28, 33], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["A subsequent study", "TEST", 0, 18]]], ["Furthermore, in a vesicular stomatitis virus (VSV) murine encephalitis model where mice infection occurring at the start of the rest period showed higher mortality than infected at the start of the active period and is associated with increased numbers of inflammatory cells 46 .", [["inflammatory cells", "ANATOMY", 256, 274], ["vesicular stomatitis", "DISEASE", 18, 38], ["encephalitis", "DISEASE", 58, 70], ["infection", "DISEASE", 88, 97], ["vesicular stomatitis virus", "ORGANISM", 18, 44], ["VSV", "ORGANISM", 46, 49], ["murine", "ORGANISM", 51, 57], ["mice", "ORGANISM", 83, 87], ["cells", "CELL", 269, 274], ["inflammatory cells", "CELL_TYPE", 256, 274], ["murine", "SPECIES", 51, 57], ["mice", "SPECIES", 83, 87], ["stomatitis virus", "SPECIES", 28, 44], ["VSV", "SPECIES", 46, 49], ["mice", "SPECIES", 83, 87], ["a vesicular stomatitis virus (VSV) murine encephalitis model", "PROBLEM", 16, 76], ["mice infection", "PROBLEM", 83, 97], ["higher mortality", "PROBLEM", 147, 163], ["increased numbers of inflammatory cells", "PROBLEM", 235, 274], ["vesicular stomatitis", "ANATOMY", 18, 38], ["encephalitis", "OBSERVATION", 58, 70], ["higher", "OBSERVATION_MODIFIER", 147, 153], ["mortality", "OBSERVATION", 154, 163], ["associated with", "UNCERTAINTY", 219, 234], ["increased", "OBSERVATION_MODIFIER", 235, 244], ["numbers", "OBSERVATION_MODIFIER", 245, 252], ["inflammatory cells", "OBSERVATION", 256, 274]]], ["Therefore, the reduction of nocturnal pathogen exposure or replication is expected to inhibit the production of inflammatory factors.Nocturnal oxygen therapy may delay the progression of COVID-19However, the rate of virus replication in the host may accelerate at the resting phase according to Rachel S.Nocturnal oxygen therapy may delay the progression of COVID-19Edgar et al, who have shown that mice infected with Murid Herpesvirus at the start of the rest phase exhibited 10-fold higher viral loads than mice infected just before their active phase 47 .", [["oxygen", "CHEMICAL", 143, 149], ["oxygen", "CHEMICAL", 314, 320], ["oxygen", "CHEMICAL", 143, 149], ["oxygen", "CHEMICAL", 314, 320], ["oxygen", "SIMPLE_CHEMICAL", 143, 149], ["COVID-19However", "GENE_OR_GENE_PRODUCT", 187, 202], ["oxygen", "SIMPLE_CHEMICAL", 314, 320], ["mice", "ORGANISM", 399, 403], ["Murid Herpesvirus", "ORGANISM", 418, 435], ["mice", "ORGANISM", 509, 513], ["inflammatory factors", "PROTEIN", 112, 132], ["mice", "SPECIES", 399, 403], ["mice", "SPECIES", 509, 513], ["mice", "SPECIES", 399, 403], ["Murid Herpesvirus", "SPECIES", 418, 435], ["mice", "SPECIES", 509, 513], ["nocturnal pathogen exposure", "PROBLEM", 28, 55], ["inflammatory factors", "PROBLEM", 112, 132], ["Nocturnal oxygen therapy", "TREATMENT", 133, 157], ["COVID", "TEST", 187, 192], ["virus replication", "TREATMENT", 216, 233], ["Rachel S.Nocturnal oxygen therapy", "TREATMENT", 295, 328], ["mice infected", "PROBLEM", 399, 412], ["Murid Herpesvirus", "PROBLEM", 418, 435], ["the rest phase", "TEST", 452, 466], ["fold higher viral loads", "PROBLEM", 480, 503], ["reduction", "OBSERVATION_MODIFIER", 15, 24], ["nocturnal", "OBSERVATION_MODIFIER", 28, 37], ["pathogen exposure", "OBSERVATION", 38, 55], ["inflammatory", "OBSERVATION_MODIFIER", 112, 124], ["oxygen therapy", "OBSERVATION", 143, 157]]], ["Whether virus replication is related to J o u r n a l P r e -p r o o f time-of-day, especially after virus infects the host, still requires further investigation.", [["virus replication", "PROBLEM", 8, 25], ["further investigation", "TEST", 140, 161]]], ["Moreover, a recent study has reported that SARS-CoV-2 from the nasal cavity is likely to be aspirated into the deep lung via gastro-esophageal reflex-associated aspiration, which may be an important route to lung infection and usually occurs at night 48 .", [["nasal cavity", "ANATOMY", 63, 75], ["lung", "ANATOMY", 116, 120], ["esophageal", "ANATOMY", 132, 142], ["lung", "ANATOMY", 208, 212], ["lung infection", "DISEASE", 208, 222], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["nasal cavity", "ORGAN", 63, 75], ["lung", "ORGAN", 116, 120], ["esophageal", "ORGAN", 132, 142], ["lung", "ORGAN", 208, 212], ["SARS-CoV", "SPECIES", 43, 51], ["a recent study", "TEST", 10, 24], ["SARS", "PROBLEM", 43, 47], ["CoV", "TEST", 48, 51], ["gastro-esophageal reflex", "PROBLEM", 125, 149], ["associated aspiration", "PROBLEM", 150, 171], ["lung infection", "PROBLEM", 208, 222], ["nasal cavity", "ANATOMY", 63, 75], ["likely to be", "UNCERTAINTY", 79, 91], ["aspirated", "OBSERVATION", 92, 101], ["deep", "ANATOMY_MODIFIER", 111, 115], ["lung", "ANATOMY", 116, 120], ["gastro", "ANATOMY", 125, 131], ["esophageal reflex", "ANATOMY", 132, 149], ["aspiration", "OBSERVATION", 161, 171], ["lung", "ANATOMY", 208, 212], ["infection", "OBSERVATION", 213, 222]]], ["Therefore, the limitation of virus replication at night would be a valid therapeutically strategy.", [["virus replication", "TREATMENT", 29, 46], ["a valid therapeutically strategy", "TREATMENT", 65, 97]]], ["Combined with our previous analysis, we speculated that nocturnal oxygen therapy could delay the progression of COVID-19 by inhibiting nocturnal virus replication.ConclusionAt present, the number of severe patients continues to increase, leading to an extremely increased demand for medical resources and comprehensive treatment.", [["oxygen", "CHEMICAL", 66, 72], ["COVID-19", "CHEMICAL", 112, 120], ["oxygen", "CHEMICAL", 66, 72], ["COVID-19", "CHEMICAL", 112, 120], ["oxygen", "SIMPLE_CHEMICAL", 66, 72], ["COVID-19", "GENE_OR_GENE_PRODUCT", 112, 120], ["nocturnal virus", "ORGANISM", 135, 150], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["our previous analysis", "TEST", 14, 35], ["nocturnal oxygen therapy", "TREATMENT", 56, 80], ["COVID", "TEST", 112, 117], ["nocturnal virus replication", "TREATMENT", 135, 162], ["an extremely increased demand", "PROBLEM", 249, 278], ["medical resources", "TREATMENT", 283, 300], ["comprehensive treatment", "TREATMENT", 305, 328], ["oxygen therapy", "OBSERVATION", 66, 80], ["severe", "OBSERVATION_MODIFIER", 199, 205]]], ["Therefore, effective and safe interventions are urgently needed to prevent the COVID-19 from mild to severe.", [["safe interventions", "TREATMENT", 25, 43], ["the COVID", "TEST", 75, 84], ["mild to severe", "PROBLEM", 93, 107], ["mild", "OBSERVATION_MODIFIER", 93, 97], ["severe", "OBSERVATION_MODIFIER", 101, 107]]], ["Based on the clinical data and literature analysis, we propose that oxygen therapy can inhibit virus replication, regulate autoimmunity and decrease the ACE2 expression in tissue.", [["tissue", "ANATOMY", 172, 178], ["oxygen", "CHEMICAL", 68, 74], ["autoimmunity", "DISEASE", 123, 135], ["oxygen", "CHEMICAL", 68, 74], ["oxygen", "SIMPLE_CHEMICAL", 68, 74], ["ACE2", "GENE_OR_GENE_PRODUCT", 153, 157], ["tissue", "TISSUE", 172, 178], ["ACE2", "PROTEIN", 153, 157], ["the clinical data", "TEST", 9, 26], ["literature analysis", "TEST", 31, 50], ["oxygen therapy", "TREATMENT", 68, 82], ["virus replication", "TREATMENT", 95, 112], ["autoimmunity", "PROBLEM", 123, 135], ["the ACE2 expression in tissue", "PROBLEM", 149, 178], ["ACE2 expression", "OBSERVATION", 153, 168]]], ["Since the virus may speed up invasion at night and increase the over production of inflammatory cytokines, combined with the fact that patients with lung diseases are prone to occur hypoxia during sleep 49 , we recommend that the application of nocturnal oxygen therapy is a therapeutic option for the patients under home quarantine.", [["lung", "ANATOMY", 149, 153], ["lung diseases", "DISEASE", 149, 162], ["hypoxia", "DISEASE", 182, 189], ["oxygen", "CHEMICAL", 255, 261], ["oxygen", "CHEMICAL", 255, 261], ["patients", "ORGANISM", 135, 143], ["lung", "ORGAN", 149, 153], ["oxygen", "SIMPLE_CHEMICAL", 255, 261], ["patients", "ORGANISM", 302, 310], ["inflammatory cytokines", "PROTEIN", 83, 105], ["patients", "SPECIES", 135, 143], ["patients", "SPECIES", 302, 310], ["the virus", "PROBLEM", 6, 15], ["inflammatory cytokines", "PROBLEM", 83, 105], ["lung diseases", "PROBLEM", 149, 162], ["hypoxia", "PROBLEM", 182, 189], ["nocturnal oxygen therapy", "TREATMENT", 245, 269], ["a therapeutic option", "TREATMENT", 273, 293], ["virus", "OBSERVATION", 10, 15], ["invasion", "OBSERVATION_MODIFIER", 29, 37], ["inflammatory cytokines", "OBSERVATION", 83, 105], ["lung", "ANATOMY", 149, 153], ["diseases", "OBSERVATION", 154, 162]]], ["Since nocturnal oxygen therapy is not a new concept and has been widely used in COPD patients, it is safe and easy to perform in clinical practice (a home oxygen concentrator is enough for a patient).", [["oxygen", "CHEMICAL", 16, 22], ["COPD", "DISEASE", 80, 84], ["oxygen", "CHEMICAL", 155, 161], ["oxygen", "CHEMICAL", 16, 22], ["oxygen", "CHEMICAL", 155, 161], ["oxygen", "SIMPLE_CHEMICAL", 16, 22], ["patients", "ORGANISM", 85, 93], ["oxygen", "SIMPLE_CHEMICAL", 155, 161], ["patient", "ORGANISM", 191, 198], ["patients", "SPECIES", 85, 93], ["patient", "SPECIES", 191, 198], ["nocturnal oxygen therapy", "TREATMENT", 6, 30], ["a home oxygen concentrator", "TREATMENT", 148, 174], ["oxygen therapy", "OBSERVATION", 16, 30]]]], "PMC6942110": [["BackgroundCritically ill patients are likely to develop respiratory and limb muscle weakness [1].", [["respiratory", "ANATOMY", 56, 67], ["limb muscle", "ANATOMY", 72, 83], ["BackgroundCritically ill", "DISEASE", 0, 24], ["respiratory and limb muscle weakness", "DISEASE", 56, 92], ["patients", "ORGANISM", 25, 33], ["limb muscle", "ORGANISM_SUBDIVISION", 72, 83], ["patients", "SPECIES", 25, 33], ["respiratory and limb muscle weakness", "PROBLEM", 56, 92], ["limb muscle", "ANATOMY", 72, 83], ["weakness", "OBSERVATION", 84, 92]]], ["It has been clearly established that intensive care unit (ICU)-acquired limb muscle weakness is a frequent condition, associated with poor prognosis [2\u20136].", [["limb muscle", "ANATOMY", 72, 83], ["muscle weakness", "DISEASE", 77, 92], ["limb", "ORGANISM_SUBDIVISION", 72, 76], ["muscle", "ORGAN", 77, 83], ["acquired limb muscle weakness", "PROBLEM", 63, 92], ["a frequent condition", "PROBLEM", 96, 116], ["limb muscle", "ANATOMY", 72, 83], ["weakness", "OBSERVATION", 84, 92]]], ["Although the consequences of respiratory muscle weakness have been less extensively investigated, some evidences suggest that it may be a risk factor for prolonged duration of mechanical ventilation [7], associated with a higher risk of readmission [8] and higher mortality [9].", [["respiratory muscle", "ANATOMY", 29, 47], ["respiratory muscle weakness", "DISEASE", 29, 56], ["muscle", "ORGAN", 41, 47], ["respiratory muscle weakness", "PROBLEM", 29, 56], ["mechanical ventilation", "TREATMENT", 176, 198], ["respiratory muscle", "ANATOMY", 29, 47], ["weakness", "OBSERVATION", 48, 56]]], ["Diaphragm dysfunction is frequent in the intensive care unit (more than 60% of mechanically ventilated patients [10]) and is associated with difficult and prolonged weaning and poor prognosis [11\u201314].", [["Diaphragm", "ANATOMY", 0, 9], ["Diaphragm dysfunction", "DISEASE", 0, 21], ["Diaphragm", "MULTI-TISSUE_STRUCTURE", 0, 9], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["Diaphragm dysfunction", "PROBLEM", 0, 21], ["difficult and prolonged weaning", "PROBLEM", 141, 172], ["poor prognosis", "PROBLEM", 177, 191], ["dysfunction", "OBSERVATION", 10, 21], ["frequent", "OBSERVATION_MODIFIER", 25, 33]]], ["Causes of diaphragm dysfunction are multifactorial and no specific treatment is currently available [10].", [["diaphragm", "ANATOMY", 10, 19], ["diaphragm dysfunction", "DISEASE", 10, 31], ["diaphragm", "ORGAN", 10, 19], ["diaphragm dysfunction", "PROBLEM", 10, 31], ["specific treatment", "TREATMENT", 58, 76], ["diaphragm", "ANATOMY", 10, 19], ["dysfunction", "OBSERVATION", 20, 31]]], ["Diaphragm dysfunction is responsible for prolonged mechanical ventilation and may contribute to the development of \u201cchronic critical illness\u201d, a devastating condition for patients and their families [15].", [["Diaphragm", "ANATOMY", 0, 9], ["Diaphragm dysfunction", "DISEASE", 0, 21], ["chronic critical illness\u201d", "DISEASE", 116, 141], ["Diaphragm", "MULTI-TISSUE_STRUCTURE", 0, 9], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["Diaphragm dysfunction", "PROBLEM", 0, 21], ["prolonged mechanical ventilation", "TREATMENT", 41, 73], ["\u201cchronic critical illness", "PROBLEM", 115, 140], ["dysfunction", "OBSERVATION", 10, 21], ["responsible for", "UNCERTAINTY", 25, 40], ["mechanical ventilation", "OBSERVATION", 51, 73], ["chronic", "OBSERVATION_MODIFIER", 116, 123]]], ["While the diaphragm undoubtedly plays a crucial role to ensure prompt and safe weaning from mechanical ventilation, recent data suggest that a substantial proportion of patients (up to 44%) can be successfully weaned from the ventilator despite the presence of diaphragm dysfunction [13, 14, 16].", [["diaphragm", "ANATOMY", 10, 19], ["diaphragm", "ANATOMY", 261, 270], ["diaphragm dysfunction", "DISEASE", 261, 282], ["diaphragm", "ORGAN", 10, 19], ["patients", "ORGANISM", 169, 177], ["diaphragm", "ORGAN", 261, 270], ["patients", "SPECIES", 169, 177], ["mechanical ventilation", "TREATMENT", 92, 114], ["the ventilator", "TREATMENT", 222, 236], ["diaphragm dysfunction", "PROBLEM", 261, 282], ["diaphragm", "ANATOMY", 10, 19], ["substantial", "OBSERVATION_MODIFIER", 143, 154], ["diaphragm", "ANATOMY", 261, 270], ["dysfunction", "OBSERVATION", 271, 282]]], ["Nevertheless, in contrast with the reported negative impact of ICU-acquired weakness on long-term survival and disabilities [3, 4, 17], it remains unclear whether diaphragm dysfunction per se is responsible for poor medium-term and long-term prognosis.", [["diaphragm", "ANATOMY", 163, 172], ["diaphragm dysfunction", "DISEASE", 163, 184], ["diaphragm", "ORGAN", 163, 172], ["acquired weakness", "PROBLEM", 67, 84], ["long-term survival", "TREATMENT", 88, 106], ["diaphragm dysfunction", "PROBLEM", 163, 184], ["poor medium-term and long-term prognosis", "PROBLEM", 211, 251], ["diaphragm", "ANATOMY", 163, 172], ["dysfunction", "OBSERVATION", 173, 184], ["long-term prognosis", "OBSERVATION_MODIFIER", 232, 251]]], ["The present study therefore used a previous cohort study conducted in our institution [13] to follow up mechanically ventilated patients in whom diaphragm and limb muscle functions were investigated at the time of liberation from mechanical ventilation.", [["diaphragm", "ANATOMY", 145, 154], ["limb muscle", "ANATOMY", 159, 170], ["patients", "ORGANISM", 128, 136], ["diaphragm", "MULTI-TISSUE_STRUCTURE", 145, 154], ["limb muscle", "ORGANISM_SUBDIVISION", 159, 170], ["patients", "SPECIES", 128, 136], ["The present study", "TEST", 0, 17], ["a previous cohort study", "TEST", 33, 56], ["mechanical ventilation", "TREATMENT", 230, 252], ["diaphragm", "ANATOMY", 145, 154], ["limb muscle", "ANATOMY", 159, 170], ["mechanical ventilation", "OBSERVATION", 230, 252]]], ["We tested the hypothesis that diaphragm dysfunction is associated with negative long-term outcomes and that the coexistence of diaphragm dysfunction and ICU-AW has a particular association on long-term prognosis, in line with the known negative synergistic effects of the two conditions on short-term prognosis.Initial study population ::: MethodsAs described elsewhere [13], patients were eligible for the study if they had been intubated and ventilated for at least 24 h and met the readiness-to-wean criteria as routinely assessed by the clinicians in charge on a daily basis according to current guidelines [20].", [["diaphragm", "ANATOMY", 30, 39], ["diaphragm", "ANATOMY", 127, 136], ["diaphragm dysfunction", "DISEASE", 30, 51], ["diaphragm dysfunction", "DISEASE", 127, 148], ["diaphragm", "ORGAN", 30, 39], ["diaphragm", "ORGAN", 127, 136], ["patients", "ORGANISM", 376, 384], ["patients", "SPECIES", 376, 384], ["diaphragm dysfunction", "PROBLEM", 30, 51], ["diaphragm dysfunction", "PROBLEM", 127, 148], ["the study", "TEST", 403, 412], ["intubated", "TREATMENT", 430, 439], ["ventilated", "TREATMENT", 444, 454], ["diaphragm", "ANATOMY", 30, 39], ["dysfunction", "OBSERVATION", 40, 51], ["long-term", "OBSERVATION_MODIFIER", 80, 89], ["diaphragm", "ANATOMY", 127, 136], ["dysfunction", "OBSERVATION", 137, 148], ["long-term prognosis", "OBSERVATION_MODIFIER", 192, 211], ["negative synergistic", "OBSERVATION_MODIFIER", 236, 256], ["short-term prognosis", "OBSERVATION_MODIFIER", 290, 310]]], ["Patients presenting factors possibly interfering with tracheal pressure measurements in response to phrenic nerve stimulation (chest tubes, neuromuscular disease), tracheostomy, a contraindication to the phrenic nerve stimulation technique (pacemaker) and patients with withholding or withdrawal of life support decisions at the time of inclusion were not enrolled.Initial study population ::: MethodsDiaphragm function and limb muscle strength were assessed on the same day once after enrolment and before starting the first spontaneous breathing trial.", [["tracheal", "ANATOMY", 54, 62], ["phrenic nerve", "ANATOMY", 100, 113], ["chest tubes", "ANATOMY", 127, 138], ["neuromuscular", "ANATOMY", 140, 153], ["phrenic nerve", "ANATOMY", 204, 217], ["limb muscle", "ANATOMY", 424, 435], ["neuromuscular disease", "DISEASE", 140, 161], ["Patients", "ORGANISM", 0, 8], ["tracheal", "MULTI-TISSUE_STRUCTURE", 54, 62], ["phrenic nerve", "MULTI-TISSUE_STRUCTURE", 100, 113], ["chest tubes", "MULTI-TISSUE_STRUCTURE", 127, 138], ["phrenic nerve", "MULTI-TISSUE_STRUCTURE", 204, 217], ["patients", "ORGANISM", 256, 264], ["limb muscle", "ORGANISM_SUBDIVISION", 424, 435], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 256, 264], ["tracheal pressure measurements", "TREATMENT", 54, 84], ["phrenic nerve stimulation", "TREATMENT", 100, 125], ["chest tubes", "TREATMENT", 127, 138], ["neuromuscular disease", "PROBLEM", 140, 161], ["tracheostomy", "TREATMENT", 164, 176], ["the phrenic nerve stimulation technique", "TREATMENT", 200, 239], ["pacemaker", "TREATMENT", 241, 250], ["withdrawal of life support", "TREATMENT", 285, 311], ["the first spontaneous breathing trial", "TREATMENT", 516, 553], ["phrenic nerve", "ANATOMY", 100, 113], ["chest", "ANATOMY", 127, 132], ["neuromuscular", "ANATOMY", 140, 153], ["disease", "OBSERVATION", 154, 161], ["tracheostomy", "OBSERVATION", 164, 176], ["phrenic nerve", "ANATOMY", 204, 217], ["limb muscle", "ANATOMY", 424, 435]]], ["Diaphragm function was assessed by the change in tracheal pressure in response to magnetic stimulation (Ptr,stim), as described previously [13] and limb muscle strength was assessed by the Medical Research Council (MRC) score in patients screened for level of consciousness and understanding [2, 21].", [["Diaphragm", "ANATOMY", 0, 9], ["tracheal", "ANATOMY", 49, 57], ["limb muscle", "ANATOMY", 148, 159], ["Diaphragm", "MULTI-TISSUE_STRUCTURE", 0, 9], ["tracheal", "MULTI-TISSUE_STRUCTURE", 49, 57], ["limb muscle", "TISSUE", 148, 159], ["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 229, 237], ["tracheal pressure", "TEST", 49, 66], ["magnetic stimulation", "TEST", 82, 102], ["stim", "TEST", 108, 112], ["tracheal", "ANATOMY", 49, 57], ["pressure", "OBSERVATION_MODIFIER", 58, 66], ["limb muscle", "ANATOMY", 148, 159]]], ["Patients with a Ptr,stim less than 11 cm H2O were considered to have diaphragm dysfunction and patients with a Ptr,stim less than 7 cmH2O were considered to have severe diaphragm dysfunction [18].", [["diaphragm", "ANATOMY", 69, 78], ["diaphragm", "ANATOMY", 169, 178], ["H2O", "CHEMICAL", 41, 44], ["diaphragm dysfunction", "DISEASE", 69, 90], ["diaphragm dysfunction", "DISEASE", 169, 190], ["H2O", "CHEMICAL", 41, 44], ["Patients", "ORGANISM", 0, 8], ["diaphragm", "ORGAN", 69, 78], ["patients", "ORGANISM", 95, 103], ["diaphragm", "ORGAN", 169, 178], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 95, 103], ["a Ptr", "TEST", 14, 19], ["stim", "TEST", 20, 24], ["diaphragm dysfunction", "PROBLEM", 69, 90], ["a Ptr", "TEST", 109, 114], ["stim", "TEST", 115, 119], ["severe diaphragm dysfunction", "PROBLEM", 162, 190], ["diaphragm", "ANATOMY", 69, 78], ["dysfunction", "OBSERVATION", 79, 90], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["diaphragm", "ANATOMY", 169, 178], ["dysfunction", "OBSERVATION", 179, 190]]], ["Patients with an MRC score less than 48 were considered to have ICU-AW [2].Data collection for long-term prognosis study ::: MethodsVariables pertaining to patient characteristics and ICU stay were collected prospectively during hospitalization: age, sex, comorbidities, the Simplified Acute Physiology Score (SAPS II) and SOFA score computed at ICU admission [22, 23].", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 156, 163], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 156, 163], ["an MRC score", "TEST", 14, 26], ["Data collection", "TEST", 75, 90], ["the Simplified Acute Physiology Score", "PROBLEM", 271, 308], ["SOFA score", "TEST", 323, 333], ["Acute", "OBSERVATION_MODIFIER", 286, 291]]], ["The dates of ICU admission, intubation, first spontaneous breathing trial, extubation, ICU discharge, hospital discharge and ICU and hospital death were obtained from the hospital medical charts.", [["death", "DISEASE", 142, 147], ["intubation", "TREATMENT", 28, 38], ["first spontaneous breathing trial", "TREATMENT", 40, 73], ["extubation", "TREATMENT", 75, 85]]], ["Survival and health-related quality of life assessment was performed as described below.", [["life assessment", "TEST", 39, 54]]], ["Hospital medical charts were analysed to identify the patient\u2019s status (dead or alive) and dates over a 2-year period following inclusion in the study.", [["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["the study", "TEST", 141, 150]]], ["Patients alive 2 years after inclusion were contacted by phone by the first author.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The patient was asked to complete the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) questionnaire to assess health-related quality of life [24, 25].", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["Outcomes Study", "TEST", 46, 60]]], ["The SF-36 questionnaire is a general quality of life questionnaire that evaluates physical and emotional quality of life.", [["The SF", "TEST", 0, 6]]], ["The SF-36 questionnaire includes eight multiple-item scales that assess physical functioning, social functioning, physical role, emotional role, mental health, pain, vitality, and general health [26].", [["pain", "DISEASE", 160, 164], ["The SF", "TEST", 0, 6], ["pain", "PROBLEM", 160, 164]]], ["Interviews were conducted by a single investigator blinded to the patient\u2019s status in relation to the presence of diaphragm dysfunction and ICU-acquired weakness in the ICU.Study outcomes ::: MethodsThe primary outcome was 2-year overall survival following inclusion, and secondary outcomes were health-related quality of life and functional disability as assessed by the SF-36 score.Statistical analysis ::: MethodsDue to the retrospective nature of this post hoc analysis, no sample size calculation could be made.", [["diaphragm", "ANATOMY", 114, 123], ["diaphragm dysfunction", "DISEASE", 114, 135], ["functional disability", "DISEASE", 331, 352], ["patient", "ORGANISM", 66, 73], ["diaphragm", "ORGAN", 114, 123], ["patient", "SPECIES", 66, 73], ["diaphragm dysfunction", "PROBLEM", 114, 135], ["acquired weakness", "PROBLEM", 144, 161], ["Methods", "TREATMENT", 192, 199], ["this post hoc analysis", "TEST", 451, 473], ["sample size calculation", "TEST", 478, 501], ["diaphragm", "ANATOMY", 114, 123], ["dysfunction", "OBSERVATION", 124, 135], ["weakness", "OBSERVATION", 153, 161]]], ["All patients from the primary cohort [13] with available data were included in the present analysis.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["available data", "TEST", 47, 61]]], ["A normal distribution was checked by a Kolmogorov\u2013Smirnov test.", [["a Kolmogorov\u2013Smirnov test", "TEST", 37, 62], ["normal", "OBSERVATION", 2, 8], ["distribution", "OBSERVATION_MODIFIER", 9, 21]]], ["Survival curves were compared by log-rank (Mantel\u2013Cox) test.Statistical analysis ::: MethodsPatient outcomes were compared by means of two classifications.", [["Survival curves", "TEST", 0, 15]]], ["First, patients were classified as follows: (1) with/without diaphragm dysfunction and (2) with/without ICU-acquired weakness.", [["diaphragm", "ANATOMY", 61, 70], ["diaphragm dysfunction", "DISEASE", 61, 82], ["patients", "ORGANISM", 7, 15], ["diaphragm", "ORGAN", 61, 70], ["patients", "SPECIES", 7, 15], ["diaphragm dysfunction", "PROBLEM", 61, 82], ["acquired weakness", "PROBLEM", 108, 125], ["without", "UNCERTAINTY", 53, 60], ["diaphragm", "ANATOMY", 61, 70], ["dysfunction", "OBSERVATION", 71, 82], ["weakness", "OBSERVATION", 117, 125]]], ["In a secondary analysis, patients were also classified according to the co-existence of diaphragm dysfunction and ICU-acquired weakness: (a) diaphragm dysfunction only, (b) ICU-acquired weakness only, (c) co-existence of diaphragm dysfunction and ICU-acquired weakness and (d) neither of these two conditions.Statistical analysis ::: MethodsThree exploratory analyses were then conducted.", [["diaphragm", "ANATOMY", 88, 97], ["diaphragm", "ANATOMY", 141, 150], ["diaphragm", "ANATOMY", 221, 230], ["diaphragm dysfunction", "DISEASE", 88, 109], ["diaphragm dysfunction", "DISEASE", 141, 162], ["weakness", "DISEASE", 186, 194], ["diaphragm dysfunction", "DISEASE", 221, 242], ["weakness", "DISEASE", 260, 268], ["patients", "ORGANISM", 25, 33], ["diaphragm", "ORGAN", 88, 97], ["diaphragm", "ORGAN", 141, 150], ["diaphragm", "ORGAN", 221, 230], ["patients", "SPECIES", 25, 33], ["a secondary analysis", "TEST", 3, 23], ["diaphragm dysfunction", "PROBLEM", 88, 109], ["acquired weakness", "PROBLEM", 118, 135], ["a) diaphragm dysfunction", "PROBLEM", 138, 162], ["acquired weakness", "PROBLEM", 177, 194], ["diaphragm dysfunction", "PROBLEM", 221, 242], ["acquired weakness", "PROBLEM", 251, 268], ["Three exploratory analyses", "TEST", 341, 367], ["diaphragm", "ANATOMY", 88, 97], ["dysfunction", "OBSERVATION", 98, 109], ["diaphragm", "ANATOMY", 141, 150], ["dysfunction", "OBSERVATION", 151, 162], ["weakness", "OBSERVATION", 186, 194], ["diaphragm", "ANATOMY", 221, 230], ["dysfunction", "OBSERVATION", 231, 242], ["weakness", "OBSERVATION", 260, 268]]], ["A first exploratory analysis assessed the 2-year survival in hospital survivors and a second exploratory analysis assessed the 2-year survival in patients with or without severe diaphragm dysfunction (Ptr,stim < 7 cmH2O).", [["diaphragm", "ANATOMY", 178, 187], ["diaphragm dysfunction", "DISEASE", 178, 199], ["patients", "ORGANISM", 146, 154], ["diaphragm", "ORGAN", 178, 187], ["patients", "SPECIES", 146, 154], ["A first exploratory analysis", "TEST", 0, 28], ["a second exploratory analysis", "TEST", 84, 113], ["severe diaphragm dysfunction", "PROBLEM", 171, 199], ["Ptr", "TEST", 201, 204], ["stim", "TEST", 205, 209], ["diaphragm", "ANATOMY", 178, 187], ["dysfunction", "OBSERVATION", 188, 199]]], ["Last, a third exploratory analysis compared SF-36 questionnaire in patients with co-existence of diaphragm dysfunction and ICU-acquired weakness and those who were free from diseases.", [["diaphragm", "ANATOMY", 97, 106], ["diaphragm dysfunction", "DISEASE", 97, 118], ["ICU-acquired weakness", "DISEASE", 123, 144], ["patients", "ORGANISM", 67, 75], ["diaphragm", "ORGAN", 97, 106], ["patients", "SPECIES", 67, 75], ["a third exploratory analysis", "TEST", 6, 34], ["SF", "TEST", 44, 46], ["diaphragm dysfunction", "PROBLEM", 97, 118], ["acquired weakness", "PROBLEM", 127, 144], ["diseases", "PROBLEM", 174, 182], ["diaphragm", "ANATOMY", 97, 106], ["dysfunction", "OBSERVATION", 107, 118], ["diseases", "OBSERVATION", 174, 182]]], ["For all final comparisons, a p-value less than or equal to 0.05 was considered statistically significant.", [["a p-value", "TEST", 27, 36]]], ["Statistical analyses were performed with Prism v.6, GraphPad Software.Patient characteristics and follow-up ::: ResultsSeventy-six patients were consecutively enrolled in the primary study (Fig. 1).", [["patients", "ORGANISM", 131, 139], ["Patient", "SPECIES", 70, 77], ["patients", "SPECIES", 131, 139], ["Statistical analyses", "TEST", 0, 20], ["Prism", "TEST", 41, 46], ["the primary study", "TEST", 171, 188]]], ["Forty-eight (63%) patients were diagnosed with diaphragm dysfunction at the time of weaning, 26 (34%) had ICU-acquired weakness, 16 (21%) had both diaphragm dysfunction and ICU-acquired weakness and 18 (24%) were free of diseases.", [["diaphragm", "ANATOMY", 47, 56], ["diaphragm", "ANATOMY", 147, 156], ["diaphragm dysfunction", "DISEASE", 47, 68], ["ICU-acquired weakness", "DISEASE", 106, 127], ["diaphragm dysfunction", "DISEASE", 147, 168], ["ICU-acquired weakness", "DISEASE", 173, 194], ["patients", "ORGANISM", 18, 26], ["diaphragm", "ORGAN", 47, 56], ["diaphragm", "ORGAN", 147, 156], ["patients", "SPECIES", 18, 26], ["diaphragm dysfunction", "PROBLEM", 47, 68], ["acquired weakness", "PROBLEM", 110, 127], ["both diaphragm dysfunction", "PROBLEM", 142, 168], ["acquired weakness", "PROBLEM", 177, 194], ["diseases", "PROBLEM", 221, 229], ["diaphragm", "ANATOMY", 47, 56], ["dysfunction", "OBSERVATION", 57, 68], ["diaphragm", "ANATOMY", 147, 156], ["dysfunction", "OBSERVATION", 157, 168], ["diseases", "OBSERVATION", 221, 229]]], ["Patient characteristics are presented in Table 1.", [["Patient", "SPECIES", 0, 7]]], ["Patients had been ventilated for an average of 4 (2\u20136) days prior to inclusion.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["ventilated", "TREATMENT", 18, 28], ["ventilated", "OBSERVATION", 18, 28]]], ["Patients who were free from diaphragm dysfunction and ICU-AW were more likely placed under mechanical ventilation for coma and were ventilated significantly shorter than others (Table 1).", [["diaphragm", "ANATOMY", 28, 37], ["diaphragm dysfunction", "DISEASE", 28, 49], ["coma", "DISEASE", 118, 122], ["Patients", "ORGANISM", 0, 8], ["diaphragm", "ORGAN", 28, 37], ["Patients", "SPECIES", 0, 8], ["diaphragm dysfunction", "PROBLEM", 28, 49], ["mechanical ventilation", "TREATMENT", 91, 113], ["coma", "PROBLEM", 118, 122], ["diaphragm", "ANATOMY", 28, 37], ["dysfunction", "OBSERVATION", 38, 49], ["mechanical ventilation", "OBSERVATION", 91, 113]]], ["Overall, 43 (57%) patients were successfully weaned from the ventilator after the first attempt.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["the ventilator", "TREATMENT", 57, 71]]], ["The mean length of ICU stay was 9 (4\u201318) days and the mean length of hospital stay was 21 (10\u201330) days.", [["mean", "OBSERVATION_MODIFIER", 4, 8], ["length", "OBSERVATION_MODIFIER", 9, 15]]], ["All ICU survivors had been liberated from mechanical ventilation at the time of ICU discharge.", [["All ICU survivors", "TREATMENT", 0, 17], ["mechanical ventilation", "TREATMENT", 42, 64], ["mechanical ventilation", "OBSERVATION", 42, 64]]], ["As 7 patients were lost to follow-up, 2-year survival was assessed in only 69 patients and secondary outcomes (health-related quality of life) were assessed in 40 patients (Fig. 1).", [["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 163, 171]]]], "PMC7132665": [["IntroductionRespiratory viruses (RV) are ubiquitous and cause a large variety of clinical symptoms.", [["IntroductionRespiratory viruses", "ORGANISM", 0, 31], ["RV", "SPECIES", 33, 35], ["IntroductionRespiratory viruses", "PROBLEM", 0, 31], ["clinical symptoms", "PROBLEM", 81, 98], ["viruses", "OBSERVATION", 24, 31], ["RV", "ANATOMY", 33, 35], ["large", "OBSERVATION_MODIFIER", 64, 69], ["variety", "OBSERVATION_MODIFIER", 70, 77]]], ["For many years, procedures for diagnosis of respiratory virus infections have included culture and serology, which are time consuming, labor intensive and insensitive.", [["respiratory virus infections", "DISEASE", 44, 72], ["respiratory virus", "ORGANISM", 44, 61], ["respiratory virus infections", "PROBLEM", 44, 72], ["culture", "TEST", 87, 94], ["serology", "TEST", 99, 107], ["labor", "PROBLEM", 135, 140], ["respiratory", "ANATOMY", 44, 55], ["virus", "OBSERVATION", 56, 61]]], ["Direct immunofluorescence assays (DFA) improved the turnaround time, but slightly compromised the sensitivity compared to culture.", [["Direct immunofluorescence assays", "TEST", 0, 32], ["DFA", "TEST", 34, 37], ["slightly compromised the sensitivity", "PROBLEM", 73, 109], ["culture", "TEST", 122, 129]]], ["More recently, molecular assays have been developed and progressively multiplexed in order to diagnose a large number of respiratory viruses in single assays.", [["respiratory viruses", "DISEASE", 121, 140], ["molecular assays", "TEST", 15, 31], ["respiratory viruses", "PROBLEM", 121, 140], ["large", "OBSERVATION_MODIFIER", 105, 110], ["respiratory viruses", "OBSERVATION", 121, 140]]], ["New viruses that could not be detected by conventional virology have been discovered.", [["New viruses", "PROBLEM", 0, 11], ["viruses", "OBSERVATION", 4, 11], ["could not be", "UNCERTAINTY", 17, 29]]], ["Various commercial multiplex respiratory virus assays are now accessible to many clinical laboratories, although their impact remains unclear.IntroductionDiagnosis of RV is frequent in children.", [["RV", "ORGAN", 167, 169], ["children", "ORGANISM", 185, 193], ["children", "SPECIES", 185, 193], ["Various commercial multiplex respiratory virus assays", "PROBLEM", 0, 53], ["respiratory virus", "OBSERVATION", 29, 46], ["RV", "ANATOMY", 167, 169], ["frequent", "OBSERVATION_MODIFIER", 173, 181]]], ["Evidence of viral infection is present in up to 43\u201367% of pediatric community-acquired pneumonia using molecular diagnostics (Ruuskanen et al., 2011).", [["viral infection", "DISEASE", 12, 27], ["pneumonia", "DISEASE", 87, 96], ["viral infection", "PROBLEM", 12, 27], ["pediatric community-acquired pneumonia", "PROBLEM", 58, 96], ["viral", "OBSERVATION_MODIFIER", 12, 17], ["infection", "OBSERVATION", 18, 27], ["pneumonia", "OBSERVATION", 87, 96]]], ["Routine diagnosis of respiratory virus infection in adult populations is more recent since respiratory viruses were considered benign for a very long time.", [["respiratory virus infection", "DISEASE", 21, 48], ["respiratory viruses", "DISEASE", 91, 110], ["respiratory virus", "ORGANISM", 21, 38], ["respiratory virus infection", "PROBLEM", 21, 48], ["adult populations", "PROBLEM", 52, 69], ["respiratory viruses", "PROBLEM", 91, 110], ["respiratory virus infection", "OBSERVATION", 21, 48], ["viruses", "OBSERVATION", 103, 110]]], ["Respiratory viruses have been detected in 15\u201356% of adult community-acquired pneumonia (Ruuskanen et al., 2011).", [["Respiratory viruses", "DISEASE", 0, 19], ["pneumonia", "DISEASE", 77, 86], ["Respiratory viruses", "PROBLEM", 0, 19], ["adult community-acquired pneumonia", "PROBLEM", 52, 86], ["viruses", "OBSERVATION", 12, 19], ["pneumonia", "OBSERVATION", 77, 86]]], ["Impact of respiratory virus diagnosis in specific pediatric and adult populations (eg, neonates, patients with cystic fibrosis, neutropenic patients or patients with chronic obstructive pulmonary disease [COPD]) is still incompletely understood.", [["cystic", "ANATOMY", 111, 117], ["pulmonary", "ANATOMY", 186, 195], ["cystic fibrosis", "DISEASE", 111, 126], ["neutropenic", "DISEASE", 128, 139], ["chronic obstructive pulmonary disease", "DISEASE", 166, 203], ["COPD", "DISEASE", 205, 209], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 140, 148], ["patients", "ORGANISM", 152, 160], ["pulmonary", "ORGAN", 186, 195], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 152, 160], ["respiratory virus diagnosis", "TREATMENT", 10, 37], ["cystic fibrosis", "PROBLEM", 111, 126], ["neutropenic", "PROBLEM", 128, 139], ["chronic obstructive pulmonary disease", "PROBLEM", 166, 203], ["COPD", "PROBLEM", 205, 209], ["respiratory virus", "OBSERVATION", 10, 27], ["cystic", "OBSERVATION_MODIFIER", 111, 117], ["fibrosis", "OBSERVATION", 118, 126], ["neutropenic", "OBSERVATION", 128, 139], ["chronic", "OBSERVATION_MODIFIER", 166, 173], ["obstructive", "OBSERVATION_MODIFIER", 174, 185], ["pulmonary", "ANATOMY", 186, 195], ["disease", "OBSERVATION", 196, 203], ["COPD", "OBSERVATION", 205, 209]]], ["This article will review available data and highlight unresolved questions about cost-effectiveness, infection control, clinical utility, and public health impact of multiplex respiratory virus assays.Multiplex respiratory virus assay technologiesMany multiplex respiratory virus assays have been published and marketed in the last years.", [["infection", "DISEASE", 101, 110], ["infection control", "TREATMENT", 101, 118], ["multiplex respiratory virus assays", "PROBLEM", 166, 200], ["Multiplex respiratory virus assay technologies", "PROBLEM", 201, 247], ["Many multiplex respiratory virus assays", "PROBLEM", 247, 286], ["respiratory virus", "OBSERVATION", 176, 193], ["respiratory virus", "OBSERVATION", 211, 228], ["respiratory virus", "OBSERVATION", 262, 279]]], ["Different nucleic acid based amplification technologies have been used to detect respiratory viruses including polymerase chain reaction (PCR), nucleic acid sequence-based amplification, transcription mediated amplification, strand displacement amplification, loop mediated isothermal amplification, rolling circle amplification, helicase-dependant amplification, and multiplex ligation-dependent probe amplification.", [["nucleic acid", "CHEMICAL", 10, 22], ["nucleic acid", "CHEMICAL", 144, 156], ["Different nucleic acid based amplification technologies", "TREATMENT", 0, 55], ["respiratory viruses", "PROBLEM", 81, 100], ["polymerase chain reaction", "PROBLEM", 111, 136], ["PCR", "TEST", 138, 141], ["nucleic acid sequence", "TEST", 144, 165], ["transcription mediated amplification", "TREATMENT", 187, 223], ["strand displacement amplification", "TREATMENT", 225, 258], ["loop mediated isothermal amplification", "TREATMENT", 260, 298], ["rolling circle amplification", "TREATMENT", 300, 328], ["helicase-dependant amplification", "TREATMENT", 330, 362], ["multiplex ligation", "TREATMENT", 368, 386], ["dependent probe amplification", "TREATMENT", 387, 416], ["respiratory viruses", "OBSERVATION", 81, 100]]], ["However, only a few of these methods are appropriate for multiplexing.", [["few", "OBSERVATION_MODIFIER", 16, 19]]], ["PCR has emerged as the easiest technology for multiplexing a large number of targets.", [["PCR", "TEST", 0, 3], ["large", "OBSERVATION_MODIFIER", 61, 66]]], ["The first multiplex respiratory virus assays used gel electrophoresis as a detection method, but it was long, labour intensive and necessitated manipulation of ethidium bromide.", [["ethidium bromide", "CHEMICAL", 160, 176], ["ethidium bromide", "CHEMICAL", 160, 176], ["ethidium bromide", "SIMPLE_CHEMICAL", 160, 176], ["The first multiplex respiratory virus assays", "PROBLEM", 0, 44], ["gel electrophoresis", "TEST", 50, 69], ["a detection method", "TEST", 73, 91], ["manipulation of ethidium bromide", "TREATMENT", 144, 176], ["respiratory virus", "OBSERVATION", 20, 37]]], ["Some assays using real-time PCR were designed with moderately multiplexed reactions (e.g., influenza A, influenza B, and influenza H1N1; influenza A, influenza B and RSV; parainfluenza 1, 2, and 3) and performed in combination to cover a larger range of viruses (e.g. Prodesse, Simplexa, Respiratory pathogens Fast-track diagnostics, Altona Diagnostics).", [["influenza A", "DISEASE", 91, 102], ["influenza B", "DISEASE", 104, 115], ["influenza H1N1", "DISEASE", 121, 135], ["influenza A", "DISEASE", 137, 148], ["influenza B", "DISEASE", 150, 161], ["parainfluenza", "DISEASE", 171, 184], ["influenza A", "ORGANISM", 91, 102], ["influenza B", "ORGANISM", 104, 115], ["influenza H1N1", "ORGANISM", 121, 135], ["influenza A", "ORGANISM", 137, 148], ["influenza B", "ORGANISM", 150, 161], ["RSV", "ORGANISM", 166, 169], ["parainfluenza 1", "ORGANISM", 171, 186], ["influenza H1N1", "SPECIES", 121, 135], ["influenza B", "SPECIES", 150, 161], ["RSV", "SPECIES", 166, 169], ["parainfluenza", "SPECIES", 171, 184], ["influenza A", "SPECIES", 91, 102], ["RSV", "SPECIES", 166, 169], ["Some assays", "TEST", 0, 11], ["real-time PCR", "TEST", 18, 31], ["moderately multiplexed reactions", "PROBLEM", 51, 83], ["influenza", "PROBLEM", 91, 100], ["influenza B", "PROBLEM", 104, 115], ["influenza", "PROBLEM", 121, 130], ["H1N1", "PROBLEM", 131, 135], ["influenza", "PROBLEM", 137, 146], ["influenza", "PROBLEM", 150, 159], ["RSV", "PROBLEM", 166, 169], ["parainfluenza", "PROBLEM", 171, 184], ["viruses", "PROBLEM", 254, 261], ["Prodesse", "TEST", 268, 276], ["Respiratory pathogens", "TEST", 288, 309], ["viruses", "OBSERVATION", 254, 261]]], ["This strategy can be adapted for quantitative results if samples are collected appropriately and standard curves amplified with the reaction.", [["samples", "ANATOMY", 57, 64], ["standard curves", "TEST", 97, 112], ["the reaction", "PROBLEM", 128, 140]]], ["However, no quantitative commercial assay is available yet.", [["quantitative commercial assay", "TEST", 12, 41], ["no", "UNCERTAINTY", 9, 11]]], ["By limiting the multiplex reaction to 3 or 4 targets, it is possible in theory to get better sensitivity by eliminating primer dimer and competition between multiple targets.", [["the multiplex reaction", "PROBLEM", 12, 34]]], ["Other assays used highly multiplexed reactions including all targets (over 20 targets) in the same reaction.", [["Other assays", "TEST", 0, 12], ["highly multiplexed reactions", "PROBLEM", 18, 46]]], ["These assays need new detection methods in order to identify easily and rapidly each target present in the specimen.", [["specimen", "ANATOMY", 107, 115], ["These assays", "TEST", 0, 12], ["new detection methods", "TEST", 18, 39]]], ["These detection technologies include microsphere hybridization associated with flow cytometer detection, LED camera detection or barcode detection (e.g., xTAG RVP, Resplex II, MultiCode-PLX), microcapillary electrophoresis (e.g., Seeplex RV12 and RV15, Respifinder, Iceplex), electrospray ionization mass spectrometry (e.g., PLEX-ID), nested-PCR with melting curve analysis (e.g., FilmArray), and solid phase hybridization microarrays (e.g., Infiniti respiratory virus panel, NGEN Respiratory Virus Analye-specific reagent, Verigen respiratory Virus Plus Nucleic Acid test, ICubate, eSensor genmark).", [["Infiniti respiratory virus", "ORGANISM", 442, 468], ["Resplex II", "PROTEIN", 164, 174], ["Infiniti respiratory virus", "SPECIES", 442, 468], ["microsphere hybridization", "TREATMENT", 37, 62], ["flow cytometer detection", "TEST", 79, 103], ["LED camera detection", "TEST", 105, 125], ["barcode detection", "TEST", 129, 146], ["xTAG", "TEST", 154, 158], ["RVP", "TEST", 159, 162], ["microcapillary electrophoresis", "TEST", 192, 222], ["Seeplex RV12", "TREATMENT", 230, 242], ["RV15", "TREATMENT", 247, 251], ["electrospray ionization mass spectrometry", "TEST", 276, 317], ["PLEX", "TEST", 325, 329], ["nested-PCR", "TEST", 335, 345], ["melting curve analysis", "TEST", 351, 373], ["FilmArray", "TEST", 381, 390], ["solid phase hybridization microarrays", "TEST", 397, 434], ["Infiniti respiratory virus panel", "TEST", 442, 474], ["NGEN", "TEST", 476, 480], ["Respiratory Virus Analye", "TEST", 481, 505], ["specific reagent", "TREATMENT", 506, 522], ["Verigen respiratory Virus", "TREATMENT", 524, 549], ["Nucleic Acid test", "TEST", 555, 572]]], ["Only a few of the numerous commercial multiplex respiratory virus assays are US Food and Drug Administration approved (xTAG RVP and RVP fast, Prodesse assays, Verigen respiratory Virus Plus Nucleic Acid test and FilmArray Respiratory panel).", [["the numerous commercial multiplex respiratory virus assays", "PROBLEM", 14, 72], ["Drug Administration", "TREATMENT", 89, 108], ["xTAG RVP", "TEST", 119, 127], ["RVP fast", "TEST", 132, 140], ["Prodesse assays", "TEST", 142, 157], ["Verigen respiratory Virus", "TREATMENT", 159, 184], ["Nucleic Acid test", "TEST", 190, 207], ["FilmArray Respiratory panel", "TEST", 212, 239], ["few", "OBSERVATION_MODIFIER", 7, 10], ["numerous", "OBSERVATION_MODIFIER", 18, 26], ["respiratory virus", "OBSERVATION", 48, 65]]], ["We have seen in the last years an increasing number of studies comparing commercial and laboratory developed assays as well as studies comparing commercial assays with each other.", [["increasing", "OBSERVATION_MODIFIER", 34, 44]]], ["These studies are difficult to perform because of the high cost of reagents and the large number of targets to validate.", [["These studies", "TEST", 0, 13], ["the high cost of reagents", "PROBLEM", 50, 75], ["large", "OBSERVATION_MODIFIER", 84, 89]]], ["The best way to perform comparison studies is to compare head to head two or three methods with prospectively collected samples.", [["head", "ANATOMY", 57, 61], ["samples", "ANATOMY", 120, 127], ["head", "ORGANISM_SUBDIVISION", 57, 61], ["head", "ORGANISM_SUBDIVISION", 65, 69], ["comparison studies", "TEST", 24, 42], ["prospectively collected samples", "TEST", 96, 127]]], ["However, because viruses have changing epidemiology, it can be difficult to collect enough samples to validate every target.", [["viruses", "PROBLEM", 17, 24]]], ["Overall, most multiplex respiratory virus assays have comparable performance, but each assay has small differences in performance among different targets depending on circulating strains.", [["most multiplex respiratory virus assays", "PROBLEM", 9, 48], ["each assay", "TEST", 82, 92], ["small differences in performance", "PROBLEM", 97, 129], ["circulating strains", "PROBLEM", 167, 186], ["respiratory virus", "OBSERVATION", 24, 41], ["small", "OBSERVATION_MODIFIER", 97, 102], ["differences", "OBSERVATION_MODIFIER", 103, 114]]], ["Problems that have been encountered are mainly lack of sensitivity for specific subtypes of adenovirus and inability to differentiate rhinovirus from enterovirus (Bibby et al., 2011, Chandrasekaran et al., 2012, Gharabaghi et al., 2011, Hayden et al., 2012, Mahony et al., 2007, Renaud et al., 2012).", [["rhinovirus", "DISEASE", 134, 144], ["enterovirus", "DISEASE", 150, 161], ["adenovirus", "ORGANISM", 92, 102], ["rhinovirus", "ORGANISM", 134, 144], ["enterovirus", "ORGANISM", 150, 161], ["adenovirus", "SPECIES", 92, 102], ["adenovirus", "PROBLEM", 92, 102], ["rhinovirus", "PROBLEM", 134, 144], ["enterovirus", "PROBLEM", 150, 161], ["adenovirus", "OBSERVATION", 92, 102]]], ["The principal differences among the multiplex respiratory virus assays concern the throughput, turnaround time, ease of use, automation, versatility, use of a closed system to reduce contamination and cost.", [["the multiplex respiratory virus assays", "TEST", 32, 70], ["automation", "TEST", 125, 135], ["a closed system", "TREATMENT", 157, 172], ["contamination", "PROBLEM", 183, 196], ["principal", "OBSERVATION_MODIFIER", 4, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25], ["respiratory virus", "OBSERVATION", 46, 63]]], ["Some contamination issues have been reported with open platforms that need manipulation of amplification products.", [["Some contamination issues", "PROBLEM", 0, 25], ["open platforms", "TREATMENT", 50, 64], ["manipulation of amplification products", "TREATMENT", 75, 113], ["contamination", "OBSERVATION", 5, 18]]], ["The ideal multiplex respiratory virus assay would be an assay that is a closed system with high throughput and a short turnaround time.", [["The ideal multiplex respiratory virus assay", "TEST", 0, 43], ["an assay", "TEST", 53, 61], ["a closed system", "PROBLEM", 70, 85], ["respiratory virus", "OBSERVATION", 20, 37], ["closed", "OBSERVATION", 72, 78], ["high", "OBSERVATION_MODIFIER", 91, 95]]], ["Although many would consider quantitative results very useful to differentiate shedding from symptomatic infection and to follow immunocompromised patients with anti-viral treatment, the literature has been inconsistent about the correlation between viral loads and symptoms (Campbell et al., 2010, Franz et al., 2010, Jansen et al., 2010, Martin et al., 2008).Multiplex respiratory virus assay technologiesIt is important to mention that multiplex PCR will detect only the targets included in the reaction and as users\u2019 dependence on molecular assays increase, the necessity for constant review of the targets will be essential.", [["infection", "DISEASE", 105, 114], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["symptomatic infection", "PROBLEM", 93, 114], ["anti-viral treatment", "TREATMENT", 161, 181], ["viral loads and symptoms", "PROBLEM", 250, 274], ["Multiplex respiratory virus assay technologies", "PROBLEM", 361, 407], ["multiplex PCR", "TEST", 439, 452], ["molecular assays", "TEST", 535, 551], ["symptomatic", "OBSERVATION_MODIFIER", 93, 104], ["infection", "OBSERVATION", 105, 114], ["respiratory virus", "OBSERVATION", 371, 388]]], ["Mutant viruses can emerge and give false negative results with molecular assays.", [["Mutant viruses", "PROBLEM", 0, 14], ["molecular assays", "TEST", 63, 79], ["viruses", "OBSERVATION", 7, 14]]], ["This limitation of multiplex PCR is important and will have to be considered in any high risk population or setting.Cost-effectivenessEven though multiplex PCR assays can detect several different viruses simultaneously and rapidly, their advantages in terms of cost reduction over other rapid diagnostic assays (DFA, antigen detection) are still unclear.", [["multiplex PCR", "TEST", 19, 32], ["multiplex PCR assays", "TEST", 146, 166], ["several different viruses", "PROBLEM", 178, 203], ["cost reduction", "TREATMENT", 261, 275], ["other rapid diagnostic assays", "TEST", 281, 310], ["DFA", "TEST", 312, 315], ["antigen detection", "TEST", 317, 334], ["viruses", "OBSERVATION", 196, 203]]], ["When rapid antigenic diagnostic tests for viral infections became widely used, several studies demonstrated their clinical utility in reducing length of hospital stay, performance of ancillary diagnostic tests and antibiotic consumption among pediatric (Bonner et al., 2003, Esposito et al., 2003, Sharma, 2002, Woo et al., 1997) (Abanses et al., 2006, Benito-Fern\u00e1ndez et al., 2006, Byington et al., 2002, Ferronato et al., 2012, Iyer et al., 2006, Noyola and Demmler, 2000) and adult (Barenfanger et al., 2000, D\u2019Heilly et al., 2008, Falsey et al., 2007) populations.", [["viral infections", "DISEASE", 42, 58], ["rapid antigenic diagnostic tests", "TEST", 5, 37], ["viral infections", "PROBLEM", 42, 58], ["several studies", "TEST", 79, 94], ["ancillary diagnostic tests", "TEST", 183, 209], ["antibiotic consumption", "TREATMENT", 214, 236]]], ["However, In the specific setting of the emergency department (ER), a recent Cochrane analysis did not show a statistically significant difference in antibiotic prescription and ER length of stay in young children presenting with acute febrile respiratory illness tested with rapid antigenic viral diagnostic assays in the ER compared to those not tested (Doan et al., 2012).", [["respiratory", "ANATOMY", 243, 254], ["febrile respiratory illness", "DISEASE", 235, 262], ["ER", "GENE_OR_GENE_PRODUCT", 177, 179], ["children", "ORGANISM", 204, 212], ["ER", "GENE_OR_GENE_PRODUCT", 322, 324], ["ER", "PROTEIN", 177, 179], ["ER", "PROTEIN", 322, 324], ["children", "SPECIES", 204, 212], ["a recent Cochrane analysis", "TEST", 67, 93], ["antibiotic prescription", "TREATMENT", 149, 172], ["acute febrile respiratory illness", "PROBLEM", 229, 262], ["rapid antigenic viral diagnostic assays", "PROBLEM", 275, 314], ["acute", "OBSERVATION_MODIFIER", 229, 234], ["febrile", "OBSERVATION_MODIFIER", 235, 242], ["respiratory illness", "OBSERVATION", 243, 262]]], ["This difference between hospitalized patients and ER patients illustrates that diagnostic tools must be used in specific settings in order to provide most benefits.Cost-effectivenessSince the advent of molecular diagnosis, different authors have tried to demonstrate that multiplex PCR could be cost-effective compared to conventional rapid diagnostic assays.", [["patients", "ORGANISM", 37, 45], ["ER", "GENE_OR_GENE_PRODUCT", 50, 52], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 53, 61], ["multiplex PCR", "PROBLEM", 272, 285], ["conventional rapid diagnostic assays", "TEST", 322, 358]]], ["Despite their reduced turnaround time, higher sensitivity and specificity and capacity to detect an extended range of viruses, clinical and financial gains afforded by PCR seem modest.", [["higher sensitivity", "PROBLEM", 39, 57], ["capacity", "TEST", 78, 86], ["an extended range of viruses", "PROBLEM", 97, 125], ["PCR", "TEST", 168, 171], ["viruses", "OBSERVATION", 118, 125]]], ["Garcia-Garcia et al. showed that, compared with conventional virology, diagnosis using respiratory virus PCR resulted in a reduction in antibiotic prescriptions (Garcia-Garcia et al., 2012).", [["respiratory virus PCR", "TEST", 87, 108], ["a reduction in antibiotic prescriptions", "TREATMENT", 121, 160], ["reduction", "OBSERVATION_MODIFIER", 123, 132]]], ["Oosterheert et al. performed a randomized controlled trial to evaluate the clinical and economic impact of real-time PCR for detection of respiratory viruses and atypical pathogens among hospitalized adults.", [["respiratory viruses", "DISEASE", 138, 157], ["a randomized controlled trial", "TREATMENT", 29, 58], ["real-time PCR", "TEST", 107, 120], ["respiratory viruses", "PROBLEM", 138, 157], ["atypical pathogens", "PROBLEM", 162, 180], ["et al", "OBSERVATION", 12, 17], ["respiratory viruses", "OBSERVATION", 138, 157]]], ["Despite a notable increase in etiologic diagnostic yield from 21% to 43%, this study failed to demonstrate any statistically significant reduction in antibiotic use, additional diagnostic tests ordered, antibiotic cost and length of hospital stay (Oosterheert et al., 2005).", [["this study", "TEST", 74, 84], ["antibiotic use", "TREATMENT", 150, 164], ["additional diagnostic tests", "TEST", 166, 193], ["antibiotic cost", "TREATMENT", 203, 218], ["notable", "OBSERVATION_MODIFIER", 10, 17], ["increase", "OBSERVATION_MODIFIER", 18, 26], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["reduction", "OBSERVATION_MODIFIER", 137, 146]]], ["Similar results were obtained by Wishaupt et al. who performed a multicenter, controlled clinical trial among pediatric patients in Netherlands.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128]]], ["They concluded that even if reverse transcriptase PCR (RT-PCR) yielded more viral diagnoses, it did not have a significant influence on patient care (Wishaupt et al., 2011).", [["patient", "ORGANISM", 136, 143], ["reverse transcriptase", "PROTEIN", 28, 49], ["patient", "SPECIES", 136, 143], ["reverse transcriptase PCR", "TEST", 28, 53], ["RT-PCR", "TEST", 55, 61]]], ["In contrast, Mahony et al. generated a cost analysis study to determine if multiplex PCR testing was more or less costly than conventional virology assays.", [["a cost analysis study", "TEST", 37, 58], ["multiplex PCR testing", "TEST", 75, 96], ["conventional virology assays", "TEST", 126, 154]]], ["In their cost calculation, they took into account the viral assay cost and the entire cost of the hospital stay, adjusted according to the test outcome (true or false positive or negative).", [["the test outcome", "TEST", 135, 151], ["false positive", "PROBLEM", 161, 175]]], ["Their results showed that performing the Luminex xTAG RVP alone was the least costly approach (Mahony et al., 2009).", [["xTAG", "CHEMICAL", 49, 53], ["the Luminex xTAG RVP", "TREATMENT", 37, 57]]], ["Because of the paucity of data available and heterogeneity of assays studied, it is difficult to conclude that molecular diagnosis is a cost-effective approach in routine use compared to conventional tests.", [["assays", "TEST", 62, 68], ["conventional tests", "TEST", 187, 205]]], ["However, it is probable that cost calculations including financial impact of molecular assays on hospital stay, antibiotic use and infection control would be favourable.", [["infection", "DISEASE", 131, 140], ["cost calculations", "PROBLEM", 29, 46], ["antibiotic use", "TREATMENT", 112, 126], ["infection control", "TREATMENT", 131, 148]]], ["More studies will be needed to determine populations or situations in which multiplex PCRs would be the most useful in order to optimize their clinical and financial impact.Cost-effectivenessFrom a strictly laboratory point of view, establishment of multiplex PCR could be efficient and cost-effective.", [["More studies", "TEST", 0, 12], ["multiplex PCRs", "TEST", 76, 90], ["multiplex PCR", "TEST", 250, 263]]], ["Dundas et al. demonstrated that in their laboratory, Luminex xTAG RVP was slightly more expensive than conventional techniques but increased laboratory efficiency by decreasing the hands-on time and operational steps.", [["Luminex xTAG RVP", "TEST", 53, 69], ["conventional techniques", "TEST", 103, 126], ["increased laboratory efficiency", "PROBLEM", 131, 162], ["increased", "OBSERVATION_MODIFIER", 131, 140], ["laboratory efficiency", "OBSERVATION", 141, 162], ["hands", "ANATOMY", 181, 186]]], ["Moreover, it offered the possibility to standardize workflow for all respiratory specimens, an attractive strategy to conform to lean methodology (Dundas et al., 2011).", [["respiratory specimens", "ANATOMY", 69, 90], ["all respiratory specimens", "TEST", 65, 90]]], ["Also, in an Australian study evaluating the performance of a laboratory developed PCR compared to DFA and viral culture, the authors concluded that molecular diagnosis was cost-effective, particularly considering its higher sensitivity, rapid turnaround time and the low cost of their technique, which was not patented (Syrmis et al., 2004).", [["an Australian study", "TEST", 9, 28], ["PCR", "TEST", 82, 85], ["DFA", "TEST", 98, 101], ["viral culture", "TEST", 106, 119]]], ["In summary, molecular diagnosis is attractive for virology laboratories in the era of increased demand and decreased availability of medical technologists.", [["virology laboratories", "TEST", 50, 71], ["increased demand", "PROBLEM", 86, 102]]], ["However, before claiming that multiplex PCR is cost-effective, each laboratory should evaluate the cost of the assay desired, the expected number of specimens to analyze, the turnaround time desired and the ability to batch specimens in order to reduce cost of the technique.Co-infectionWith the use of multiplex respiratory virus assays, high rates of viral co-infections have been reported ranging from 10% to 50% depending on different populations.", [["specimens", "ANATOMY", 149, 158], ["viral co-infections", "DISEASE", 353, 372], ["multiplex PCR", "TEST", 30, 43], ["the assay", "TEST", 107, 116], ["the technique", "TREATMENT", 261, 274], ["multiplex respiratory virus assays", "PROBLEM", 303, 337], ["viral co-infections", "PROBLEM", 353, 372], ["respiratory virus", "OBSERVATION", 313, 330], ["viral co-infections", "OBSERVATION", 353, 372]]], ["Younger children, particularly if attending daycare, have higher rates of co-infections.", [["co-infections", "DISEASE", 74, 87], ["children", "ORGANISM", 8, 16], ["children", "SPECIES", 8, 16], ["co-infections", "PROBLEM", 74, 87], ["co-infections", "OBSERVATION", 74, 87]]], ["Many studies performed in different settings including outpatients, inpatients, and children with upper respiratory tract infection, bronchiolitis or pneumonia have tried to determine if co-infections have an impact on symptoms or illness outcome.", [["upper respiratory tract", "ANATOMY", 98, 121], ["upper respiratory tract infection", "DISEASE", 98, 131], ["bronchiolitis", "DISEASE", 133, 146], ["pneumonia", "DISEASE", 150, 159], ["illness", "DISEASE", 231, 238], ["outpatients", "ORGANISM", 55, 66], ["children", "ORGANISM", 84, 92], ["upper respiratory tract", "ORGANISM_SUBDIVISION", 98, 121], ["outpatients", "SPECIES", 55, 66], ["children", "SPECIES", 84, 92], ["Many studies", "TEST", 0, 12], ["upper respiratory tract infection", "PROBLEM", 98, 131], ["bronchiolitis", "PROBLEM", 133, 146], ["pneumonia", "PROBLEM", 150, 159], ["co-infections", "PROBLEM", 187, 200], ["symptoms", "PROBLEM", 219, 227], ["illness outcome", "PROBLEM", 231, 246], ["upper", "ANATOMY_MODIFIER", 98, 103], ["respiratory tract", "ANATOMY", 104, 121], ["infection", "OBSERVATION", 122, 131], ["bronchiolitis", "OBSERVATION", 133, 146], ["pneumonia", "OBSERVATION", 150, 159]]], ["Some studies have shown more fever, longer hospital stay, more progression to pneumonia, more hypoxia and more antibiotic use (Aberle et al., 2005, Calvo et al., 2008, Esposito et al., 2012, Franz et al., 2010, Paranhos-Baccala et al., 2008), while many others have shown no difference or sometimes a protective effect (Legg et al., 2005, Marguet et al., 2009, Martin et al., 2012, Papenburg et al., 2012, Renois et al., 2010).", [["fever", "DISEASE", 29, 34], ["pneumonia", "DISEASE", 78, 87], ["hypoxia", "DISEASE", 94, 101], ["Some studies", "TEST", 0, 12], ["fever", "PROBLEM", 29, 34], ["pneumonia", "PROBLEM", 78, 87], ["hypoxia", "PROBLEM", 94, 101], ["more", "OBSERVATION_MODIFIER", 24, 28], ["fever", "OBSERVATION", 29, 34], ["pneumonia", "OBSERVATION", 78, 87]]], ["Esper et al. determined the presence of a protective effect when copathogens with H1N1 influenza included rhinovirus and a worse outcome when the co-infection included other respiratory viruses (Esper et al., 2011).", [["influenza", "DISEASE", 87, 96], ["rhinovirus", "DISEASE", 106, 116], ["co-infection", "DISEASE", 146, 158], ["respiratory viruses", "DISEASE", 174, 193], ["H1N1 influenza", "ORGANISM", 82, 96], ["rhinovirus", "ORGANISM", 106, 116], ["H1N1 influenza", "SPECIES", 82, 96], ["copathogens", "PROBLEM", 65, 76], ["H1N1 influenza", "PROBLEM", 82, 96], ["rhinovirus", "PROBLEM", 106, 116], ["the co-infection", "PROBLEM", 142, 158], ["other respiratory viruses", "PROBLEM", 168, 193], ["respiratory viruses", "OBSERVATION", 174, 193]]], ["Another unresolved question about respiratory viral co-infections is whether they are random.", [["respiratory viral co-infections", "DISEASE", 34, 65], ["respiratory viral co-infections", "PROBLEM", 34, 65], ["viral co-infections", "OBSERVATION", 46, 65]]], ["Two studies have shown statistical correlation for associations between specific viruses but these associations were different from each other and a third study did not show any association (Brunstein et al., 2008, Peng et al., 2009, Tanner et al., 2012).", [["Two studies", "TEST", 0, 11], ["specific viruses", "PROBLEM", 72, 88], ["a third study", "TEST", 147, 160], ["viruses", "OBSERVATION", 81, 88]]], ["Multiplex respiratory virus assays will definitively help to elucidate the interpretation of co-infections, allowing more people to perform studies and accumulate data.", [["co-infections", "DISEASE", 93, 106], ["people", "ORGANISM", 122, 128], ["people", "SPECIES", 122, 128], ["Multiplex respiratory virus assays", "TEST", 0, 34], ["co-infections", "PROBLEM", 93, 106], ["studies", "TEST", 140, 147], ["respiratory virus", "OBSERVATION", 10, 27]]], ["However, it is possible that interpretation of those data necessitate quantitative results in order to really discriminate true co-infections from asymptomatic shedding.Infection controlThe availability of rapid diagnostic assays is essential to optimize the infection control team\u2019s efforts to reduce transmission of virulent or resistant pathogens in hospitals.", [["co-infections", "DISEASE", 128, 141], ["infection", "DISEASE", 259, 268], ["those data", "TEST", 47, 57], ["true co-infections", "PROBLEM", 123, 141], ["asymptomatic shedding", "PROBLEM", 147, 168], ["Infection control", "PROBLEM", 169, 186], ["rapid diagnostic assays", "TEST", 206, 229], ["the infection", "PROBLEM", 255, 268], ["virulent", "PROBLEM", 318, 326], ["resistant pathogens", "PROBLEM", 330, 349], ["co-infections", "OBSERVATION", 128, 141], ["infection", "OBSERVATION", 259, 268]]], ["Their usefulness is well illustrated by the widespread use of PCR for detection of vancomycin resistant enterococci, methicillin resistant staphylococcus aureus or Clostridium difficile and the subsequent guidance of infection control measures, especially patient cohorting.", [["vancomycin", "CHEMICAL", 83, 93], ["enterococci", "CHEMICAL", 104, 115], ["methicillin", "CHEMICAL", 117, 128], ["staphylococcus aureus", "DISEASE", 139, 160], ["Clostridium difficile", "DISEASE", 164, 185], ["infection", "DISEASE", 217, 226], ["vancomycin", "CHEMICAL", 83, 93], ["methicillin", "CHEMICAL", 117, 128], ["vancomycin", "SIMPLE_CHEMICAL", 83, 93], ["methicillin resistant staphylococcus aureus", "ORGANISM", 117, 160], ["Clostridium difficile", "ORGANISM", 164, 185], ["patient", "ORGANISM", 256, 263], ["staphylococcus aureus", "SPECIES", 139, 160], ["Clostridium difficile", "SPECIES", 164, 185], ["patient", "SPECIES", 256, 263], ["staphylococcus aureus", "SPECIES", 139, 160], ["Clostridium difficile", "SPECIES", 164, 185], ["PCR", "TEST", 62, 65], ["vancomycin resistant enterococci", "PROBLEM", 83, 115], ["methicillin resistant staphylococcus aureus", "PROBLEM", 117, 160], ["Clostridium difficile", "PROBLEM", 164, 185], ["infection control measures", "TREATMENT", 217, 243], ["Clostridium difficile", "OBSERVATION", 164, 185], ["infection", "OBSERVATION", 217, 226]]], ["It seems evident and intuitive that viral diagnostic assays, and more precisely multiplex PCR, could afford similar advantages.", [["viral diagnostic assays", "TEST", 36, 59], ["multiplex PCR", "TEST", 80, 93]]], ["A rapid and precise etiologic diagnosis could be valuable to reduce nosocomial respiratory viral infections.", [["respiratory", "ANATOMY", 79, 90], ["respiratory viral infections", "DISEASE", 79, 107], ["nosocomial respiratory viral infections", "PROBLEM", 68, 107], ["viral infections", "OBSERVATION", 91, 107]]], ["The benefits could even be more substantial in pediatric units (Mills et al., 2011, Posfay-Barbe et al., 2008, Zorc and Hall, 2010) where upper and lower respiratory tract infections are frequent, co-infections with two or more viruses not unusual, and patients less likely to comply with \u201crespiratory etiquette.\u201d", [["lower respiratory tract", "ANATOMY", 148, 171], ["respiratory tract infections", "DISEASE", 154, 182], ["co-infections", "DISEASE", 197, 210], ["upper", "ORGANISM_SUBDIVISION", 138, 143], ["lower", "ORGANISM", 148, 153], ["respiratory tract", "ORGANISM_SUBDIVISION", 154, 171], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 253, 261], ["upper and lower respiratory tract infections", "PROBLEM", 138, 182], ["co-infections", "PROBLEM", 197, 210], ["upper", "ANATOMY_MODIFIER", 138, 143], ["lower", "ANATOMY_MODIFIER", 148, 153], ["respiratory tract", "ANATOMY", 154, 171], ["infections", "OBSERVATION", 172, 182]]], ["However, most cohorting measures still currently rely on observation of clinical signs and symptoms instead of objective viral diagnostic data.", [["clinical signs", "TEST", 72, 86], ["symptoms", "PROBLEM", 91, 99], ["objective viral diagnostic data", "TEST", 111, 142]]], ["Although several authors (Gunson and Carman, 2011, L\u00e9tant et al., 2007, Templeton et al., 2004) have mentioned that performing multiplex PCR in an institution will be beneficial for infection control, no study has been aimed at demonstrating this hypothesis.", [["infection", "DISEASE", 182, 191], ["multiplex PCR", "TEST", 127, 140], ["infection control", "TREATMENT", 182, 199], ["study", "TEST", 204, 209], ["this hypothesis", "PROBLEM", 242, 257]]], ["Also, even if a strategy of immediate testing and cohorting is preferred, it is very difficult and challenging for the clinical microbiology laboratory to accommodate.", [["immediate testing", "TEST", 28, 45]]], ["For cost-effective reasons, laboratories often have to batch specimens and consequently perform the technique only once or twice a day.", [["specimens", "ANATOMY", 61, 70], ["batch specimens", "TEST", 55, 70], ["the technique", "TREATMENT", 96, 109]]], ["This results in a turnaround time significantly longer than one needed for the implementation of infection control measures in a timely fashion.Public healthRecent outbreaks of severe acute respiratory syndromes including severe acute respiratory syndrome (SARS) HCoV, avian influenza H5N1 and pandemic influenza H1N1 have highlighted the necessity of effective respiratory virus surveillance.", [["respiratory", "ANATOMY", 190, 201], ["infection", "DISEASE", 97, 106], ["acute respiratory syndromes", "DISEASE", 184, 211], ["acute respiratory syndrome", "DISEASE", 229, 255], ["SARS", "DISEASE", 257, 261], ["influenza H5N1", "DISEASE", 275, 289], ["influenza H1N1", "DISEASE", 303, 317], ["avian influenza H5N1", "ORGANISM", 269, 289], ["pandemic influenza H1N1", "ORGANISM", 294, 317], ["avian influenza H5N1", "SPECIES", 269, 289], ["pandemic influenza H1N1", "SPECIES", 294, 317], ["HCoV", "SPECIES", 263, 267], ["infection control measures", "TREATMENT", 97, 123], ["severe acute respiratory syndromes", "PROBLEM", 177, 211], ["severe acute respiratory syndrome", "PROBLEM", 222, 255], ["SARS) HCoV", "PROBLEM", 257, 267], ["avian influenza H5N1", "PROBLEM", 269, 289], ["pandemic influenza H1N1", "PROBLEM", 294, 317], ["effective respiratory virus surveillance", "TREATMENT", 352, 392], ["infection", "OBSERVATION", 97, 106], ["severe", "OBSERVATION_MODIFIER", 177, 183], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["respiratory syndromes", "OBSERVATION", 190, 211], ["severe", "OBSERVATION_MODIFIER", 222, 228], ["acute", "OBSERVATION_MODIFIER", 229, 234], ["respiratory syndrome", "OBSERVATION", 235, 255], ["respiratory virus", "OBSERVATION", 362, 379]]], ["As human population increases, more contacts with animals are encountered, urbanization is rapidly evolving in developing countries and risks of pandemic are significant.", [["human", "ORGANISM", 3, 8], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["pandemic", "PROBLEM", 145, 153]]], ["Many public health institutions around the world have developed a more structured network of respiratory virus surveillance, which often includes sentinel hospitals to report their detection rates of various viruses.", [["respiratory virus surveillance", "TEST", 93, 123], ["various viruses", "PROBLEM", 200, 215], ["respiratory virus", "OBSERVATION", 93, 110], ["various viruses", "OBSERVATION", 200, 215]]], ["For many years, surveillance networks focused on influenza, but discovery of SARS HCoV reinforced the potential of any respiratory virus to emerge and cause severe diseases.", [["influenza", "DISEASE", 49, 58], ["SARS", "DISEASE", 77, 81], ["SARS HCoV", "ORGANISM", 77, 86], ["HCoV", "SPECIES", 82, 86], ["surveillance networks", "TEST", 16, 37], ["influenza", "PROBLEM", 49, 58], ["SARS HCoV", "PROBLEM", 77, 86], ["any respiratory virus", "PROBLEM", 115, 136], ["severe diseases", "PROBLEM", 157, 172], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["diseases", "OBSERVATION", 164, 172]]], ["Even rhinovirus has been associated with severe outbreaks of influenza-like illness among institutional outbreaks (Longtin et al., 2010).", [["influenza-like illness", "DISEASE", 61, 83], ["rhinovirus", "ORGANISM", 5, 15], ["rhinovirus", "PROBLEM", 5, 15], ["influenza", "PROBLEM", 61, 70], ["rhinovirus", "OBSERVATION", 5, 15], ["associated with", "UNCERTAINTY", 25, 40], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["outbreaks", "OBSERVATION_MODIFIER", 48, 57], ["influenza", "OBSERVATION", 61, 70]]], ["The economic impact of respiratory virus outbreaks has been modeled, highlighting another role of respiratory virus surveillance (Achonu et al., 2005, Halasa et al., 2005).", [["respiratory virus outbreaks", "DISEASE", 23, 50], ["respiratory virus outbreaks", "PROBLEM", 23, 50], ["economic", "OBSERVATION_MODIFIER", 4, 12], ["respiratory virus", "OBSERVATION", 23, 40]]], ["The extended use of multiplex respiratory assays in clinical laboratories will improve surveillance efficacy and will procure benefits to the general community (Fox, 2007, Wong et al., 2009).Immunocompromised patients ::: Special population managementThe major impact of respiratory virus infections in adult and pediatric patients with hematologic malignancies, hematopoietic stem cell transplantation and solid organ transplantation has been recognized over the last decade.", [["hematologic malignancies", "ANATOMY", 337, 361], ["hematopoietic stem cell", "ANATOMY", 363, 386], ["solid organ", "ANATOMY", 407, 418], ["respiratory virus infections", "DISEASE", 271, 299], ["hematologic malignancies", "DISEASE", 337, 361], ["patients", "ORGANISM", 209, 217], ["respiratory virus", "ORGANISM", 271, 288], ["patients", "ORGANISM", 323, 331], ["hematologic malignancies", "CANCER", 337, 361], ["hematopoietic stem cell", "CELL", 363, 386], ["organ", "ORGAN", 413, 418], ["patients", "SPECIES", 209, 217], ["patients", "SPECIES", 323, 331], ["multiplex respiratory assays", "TEST", 20, 48], ["clinical laboratories", "TEST", 52, 73], ["Special population management", "TREATMENT", 222, 251], ["respiratory virus infections", "PROBLEM", 271, 299], ["hematologic malignancies", "PROBLEM", 337, 361], ["hematopoietic stem cell transplantation", "TREATMENT", 363, 402], ["solid organ transplantation", "TREATMENT", 407, 434], ["respiratory virus infections", "OBSERVATION", 271, 299], ["hematologic malignancies", "OBSERVATION", 337, 361], ["hematopoietic stem cell transplantation", "OBSERVATION", 363, 402], ["solid organ transplantation", "OBSERVATION", 407, 434]]], ["In the most immunocompromised populations, respiratory viruses have a high rate of progression to pneumonia (20-40%) and among those patients, mortality ranging from 30% to 50%.", [["respiratory viruses", "DISEASE", 43, 62], ["pneumonia", "DISEASE", 98, 107], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["respiratory viruses", "PROBLEM", 43, 62], ["pneumonia", "PROBLEM", 98, 107], ["mortality", "TEST", 143, 152], ["most", "OBSERVATION_MODIFIER", 7, 11], ["immunocompromised", "OBSERVATION_MODIFIER", 12, 29], ["respiratory viruses", "OBSERVATION", 43, 62], ["high", "OBSERVATION_MODIFIER", 70, 74], ["progression", "OBSERVATION_MODIFIER", 83, 94], ["pneumonia", "OBSERVATION", 98, 107]]], ["It is also possible that respiratory virus infections that are unrecognized because of benign symptoms have an impact on long-term pulmonary function by modulating lung immunologic defenses.", [["pulmonary", "ANATOMY", 131, 140], ["lung", "ANATOMY", 164, 168], ["respiratory virus infections", "DISEASE", 25, 53], ["respiratory virus", "ORGANISM", 25, 42], ["pulmonary", "ORGAN", 131, 140], ["lung", "ORGAN", 164, 168], ["respiratory virus infections", "PROBLEM", 25, 53], ["benign symptoms", "PROBLEM", 87, 102], ["modulating lung immunologic defenses", "PROBLEM", 153, 189], ["is also possible", "UNCERTAINTY", 3, 19], ["respiratory virus", "OBSERVATION", 25, 42], ["long-term", "OBSERVATION_MODIFIER", 121, 130], ["pulmonary", "ANATOMY", 131, 140], ["lung", "ANATOMY", 164, 168], ["immunologic defenses", "OBSERVATION", 169, 189]]], ["Adenovirus infections in the transplant setting have the potential to replicate in most organs causing hepatitis, pneumonitis, nephritis, colitis, encephalitis, and death.", [["organs", "ANATOMY", 88, 94], ["Adenovirus infections", "DISEASE", 0, 21], ["hepatitis", "DISEASE", 103, 112], ["pneumonitis", "DISEASE", 114, 125], ["nephritis", "DISEASE", 127, 136], ["colitis", "DISEASE", 138, 145], ["encephalitis", "DISEASE", 147, 159], ["death", "DISEASE", 165, 170], ["Adenovirus", "ORGANISM", 0, 10], ["organs", "ORGAN", 88, 94], ["colitis", "PATHOLOGICAL_FORMATION", 138, 145], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus infections", "PROBLEM", 0, 21], ["hepatitis", "PROBLEM", 103, 112], ["pneumonitis", "PROBLEM", 114, 125], ["nephritis", "PROBLEM", 127, 136], ["colitis", "PROBLEM", 138, 145], ["encephalitis", "PROBLEM", 147, 159], ["death", "PROBLEM", 165, 170], ["infections", "OBSERVATION", 11, 21], ["hepatitis", "OBSERVATION", 103, 112], ["pneumonitis", "OBSERVATION", 114, 125], ["nephritis", "OBSERVATION", 127, 136], ["colitis", "OBSERVATION", 138, 145], ["encephalitis", "OBSERVATION", 147, 159]]], ["Studies have looked specifically at some viruses that would not have been detected by conventional virology (i.e., rhinovirus, coronavirus, human metapneumovirus), describing the possible complications associated with those viruses.", [["rhinovirus, coronavirus, human metapneumovirus", "DISEASE", 115, 161], ["rhinovirus", "ORGANISM", 115, 125], ["coronavirus", "ORGANISM", 127, 138], ["human", "ORGANISM", 140, 145], ["metapneumovirus", "ORGANISM", 146, 161], ["coronavirus", "SPECIES", 127, 138], ["human", "SPECIES", 140, 145], ["metapneumovirus", "SPECIES", 146, 161], ["human metapneumovirus", "SPECIES", 140, 161], ["Studies", "TEST", 0, 7], ["some viruses", "PROBLEM", 36, 48], ["rhinovirus", "PROBLEM", 115, 125], ["coronavirus", "PROBLEM", 127, 138], ["human metapneumovirus", "PROBLEM", 140, 161], ["those viruses", "PROBLEM", 218, 231]]], ["Because the number of respiratory viruses impacting the outcome of transplantation has been consistently increasing, screening for multiple respiratory viruses is now considered the best practice.", [["respiratory viruses", "DISEASE", 22, 41], ["respiratory viruses", "DISEASE", 140, 159], ["respiratory viruses", "PROBLEM", 22, 41], ["transplantation", "TREATMENT", 67, 82], ["screening", "TEST", 117, 126], ["multiple respiratory viruses", "PROBLEM", 131, 159], ["respiratory viruses", "OBSERVATION", 22, 41], ["transplantation", "OBSERVATION", 67, 82], ["increasing", "OBSERVATION_MODIFIER", 105, 115], ["respiratory viruses", "OBSERVATION", 140, 159]]], ["Laboratory developed real-time PCR assays and multiplex respiratory virus assays have been shown to be superior to conventional virology in the setting of hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT) (Kuypers et al., 2009, Lee et al., 2012, van Elden et al., 2002, van Kraaij et al., 2005, Weinberg et al., 2002).", [["hematopoietic stem cell", "ANATOMY", 155, 178], ["HSCT", "ANATOMY", 196, 200], ["solid organ", "ANATOMY", 205, 216], ["hematopoietic stem cell", "CELL", 155, 178], ["organ", "ORGAN", 211, 216], ["respiratory virus", "SPECIES", 56, 73], ["PCR assays", "TEST", 31, 41], ["multiplex respiratory virus assays", "TEST", 46, 80], ["hematopoietic stem cell transplantation", "TREATMENT", 155, 194], ["solid organ transplantation", "TREATMENT", 205, 232], ["hematopoietic stem cell transplantation", "OBSERVATION", 155, 194]]], ["Kuypers et al. showed that multiplex real-time PCR was two times more sensitive than culture and over four times more sensitive than direct immunofluorescence in HSCT patients.", [["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["multiplex real-time PCR", "TEST", 27, 50], ["culture", "TEST", 85, 92], ["direct immunofluorescence", "TEST", 133, 158]]], ["Patients that were positive only by real-time PCR had lower viral loads.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["real-time PCR", "TEST", 36, 49], ["lower viral loads", "PROBLEM", 54, 71], ["viral loads", "OBSERVATION", 60, 71]]], ["No studies have looked yet at the impact of detecting low viral loads in the transplant setting, but the potential to reactivate respiratory viruses in the context of increasing immunosuppression for graft versus host disease or acute rejection is well known.", [["graft", "ANATOMY", 200, 205], ["respiratory viruses", "DISEASE", 129, 148], ["graft versus host disease", "DISEASE", 200, 225], ["graft", "TISSUE", 200, 205], ["studies", "TEST", 3, 10], ["low viral loads", "PROBLEM", 54, 69], ["respiratory viruses", "PROBLEM", 129, 148], ["increasing immunosuppression", "TREATMENT", 167, 195], ["graft versus host disease", "PROBLEM", 200, 225], ["acute rejection", "PROBLEM", 229, 244], ["viral loads", "OBSERVATION", 58, 69], ["transplant", "ANATOMY", 77, 87], ["respiratory viruses", "OBSERVATION", 129, 148], ["increasing", "OBSERVATION_MODIFIER", 167, 177], ["immunosuppression", "OBSERVATION", 178, 195], ["graft versus host disease", "OBSERVATION", 200, 225], ["acute", "OBSERVATION_MODIFIER", 229, 234], ["rejection", "OBSERVATION", 235, 244]]], ["Hammond et al. also described the superiority of a multiplex respiratory virus assay for detection of respiratory viruses among HSCT and SOT patients.", [["respiratory viruses", "DISEASE", 102, 121], ["HSCT", "CANCER", 128, 132], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["a multiplex respiratory virus assay", "TEST", 49, 84], ["respiratory viruses", "PROBLEM", 102, 121], ["respiratory viruses", "OBSERVATION", 102, 121]]], ["Two times more viruses were detected by a multiplex real-time PCR assay (Idaho FilmArray RVP) compared to conventional assays, with the majority of the viruses that were not detected by conventional virology being rhinovirus, enterovirus, human metapneumovirus, and coronavirus (Hammond et al., 2012).", [["enterovirus, human metapneumovirus, and coronavirus", "DISEASE", 226, 277], ["rhinovirus", "ORGANISM", 214, 224], ["enterovirus", "ORGANISM", 226, 237], ["human", "ORGANISM", 239, 244], ["metapneumovirus", "ORGANISM", 245, 260], ["human", "SPECIES", 239, 244], ["metapneumovirus", "SPECIES", 245, 260], ["coronavirus", "SPECIES", 266, 277], ["human metapneumovirus", "SPECIES", 239, 260], ["Two times more viruses", "PROBLEM", 0, 22], ["Idaho FilmArray RVP", "TEST", 73, 92], ["conventional assays", "TEST", 106, 125], ["the viruses", "PROBLEM", 148, 159], ["rhinovirus", "PROBLEM", 214, 224], ["enterovirus", "PROBLEM", 226, 237], ["human metapneumovirus", "PROBLEM", 239, 260], ["viruses", "OBSERVATION", 15, 22], ["viruses", "OBSERVATION", 152, 159]]], ["Similar results were described by Murali et al. (Murali et al., 2009) using the MultiCode-Plx Respiratory Panel which detected three times more viruses in patients with hematologic malignancies than did conventional methods and by Schnell et al. (Schnell et al., 2012) using the Respifinder19, which detected over 6 times more virus in immunocompromised patients with acute respiratory failure than did direct immunofluorescence.", [["hematologic malignancies", "ANATOMY", 169, 193], ["respiratory", "ANATOMY", 374, 385], ["hematologic malignancies", "DISEASE", 169, 193], ["acute respiratory failure", "DISEASE", 368, 393], ["patients", "ORGANISM", 155, 163], ["hematologic malignancies", "CANCER", 169, 193], ["patients", "ORGANISM", 354, 362], ["patients", "SPECIES", 155, 163], ["patients", "SPECIES", 354, 362], ["Respiratory Panel", "TEST", 94, 111], ["hematologic malignancies", "PROBLEM", 169, 193], ["the Respifinder19", "TREATMENT", 275, 292], ["acute respiratory failure", "PROBLEM", 368, 393], ["acute", "OBSERVATION_MODIFIER", 368, 373], ["respiratory failure", "OBSERVATION", 374, 393]]], ["Hayden et al. (Hayden et al., 2012) compared 2 multiplex respiratory virus assays with real-time PCR in immunocompromised children.", [["children", "ORGANISM", 122, 130], ["children", "SPECIES", 122, 130], ["multiplex respiratory virus assays", "TEST", 47, 81]]], ["FilmArray RVP and the Resplex II Panel v2.0 had similar performance in immunocompromised children under 2 years-old but FilmArray RVP had a better performance than the Resplex in older children.", [["children", "ORGANISM", 89, 97], ["children", "ORGANISM", 185, 193], ["children", "SPECIES", 89, 97], ["children", "SPECIES", 185, 193], ["FilmArray RVP", "TEST", 0, 13], ["the Resplex II Panel", "TEST", 18, 38], ["FilmArray RVP", "TEST", 120, 133]]], ["This can be explained by lower viral load shedding in older patients and lower sensitivity of the Resplex assay.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["lower viral load shedding", "PROBLEM", 25, 50], ["the Resplex assay", "TEST", 94, 111], ["lower", "OBSERVATION_MODIFIER", 25, 30], ["viral load", "OBSERVATION", 31, 41]]], ["In the same study, the sensitivity of the FilmArray RVP was comparable to real-time PCR while the Resplex was significantly less sensitive than real-time PCR.", [["the FilmArray RVP", "TEST", 38, 55], ["real-time PCR", "TEST", 74, 87], ["the Resplex", "TEST", 94, 105]]], ["Babady et al.(Babady et al., 2012) compared the FilmArray RVP and the xTAG RVP Fast with conventional methods in a pediatric cancer hospital.", [["cancer", "ANATOMY", 125, 131], ["cancer", "DISEASE", 125, 131], ["cancer", "CANCER", 125, 131], ["the FilmArray RVP", "TEST", 44, 61], ["cancer", "OBSERVATION", 125, 131]]], ["Both multiplex assays detected 2 times more viruses than conventional methods and the FilmArray RVP had a significantly higher sensitivity than the xTAG RVP Fast even after resolution of discordant results.", [["Both multiplex assays", "TEST", 0, 21], ["conventional methods", "TEST", 57, 77], ["the FilmArray RVP", "TEST", 82, 99], ["the xTAG RVP", "TEST", 144, 156]]], ["Viruses detected only by qualitative multiplex assays compared to conventional methods probably have low viral loads, as shown by quantitative real-time PCR analyses in Kuypers et al. (Kuypers et al., 2009).", [["Viruses", "PROBLEM", 0, 7], ["qualitative multiplex assays", "TEST", 25, 53], ["conventional methods", "TEST", 66, 86], ["low viral loads", "PROBLEM", 101, 116], ["PCR analyses", "TEST", 153, 165], ["low", "OBSERVATION_MODIFIER", 101, 104], ["viral loads", "OBSERVATION", 105, 116]]], ["However, interpretation of a positive qualitative multiplex assay result can be more difficult than interpretation of a quantitative result.", [["a positive qualitative multiplex assay result", "PROBLEM", 27, 72]]], ["Although correlations between viral loads and symptoms or clinical outcome have been performed, more studies are needed to interpret the significance of high and low viral loads (Campbell et al., 2010, Milano et al., 2010, Peck et al., 2007).", [["viral loads", "TEST", 30, 41], ["symptoms", "PROBLEM", 46, 54], ["high and low viral loads", "PROBLEM", 153, 177]]], ["While most studies looking at the clinical impact of respiratory viruses in HSCT patients were done using laboratory-developed real-time PCR, it is likely that similar studies using commercial multiplex assays would have similar results.", [["respiratory viruses", "DISEASE", 53, 72], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["respiratory viruses", "PROBLEM", 53, 72], ["commercial multiplex assays", "TEST", 182, 209], ["respiratory", "ANATOMY", 53, 64], ["viruses", "OBSERVATION", 65, 72]]], ["In lung transplant patients, the XTAG RVP assay was used to evaluate the clinical impact of community-acquired respiratory viruses.", [["lung transplant", "ANATOMY", 3, 18], ["respiratory viruses", "DISEASE", 111, 130], ["lung", "ORGAN", 3, 7], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["the XTAG RVP assay", "TEST", 29, 47], ["community-acquired respiratory viruses", "PROBLEM", 92, 130], ["lung", "ANATOMY", 3, 7], ["transplant", "OBSERVATION", 8, 18], ["respiratory viruses", "OBSERVATION", 111, 130]]], ["Kumar et al. (Kumar et al., 2010) described an increased risk of biopsy proven acute rejection reaching 33.3% within 3 months following a respiratory virus infection compared to 6.7% in the group without infection.", [["respiratory virus infection", "DISEASE", 138, 165], ["infection", "DISEASE", 204, 213], ["biopsy", "TEST", 65, 71], ["acute rejection", "PROBLEM", 79, 94], ["a respiratory virus infection", "PROBLEM", 136, 165], ["infection", "PROBLEM", 204, 213], ["biopsy", "OBSERVATION", 65, 71], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["rejection", "OBSERVATION", 85, 94], ["respiratory", "ANATOMY", 138, 149], ["virus", "OBSERVATION", 150, 155], ["without", "UNCERTAINTY", 196, 203], ["infection", "OBSERVATION", 204, 213]]], ["Using multiplex assays in a larger scale will help to understand the role that these viruses have in the transplant setting.Immunocompromised patients ::: Special population managementIt is important to note that in immunocompromised patients, not only influenza is treatable but RSV, adenovirus and possibly parainfluenza and human metapneumovirus as well.", [["influenza", "DISEASE", 253, 262], ["parainfluenza and human metapneumovirus", "DISEASE", 309, 348], ["patients", "ORGANISM", 142, 150], ["patients", "ORGANISM", 234, 242], ["RSV", "ORGANISM", 280, 283], ["adenovirus", "ORGANISM", 285, 295], ["parainfluenza", "ORGANISM", 309, 322], ["human", "ORGANISM", 327, 332], ["metapneumovirus", "ORGANISM", 333, 348], ["patients", "SPECIES", 142, 150], ["patients", "SPECIES", 234, 242], ["parainfluenza", "SPECIES", 309, 322], ["human", "SPECIES", 327, 332], ["metapneumovirus", "SPECIES", 333, 348], ["RSV", "SPECIES", 280, 283], ["adenovirus", "SPECIES", 285, 295], ["human metapneumovirus", "SPECIES", 327, 348], ["multiplex assays", "TEST", 6, 22], ["a larger scale", "TREATMENT", 26, 40], ["these viruses", "PROBLEM", 79, 92], ["Special population management", "TREATMENT", 155, 184], ["influenza", "PROBLEM", 253, 262], ["RSV", "PROBLEM", 280, 283], ["adenovirus", "PROBLEM", 285, 295], ["parainfluenza", "PROBLEM", 309, 322], ["human metapneumovirus", "PROBLEM", 327, 348], ["viruses", "OBSERVATION", 85, 92], ["possibly", "UNCERTAINTY", 300, 308], ["parainfluenza", "OBSERVATION", 309, 322], ["metapneumovirus", "OBSERVATION", 333, 348]]], ["Some studies have suggested that treatment of these viruses with ribavirin, cidofovir, specific immunoglobulins, or new drugs coming up the pipeline (DAS 181, CMX001, ALN-RSV01) may have positive outcomes.", [["ribavirin", "CHEMICAL", 65, 74], ["cidofovir", "CHEMICAL", 76, 85], ["ALN-RSV01", "CHEMICAL", 167, 176], ["ribavirin", "CHEMICAL", 65, 74], ["cidofovir", "CHEMICAL", 76, 85], ["ALN-RSV01", "CHEMICAL", 167, 176], ["ribavirin", "SIMPLE_CHEMICAL", 65, 74], ["cidofovir", "SIMPLE_CHEMICAL", 76, 85], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 96, 111], ["Some studies", "TEST", 0, 12], ["these viruses", "PROBLEM", 46, 59], ["ribavirin", "TREATMENT", 65, 74], ["cidofovir", "TREATMENT", 76, 85], ["specific immunoglobulins", "TREATMENT", 87, 111], ["new drugs", "TREATMENT", 116, 125], ["ALN-RSV01", "TREATMENT", 167, 176], ["viruses", "OBSERVATION", 52, 59]]], ["In immunocompromised patients infected with untreatable viruses, immunosuppression reduction can have a significant impact.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["untreatable viruses", "PROBLEM", 44, 63], ["immunosuppression reduction", "TREATMENT", 65, 92], ["immunocompromised", "OBSERVATION", 3, 20], ["infected", "OBSERVATION_MODIFIER", 30, 38], ["untreatable", "OBSERVATION_MODIFIER", 44, 55], ["viruses", "OBSERVATION", 56, 63], ["significant", "OBSERVATION_MODIFIER", 104, 115], ["impact", "OBSERVATION_MODIFIER", 116, 122]]], ["Use of antiviral drugs in immunocompromised patients is often another reason highlighting the necessity of rapid diagnosis.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["antiviral drugs", "TREATMENT", 7, 22]]], ["The FilmArray respiratory virus panel has the advantage of a short turnaround time (1 hour), similar to direct immunofluorescence, with increased sensitivity and therefore may be particularly useful in an immunocompromised population, although the results are qualitative.", [["FilmArray respiratory virus", "SPECIES", 4, 31], ["The FilmArray respiratory virus panel", "TEST", 0, 37], ["direct immunofluorescence", "TEST", 104, 129], ["increased sensitivity", "PROBLEM", 136, 157], ["an immunocompromised population", "PROBLEM", 202, 233], ["immunocompromised", "OBSERVATION", 205, 222]]], ["The impact of using expensive multiplex molecular assays in immunocompromised patients has not been evaluated in comparative studies to look at cost-effectiveness, morbidity, and mortality.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["expensive multiplex molecular assays", "TEST", 20, 56], ["comparative studies", "TEST", 113, 132], ["morbidity", "PROBLEM", 164, 173]]], ["Nevertheless, most transplant centers are already using multiplex assays because of the significant impact of respiratory virus infection in this population.Immunocompromised patients ::: Special population managementAnother aspect of the cost-effectiveness of respiratory virus detection is related to management of febrile neutropenia.", [["respiratory virus infection", "DISEASE", 110, 137], ["febrile neutropenia", "DISEASE", 317, 336], ["respiratory virus", "ORGANISM", 110, 127], ["patients", "ORGANISM", 175, 183], ["respiratory virus", "ORGANISM", 261, 278], ["patients", "SPECIES", 175, 183], ["multiplex assays", "TEST", 56, 72], ["respiratory virus infection", "PROBLEM", 110, 137], ["Special population management", "TREATMENT", 188, 217], ["respiratory virus detection", "PROBLEM", 261, 288], ["febrile neutropenia", "PROBLEM", 317, 336], ["significant", "OBSERVATION_MODIFIER", 88, 99], ["respiratory virus infection", "OBSERVATION", 110, 137], ["respiratory virus", "OBSERVATION", 261, 278], ["febrile", "OBSERVATION_MODIFIER", 317, 324], ["neutropenia", "OBSERVATION", 325, 336]]], ["Respiratory viruses are frequently identified in hematological patients with or without HSCT presenting with febrile neutropenia (Hakim et al., 2009, Koskenvuo et al., 2008, Lindblom et al., 2010, \u00d6hrmalm et al., 2012, Suryadevara et al., 2012, Torres et al., 2012).", [["hematological", "ANATOMY", 49, 62], ["Respiratory viruses", "DISEASE", 0, 19], ["febrile neutropenia", "DISEASE", 109, 128], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["Respiratory viruses", "PROBLEM", 0, 19], ["febrile neutropenia", "PROBLEM", 109, 128], ["viruses", "OBSERVATION", 12, 19]]], ["It is possible that detection of respiratory viruses by means of multiplex assays would change the management of less immunocompromised patients, leading to outpatient management, reduced antimicrobial use or earlier discharge as shown by Torres et al. (Torres et al., 2012).", [["respiratory viruses", "DISEASE", 33, 52], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["respiratory viruses", "PROBLEM", 33, 52], ["multiplex assays", "TEST", 65, 81], ["the management", "TREATMENT", 95, 109], ["outpatient management", "TREATMENT", 157, 178], ["respiratory viruses", "OBSERVATION", 33, 52]]], ["Screening for respiratory viruses with multiplex assays in asymptomatic pre and post-transplantation patients is another unresolved question that can impact cost of care and outcome.", [["respiratory viruses", "DISEASE", 14, 33], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["Screening", "TEST", 0, 9], ["respiratory viruses", "PROBLEM", 14, 33], ["multiplex assays", "TEST", 39, 55]]], ["A study by Peck et al. (Peck et al., 2004) suggested that delaying transplantation was a better option when symptomatic RSV upper respiratory tract infection was present but no clear data were available on asymptomatic RSV or even symptomatic, more benign viruses such as rhinovirus or coronavirus.Immunocompromised patients ::: Special population managementMany reports have highlighted the frequency of respiratory virus outbreaks in hematologic and transplant settings.", [["upper respiratory tract", "ANATOMY", 124, 147], ["hematologic", "ANATOMY", 436, 447], ["RSV upper respiratory tract infection", "DISEASE", 120, 157], ["rhinovirus or coronavirus", "DISEASE", 272, 297], ["respiratory virus outbreaks", "DISEASE", 405, 432], ["RSV", "ORGANISM", 120, 123], ["upper", "ORGANISM_SUBDIVISION", 124, 129], ["respiratory tract", "ORGANISM_SUBDIVISION", 130, 147], ["RSV", "ORGANISM", 219, 222], ["rhinovirus", "ORGANISM", 272, 282], ["coronavirus", "ORGANISM", 286, 297], ["patients", "ORGANISM", 316, 324], ["respiratory virus", "ORGANISM", 405, 422], ["hematologic", "CANCER", 436, 447], ["patients", "SPECIES", 316, 324], ["RSV", "SPECIES", 120, 123], ["RSV", "SPECIES", 219, 222], ["A study", "TEST", 0, 7], ["delaying transplantation", "TREATMENT", 58, 82], ["symptomatic RSV upper respiratory tract infection", "PROBLEM", 108, 157], ["asymptomatic RSV", "PROBLEM", 206, 222], ["benign viruses", "PROBLEM", 249, 263], ["rhinovirus", "PROBLEM", 272, 282], ["coronavirus", "PROBLEM", 286, 297], ["Special population management", "TREATMENT", 329, 358], ["respiratory virus outbreaks", "PROBLEM", 405, 432], ["transplant settings", "TREATMENT", 452, 471], ["upper", "ANATOMY_MODIFIER", 124, 129], ["respiratory tract", "ANATOMY", 130, 147], ["infection", "OBSERVATION", 148, 157], ["benign", "OBSERVATION_MODIFIER", 249, 255], ["viruses", "OBSERVATION", 256, 263], ["rhinovirus", "OBSERVATION", 272, 282], ["respiratory virus", "OBSERVATION", 405, 422]]], ["Detection of respiratory viruses in HSCT patients can prolong hospitalization for days and even weeks.", [["respiratory viruses", "DISEASE", 13, 32], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["respiratory viruses", "PROBLEM", 13, 32], ["respiratory viruses", "OBSERVATION", 13, 32]]], ["One of the biggest impacts that multiplex assays may have in the management of immunocompromised patients will concern infection control practices.", [["infection", "DISEASE", 119, 128], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["multiplex assays", "TEST", 32, 48], ["immunocompromised patients", "PROBLEM", 79, 105], ["infection control practices", "TREATMENT", 119, 146], ["biggest", "OBSERVATION_MODIFIER", 11, 18], ["immunocompromised", "OBSERVATION", 79, 96]]], ["However, because of prolonged shedding with very low viral loads in asymptomatic patients, many patients will require long term isolation.", [["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 96, 104], ["prolonged shedding", "PROBLEM", 20, 38], ["very low viral loads", "PROBLEM", 44, 64], ["long term isolation", "TREATMENT", 118, 137], ["long term", "OBSERVATION_MODIFIER", 118, 127]]], ["Unnecessary isolation has been associated with higher cost, lower quality of life and reduced quality of care (Abad et al., 2010, Morgan et al., 2009).", [["Unnecessary isolation", "TREATMENT", 0, 21], ["higher", "OBSERVATION_MODIFIER", 47, 53], ["cost", "OBSERVATION", 54, 58]]], ["Ferguson et al. have suggested using a clinical scoring system to screen and to apply infection control procedures (Ferguson et al., 2011).", [["infection", "DISEASE", 86, 95], ["a clinical scoring system", "TEST", 37, 62], ["infection control procedures", "TREATMENT", 86, 114]]], ["Clearly, the best infection control practice with long term asymptomatic shedders has not been determined yet and molecular epidemiology might be helpful in resolving that issue.Cystic fibrosis ::: Special population managementFor many years, viral respiratory tract infections have been recognized as a cause of pulmonary exacerbations and decreased lung functions among cystic fibrosis (CF) patients.(Armstrong et al., 1998, Collinson et al., 1996, Ramsey Bw, 1989, van Ewijk et al., 2008, Wang et al., 1984) Respiratory viruses are also considered predisposing factors for secondary bacterial infection (Collinson et al., 1996, Johansen and Hoiby, 1992, Petersen et al., 1981) and hospitalization (Armstrong et al., 1998, Wang et al., 1984).", [["Cystic", "ANATOMY", 178, 184], ["respiratory tract", "ANATOMY", 249, 266], ["pulmonary", "ANATOMY", 313, 322], ["lung", "ANATOMY", 351, 355], ["infection", "DISEASE", 18, 27], ["Cystic fibrosis", "DISEASE", 178, 193], ["viral respiratory tract infections", "DISEASE", 243, 277], ["pulmonary exacerbations", "DISEASE", 313, 336], ["cystic fibrosis", "DISEASE", 372, 387], ["CF", "DISEASE", 389, 391], ["Respiratory viruses", "DISEASE", 511, 530], ["bacterial infection", "DISEASE", 586, 605], ["Cystic", "ORGAN", 178, 184], ["viral respiratory tract", "ORGANISM", 243, 266], ["pulmonary", "ORGAN", 313, 322], ["lung", "ORGAN", 351, 355], ["cystic fibrosis", "PATHOLOGICAL_FORMATION", 372, 387], ["patients", "ORGANISM", 393, 401], ["patients", "SPECIES", 393, 401], ["long term asymptomatic shedders", "PROBLEM", 50, 81], ["Cystic fibrosis", "PROBLEM", 178, 193], ["Special population management", "TREATMENT", 198, 227], ["viral respiratory tract infections", "PROBLEM", 243, 277], ["pulmonary exacerbations", "PROBLEM", 313, 336], ["decreased lung functions", "PROBLEM", 341, 365], ["cystic fibrosis", "PROBLEM", 372, 387], ["Respiratory viruses", "PROBLEM", 511, 530], ["secondary bacterial infection", "PROBLEM", 576, 605], ["fibrosis", "OBSERVATION", 185, 193], ["respiratory tract", "ANATOMY", 249, 266], ["pulmonary", "ANATOMY", 313, 322], ["exacerbations", "OBSERVATION", 323, 336], ["decreased", "OBSERVATION_MODIFIER", 341, 350], ["lung", "ANATOMY", 351, 355], ["cystic", "OBSERVATION_MODIFIER", 372, 378], ["fibrosis", "OBSERVATION", 379, 387], ["Respiratory", "ANATOMY", 511, 522], ["viruses", "OBSERVATION", 523, 530], ["bacterial", "OBSERVATION_MODIFIER", 586, 595], ["infection", "OBSERVATION", 596, 605]]], ["Before the advent of molecular assays, viral diagnostic tests in CF populations had poor detection rates.", [["molecular assays", "TEST", 21, 37], ["viral diagnostic tests", "TEST", 39, 61]]], ["This was explained by factors intrinsic to CF specimens, such as their mucoid nature and the bacterial or fungal overgrowth that inhibited or compromised virus recovery.", [["CF specimens", "ANATOMY", 43, 55], ["CF specimens", "TEST", 43, 55], ["the bacterial or fungal overgrowth", "PROBLEM", 89, 123], ["compromised virus recovery", "PROBLEM", 142, 168], ["bacterial", "OBSERVATION_MODIFIER", 93, 102], ["fungal overgrowth", "OBSERVATION", 106, 123]]], ["Other factors were inherent limits of the techniques used: poor sensitivity of serologic assays, inability to recover noncultivable or newly identified viruses such as rhinovirus, coronavirus and metapneumovirus.", [["rhinovirus, coronavirus and metapneumovirus", "DISEASE", 168, 211], ["rhinovirus", "ORGANISM", 168, 178], ["coronavirus", "ORGANISM", 180, 191], ["metapneumovirus", "ORGANISM", 196, 211], ["coronavirus and metapneumovirus", "SPECIES", 180, 211], ["serologic assays", "TEST", 79, 95], ["noncultivable", "PROBLEM", 118, 131], ["newly identified viruses", "PROBLEM", 135, 159], ["rhinovirus", "PROBLEM", 168, 178], ["coronavirus", "PROBLEM", 180, 191], ["metapneumovirus", "PROBLEM", 196, 211], ["viruses", "OBSERVATION", 152, 159], ["metapneumovirus", "OBSERVATION", 196, 211]]], ["More recently, studies using multiplex PCR have evaluated the frequency and clinical impact of respiratory viral illnesses in CF patients.", [["respiratory viral illnesses", "DISEASE", 95, 122], ["CF", "DISEASE", 126, 128], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["multiplex PCR", "TEST", 29, 42], ["respiratory viral illnesses in CF patients", "PROBLEM", 95, 137], ["respiratory", "ANATOMY", 95, 106], ["viral illnesses", "OBSERVATION", 107, 122]]], ["Their results demonstrated that viral respiratory tract infections are a frequent cause of respiratory illnesses in the CF population involving 49 to 60% of acute exacerbations (Asner et al., 2012, Burns et al., 2012, Olesen et al., 2006, Wat et al., 2008) and that the duration and severity of symptoms in the CF population was increased compared to healthy control subjects (Burns et al., 2012, van Ewijk et al., 2008).", [["respiratory tract", "ANATOMY", 38, 55], ["respiratory", "ANATOMY", 91, 102], ["viral respiratory tract infections", "DISEASE", 32, 66], ["respiratory illnesses", "DISEASE", 91, 112], ["viral respiratory tract", "ORGANISM", 32, 55], ["viral respiratory tract infections", "PROBLEM", 32, 66], ["respiratory illnesses", "PROBLEM", 91, 112], ["the CF population", "PROBLEM", 116, 133], ["acute exacerbations", "PROBLEM", 157, 176], ["symptoms", "PROBLEM", 295, 303], ["the CF population", "PROBLEM", 307, 324], ["viral", "OBSERVATION_MODIFIER", 32, 37], ["respiratory tract infections", "OBSERVATION", 38, 66], ["respiratory illnesses", "OBSERVATION", 91, 112], ["acute", "OBSERVATION_MODIFIER", 157, 162], ["exacerbations", "OBSERVATION", 163, 176], ["increased", "OBSERVATION_MODIFIER", 329, 338]]], ["The higher viral diagnostic yield afforded by multiplex PCR confirmed that those assays are adequate and reliable for CF respiratory specimen analysis (Asner et al., 2012, Wat et al., 2008).", [["multiplex PCR", "TEST", 46, 59], ["those assays", "TEST", 75, 87], ["CF respiratory specimen analysis", "TEST", 118, 150]]], ["One study by Asner et al. concluded that viral-related exacerbations detected by Resplex II v2.0 were associated with worse severity and quality of life scores compared to non-viral exacerbations(Asner et al., 2012).", [["exacerbations", "DISEASE", 55, 68], ["One study", "TEST", 0, 9], ["viral-related exacerbations", "PROBLEM", 41, 68], ["Resplex II v", "TEST", 81, 93], ["worse severity and quality of life scores", "PROBLEM", 118, 159], ["non-viral exacerbations", "PROBLEM", 172, 195], ["viral", "OBSERVATION", 41, 46]]], ["These results suggest that respiratory viruses should be seriously considered in the differential diagnosis of acute pulmonary exacerbations in CF subjects, considering that sensitive and specific diagnostic assays are now available and that antiviral therapy may be relevant and useful in some circumstances.", [["pulmonary", "ANATOMY", 117, 126], ["respiratory viruses", "DISEASE", 27, 46], ["acute pulmonary exacerbations", "DISEASE", 111, 140], ["pulmonary", "ORGAN", 117, 126], ["respiratory viruses", "PROBLEM", 27, 46], ["acute pulmonary exacerbations in CF subjects", "PROBLEM", 111, 155], ["specific diagnostic assays", "TEST", 188, 214], ["antiviral therapy", "TREATMENT", 242, 259], ["respiratory viruses", "OBSERVATION", 27, 46], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["pulmonary", "ANATOMY", 117, 126], ["exacerbations", "OBSERVATION", 127, 140]]], ["Finally, a confirmed viral etiology may help physicians decide to suspend antibiotic treatment, thereby minimizing antibiotic resistance emergence, a critical prognostic outcome for these patients.Neonates ::: Special population managementPremature infants with or without bronchopulmonary dysplasia and infants with congenital heart disease represent another high-risk population for respiratory virus infection.", [["bronchopulmonary dysplasia", "ANATOMY", 273, 299], ["heart", "ANATOMY", 328, 333], ["bronchopulmonary dysplasia", "DISEASE", 273, 299], ["congenital heart disease", "DISEASE", 317, 341], ["respiratory virus infection", "DISEASE", 385, 412], ["patients", "ORGANISM", 188, 196], ["Neonates", "ORGANISM", 197, 205], ["infants", "ORGANISM", 249, 256], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 273, 299], ["infants", "ORGANISM", 304, 311], ["heart", "ORGAN", 328, 333], ["respiratory virus", "ORGANISM", 385, 402], ["patients", "SPECIES", 188, 196], ["Neonates", "SPECIES", 197, 205], ["infants", "SPECIES", 249, 256], ["infants", "SPECIES", 304, 311], ["antibiotic treatment", "TREATMENT", 74, 94], ["antibiotic resistance emergence", "TREATMENT", 115, 146], ["Special population management", "TREATMENT", 210, 239], ["Premature infants", "PROBLEM", 239, 256], ["bronchopulmonary dysplasia", "PROBLEM", 273, 299], ["congenital heart disease", "PROBLEM", 317, 341], ["respiratory virus infection", "PROBLEM", 385, 412], ["without", "UNCERTAINTY", 265, 272], ["bronchopulmonary", "ANATOMY", 273, 289], ["dysplasia", "OBSERVATION", 290, 299], ["heart", "ANATOMY", 328, 333], ["disease", "OBSERVATION", 334, 341], ["respiratory virus", "OBSERVATION", 385, 402]]], ["Abundant literature on RSV and other respiratory virus infections in neonates has been published.", [["respiratory virus infections", "DISEASE", 37, 65], ["RSV", "ORGANISM", 23, 26], ["respiratory virus", "ORGANISM", 37, 54], ["neonates", "ORGANISM", 69, 77], ["RSV", "SPECIES", 23, 26], ["RSV", "SPECIES", 23, 26], ["RSV", "PROBLEM", 23, 26], ["other respiratory virus infections in neonates", "PROBLEM", 31, 77], ["RSV", "OBSERVATION", 23, 26], ["respiratory virus", "OBSERVATION", 37, 54]]], ["Older studies using conventional virology showed a relatively low incidence of viral infection in outpatient neonates with bronchopulmonary dysplasia (11% of visits for respiratory worsening) but morbidity was significant (Kinney et al., 1995).", [["bronchopulmonary dysplasia", "ANATOMY", 123, 149], ["respiratory", "ANATOMY", 169, 180], ["viral infection", "DISEASE", 79, 94], ["bronchopulmonary dysplasia", "DISEASE", 123, 149], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 123, 149], ["Older studies", "TEST", 0, 13], ["conventional virology", "TEST", 20, 41], ["viral infection in outpatient neonates", "PROBLEM", 79, 117], ["bronchopulmonary dysplasia", "PROBLEM", 123, 149], ["respiratory worsening", "PROBLEM", 169, 190], ["morbidity", "PROBLEM", 196, 205], ["viral", "OBSERVATION_MODIFIER", 79, 84], ["infection", "OBSERVATION", 85, 94], ["bronchopulmonary", "ANATOMY", 123, 139], ["dysplasia", "OBSERVATION", 140, 149]]], ["A retrospective study over 12 years reported respiratory viral infections in a neonatal intensive care unit (NICU) in less than 1% of infants (Verboon-Maciolek et al., 2005).", [["respiratory viral infections", "DISEASE", 45, 73], ["infants", "ORGANISM", 134, 141], ["infants", "SPECIES", 134, 141], ["A retrospective study", "TEST", 0, 21], ["respiratory viral infections", "PROBLEM", 45, 73], ["viral infections", "OBSERVATION", 57, 73]]], ["Many outbreaks with various respiratory viruses have been described with severe medical and economic impact (Faden et al., 2005, Gagneur et al., 2002, Halasa, Halasa et al., 2005, Sagrera et al., 2002).", [["respiratory viruses", "DISEASE", 28, 47], ["various respiratory viruses", "PROBLEM", 20, 47], ["respiratory viruses", "OBSERVATION", 28, 47]]], ["A recent study prospectively screened symptomatic and asymptomatic premature infants in a NICU using Xtag multiplex PCR twice weekly.", [["infants", "ORGANISM", 77, 84], ["infants", "SPECIES", 77, 84], ["A recent study", "TEST", 0, 14], ["asymptomatic premature infants", "PROBLEM", 54, 84], ["Xtag multiplex PCR", "TREATMENT", 101, 119]]], ["Respiratory viruses were identified in 52% of prematurely born infants during their birth hospitalization.", [["Respiratory viruses", "DISEASE", 0, 19], ["infants", "ORGANISM", 63, 70], ["infants", "SPECIES", 63, 70], ["Respiratory viruses", "PROBLEM", 0, 19], ["viruses", "OBSERVATION", 12, 19]]], ["Length of hospital stay was significantly longer (70 days vs 35 days) and bronchopulmonary dysplasia was more frequent in infected infants (Bennett et al., 2012).", [["bronchopulmonary dysplasia", "ANATOMY", 74, 100], ["bronchopulmonary dysplasia", "DISEASE", 74, 100], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 74, 100], ["infants", "ORGANISM", 131, 138], ["infants", "SPECIES", 131, 138], ["bronchopulmonary dysplasia", "PROBLEM", 74, 100], ["bronchopulmonary", "ANATOMY", 74, 90], ["dysplasia", "OBSERVATION", 91, 100]]], ["This study is unique because it is the first to highlight the impact of respiratory virus infections that would not have been suspected by clinicians and raise questions about more intensive monitoring in this setting.", [["respiratory virus infections", "DISEASE", 72, 100], ["respiratory virus", "ORGANISM", 72, 89], ["This study", "TEST", 0, 10], ["respiratory virus infections", "PROBLEM", 72, 100], ["intensive monitoring", "TEST", 181, 201], ["respiratory virus", "OBSERVATION", 72, 89]]], ["Human rhinovirus was identified using molecular diagnosis as the most frequent cause of hospitalization in very low-birth-weight infants after their initial discharge (Miller et al., 2012).", [["Human", "ORGANISM", 0, 5], ["rhinovirus", "ORGANISM", 6, 16], ["infants", "ORGANISM", 129, 136], ["Human", "SPECIES", 0, 5], ["infants", "SPECIES", 129, 136], ["Human rhinovirus", "SPECIES", 0, 16], ["Human rhinovirus", "PROBLEM", 0, 16]]], ["Similarly, a commercial multiplex PCR (Seeplex RV12 ACE detection) was used to diagnose respiratory infections in infants with congenital heart disease, another major risk factor for severe disease.", [["respiratory", "ANATOMY", 88, 99], ["heart", "ANATOMY", 138, 143], ["respiratory infections", "DISEASE", 88, 110], ["congenital heart disease", "DISEASE", 127, 151], ["infants", "ORGANISM", 114, 121], ["heart", "ORGAN", 138, 143], ["infants", "SPECIES", 114, 121], ["a commercial multiplex PCR", "TEST", 11, 37], ["Seeplex RV12 ACE detection", "TREATMENT", 39, 65], ["respiratory infections", "PROBLEM", 88, 110], ["congenital heart disease", "PROBLEM", 127, 151], ["severe disease", "PROBLEM", 183, 197], ["respiratory", "ANATOMY", 88, 99], ["infections", "OBSERVATION", 100, 110], ["heart", "ANATOMY", 138, 143], ["disease", "OBSERVATION", 144, 151], ["severe", "OBSERVATION_MODIFIER", 183, 189], ["disease", "OBSERVATION", 190, 197]]], ["In comparison with DFA, the sensitivity of multiplex PCR was better, detecting respiratory viruses in 51.3% of samples vs. 33.3% (Kanashiro et al., 2011).", [["samples", "ANATOMY", 111, 118], ["respiratory viruses", "DISEASE", 79, 98], ["DFA", "CHEMICAL", 19, 22], ["DFA", "TEST", 19, 22], ["multiplex PCR", "TEST", 43, 56], ["respiratory viruses", "PROBLEM", 79, 98], ["samples", "TEST", 111, 118], ["respiratory viruses", "OBSERVATION", 79, 98]]], ["The utility of multiplex PCR in neonates and infants with congenital heart disease seems obvious, but more data are necessary to explore the impact of population screening in the NICU.COPD ::: Special population managementRespiratory viruses have been identified as a major cause of COPD exacerbations, occurring in 34\u201356% of episodes, with rhinovirus being the most frequent respiratory virus detected (Hutchinson et al., 2007, Kherad et al., 2010, McManus et al., 2008, Mohan et al., 2010, Rohde et al., 2003, Seemungal et al., 2001).", [["heart", "ANATOMY", 69, 74], ["congenital heart disease", "DISEASE", 58, 82], ["COPD", "DISEASE", 184, 188], ["Respiratory viruses", "DISEASE", 222, 241], ["COPD", "DISEASE", 283, 287], ["neonates", "ORGANISM", 32, 40], ["infants", "ORGANISM", 45, 52], ["heart", "ORGAN", 69, 74], ["rhinovirus", "ORGANISM", 341, 351], ["infants", "SPECIES", 45, 52], ["multiplex PCR", "TEST", 15, 28], ["congenital heart disease", "PROBLEM", 58, 82], ["population screening", "TEST", 151, 171], ["COPD", "PROBLEM", 184, 188], ["Special population management", "TREATMENT", 193, 222], ["Respiratory viruses", "PROBLEM", 222, 241], ["COPD exacerbations", "PROBLEM", 283, 301], ["episodes", "PROBLEM", 326, 334], ["rhinovirus", "PROBLEM", 341, 351], ["frequent respiratory virus", "PROBLEM", 367, 393], ["heart", "ANATOMY", 69, 74], ["disease", "OBSERVATION", 75, 82], ["Respiratory viruses", "OBSERVATION", 222, 241], ["COPD", "OBSERVATION", 283, 287], ["rhinovirus", "OBSERVATION", 341, 351], ["respiratory virus", "OBSERVATION", 376, 393]]], ["The high rate of virus detection during acute exacerbations of COPD has raised questions about the role of antibiotics in that circumstance (Rosell et al., 2005), (Kherad et al., 2010).", [["COPD", "DISEASE", 63, 67], ["virus detection", "TREATMENT", 17, 32], ["acute exacerbations of COPD", "PROBLEM", 40, 67], ["antibiotics", "TREATMENT", 107, 118], ["high", "OBSERVATION_MODIFIER", 4, 8], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["exacerbations", "OBSERVATION", 46, 59], ["COPD", "OBSERVATION", 63, 67]]], ["Current guidelines still recommend the administration of antibiotics based on clinical criteria without considering diagnostic assays for respiratory viruses (Global Strategy for the Diagnosis MaPoC, 2011).", [["respiratory viruses", "DISEASE", 138, 157], ["antibiotics", "TREATMENT", 57, 68], ["diagnostic assays", "TEST", 116, 133], ["respiratory viruses", "PROBLEM", 138, 157]]], ["Some studies have used procalcitonin-based guidelines to decrease the use of antibiotics (Stolz et al., 2007).", [["Some studies", "TEST", 0, 12], ["procalcitonin", "TEST", 23, 36], ["antibiotics", "TREATMENT", 77, 88]]], ["Kherad et al. tried to corroborate viral diagnosis with use of biomarkers (C-reactive protein and procalcitonin) in order to strength viral diagnosis and rule out bacterial infection, but the difference in biomarkers levels was not significant between the group with and without viral infection (Kherad et al., 2010).", [["bacterial infection", "DISEASE", 163, 182], ["viral infection", "DISEASE", 279, 294], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 75, 93], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 98, 111], ["C-reactive protein", "PROTEIN", 75, 93], ["procalcitonin", "PROTEIN", 98, 111], ["biomarkers", "TEST", 63, 73], ["C-reactive protein", "TREATMENT", 75, 93], ["procalcitonin", "TEST", 98, 111], ["bacterial infection", "PROBLEM", 163, 182], ["biomarkers levels", "TEST", 206, 223], ["viral infection", "PROBLEM", 279, 294], ["bacterial", "OBSERVATION_MODIFIER", 163, 172], ["infection", "OBSERVATION", 173, 182], ["without", "UNCERTAINTY", 271, 278], ["viral", "OBSERVATION_MODIFIER", 279, 284], ["infection", "OBSERVATION", 285, 294]]], ["However, in that study, biomarker levels were often performed after beginning antibiotic treatment.", [["that study", "TEST", 12, 22], ["biomarker levels", "TEST", 24, 40], ["beginning antibiotic treatment", "TREATMENT", 68, 98]]], ["No studies have yet looked at clinical outcome of not treating with antibiotics in the presence of virus detection or at the cost-effectiveness of respiratory virus assays in that population (Varkey & Varkey, 2008).ConclusionsMultiplex respiratory virus assays are not used yet to their full potential as an aid in clinical management.", [["antibiotics", "TREATMENT", 68, 79], ["virus detection", "PROBLEM", 99, 114], ["respiratory virus assays", "PROBLEM", 147, 171], ["Multiplex respiratory virus assays", "TEST", 226, 260], ["clinical management", "TREATMENT", 315, 334], ["virus", "OBSERVATION", 99, 104], ["respiratory virus", "OBSERVATION", 147, 164], ["respiratory virus", "OBSERVATION", 236, 253]]], ["Many laboratories are already using it for different purpose but specific settings where it can be most useful have to be determined.", [["Many laboratories", "TEST", 0, 17]]], ["Pediatric pneumonia, febrile neutropenia, CF, and COPD exacerbations are some examples where multiplex respiratory virus assays could reduce antibiotic prescription.", [["pneumonia", "DISEASE", 10, 19], ["febrile neutropenia", "DISEASE", 21, 40], ["CF", "DISEASE", 42, 44], ["COPD", "DISEASE", 50, 54], ["Pediatric pneumonia", "PROBLEM", 0, 19], ["febrile neutropenia", "PROBLEM", 21, 40], ["CF", "PROBLEM", 42, 44], ["COPD exacerbations", "PROBLEM", 50, 68], ["multiplex respiratory virus assays", "PROBLEM", 93, 127], ["antibiotic prescription", "TREATMENT", 141, 164], ["pneumonia", "OBSERVATION", 10, 19], ["febrile", "OBSERVATION_MODIFIER", 21, 28], ["neutropenia", "OBSERVATION", 29, 40], ["COPD", "OBSERVATION", 50, 54], ["respiratory virus", "OBSERVATION", 103, 120]]], ["Systematic patient screening in immunocompromised or neonatal units could potentially prevent outbreaks and improve patient care.", [["patient", "ORGANISM", 11, 18], ["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 11, 18], ["patient", "SPECIES", 116, 123], ["Systematic patient screening", "TEST", 0, 28], ["neonatal units", "TREATMENT", 53, 67]]], ["More data on the cost effectiveness of respiratory virus detection and infection control procedures are critically needed in order to use multiplex respiratory virus assays appropriately.", [["infection", "DISEASE", 71, 80], ["respiratory virus detection", "TREATMENT", 39, 66], ["infection control procedures", "TREATMENT", 71, 99], ["multiplex respiratory virus assays", "TEST", 138, 172], ["respiratory virus", "OBSERVATION", 39, 56]]]], "PMC7192106": [], "2cbfb121b9aa939783bc8da1ba5c91204662b047": [["IntroductionThe human central nervous system (CNS) disease multiple sclerosis (MS) is characterized by focal areas of demyelination associated with inflammation.", [["central nervous system", "ANATOMY", 22, 44], ["CNS", "ANATOMY", 46, 49], ["human central nervous system (CNS) disease", "DISEASE", 16, 58], ["multiple sclerosis", "DISEASE", 59, 77], ["MS", "DISEASE", 79, 81], ["demyelination", "DISEASE", 118, 131], ["inflammation", "DISEASE", 148, 160], ["human", "ORGANISM", 16, 21], ["central nervous system", "ANATOMICAL_SYSTEM", 22, 44], ["CNS", "ANATOMICAL_SYSTEM", 46, 49], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["CNS) disease multiple sclerosis (MS)", "PROBLEM", 46, 82], ["demyelination", "PROBLEM", 118, 131], ["inflammation", "PROBLEM", 148, 160], ["human", "ANATOMY_MODIFIER", 16, 21], ["central", "ANATOMY_MODIFIER", 22, 29], ["nervous system", "ANATOMY", 30, 44], ["CNS", "ANATOMY", 46, 49], ["multiple", "OBSERVATION_MODIFIER", 59, 67], ["sclerosis", "OBSERVATION", 68, 77], ["focal", "OBSERVATION_MODIFIER", 103, 108], ["areas", "OBSERVATION_MODIFIER", 109, 114], ["demyelination", "OBSERVATION", 118, 131], ["inflammation", "OBSERVATION", 148, 160]]], ["Whether the demyelination reflects a primary injury to the myelin sheath or to the oligodendrocyte (OGC), the myelin producing cell, remains speculative.", [["myelin sheath", "ANATOMY", 59, 72], ["oligodendrocyte", "ANATOMY", 83, 98], ["OGC", "ANATOMY", 100, 103], ["myelin", "ANATOMY", 110, 116], ["cell", "ANATOMY", 127, 131], ["demyelination", "DISEASE", 12, 25], ["myelin sheath", "CELLULAR_COMPONENT", 59, 72], ["oligodendrocyte", "CELL", 83, 98], ["OGC", "CANCER", 100, 103], ["myelin", "CELLULAR_COMPONENT", 110, 116], ["cell", "CELL", 127, 131], ["oligodendrocyte", "CELL_TYPE", 83, 98], ["myelin producing cell", "CELL_TYPE", 110, 131], ["the demyelination", "PROBLEM", 8, 25], ["a primary injury", "PROBLEM", 35, 51], ["the myelin sheath", "TREATMENT", 55, 72], ["the myelin producing cell", "PROBLEM", 106, 131], ["demyelination", "OBSERVATION", 12, 25], ["primary", "OBSERVATION_MODIFIER", 37, 44], ["injury", "OBSERVATION", 45, 51], ["myelin sheath", "OBSERVATION", 59, 72], ["oligodendrocyte", "ANATOMY", 83, 98], ["cell", "OBSERVATION", 127, 131]]], ["A possible explanation for damage to myelin and/or the OGCs as observed in MS may be cellular immune-mediated injury.", [["myelin", "ANATOMY", 37, 43], ["OGCs", "ANATOMY", 55, 59], ["cellular", "ANATOMY", 85, 93], ["MS", "DISEASE", 75, 77], ["myelin", "CELLULAR_COMPONENT", 37, 43], ["OGCs", "GENE_OR_GENE_PRODUCT", 55, 59], ["cellular", "CELL", 85, 93], ["damage to myelin", "PROBLEM", 27, 43], ["the OGCs", "PROBLEM", 51, 59], ["cellular immune-mediated injury", "PROBLEM", 85, 116], ["possible explanation for", "UNCERTAINTY", 2, 26], ["injury", "OBSERVATION", 110, 116]]], ["The involvement of such mechanisms is suggested by the presence of activated CD8 + and CD4 + T-lymphocytes and macrophages in the MS lesions and the demonstration that T-lymphocytes are required for the passive transfer of the animal model of MS, experimental allergic encephalomyelitis (EAE) (Mokhtarian et al., 1984) .IntroductionA requirement for antigen-specific T-cell-mediated cytotoxicity is recognition of major histocompatibility complex (MHC) antigens in association with the antigen on the target cell surface.", [["CD8 + and CD4 + T-lymphocytes", "ANATOMY", 77, 106], ["macrophages", "ANATOMY", 111, 122], ["MS lesions", "ANATOMY", 130, 140], ["T-lymphocytes", "ANATOMY", 168, 181], ["T-cell", "ANATOMY", 367, 373], ["cell surface", "ANATOMY", 508, 520], ["MS", "DISEASE", 243, 245], ["allergic encephalomyelitis", "DISEASE", 260, 286], ["EAE", "DISEASE", 288, 291], ["CD8", "GENE_OR_GENE_PRODUCT", 77, 80], ["CD4", "GENE_OR_GENE_PRODUCT", 87, 90], ["macrophages", "CELL", 111, 122], ["MS lesions", "CANCER", 130, 140], ["T-lymphocytes", "CELL", 168, 181], ["antigen", "GENE_OR_GENE_PRODUCT", 350, 357], ["T-cell", "CELL", 367, 373], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 414, 446], ["cell surface", "CELLULAR_COMPONENT", 508, 520], ["CD8", "PROTEIN", 77, 80], ["CD4", "PROTEIN", 87, 90], ["T-lymphocytes", "CELL_TYPE", 93, 106], ["macrophages", "CELL_TYPE", 111, 122], ["T-lymphocytes", "CELL_TYPE", 168, 181], ["major histocompatibility complex (MHC) antigens", "PROTEIN", 414, 461], ["activated CD8", "TEST", 67, 80], ["CD4", "TEST", 87, 90], ["T-lymphocytes", "PROBLEM", 93, 106], ["macrophages", "PROBLEM", 111, 122], ["the MS lesions", "PROBLEM", 126, 140], ["experimental allergic encephalomyelitis", "PROBLEM", 247, 286], ["IntroductionA requirement", "TEST", 320, 345], ["antigen", "TEST", 350, 357], ["mediated cytotoxicity", "PROBLEM", 374, 395], ["major histocompatibility complex (MHC) antigens", "PROBLEM", 414, 461], ["lymphocytes", "ANATOMY", 95, 106], ["macrophages", "OBSERVATION_MODIFIER", 111, 122], ["MS", "OBSERVATION_MODIFIER", 130, 132], ["lesions", "OBSERVATION", 133, 140], ["allergic encephalomyelitis", "OBSERVATION", 260, 286], ["target cell", "OBSERVATION", 501, 512], ["surface", "OBSERVATION_MODIFIER", 513, 520]]], ["Most antigen-specific cytotoxic lymphocytes are 0165-5728/90/$03.50 \u00a9 1990 Elsevier Science Publishers B.V. (Biomedical Division) contained in the CD8 + suppressor/cytotoxic Tlymphocyte subset and are MHC class I restricted; however, cytotoxicity mediated by CD4 + class II-restricted lymphocytes has also been described (Jacobson et al., 1984) .", [["cytotoxic lymphocytes", "ANATOMY", 22, 43], ["CD4 + class II-restricted lymphocytes", "ANATOMY", 259, 296], ["antigen", "GENE_OR_GENE_PRODUCT", 5, 12], ["lymphocytes", "CELL", 32, 43], ["CD8", "GENE_OR_GENE_PRODUCT", 147, 150], ["CD4 + class II", "GENE_OR_GENE_PRODUCT", 259, 273], ["lymphocytes", "CELL", 285, 296], ["cytotoxic lymphocytes", "CELL_TYPE", 22, 43], ["CD8", "PROTEIN", 147, 150], ["cytotoxic Tlymphocyte subset", "CELL_TYPE", 164, 192], ["MHC class I", "PROTEIN", 201, 212], ["CD4", "PROTEIN", 259, 262], ["class II-restricted lymphocytes", "CELL_TYPE", 265, 296], ["Most antigen", "TEST", 0, 12], ["cytotoxic Tlymphocyte subset", "PROBLEM", 164, 192], ["cytotoxicity", "TEST", 234, 246], ["CD4 + class II-restricted lymphocytes", "PROBLEM", 259, 296], ["cytotoxic lymphocytes", "OBSERVATION", 22, 43], ["restricted lymphocytes", "OBSERVATION", 274, 296]]], ["Although in situ expression of MHC antigens is confined to endothelial cells in normal CNS, both MHC class I and class II antigens are detectable on astrocytes, endothelial cells and macrophages/microglia in and adjacent to the MS lesion (Traugott, 1987) .IntroductionImmunohistochemical data on OGCs in situ are to date limited.", [["endothelial cells", "ANATOMY", 59, 76], ["CNS", "ANATOMY", 87, 90], ["astrocytes", "ANATOMY", 149, 159], ["endothelial cells", "ANATOMY", 161, 178], ["macrophages", "ANATOMY", 183, 194], ["microglia", "ANATOMY", 195, 204], ["MS lesion", "ANATOMY", 228, 237], ["OGCs", "ANATOMY", 296, 300], ["MHC antigens", "GENE_OR_GENE_PRODUCT", 31, 43], ["endothelial cells", "CELL", 59, 76], ["CNS", "ANATOMICAL_SYSTEM", 87, 90], ["MHC class I", "GENE_OR_GENE_PRODUCT", 97, 108], ["class II antigens", "GENE_OR_GENE_PRODUCT", 113, 130], ["astrocytes", "CELL", 149, 159], ["endothelial cells", "CELL", 161, 178], ["macrophages", "CELL", 183, 194], ["microglia", "CELL", 195, 204], ["MHC antigens", "PROTEIN", 31, 43], ["endothelial cells", "CELL_TYPE", 59, 76], ["MHC class I and class II antigens", "PROTEIN", 97, 130], ["astrocytes", "CELL_TYPE", 149, 159], ["endothelial cells", "CELL_TYPE", 161, 178], ["macrophages", "CELL_TYPE", 183, 194], ["microglia", "CELL_TYPE", 195, 204], ["class II antigens", "TEST", 113, 130], ["endothelial cells", "TEST", 161, 178], ["microglia", "PROBLEM", 195, 204], ["the MS lesion", "PROBLEM", 224, 237], ["Immunohistochemical data", "TEST", 268, 292], ["OGCs", "TEST", 296, 300], ["endothelial cells", "OBSERVATION", 59, 76], ["CNS", "ANATOMY", 87, 90], ["endothelial cells", "OBSERVATION", 161, 178], ["macrophages", "OBSERVATION", 183, 194], ["microglia", "ANATOMY", 195, 204], ["MS", "OBSERVATION_MODIFIER", 228, 230], ["lesion", "OBSERVATION", 231, 237]]], ["We have recently demonstrated the expression of MHC class I antigens on human adult OGCs, in cultures of tissue derived from young adults undergoing surgery as a treatment for intractable seizures (Grenier et al., 1989) .", [["adult OGCs", "ANATOMY", 78, 88], ["cultures", "ANATOMY", 93, 101], ["tissue", "ANATOMY", 105, 111], ["seizures", "DISEASE", 188, 196], ["MHC class I antigens", "GENE_OR_GENE_PRODUCT", 48, 68], ["human", "ORGANISM", 72, 77], ["OGCs", "CELL", 84, 88], ["tissue", "TISSUE", 105, 111], ["adults", "ORGANISM", 131, 137], ["MHC class I antigens", "PROTEIN", 48, 68], ["human adult OGCs", "CELL_TYPE", 72, 88], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["surgery", "TREATMENT", 149, 156], ["a treatment", "TREATMENT", 160, 171], ["intractable seizures", "PROBLEM", 176, 196]]], ["These findings were in accordance with studies on human glial cell cultures established from postmortem tissue (Kim et al., 1985) .", [["glial cell cultures", "ANATOMY", 56, 75], ["postmortem tissue", "ANATOMY", 93, 110], ["human", "ORGANISM", 50, 55], ["glial cell cultures", "CELL", 56, 75], ["postmortem tissue", "TISSUE", 93, 110], ["human glial cell cultures", "CELL_LINE", 50, 75], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["human glial cell cultures", "TEST", 50, 75]]], ["We did not detect any MHC class II expression on the OGCs, whereas a proportion of the astrocytes in the cultures did express those antigens (Grenier et al., 1989 ).IntroductionIn the current study we used a 51Cr release assay to demonstrate the susceptibility of human OGCs to lysis by allo-reactive class I-directed cytotoxic T-lymphocytes.Materials and methodsHuman OGC-enriched cell culture Tissue from temporal lobe or corpus callosum was removed in fragments by ultrasonic aspiration or resected en bloc as part of surgical treatment of young adult patients suffering from intractable seizures.", [["OGCs", "ANATOMY", 53, 57], ["astrocytes", "ANATOMY", 87, 97], ["cultures", "ANATOMY", 105, 113], ["OGCs", "ANATOMY", 270, 274], ["cytotoxic T-lymphocytes", "ANATOMY", 318, 341], ["cell", "ANATOMY", 382, 386], ["Tissue", "ANATOMY", 395, 401], ["temporal lobe", "ANATOMY", 407, 420], ["corpus callosum", "ANATOMY", 424, 439], ["fragments", "ANATOMY", 455, 464], ["en bloc", "ANATOMY", 502, 509], ["seizures", "DISEASE", 591, 599], ["MHC class II", "GENE_OR_GENE_PRODUCT", 22, 34], ["OGCs", "PATHOLOGICAL_FORMATION", 53, 57], ["astrocytes", "CELL", 87, 97], ["human", "ORGANISM", 264, 269], ["OGCs", "CELL", 270, 274], ["T-lymphocytes", "CELL", 328, 341], ["Human", "ORGANISM", 363, 368], ["OGC", "CELL", 369, 372], ["cell", "CELL", 382, 386], ["Tissue", "TISSUE", 395, 401], ["temporal lobe", "MULTI-TISSUE_STRUCTURE", 407, 420], ["corpus callosum", "MULTI-TISSUE_STRUCTURE", 424, 439], ["patients", "ORGANISM", 555, 563], ["MHC class II", "PROTEIN", 22, 34], ["OGCs", "CELL_TYPE", 53, 57], ["astrocytes", "CELL_TYPE", 87, 97], ["antigens", "PROTEIN", 132, 140], ["human OGCs", "CELL_TYPE", 264, 274], ["allo-reactive class I-directed cytotoxic T-lymphocytes", "CELL_TYPE", 287, 341], ["Human OGC-enriched cell culture", "CELL_LINE", 363, 394], ["human", "SPECIES", 264, 269], ["Human", "SPECIES", 363, 368], ["patients", "SPECIES", 555, 563], ["human", "SPECIES", 264, 269], ["Human", "SPECIES", 363, 368], ["the cultures", "TEST", 101, 113], ["the current study", "TEST", 180, 197], ["a 51Cr release assay", "TEST", 206, 226], ["lysis", "TREATMENT", 278, 283], ["methodsHuman OGC", "TEST", 356, 372], ["enriched cell culture", "TEST", 373, 394], ["corpus callosum", "PROBLEM", 424, 439], ["ultrasonic aspiration", "TREATMENT", 468, 489], ["resected en bloc", "TREATMENT", 493, 509], ["surgical treatment", "TREATMENT", 521, 539], ["intractable seizures", "PROBLEM", 579, 599], ["astrocytes", "ANATOMY", 87, 97], ["enriched cell culture Tissue", "OBSERVATION", 373, 401], ["temporal lobe", "ANATOMY", 407, 420], ["corpus callosum", "ANATOMY", 424, 439], ["intractable", "OBSERVATION_MODIFIER", 579, 590], ["seizures", "OBSERVATION", 591, 599]]], ["The isolation procedure was adapted from that reported by Kim et al. (1983) .", [["The isolation procedure", "TREATMENT", 0, 23]]], ["Meninges and blood vessels were removed from the block specimens and the fragmented tissue was washed extensively to remove the blood.", [["Meninges", "ANATOMY", 0, 8], ["blood vessels", "ANATOMY", 13, 26], ["specimens", "ANATOMY", 55, 64], ["tissue", "ANATOMY", 84, 90], ["blood", "ANATOMY", 128, 133], ["Meninges", "CANCER", 0, 8], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 13, 26], ["tissue", "TISSUE", 84, 90], ["blood", "ORGANISM_SUBSTANCE", 128, 133], ["the block specimens", "TEST", 45, 64], ["the fragmented tissue", "PROBLEM", 69, 90], ["the blood", "TEST", 124, 133], ["blood vessels", "ANATOMY", 13, 26], ["fragmented", "OBSERVATION_MODIFIER", 73, 83], ["tissue", "OBSERVATION", 84, 90], ["blood", "ANATOMY", 128, 133]]], ["The tissue was enzymatically dissociated by use of 0.25% trypsin (Gibco Canada, Burlington, Ont., Canada) in Ca 2+-and Mg2+-free phosphate-buffered saline (PBS) for 1 h at 37\u00b0C in a humidified 5% CO2 incubator.", [["tissue", "ANATOMY", 4, 10], ["Ca", "CHEMICAL", 109, 111], ["Mg2", "CHEMICAL", 119, 122], ["phosphate", "CHEMICAL", 129, 138], ["CO2", "CHEMICAL", 196, 199], ["Ca 2+", "CHEMICAL", 109, 114], ["Mg2+", "CHEMICAL", 119, 123], ["phosphate", "CHEMICAL", 129, 138], ["CO2", "CHEMICAL", 196, 199], ["tissue", "TISSUE", 4, 10], ["trypsin", "SIMPLE_CHEMICAL", 57, 64], ["Ca 2+", "SIMPLE_CHEMICAL", 109, 114], ["Mg2+-free phosphate-buffered saline", "SIMPLE_CHEMICAL", 119, 154], ["CO2", "SIMPLE_CHEMICAL", 196, 199], ["Ca", "TEST", 109, 111], ["Mg2", "TEST", 119, 122], ["free phosphate", "TREATMENT", 124, 138], ["buffered saline (PBS", "TREATMENT", 139, 159], ["a humidified 5% CO2 incubator", "TREATMENT", 180, 209], ["tissue", "ANATOMY", 4, 10]]], ["Trypsin was inactivated by addition of fetal calf serum (FCS; Gibco Canada) and the tissue was further mechanically dissociated by passage through two nylon meshes (210 and 132 /~m pore size; Industrial Fabrics Corporation, Minneapolis, MN, U.S.A.).", [["fetal calf serum", "ANATOMY", 39, 55], ["tissue", "ANATOMY", 84, 90], ["Trypsin", "CHEMICAL", 0, 7], ["Trypsin", "GENE_OR_GENE_PRODUCT", 0, 7], ["fetal calf", "ORGANISM_SUBSTANCE", 39, 49], ["serum", "ORGANISM_SUBSTANCE", 50, 55], ["FCS", "ORGANISM_SUBSTANCE", 57, 60], ["tissue", "TISSUE", 84, 90], ["calf", "SPECIES", 45, 49], ["Trypsin", "TREATMENT", 0, 7], ["fetal calf serum", "TEST", 39, 55], ["two nylon meshes", "TREATMENT", 147, 163], ["fetal calf", "ANATOMY", 39, 49], ["tissue", "ANATOMY", 84, 90], ["nylon meshes", "OBSERVATION", 151, 163], ["size", "OBSERVATION_MODIFIER", 186, 190]]], ["The obtained suspension was washed once and separated on a 30% Percoll (Pharmacia LKB, Montreal, Que., Canada) gradient in a Beckman J2-21M/E centrifuge with a fixed angle 17J rotor (15,000 rpm at 4\u00b0C for 30 min).", [["a fixed angle 17J rotor", "TREATMENT", 158, 181]]], ["The gradient resulted in formation of an upper layer of PBS, a layer of densely packed myelin, a clear layer of glial cell suspension and a narrow band of red blood cells at the bottom.", [["myelin", "ANATOMY", 87, 93], ["glial cell", "ANATOMY", 112, 122], ["red blood cells", "ANATOMY", 155, 170], ["myelin", "CELLULAR_COMPONENT", 87, 93], ["glial cell", "CELL", 112, 122], ["red blood cells", "CELL", 155, 170], ["red blood cells", "CELL_TYPE", 155, 170], ["an upper layer of PBS", "PROBLEM", 38, 59], ["densely packed myelin", "PROBLEM", 72, 93], ["glial cell suspension", "TREATMENT", 112, 133], ["a narrow band of red blood cells", "PROBLEM", 138, 170], ["gradient", "OBSERVATION_MODIFIER", 4, 12], ["upper layer", "OBSERVATION_MODIFIER", 41, 52], ["PBS", "OBSERVATION", 56, 59], ["layer", "OBSERVATION_MODIFIER", 63, 68], ["densely", "OBSERVATION_MODIFIER", 72, 79], ["packed myelin", "OBSERVATION", 80, 93], ["clear", "OBSERVATION_MODIFIER", 97, 102], ["layer", "OBSERVATION_MODIFIER", 103, 108], ["glial cell suspension", "OBSERVATION", 112, 133], ["narrow", "OBSERVATION_MODIFIER", 140, 146], ["band", "OBSERVATION_MODIFIER", 147, 151], ["red blood cells", "OBSERVATION", 155, 170], ["bottom", "ANATOMY_MODIFIER", 178, 184]]], ["Glial cells were recovered, diluted in PBS and washed 3 times at 1800, 1500 and 1200 rpm respectively in a Beckman IEC Centra-8R centrifuge with swinging bucket 216 rotor.", [["Glial cells", "ANATOMY", 0, 11], ["Glial cells", "CELL", 0, 11], ["Glial cells", "CELL_TYPE", 0, 11], ["Glial cells", "PROBLEM", 0, 11]]], ["Viable cell numbers, usually > 90%, were estimated under a haemocytometer by trypan blue exclusion and cells were resuspended in Dulbecco's modified Eagle medium (DMEM; Gibco Canada) supplemented with penicillin 2.5 U/ml, streptomycin 2.5/tg/ml, glutamine 2 mM (all from Gibco Canada) and 10% FCS and plated on 80 cm 2 tissue culture flasks (Nunclon, Gibco Canada).", [["cell", "ANATOMY", 7, 11], ["cells", "ANATOMY", 103, 108], ["trypan blue", "CHEMICAL", 77, 88], ["penicillin", "CHEMICAL", 201, 211], ["streptomycin", "CHEMICAL", 222, 234], ["glutamine", "CHEMICAL", 246, 255], ["trypan blue", "CHEMICAL", 77, 88], ["penicillin", "CHEMICAL", 201, 211], ["streptomycin", "CHEMICAL", 222, 234], ["glutamine", "CHEMICAL", 246, 255], ["Viable cell", "CELL", 0, 11], ["trypan blue", "SIMPLE_CHEMICAL", 77, 88], ["cells", "CELL", 103, 108], ["penicillin", "SIMPLE_CHEMICAL", 201, 211], ["streptomycin", "SIMPLE_CHEMICAL", 222, 234], ["glutamine", "SIMPLE_CHEMICAL", 246, 255], ["Viable cell numbers", "TEST", 0, 19], ["penicillin", "TREATMENT", 201, 211], ["streptomycin", "TREATMENT", 222, 234], ["glutamine", "TREATMENT", 246, 255], ["10% FCS", "TREATMENT", 289, 296], ["cell numbers", "OBSERVATION", 7, 19]]], ["After 24-48 h, floating cells were removed and plated on poly-Llysine (10 /xg/ml, Sigma, St. Louis, MO, U.S.A.) coated cell culture flasks at a density of 10 6 per ml in DMEM supplemented with 5% human AB + serum (normal human serum, NHS).Immunocytochemical stainingThe proportion of OGC as well as the expression of MHC class I antigens was assessed by a double-immunofluorescence technique with the monoclonal pan-class I antibody W6/32 (gift from Dr. R. Sekaly, Montreal) and a polyclonal anti-2', 3'-cyclic nucleotide phosphodiesterase (CNPase) antibody (gift from Dr. P. Braun, Montreal) as described previously (Grenier et al., 1989) .Chromium release assayGlial cells were trypsinized and plated on a flat-bottom 96-well plate, at least 2 days prior to the assay (density of 5 \u00d7 10 4 per well in RPMI 10% NHS).", [["cells", "ANATOMY", 24, 29], ["cell", "ANATOMY", 119, 123], ["serum", "ANATOMY", 207, 212], ["serum", "ANATOMY", 227, 232], ["OGC", "ANATOMY", 284, 287], ["assayGlial cells", "ANATOMY", 658, 674], ["poly-Llysine", "CHEMICAL", 57, 69], ["3'-cyclic nucleotide", "CHEMICAL", 501, 521], ["Chromium", "CHEMICAL", 641, 649], ["poly-Llysine", "CHEMICAL", 57, 69], ["Chromium", "CHEMICAL", 641, 649], ["cells", "CELL", 24, 29], ["poly-Llysine", "SIMPLE_CHEMICAL", 57, 69], ["cell", "CELL", 119, 123], ["human", "ORGANISM", 196, 201], ["AB", "CELL", 202, 204], ["serum", "ORGANISM_SUBSTANCE", 207, 212], ["human", "ORGANISM", 221, 226], ["serum", "ORGANISM_SUBSTANCE", 227, 232], ["OGC", "CANCER", 284, 287], ["MHC class I antigens", "GENE_OR_GENE_PRODUCT", 317, 337], ["3'-cyclic nucleotide phosphodiesterase", "GENE_OR_GENE_PRODUCT", 501, 539], ["CNPase", "GENE_OR_GENE_PRODUCT", 541, 547], ["Chromium", "SIMPLE_CHEMICAL", 641, 649], ["assayGlial cells", "CELL", 658, 674], ["floating cells", "CELL_TYPE", 15, 29], ["OGC", "PROTEIN", 284, 287], ["MHC class I antigens", "PROTEIN", 317, 337], ["monoclonal pan-class I antibody W6/32", "PROTEIN", 401, 438], ["polyclonal anti-2', 3'-cyclic nucleotide phosphodiesterase (CNPase) antibody", "PROTEIN", 481, 557], ["assayGlial cells", "CELL_LINE", 658, 674], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 221, 226], ["floating cells", "PROBLEM", 15, 29], ["poly-Llysine", "TREATMENT", 57, 69], ["coated cell culture flasks", "TEST", 112, 138], ["human AB + serum", "TEST", 196, 212], ["Immunocytochemical staining", "TEST", 239, 266], ["the monoclonal pan-class I antibody", "TEST", 397, 432], ["a polyclonal anti", "TREATMENT", 479, 496], ["cyclic nucleotide phosphodiesterase", "TREATMENT", 504, 539], ["Chromium release assayGlial cells", "PROBLEM", 641, 674], ["the assay", "TEST", 760, 769], ["assayGlial cells", "OBSERVATION", 658, 674]]], ["The cells were labelled with 51Cr (1 ~Ci per well) overnight.", [["cells", "ANATOMY", 4, 9], ["51Cr", "CHEMICAL", 29, 33], ["51Cr", "CHEMICAL", 29, 33], ["cells", "CELL", 4, 9], ["Ci", "TEST", 38, 40]]], ["Average labelling with 51Cr was approximately 5400 counts per minute (cpm) per well, with a range of approximately 1100-20,000 cpm/well over all experiments.", [["51Cr", "CHEMICAL", 23, 27]]], ["No correlation was observed between total 51Cr labelling and the percentage of OGCs in the culture when assessed in a series of cultures containing 10-90% OGCs.", [["OGCs", "ANATOMY", 79, 83], ["OGCs", "ANATOMY", 155, 159], ["51Cr", "CHEMICAL", 42, 46], ["51Cr", "SIMPLE_CHEMICAL", 42, 46], ["OGCs", "PATHOLOGICAL_FORMATION", 79, 83], ["OGCs", "PATHOLOGICAL_FORMATION", 155, 159], ["OGCs", "CELL_TYPE", 79, 83], ["total 51Cr labelling", "TEST", 36, 56], ["the culture", "TEST", 87, 98], ["cultures", "TEST", 128, 136]]], ["On the day of the assay, cells were gently washed twice and allowed to stand for 30 min before lectin-activated or mixed lymphocyte culture (MLC)-activated lymphocytes (effector cells), prepared as described below, were added to triplicate or quadruplicate wells.", [["cells", "ANATOMY", 25, 30], ["lymphocyte", "ANATOMY", 121, 131], ["lymphocytes", "ANATOMY", 156, 167], ["effector cells", "ANATOMY", 169, 183], ["cells", "CELL", 25, 30], ["lectin", "GENE_OR_GENE_PRODUCT", 95, 101], ["lymphocyte", "CELL", 121, 131], ["MLC", "CELL", 141, 144], ["lymphocytes", "CELL", 156, 167], ["effector cells", "CELL", 169, 183], ["lectin", "PROTEIN", 95, 101], ["activated or mixed lymphocyte culture", "CELL_LINE", 102, 139], ["activated lymphocytes", "CELL_TYPE", 146, 167], ["effector cells", "CELL_TYPE", 169, 183], ["the assay", "TEST", 14, 23], ["lectin", "TEST", 95, 101], ["mixed lymphocyte culture", "TEST", 115, 139], ["activated lymphocytes (effector cells", "PROBLEM", 146, 183]]], ["In most studies a 10 : 1 effector/target ratio was used, except where indicated in the Results section.", [["target ratio", "TEST", 34, 46]]], ["After a 5-6 h incubation with the lymphocytes, supernatants (A) were removed and counted in an LKB 1272 Clinigamma counter.", [["lymphocytes", "ANATOMY", 34, 45], ["supernatants", "ANATOMY", 47, 59], ["lymphocytes", "CELL", 34, 45], ["lymphocytes", "CELL_TYPE", 34, 45], ["the lymphocytes", "TREATMENT", 30, 45], ["lymphocytes", "ANATOMY", 34, 45]]], ["Aliquots of 5 N NaOH were added to each well for 20 rain and supernatants (B) removed and counted for remaining radioactivity.", [["Aliquots", "ANATOMY", 0, 8], ["supernatants", "ANATOMY", 61, 73], ["5 N NaOH", "CHEMICAL", 12, 20], ["NaOH", "CHEMICAL", 16, 20], ["NaOH", "SIMPLE_CHEMICAL", 16, 20], ["5 N NaOH", "TREATMENT", 12, 20], ["supernatants (B)", "TREATMENT", 61, 77]]], ["The percentage lysis was calculated by dividing the cpm of supernatant A by the total labelling (supernatants A + B).", [["supernatant", "ANATOMY", 59, 70], ["supernatants", "ANATOMY", 97, 109], ["The percentage lysis", "TREATMENT", 0, 20], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["lysis", "OBSERVATION", 15, 20]]], ["The value for specific lysis was obtained by subtracting the mean percentage of spontaneous release in 51Cr-labelled control wells which had been incubated with media only.Mononuclear cell isolationBlood collected in heparinized tubes was separated on a Ficoll-Hypaque gradient (Pharmacia LKB).", [["Mononuclear cell", "ANATOMY", 172, 188], ["Blood", "ANATOMY", 198, 203], ["tubes", "ANATOMY", 229, 234], ["51Cr", "CHEMICAL", 103, 107], ["51Cr", "CHEMICAL", 103, 107], ["51Cr", "SIMPLE_CHEMICAL", 103, 107], ["Mononuclear cell", "CELL", 172, 188], ["Blood", "ORGANISM_SUBSTANCE", 198, 203], ["heparinized tubes", "ORGANISM_SUBSTANCE", 217, 234], ["The value", "TEST", 0, 9], ["specific lysis", "TEST", 14, 28], ["spontaneous release", "TREATMENT", 80, 99], ["51Cr-labelled control wells", "TREATMENT", 103, 130], ["Mononuclear cell isolation", "TREATMENT", 172, 198], ["heparinized tubes", "TREATMENT", 217, 234], ["a Ficoll-Hypaque gradient", "TREATMENT", 252, 277], ["cell isolation", "OBSERVATION", 184, 198], ["heparinized tubes", "OBSERVATION", 217, 234]]], ["Mononuclear cells (MNCs) were recovered, washed 3 times in PBS and cultured in RPMI 1640 (Gibco Canada) supplemented with penicilfin 2.5 U/ml, streptomycin 2.5/~g/ml, glutamine 2 mM and 10% FCS or NHS.Lectin activation of MNCsMNCs from a healthy donor were activated by incubation with concanavalin A (ConA) (10 /~g/ml, Sigma) in RPMI containing 10% FCS for 2-3 days.", [["Mononuclear cells", "ANATOMY", 0, 17], ["MNCs", "ANATOMY", 19, 23], ["MNCsMNCs", "ANATOMY", 222, 230], ["penicilfin", "CHEMICAL", 122, 132], ["streptomycin", "CHEMICAL", 143, 155], ["glutamine", "CHEMICAL", 167, 176], ["concanavalin A", "CHEMICAL", 286, 300], ["penicilfin", "CHEMICAL", 122, 132], ["streptomycin", "CHEMICAL", 143, 155], ["glutamine", "CHEMICAL", 167, 176], ["Mononuclear cells", "CELL", 0, 17], ["MNCs", "CELL", 19, 23], ["penicilfin", "SIMPLE_CHEMICAL", 122, 132], ["streptomycin", "SIMPLE_CHEMICAL", 143, 155], ["glutamine", "SIMPLE_CHEMICAL", 167, 176], ["Lectin", "GENE_OR_GENE_PRODUCT", 201, 207], ["MNCsMNCs", "SIMPLE_CHEMICAL", 222, 230], ["concanavalin A", "SIMPLE_CHEMICAL", 286, 300], ["ConA", "SIMPLE_CHEMICAL", 302, 306], ["Mononuclear cells", "CELL_TYPE", 0, 17], ["MNCs", "CELL_TYPE", 19, 23], ["MNCsMNCs", "CELL_TYPE", 222, 230], ["Mononuclear cells", "TEST", 0, 17], ["MNCs", "TEST", 19, 23], ["penicilfin", "TREATMENT", 122, 132], ["streptomycin", "TREATMENT", 143, 155], ["glutamine", "TREATMENT", 167, 176], ["Lectin activation of MNCsMNCs", "PROBLEM", 201, 230], ["a healthy donor", "TREATMENT", 236, 251], ["concanavalin A (ConA)", "TREATMENT", 286, 307]]], ["The cells were then harvested, washed 3 times to remove free lectin and added to 51Crlabelled glial cells in the cytotoxicity assay, either in the presence of ConA (10 #g/ml) or in the presence of a-methyl-D-mannoside (2 mM, Sigma), to block ConA binding sites (Suzumura and Siiberberg, 1985) .", [["cells", "ANATOMY", 4, 9], ["51Crlabelled glial cells", "ANATOMY", 81, 105], ["ConA", "CHEMICAL", 159, 163], ["a-methyl-D-mannoside", "CHEMICAL", 197, 217], ["a-methyl-D-mannoside", "CHEMICAL", 197, 217], ["cells", "CELL", 4, 9], ["lectin", "GENE_OR_GENE_PRODUCT", 61, 67], ["glial cells", "CELL", 94, 105], ["ConA", "SIMPLE_CHEMICAL", 159, 163], ["a-methyl-D-mannoside", "SIMPLE_CHEMICAL", 197, 217], ["ConA", "GENE_OR_GENE_PRODUCT", 242, 246], ["lectin", "PROTEIN", 61, 67], ["51Crlabelled glial cells", "CELL_LINE", 81, 105], ["ConA binding sites", "PROTEIN", 242, 260], ["free lectin", "TREATMENT", 56, 67], ["the cytotoxicity assay", "TEST", 109, 131], ["glial cells", "OBSERVATION", 94, 105]]], ["Non-activated cells maintained in culture for 2-3 days were used as controls.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["Non-activated cells", "CELL_LINE", 0, 19], ["Non-activated cells", "PROBLEM", 0, 19], ["culture", "TEST", 34, 41]]], ["The degree of lysis mediated by activated versus nonactivated cells, in the presence or absence of ConA, was compared using the paired t-test.", [["cells", "ANATOMY", 62, 67], ["cells", "CELL", 62, 67], ["ConA", "GENE_OR_GENE_PRODUCT", 99, 103], ["nonactivated cells", "CELL_TYPE", 49, 67], ["ConA", "PROTEIN", 99, 103], ["lysis", "PROBLEM", 14, 19], ["activated versus nonactivated cells", "PROBLEM", 32, 67], ["the paired t-test", "TEST", 124, 141], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["lysis", "OBSERVATION", 14, 19]]], ["Proliferation rates of activated and non-activated lymphocytes were measured by incorporation of [3H]thymidine (ICN-Radiochemicals, Montreal, Que., Canada) after a 5 h pulse with 1/~Ci per 10 5 lymphocytes.Mixed lymphocyte cultureMNCs from the glial cell donor were typed for all HLA-A, B, C epitopes (the MHC class I antigens) in the tissue typing laboratory, Royal Victoria Hospital (Dr. R.D. Guttmann).", [["lymphocytes", "ANATOMY", 51, 62], ["lymphocytes", "ANATOMY", 194, 205], ["lymphocyte", "ANATOMY", 212, 222], ["glial cell", "ANATOMY", 244, 254], ["tissue", "ANATOMY", 335, 341], ["[3H]thymidine", "CHEMICAL", 97, 110], ["[3H]thymidine", "CHEMICAL", 97, 110], ["lymphocytes", "CELL", 51, 62], ["[3H]thymidine", "SIMPLE_CHEMICAL", 97, 110], ["lymphocytes", "CELL", 194, 205], ["lymphocyte", "CELL", 212, 222], ["glial cell", "CELL", 244, 254], ["HLA-A", "GENE_OR_GENE_PRODUCT", 280, 285], ["B, C epitopes", "GENE_OR_GENE_PRODUCT", 287, 300], ["MHC class I antigens", "GENE_OR_GENE_PRODUCT", 306, 326], ["tissue", "TISSUE", 335, 341], ["non-activated lymphocytes", "CELL_TYPE", 37, 62], ["lymphocytes", "CELL_TYPE", 194, 205], ["lymphocyte cultureMNCs", "CELL_TYPE", 212, 234], ["glial cell", "CELL_TYPE", 244, 254], ["HLA-A, B, C epitopes", "PROTEIN", 280, 300], ["MHC class I antigens", "PROTEIN", 306, 326], ["Proliferation rates", "TEST", 0, 19], ["activated and non-activated lymphocytes", "PROBLEM", 23, 62], ["thymidine", "TREATMENT", 101, 110], ["Ci", "TEST", 182, 184], ["Mixed lymphocyte cultureMNCs", "TEST", 206, 234], ["the glial cell", "TEST", 240, 254], ["all HLA", "TEST", 276, 283], ["C epitopes", "PROBLEM", 290, 300], ["lymphocyte cultureMNCs", "OBSERVATION", 212, 234], ["glial cell", "OBSERVATION", 244, 254], ["tissue", "ANATOMY", 335, 341]]], ["HLA class II typing was not performed.Mixed lymphocyte cultureCytotoxic responder lymphocytes directed against the glial cell donor and against an HLA-A, B, C discordant control donor were generated in a one-way mixed lymphocyte culture (MLC), as follows.", [["lymphocyte", "ANATOMY", 44, 54], ["lymphocytes", "ANATOMY", 82, 93], ["glial cell", "ANATOMY", 115, 125], ["lymphocyte", "ANATOMY", 218, 228], ["HLA class II", "GENE_OR_GENE_PRODUCT", 0, 12], ["lymphocyte", "CELL", 44, 54], ["cultureCytotoxic responder lymphocytes", "CELL", 55, 93], ["glial cell donor", "CELL", 115, 131], ["HLA-A", "GENE_OR_GENE_PRODUCT", 147, 152], ["B, C", "CELL", 154, 158], ["lymphocyte", "CELL", 218, 228], ["HLA class II", "PROTEIN", 0, 12], ["lymphocyte cultureCytotoxic responder lymphocytes", "CELL_TYPE", 44, 93], ["mixed lymphocyte culture", "CELL_LINE", 212, 236], ["MLC", "CELL_LINE", 238, 241], ["HLA class II typing", "TEST", 0, 19], ["Mixed lymphocyte cultureCytotoxic responder lymphocytes", "TREATMENT", 38, 93], ["the glial cell donor", "TREATMENT", 111, 131], ["an HLA", "TEST", 144, 150], ["C discordant control donor", "TREATMENT", 157, 183], ["lymphocyte cultureCytotoxic", "OBSERVATION", 44, 71], ["responder lymphocytes", "OBSERVATION", 72, 93], ["glial cell donor", "OBSERVATION", 115, 131]]], ["MNCs from the patient and from the control donor were depleted of T-lymphocytes by rosetting with neuraminidase-treated sheep erythrocytes (Frappier Diagnostic, Laval, Que., Canada).", [["MNCs", "ANATOMY", 0, 4], ["T-lymphocytes", "ANATOMY", 66, 79], ["erythrocytes", "ANATOMY", 126, 138], ["MNCs", "CELL", 0, 4], ["patient", "ORGANISM", 14, 21], ["T-lymphocytes", "CELL", 66, 79], ["rosetting", "CELL", 83, 92], ["neuraminidase", "SIMPLE_CHEMICAL", 98, 111], ["sheep", "ORGANISM", 120, 125], ["erythrocytes", "CELL", 126, 138], ["MNCs", "CELL_TYPE", 0, 4], ["T-lymphocytes", "CELL_TYPE", 66, 79], ["neuraminidase", "PROTEIN", 98, 111], ["sheep erythrocytes", "CELL_TYPE", 120, 138], ["patient", "SPECIES", 14, 21], ["sheep", "SPECIES", 120, 125], ["sheep", "SPECIES", 120, 125], ["MNCs", "TEST", 0, 4], ["neuraminidase", "TEST", 98, 111], ["sheep erythrocytes", "PROBLEM", 120, 138]]], ["Non-rosetting cells (E-cells, i.e. Blymphocytes and macrophages) were recovered from a Ficoll-Hypaque gradient and irradiated (3000 Rad, AECL Gammacell 1000 irradiator).", [["Non-rosetting cells", "ANATOMY", 0, 19], ["E-cells", "ANATOMY", 21, 28], ["Blymphocytes", "ANATOMY", 35, 47], ["macrophages", "ANATOMY", 52, 63], ["cells", "CELL", 14, 19], ["E-cells", "CELL", 21, 28], ["Blymphocytes", "CELL", 35, 47], ["macrophages", "CELL", 52, 63], ["Non-rosetting cells", "CELL_LINE", 0, 19], ["E-cells", "CELL_TYPE", 21, 28], ["Blymphocytes", "CELL_TYPE", 35, 47], ["macrophages", "CELL_TYPE", 52, 63], ["E-cells", "TEST", 21, 28], ["Blymphocytes", "TEST", 35, 47], ["macrophages", "TEST", 52, 63], ["macrophages", "ANATOMY", 52, 63]]], ["Whole MNCs isolated from peripheral blood from a second healthy donor, who was discordant with both the glial cell donor and with the other stimulator cell donor, were used as responder cells.", [["MNCs", "ANATOMY", 6, 10], ["peripheral blood", "ANATOMY", 25, 41], ["glial cell", "ANATOMY", 104, 114], ["cell", "ANATOMY", 151, 155], ["cells", "ANATOMY", 186, 191], ["MNCs", "CELL", 6, 10], ["peripheral blood", "ORGANISM_SUBSTANCE", 25, 41], ["glial cell", "CELL", 104, 114], ["cell", "CELL", 151, 155], ["cells", "CELL", 186, 191], ["MNCs", "CELL_TYPE", 6, 10], ["responder cells", "CELL_TYPE", 176, 191], ["Whole MNCs", "PROBLEM", 0, 10], ["peripheral blood", "PROBLEM", 25, 41], ["the glial cell donor", "TREATMENT", 100, 120], ["the other stimulator cell donor", "TREATMENT", 130, 161], ["peripheral", "ANATOMY_MODIFIER", 25, 35], ["blood", "ANATOMY", 36, 41], ["glial cell donor", "OBSERVATION", 104, 120]]], ["These responder MNCs were incubated in a 3:1 ratio with irradiated E-cells from patient or control donor, in RPMI supplemented with 10% NHS.", [["MNCs", "ANATOMY", 16, 20], ["E-cells", "ANATOMY", 67, 74], ["MNCs", "CELL", 16, 20], ["E-cells", "CELL", 67, 74], ["patient", "ORGANISM", 80, 87], ["responder MNCs", "CELL_TYPE", 6, 20], ["irradiated E-cells", "CELL_LINE", 56, 74], ["patient", "SPECIES", 80, 87], ["irradiated E-cells", "TREATMENT", 56, 74]]], ["Some MNCs were maintained in culture without stimulation.", [["MNCs", "ANATOMY", 5, 9], ["MNCs", "CELL", 5, 9], ["MNCs", "CELL_TYPE", 5, 9], ["Some MNCs", "TEST", 0, 9], ["culture", "TEST", 29, 36], ["stimulation", "PROBLEM", 45, 56]]], ["On day 7 viable cells were recovered from a Ficoll gradient and used as the source of cytotoxic cells in the 51Cr release assay.", [["cells", "ANATOMY", 16, 21], ["cells", "ANATOMY", 96, 101], ["cells", "CELL", 16, 21], ["cells", "CELL", 96, 101], ["51Cr", "SIMPLE_CHEMICAL", 109, 113], ["cytotoxic cells", "CELL_TYPE", 86, 101], ["a Ficoll gradient", "TREATMENT", 42, 59], ["cytotoxic cells", "PROBLEM", 86, 101], ["the 51Cr release assay", "TEST", 105, 127], ["Ficoll gradient", "OBSERVATION", 44, 59], ["cytotoxic cells", "OBSERVATION", 86, 101]]], ["Proliferation rates of the recovered cells were assessed by measurement of [3H]thymidine uptake.Mixed lymphocyte cultureIn two experiments, enriched CD8 \u00f7 and CD4 \u00f7 subsets were obtained from the MLC-derived lymphocytes by using OKT4 or OKT8 antibody (Ortho Diagnostic Systems, Don Mills, Ont., Canada) in a 'panning' technique for negative cell selection, as previously described (Rosenkoetter et al., 1984) .", [["cells", "ANATOMY", 37, 42], ["lymphocyte", "ANATOMY", 102, 112], ["CD8 \u00f7", "ANATOMY", 149, 154], ["CD4 \u00f7 subsets", "ANATOMY", 159, 172], ["MLC-derived lymphocytes", "ANATOMY", 196, 219], ["cell", "ANATOMY", 341, 345], ["[3H]thymidine", "CHEMICAL", 75, 88], ["[3H]thymidine", "CHEMICAL", 75, 88], ["cells", "CELL", 37, 42], ["[3H]thymidine", "SIMPLE_CHEMICAL", 75, 88], ["lymphocyte", "CELL", 102, 112], ["CD8", "GENE_OR_GENE_PRODUCT", 149, 152], ["CD4", "GENE_OR_GENE_PRODUCT", 159, 162], ["MLC-derived lymphocytes", "CELL", 196, 219], ["OKT4", "GENE_OR_GENE_PRODUCT", 229, 233], ["OKT8", "GENE_OR_GENE_PRODUCT", 237, 241], ["cell", "CELL", 341, 345], ["CD8 \u00f7 and CD4 \u00f7 subsets", "CELL_TYPE", 149, 172], ["MLC-derived lymphocytes", "CELL_LINE", 196, 219], ["OKT4", "PROTEIN", 229, 233], ["OKT8 antibody", "PROTEIN", 237, 250], ["Proliferation rates", "TEST", 0, 19], ["thymidine uptake", "TEST", 79, 95], ["Mixed lymphocyte cultureIn", "TEST", 96, 122], ["CD4 \u00f7 subsets", "TEST", 159, 172], ["the MLC", "TEST", 192, 199], ["OKT4", "TEST", 229, 233], ["OKT8 antibody", "TEST", 237, 250], ["a 'panning' technique", "TREATMENT", 306, 327], ["negative cell selection", "TREATMENT", 332, 355], ["recovered cells", "OBSERVATION", 27, 42], ["negative cell selection", "OBSERVATION", 332, 355]]], ["This technique routinely yields > 85-90% enrichment of the desired T-cell subset as determined by fluorescence-activated cell sorting (FACS) analysis (Antel et al., 1986) .Immunocytochemical properties of cultured human OGCAs shown in Fig. 1 , MHC class I antigen expression was detectable on the soma and cell processes of CNPase-positive cells, even though the class I antigens were not detectable on brain tissue sections (Grenier et al., 1989) .", [["T-cell", "ANATOMY", 67, 73], ["cell", "ANATOMY", 121, 125], ["OGCAs", "ANATOMY", 220, 225], ["soma", "ANATOMY", 297, 301], ["cell", "ANATOMY", 306, 310], ["cells", "ANATOMY", 340, 345], ["brain tissue sections", "ANATOMY", 403, 424], ["T-cell", "CELL", 67, 73], ["cell", "CELL", 121, 125], ["human", "ORGANISM", 214, 219], ["OGCAs", "CELL", 220, 225], ["MHC class I antigen", "GENE_OR_GENE_PRODUCT", 244, 263], ["soma", "CELLULAR_COMPONENT", 297, 301], ["cell", "CELL", 306, 310], ["CNPase", "GENE_OR_GENE_PRODUCT", 324, 330], ["class I antigens", "GENE_OR_GENE_PRODUCT", 363, 379], ["brain tissue sections", "MULTI-TISSUE_STRUCTURE", 403, 424], ["T-cell subset", "CELL_TYPE", 67, 80], ["cultured human OGCAs", "CELL_LINE", 205, 225], ["MHC class I antigen", "PROTEIN", 244, 263], ["CNPase", "PROTEIN", 324, 330], ["class I antigens", "PROTEIN", 363, 379], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 214, 219], ["This technique", "TEST", 0, 14], ["Immunocytochemical properties", "TEST", 172, 201], ["cultured human OGCAs", "TEST", 205, 225], ["CNPase", "TEST", 324, 330], ["positive cells", "PROBLEM", 331, 345], ["positive cells", "OBSERVATION", 331, 345]]], ["The percentage OGCs in the cultures ranged from approximately 60 to 90%.Lectin-dependent cytotoxicityMean specific cytolysis mediated by ConAactivated lymphocytes at a 10:1 effector/target ratio, in the presence of the lectin was 24.3 +__ 3.4%, n = 12 (range 15-52%).", [["ConAactivated lymphocytes", "ANATOMY", 137, 162], ["Lectin", "GENE_OR_GENE_PRODUCT", 72, 78], ["ConAactivated lymphocytes", "CELL", 137, 162], ["lectin", "GENE_OR_GENE_PRODUCT", 219, 225], ["ConAactivated lymphocytes", "CELL_TYPE", 137, 162], ["lectin", "PROTEIN", 219, 225], ["The percentage OGCs", "TEST", 0, 19], ["the cultures", "TEST", 23, 35], ["Lectin-dependent cytotoxicity", "PROBLEM", 72, 101], ["Mean specific cytolysis", "TEST", 101, 124], ["ConAactivated lymphocytes", "PROBLEM", 137, 162], ["target ratio", "TEST", 182, 194], ["the lectin", "TEST", 215, 225], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["OGCs", "OBSERVATION", 15, 19], ["dependent", "OBSERVATION_MODIFIER", 79, 88], ["cytotoxicity", "OBSERVATION_MODIFIER", 89, 101], ["cytolysis", "OBSERVATION", 115, 124]]], ["ConA-activated lymphocytes induced significantly less lysis when the lectin was deleted from the cytotoxicity assay and ConA-binding sites were blocked with a-methylt)-mannoside (mean lysis 15.0 + 4.1%, p < 0.01, paired t-test).", [["lymphocytes", "ANATOMY", 15, 26], ["a-methylt)-mannoside", "CHEMICAL", 157, 177], ["a-methylt)-mannoside", "CHEMICAL", 157, 177], ["ConA", "GENE_OR_GENE_PRODUCT", 0, 4], ["lymphocytes", "CELL", 15, 26], ["lectin", "GENE_OR_GENE_PRODUCT", 69, 75], ["ConA", "SIMPLE_CHEMICAL", 120, 124], ["a-methylt)-mannoside", "SIMPLE_CHEMICAL", 157, 177], ["ConA", "PROTEIN", 0, 4], ["activated lymphocytes", "CELL_TYPE", 5, 26], ["lectin", "PROTEIN", 69, 75], ["ConA", "PROTEIN", 120, 124], ["activated lymphocytes", "PROBLEM", 5, 26], ["the lectin", "TEST", 65, 75], ["the cytotoxicity assay", "TEST", 93, 115], ["mannoside", "TREATMENT", 168, 177], ["mean lysis", "TEST", 179, 189], ["paired t-test", "TEST", 213, 226]]], ["Non-activated lymphocytes did not induce significant lysis of OGCs (0.7 + 4.7%), even in the presence of ConA (7.2 +_ 3.1%).", [["lymphocytes", "ANATOMY", 14, 25], ["OGCs", "ANATOMY", 62, 66], ["OGCs", "DISEASE", 62, 66], ["lymphocytes", "CELL", 14, 25], ["OGCs", "PATHOLOGICAL_FORMATION", 62, 66], ["ConA", "GENE_OR_GENE_PRODUCT", 105, 109], ["Non-activated lymphocytes", "CELL_TYPE", 0, 25], ["Non-activated lymphocytes", "PROBLEM", 0, 25], ["significant lysis of OGCs", "PROBLEM", 41, 66], ["ConA", "TEST", 105, 109], ["lymphocytes", "OBSERVATION", 14, 25], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["lysis", "OBSERVATION", 53, 58], ["ConA", "OBSERVATION", 105, 109]]], ["No correlation was found between cytolytic activity and levels of [3H]thymidine incorporation by activated lymphocytes (results not shown).", [["lymphocytes", "ANATOMY", 107, 118], ["[3H]thymidine", "CHEMICAL", 66, 79], ["[3H]thymidine", "CHEMICAL", 66, 79], ["[3H]thymidine", "SIMPLE_CHEMICAL", 66, 79], ["lymphocytes", "CELL", 107, 118], ["activated lymphocytes", "CELL_TYPE", 97, 118], ["cytolytic activity", "TEST", 33, 51], ["3H]thymidine incorporation", "TREATMENT", 67, 93], ["activated lymphocytes", "TEST", 97, 118]]], ["The mean level of spontaneous lysis of OGC-enriched cultures was 22 _+ 3%.Mixed lymphocyte culture-activated cytotoxicityIn each of four experiments, responder lymphocytes allo-activated against the glial cell donor's E-cells exhibited significantly higher in vitro cytotoxic activity against the glia than did the same responder lymphocytes activated by E-cells from the donor discordant for MHC class I with the glial cell donor ( p < 0.02 in the paired t-test; Fig. 2 ).", [["OGC", "ANATOMY", 39, 42], ["cultures", "ANATOMY", 52, 60], ["lymphocyte", "ANATOMY", 80, 90], ["lymphocytes", "ANATOMY", 160, 171], ["glial cell", "ANATOMY", 199, 209], ["E-cells", "ANATOMY", 218, 225], ["glia", "ANATOMY", 297, 301], ["lymphocytes", "ANATOMY", 330, 341], ["E-cells", "ANATOMY", 355, 362], ["glial cell", "ANATOMY", 414, 424], ["OGC", "CELL", 39, 42], ["lymphocyte", "CELL", 80, 90], ["lymphocytes", "CELL", 160, 171], ["glial cell donor", "CELL", 199, 215], ["E-cells", "CELL", 218, 225], ["glia", "CELL", 297, 301], ["lymphocytes", "CELL", 330, 341], ["E-cells", "CELL", 355, 362], ["glial cell", "CELL", 414, 424], ["OGC-enriched cultures", "CELL_LINE", 39, 60], ["responder lymphocytes", "CELL_TYPE", 150, 171], ["E-cells", "CELL_LINE", 218, 225], ["glia", "CELL_TYPE", 297, 301], ["responder lymphocytes", "CELL_TYPE", 320, 341], ["E-cells", "CELL_TYPE", 355, 362], ["MHC class I", "PROTEIN", 393, 404], ["spontaneous lysis", "TREATMENT", 18, 35], ["OGC", "TEST", 39, 42], ["enriched cultures", "TEST", 43, 60], ["Mixed lymphocyte culture", "TEST", 74, 98], ["activated cytotoxicity", "PROBLEM", 99, 121], ["the glial cell donor's E-cells", "TEST", 195, 225], ["the glial cell donor", "TREATMENT", 410, 430], ["the paired t-test", "TEST", 445, 462], ["lymphocyte culture", "OBSERVATION", 80, 98], ["glial cell", "OBSERVATION", 199, 209], ["cytotoxic activity", "OBSERVATION", 266, 284], ["glia", "ANATOMY", 297, 301], ["glial cell", "OBSERVATION", 414, 424]]], ["With the latter, levels of glial cell lysis were not significantly different from those in- duced with non-activated cultured lymphocytes from the responder donor.", [["glial cell", "ANATOMY", 27, 37], ["lymphocytes", "ANATOMY", 126, 137], ["glial cell", "CELL", 27, 37], ["lymphocytes", "CELL", 126, 137], ["non-activated cultured lymphocytes", "CELL_LINE", 103, 137], ["glial cell lysis", "TEST", 27, 43], ["non-activated cultured lymphocytes", "PROBLEM", 103, 137], ["the responder donor", "TREATMENT", 143, 162], ["glial cell lysis", "OBSERVATION", 27, 43]]], ["The levels of specific lysis varied as a function of effector/target ratio (Fig. 3) .", [["specific lysis", "TEST", 14, 28], ["lysis", "OBSERVATION", 23, 28]]], ["(Table 1) .Lymphocyte activation as measured by [3H]thymidine incorporation did not differ significantly between the responder MNCs allo-activated by E-cells from glial cell and control donorIn an additional experiment (Table 2) , the number of OGCs surviving after co-culture with allo-activated MNCs for 4 h was determined.", [["Lymphocyte", "ANATOMY", 11, 21], ["MNCs", "ANATOMY", 127, 131], ["E-cells", "ANATOMY", 150, 157], ["glial cell", "ANATOMY", 163, 173], ["OGCs", "ANATOMY", 245, 249], ["MNCs", "ANATOMY", 297, 301], ["[3H]thymidine", "CHEMICAL", 48, 61], ["[3H]thymidine", "CHEMICAL", 48, 61], ["Lymphocyte", "CELL", 11, 21], ["[3H]thymidine", "SIMPLE_CHEMICAL", 48, 61], ["MNCs", "CELL", 127, 131], ["E-cells", "CELL", 150, 157], ["glial cell", "CELL", 163, 173], ["OGCs", "CELL", 245, 249], ["MNCs", "CELL", 297, 301], ["responder MNCs", "CELL_TYPE", 117, 131], ["E-cells", "CELL_TYPE", 150, 157], ["glial cell", "CELL_TYPE", 163, 173], ["OGCs", "CELL_TYPE", 245, 249], ["allo-activated MNCs", "CELL_TYPE", 282, 301], ["Lymphocyte activation", "TEST", 11, 32], ["thymidine incorporation", "PROBLEM", 52, 75], ["the responder MNCs", "TEST", 113, 131], ["allo-activated MNCs", "TREATMENT", 282, 301], ["glial cell", "OBSERVATION", 163, 173]]], ["In this experiment > 90% of the glial cells were GalC \u00f7.", [["glial cells", "ANATOMY", 32, 43], ["glial cells", "CELL", 32, 43], ["glial cells", "CELL_TYPE", 32, 43], ["GalC", "PROTEIN", 49, 53], ["the glial cells", "TEST", 28, 43], ["glial cells", "ANATOMY", 32, 43]]], ["Addition of the allo-activated MNCs resulted in a 45% reduction in the total number ofFractionation and specificity of MLC-actioated cytotoxic lymphocytesIn two experiments (Fig. 4A) , we observed that CD8 \u00f7 cell-mediated lysis exceeded that mediated by the CD4+-enriched subset.", [["MNCs", "ANATOMY", 31, 35], ["cytotoxic lymphocytes", "ANATOMY", 133, 154], ["CD8 \u00f7 cell", "ANATOMY", 202, 212], ["MNCs", "CELL", 31, 35], ["MLC", "GENE_OR_GENE_PRODUCT", 119, 122], ["cytotoxic lymphocytes", "CELL", 133, 154], ["CD8", "GENE_OR_GENE_PRODUCT", 202, 205], ["cell", "CELL", 208, 212], ["CD4", "GENE_OR_GENE_PRODUCT", 258, 261], ["allo-activated MNCs", "CELL_LINE", 16, 35], ["MLC-actioated cytotoxic lymphocytes", "CELL_LINE", 119, 154], ["CD8", "PROTEIN", 202, 205], ["CD4", "PROTEIN", 258, 261], ["the allo-activated MNCs", "TEST", 12, 35], ["a 45% reduction", "TREATMENT", 48, 63], ["MLC", "TEST", 119, 122], ["actioated cytotoxic lymphocytes", "PROBLEM", 123, 154], ["CD8", "TEST", 202, 205], ["mediated lysis", "TREATMENT", 213, 227], ["cytotoxic lymphocytes", "OBSERVATION", 133, 154], ["enriched subset", "OBSERVATION", 263, 278]]], ["The cultures usedQUANTITATIVE ASSESSMENT OF LYSIS OF OLIGO-DENDROCYTES (GalC \u00f7 CELLS) BY ALLO-ACTIVATED MNCsCell number represents the number of GalC + cells counted in 15 high-power fields (magnification 250 x ) in cultures containing OGCs either with culture medium alone, or co-cultured with allo-activated MNCs (activated with the glial cell donor's E-cells) or non-activated MNCs.", [["GalC + cells", "ANATOMY", 145, 157], ["cultures", "ANATOMY", 216, 224], ["OGCs", "ANATOMY", 236, 240], ["MNCs", "ANATOMY", 310, 314], ["glial cell donor's E-cells", "ANATOMY", 335, 361], ["MNCs", "ANATOMY", 380, 384], ["GalC + cells", "CELL", 145, 157], ["OGCs", "CELL", 236, 240], ["MNCs", "CELL", 310, 314], ["glial cell donor's E-cells", "CELL", 335, 361], ["MNCs", "CELL", 380, 384], ["GalC + cells", "CELL_LINE", 145, 157], ["OGCs", "CELL_TYPE", 236, 240], ["allo-activated MNCs", "CELL_TYPE", 295, 314], ["E-cells", "CELL_TYPE", 354, 361], ["non-activated MNCs", "CELL_TYPE", 366, 384], ["The cultures", "TEST", 0, 12], ["OLIGO", "TEST", 53, 58], ["GalC + cells", "TEST", 145, 157], ["cultures containing OGCs", "TEST", 216, 240], ["culture medium", "TEST", 253, 267], ["allo-activated MNCs", "PROBLEM", 295, 314], ["non-activated MNCs", "PROBLEM", 366, 384]]], ["GalC \u00f7 ceils accounted for 90-95% of cells in the culture as determined by double immunostaining with anti-GalC and anti-glial fibrillary acidic protein (GFAP) antibodies.", [["cells", "ANATOMY", 37, 42], ["GalC", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 37, 42], ["anti-GalC", "GENE_OR_GENE_PRODUCT", 102, 111], ["anti-glial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 116, 152], ["GFAP", "GENE_OR_GENE_PRODUCT", 154, 158], ["GalC", "PROTEIN", 0, 4], ["anti-GalC", "PROTEIN", 102, 111], ["anti-glial fibrillary acidic protein (GFAP) antibodies", "PROTEIN", 116, 170], ["GalC \u00f7 ceils", "TEST", 0, 12], ["the culture", "TEST", 46, 57], ["double immunostaining", "TEST", 75, 96], ["anti-GalC", "TEST", 102, 111], ["anti-glial fibrillary acidic protein", "TEST", 116, 152], ["GFAP) antibodies", "TEST", 154, 170]]], ["MNCs were added to glial cells in a 10 : 1 ratio for 4 h.", [["MNCs", "ANATOMY", 0, 4], ["glial cells", "ANATOMY", 19, 30], ["MNCs", "CELL", 0, 4], ["glial cells", "CELL", 19, 30], ["MNCs", "CELL_TYPE", 0, 4], ["glial cells", "CELL_TYPE", 19, 30], ["MNCs", "TEST", 0, 4], ["glial cells", "TEST", 19, 30]]], ["The percentage specific lysis mediated by the allo-activated MNCs in a parallel 51Cr-labelled culture was 41%; specific lysis by non-activated MNCs was 10% for these studies contained 70% and 80% OGCs respectively.", [["MNCs", "ANATOMY", 61, 65], ["MNCs", "ANATOMY", 143, 147], ["51Cr", "CHEMICAL", 80, 84], ["MNCs", "CELL", 61, 65], ["51Cr", "SIMPLE_CHEMICAL", 80, 84], ["MNCs", "CELL", 143, 147], ["allo-activated MNCs", "CELL_LINE", 46, 65], ["non-activated MNCs", "CELL_TYPE", 129, 147], ["The percentage specific lysis", "TREATMENT", 0, 29], ["the allo-activated MNCs", "TEST", 42, 65], ["a parallel 51Cr-labelled culture", "TEST", 69, 101], ["specific lysis", "TEST", 111, 125], ["non-activated MNCs", "TEST", 129, 147], ["these studies", "TEST", 160, 173], ["lysis", "OBSERVATION", 24, 29]]], ["That the CD8+-mediated cytolytic activity was dependent on class I expression on the target cells was suggested by the finding that CD8 + cell-mediated cytotoxic activity could be blocked at least in part by a 30 min pre-incubation of the glia with the anti-class I MHC antibody W6/32 (Fig. 4B ).DiscussionIn the present study we have demonstrated the cytotoxic activity of CD8 + class I-directed lymphocytes against OGC-enriched glial cell cultures.", [["cells", "ANATOMY", 92, 97], ["CD8 + cell", "ANATOMY", 132, 142], ["glia", "ANATOMY", 239, 243], ["lymphocytes", "ANATOMY", 397, 408], ["OGC", "ANATOMY", 417, 420], ["glial cell cultures", "ANATOMY", 430, 449], ["CD8", "GENE_OR_GENE_PRODUCT", 9, 12], ["cells", "CELL", 92, 97], ["CD8", "GENE_OR_GENE_PRODUCT", 132, 135], ["cell", "CELL", 138, 142], ["glia", "CELL", 239, 243], ["CD8 + class I", "GENE_OR_GENE_PRODUCT", 374, 387], ["lymphocytes", "CELL", 397, 408], ["OGC", "CELL", 417, 420], ["glial cell cultures", "CELL", 430, 449], ["CD8", "PROTEIN", 9, 12], ["target cells", "CELL_TYPE", 85, 97], ["CD8", "PROTEIN", 132, 135], ["glia", "CELL_TYPE", 239, 243], ["anti-class I MHC antibody", "PROTEIN", 253, 278], ["W6/32", "PROTEIN", 279, 284], ["Fig. 4B", "PROTEIN", 286, 293], ["CD8 + class I-directed lymphocytes", "CELL_TYPE", 374, 408], ["OGC-enriched glial cell cultures", "CELL_LINE", 417, 449], ["the CD8", "TEST", 5, 12], ["mediated cytolytic activity", "PROBLEM", 14, 41], ["CD8", "TEST", 132, 135], ["cytotoxic activity", "PROBLEM", 152, 170], ["the anti-class I MHC antibody", "TEST", 249, 278], ["the present study", "TEST", 309, 326], ["OGC", "TEST", 417, 420], ["glial cell cultures", "TEST", 430, 449], ["cytolytic activity", "OBSERVATION", 23, 41], ["cytotoxic activity", "OBSERVATION", 152, 170], ["glia", "ANATOMY", 239, 243], ["glial cell cultures", "OBSERVATION", 430, 449]]], ["We have previously shown that a large proportion of human OGCs in vitro express MHC class I antigens (Grenier et al., 1989) , implying a potential susceptibility to lysis by cytotoxic Tlymphocytes (CTL).", [["OGCs", "ANATOMY", 58, 62], ["human", "ORGANISM", 52, 57], ["OGCs", "CELL", 58, 62], ["MHC class I antigens", "GENE_OR_GENE_PRODUCT", 80, 100], ["cytotoxic Tlymphocytes", "CELL", 174, 196], ["CTL", "CELL", 198, 201], ["human OGCs", "CELL_TYPE", 52, 62], ["MHC class I antigens", "PROTEIN", 80, 100], ["cytotoxic Tlymphocytes", "CELL_TYPE", 174, 196], ["CTL", "CELL_TYPE", 198, 201], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["a potential susceptibility to lysis", "PROBLEM", 135, 170], ["large", "OBSERVATION_MODIFIER", 32, 37], ["cytotoxic Tlymphocytes", "OBSERVATION", 174, 196]]], ["We have not detected expression of MHC class II antigens on OGCs, a finding consistent with that of others in studies on spontaneous and cytokine-induced expression of MHC antigens on murine glial cell cultures from immature animals (Wong et al., 1984; Suzumura et al., 1986b) , on human glial cultures established from autopsy material Hirayama et al., 1986 ) and on human fetal glial cultures (Mauerhoff et al., 1988) .", [["OGCs", "ANATOMY", 60, 64], ["glial cell cultures", "ANATOMY", 191, 210], ["glial cultures", "ANATOMY", 288, 302], ["fetal glial cultures", "ANATOMY", 374, 394], ["MHC class II antigens", "GENE_OR_GENE_PRODUCT", 35, 56], ["OGCs", "PATHOLOGICAL_FORMATION", 60, 64], ["MHC antigens", "GENE_OR_GENE_PRODUCT", 168, 180], ["murine", "ORGANISM", 184, 190], ["glial cell cultures", "CELL", 191, 210], ["human", "ORGANISM", 282, 287], ["glial cultures", "CELL", 288, 302], ["human", "ORGANISM", 368, 373], ["fetal glial cultures", "CELL", 374, 394], ["MHC class II antigens", "PROTEIN", 35, 56], ["OGCs", "CELL_TYPE", 60, 64], ["cytokine", "PROTEIN", 137, 145], ["MHC antigens", "PROTEIN", 168, 180], ["murine glial cell cultures", "CELL_LINE", 184, 210], ["human glial cultures", "CELL_LINE", 282, 302], ["human fetal glial cultures", "CELL_LINE", 368, 394], ["murine", "SPECIES", 184, 190], ["human", "SPECIES", 282, 287], ["human", "SPECIES", 368, 373], ["human", "SPECIES", 282, 287], ["human", "SPECIES", 368, 373], ["MHC antigens", "PROBLEM", 168, 180], ["murine glial cell cultures", "TEST", 184, 210], ["immature animals", "PROBLEM", 216, 232], ["human glial cultures", "TEST", 282, 302], ["human fetal glial cultures", "TEST", 368, 394], ["consistent with", "UNCERTAINTY", 76, 91], ["glial cell", "OBSERVATION", 191, 201]]], ["In CNS tissue from the same patients whose cultured glial cells expressed MHC class I antigens, we could not detect MHC antigens on tissue sections, using immunohistochemical techniques (Grenier et al., 1989) .", [["CNS tissue", "ANATOMY", 3, 13], ["glial cells", "ANATOMY", 52, 63], ["tissue sections", "ANATOMY", 132, 147], ["CNS tissue", "TISSUE", 3, 13], ["patients", "ORGANISM", 28, 36], ["glial cells", "CELL", 52, 63], ["MHC class I antigens", "GENE_OR_GENE_PRODUCT", 74, 94], ["MHC antigens", "GENE_OR_GENE_PRODUCT", 116, 128], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 132, 147], ["cultured glial cells", "CELL_LINE", 43, 63], ["MHC class I antigens", "PROTEIN", 74, 94], ["MHC antigens", "PROTEIN", 116, 128], ["patients", "SPECIES", 28, 36], ["tissue sections", "TEST", 132, 147], ["immunohistochemical techniques", "TEST", 155, 185], ["CNS", "ANATOMY", 3, 6], ["tissue", "OBSERVATION", 7, 13]]], ["Whether the differences between in situ and in vitro expression of MHC antigens on OGCs reflect technical or biological factors remains under study.DiscussionWe applied a 5aCr release assay to demonstrate cellular immune-mediated lysis of OGCs.", [["OGCs", "ANATOMY", 83, 87], ["cellular", "ANATOMY", 205, 213], ["OGCs", "ANATOMY", 239, 243], ["OGCs", "DISEASE", 239, 243], ["MHC antigens", "GENE_OR_GENE_PRODUCT", 67, 79], ["OGCs", "CANCER", 83, 87], ["5aCr", "SIMPLE_CHEMICAL", 171, 175], ["cellular", "CELL", 205, 213], ["OGCs", "PATHOLOGICAL_FORMATION", 239, 243], ["MHC antigens", "PROTEIN", 67, 79], ["OGCs", "CELL_TYPE", 239, 243], ["a 5aCr release assay", "TREATMENT", 169, 189], ["cellular immune-mediated lysis of OGCs", "TREATMENT", 205, 243]]], ["This assay system has been used by others in studies of cytotoxicity to murine OGCs as mediated by human serum (Suzumura et al., 1986a) and by myelin basic protein-reactive CD4 + cell lines (Kawai and Zweiman, 1988) .", [["OGCs", "ANATOMY", 79, 83], ["serum", "ANATOMY", 105, 110], ["CD4 + cell lines", "ANATOMY", 173, 189], ["murine", "ORGANISM", 72, 78], ["OGCs", "CELL", 79, 83], ["human", "ORGANISM", 99, 104], ["serum", "ORGANISM_SUBSTANCE", 105, 110], ["myelin basic protein", "GENE_OR_GENE_PRODUCT", 143, 163], ["CD4", "GENE_OR_GENE_PRODUCT", 173, 176], ["murine OGCs", "CELL_TYPE", 72, 83], ["myelin basic protein-reactive CD4 + cell lines", "CELL_LINE", 143, 189], ["murine", "SPECIES", 72, 78], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["This assay system", "TEST", 0, 17], ["human serum", "TEST", 99, 110], ["myelin basic protein", "TEST", 143, 163], ["reactive CD4 + cell lines", "OBSERVATION", 164, 189]]], ["Our studies indicated that OGCs and non-OGCs in our cultures were comparably labelled with 51Cr.DiscussionThe lectin-dependent cytotoxicity assay provided a means to assess susceptibility of cells in our OGC-enriched cultures to T-cell-mediated ly-sis which was neither antigen specific nor MHC restricted.", [["OGCs", "ANATOMY", 27, 31], ["non-OGCs", "ANATOMY", 36, 44], ["cultures", "ANATOMY", 52, 60], ["cells", "ANATOMY", 191, 196], ["cultures", "ANATOMY", 217, 225], ["T-cell", "ANATOMY", 229, 235], ["51Cr", "CHEMICAL", 91, 95], ["51Cr", "CHEMICAL", 91, 95], ["OGCs", "CELL", 27, 31], ["non-OGCs", "CELL", 36, 44], ["51Cr", "SIMPLE_CHEMICAL", 91, 95], ["lectin", "GENE_OR_GENE_PRODUCT", 110, 116], ["cells", "CELL", 191, 196], ["OGC", "SIMPLE_CHEMICAL", 204, 207], ["cultures", "CELL", 217, 225], ["T-cell", "CELL", 229, 235], ["OGCs", "CELL_TYPE", 27, 31], ["non-OGCs", "CELL_TYPE", 36, 44], ["lectin", "PROTEIN", 110, 116], ["OGC-enriched cultures", "CELL_LINE", 204, 225], ["MHC", "PROTEIN", 291, 294], ["Our studies", "TEST", 0, 11], ["OGCs", "TEST", 27, 31], ["our cultures", "TEST", 48, 60], ["The lectin-dependent cytotoxicity assay", "TEST", 106, 145], ["susceptibility of cells", "PROBLEM", 173, 196], ["our OGC", "TEST", 200, 207], ["enriched cultures", "TEST", 208, 225]]], ["The presence of an agglutinizing lectin, such as ConA, in the assay provides the required contact between cytotoxic-effector cell and target cell to permit cytolysis (Bevan and Cohn, 1975 ). a-Methyl-o-mannoside, a competitive blocker of ConA, was added in control assays in an attempt to prevent the agglutinizing effect of any residual ConA on stimulated lymphocytes.", [["cell", "ANATOMY", 125, 129], ["cell", "ANATOMY", 141, 145], ["lymphocytes", "ANATOMY", 357, 368], ["a-Methyl-o-mannoside", "CHEMICAL", 191, 211], ["ConA", "CHEMICAL", 238, 242], ["a-Methyl-o-mannoside", "CHEMICAL", 191, 211], ["lectin", "GENE_OR_GENE_PRODUCT", 33, 39], ["ConA", "GENE_OR_GENE_PRODUCT", 49, 53], ["cell", "CELL", 125, 129], ["cell", "CELL", 141, 145], ["a-Methyl-o-mannoside", "SIMPLE_CHEMICAL", 191, 211], ["ConA", "SIMPLE_CHEMICAL", 238, 242], ["ConA", "SIMPLE_CHEMICAL", 338, 342], ["lymphocytes", "CELL", 357, 368], ["agglutinizing lectin", "PROTEIN", 19, 39], ["ConA", "PROTEIN", 49, 53], ["cytotoxic-effector cell", "CELL_TYPE", 106, 129], ["target cell", "CELL_TYPE", 134, 145], ["ConA", "PROTEIN", 338, 342], ["stimulated lymphocytes", "CELL_TYPE", 346, 368], ["an agglutinizing lectin", "PROBLEM", 16, 39], ["cytotoxic-effector cell", "TREATMENT", 106, 129], ["target cell", "PROBLEM", 134, 145], ["cytolysis", "TEST", 156, 165], ["a-Methyl", "TREATMENT", 191, 199], ["mannoside", "TREATMENT", 202, 211], ["a competitive blocker of ConA", "TREATMENT", 213, 242], ["any residual ConA on stimulated lymphocytes", "PROBLEM", 325, 368], ["agglutinizing lectin", "OBSERVATION", 19, 39], ["effector cell", "OBSERVATION", 116, 129], ["stimulated lymphocytes", "OBSERVATION", 346, 368]]], ["We did, however, observe that some glial cell lysis occurred in the absence of added lectin in the assay.", [["glial cell", "ANATOMY", 35, 45], ["glial cell", "CELL", 35, 45], ["lectin", "GENE_OR_GENE_PRODUCT", 85, 91], ["lectin", "PROTEIN", 85, 91], ["some glial cell lysis", "PROBLEM", 30, 51], ["glial cell lysis", "OBSERVATION", 35, 51]]], ["Whether residual cell-cell binding occurred or whether soluble factors released by the activated effector cells induced the low level of lysis was not resolved by our study.DiscussionEffector lymphocytes allo-activated with the glial cell donor's E-cells induced a higher degree of lysis of glial ceils than did lymphocytes from the same effector cell donor, allo-activated by Ecells bearing MHC class I eptitopes different from the glia.", [["cell", "ANATOMY", 17, 21], ["cell", "ANATOMY", 22, 26], ["effector cells", "ANATOMY", 97, 111], ["DiscussionEffector lymphocytes", "ANATOMY", 173, 203], ["glial cell", "ANATOMY", 228, 238], ["E-cells", "ANATOMY", 247, 254], ["glial ceils", "ANATOMY", 291, 302], ["lymphocytes", "ANATOMY", 312, 323], ["cell", "ANATOMY", 347, 351], ["glia", "ANATOMY", 433, 437], ["cell", "CELL", 17, 21], ["cell", "CELL", 22, 26], ["cells", "CELL", 106, 111], ["DiscussionEffector lymphocytes", "CELL", 173, 203], ["glial cell donor", "CELL", 228, 244], ["E-cells", "CELL", 247, 254], ["glial ceils", "CELL", 291, 302], ["lymphocytes", "CELL", 312, 323], ["effector cell", "CELL", 338, 351], ["Ecells", "CELL", 377, 383], ["glia", "CELL", 433, 437], ["soluble factors", "PROTEIN", 55, 70], ["activated effector cells", "CELL_TYPE", 87, 111], ["DiscussionEffector lymphocytes", "CELL_TYPE", 173, 203], ["glial cell donor's E-cells", "CELL_TYPE", 228, 254], ["glial ceils", "CELL_TYPE", 291, 302], ["lymphocytes", "CELL_TYPE", 312, 323], ["Ecells", "PROTEIN", 377, 383], ["MHC class I eptitopes", "PROTEIN", 392, 413], ["glia", "CELL_TYPE", 433, 437], ["residual cell-cell binding", "PROBLEM", 8, 34], ["soluble factors", "PROBLEM", 55, 70], ["the activated effector cells", "PROBLEM", 83, 111], ["lysis", "TREATMENT", 137, 142], ["our study", "TEST", 163, 172], ["lysis of glial ceils", "PROBLEM", 282, 302], ["lymphocytes", "PROBLEM", 312, 323], ["residual cell-cell binding", "OBSERVATION", 8, 34], ["lysis", "OBSERVATION", 137, 142], ["higher degree", "OBSERVATION_MODIFIER", 265, 278], ["lysis", "OBSERVATION", 282, 287], ["glial ceils", "OBSERVATION", 291, 302], ["effector cell donor", "OBSERVATION", 338, 357], ["glia", "ANATOMY", 433, 437]]], ["The levels of specific lysis observed in cultures which contained > 70% and > 80% OGCs ruled out the possibility that a population of non-OGC cells were exclusively the targets of MHC class I-dependent lysis.", [["cultures", "ANATOMY", 41, 49], ["non-OGC cells", "ANATOMY", 134, 147], ["non-OGC cells", "CELL", 134, 147], ["MHC class I", "GENE_OR_GENE_PRODUCT", 180, 191], ["non-OGC cells", "CELL_LINE", 134, 147], ["MHC class I", "PROTEIN", 180, 191], ["specific lysis", "TEST", 14, 28], ["cultures", "TEST", 41, 49], ["a population of non-OGC cells", "PROBLEM", 118, 147], ["dependent lysis", "TREATMENT", 192, 207], ["lysis", "OBSERVATION", 23, 28]]], ["The observation was confirmed by separate studies showing quantitative reductions in OGCs following exposure to allo-activated MNCs.", [["OGCs", "ANATOMY", 85, 89], ["MNCs", "ANATOMY", 127, 131], ["OGCs", "SIMPLE_CHEMICAL", 85, 89], ["MNCs", "CELL", 127, 131], ["OGCs", "CELL_TYPE", 85, 89], ["allo-activated MNCs", "CELL_TYPE", 112, 131], ["separate studies", "TEST", 33, 49], ["quantitative reductions in OGCs", "PROBLEM", 58, 89], ["allo-activated MNCs", "TREATMENT", 112, 131], ["reductions", "OBSERVATION_MODIFIER", 71, 81]]], ["Our conclusion regarding the susceptibility of OGCs to MHC class I-restricted lysis was further supported by the findings that cytotoxicity by CD8 + class I-dependent lymphocytes exceeded that by CD4 + class II-dependent lymphocytes and specific cell lysis could be reduced by anti-MHC class I antibodies.", [["lymphocytes", "ANATOMY", 167, 178], ["lymphocytes", "ANATOMY", 221, 232], ["cell", "ANATOMY", 246, 250], ["OGCs", "CANCER", 47, 51], ["CD8 + class I", "GENE_OR_GENE_PRODUCT", 143, 156], ["lymphocytes", "CELL", 167, 178], ["CD4 + class II", "GENE_OR_GENE_PRODUCT", 196, 210], ["lymphocytes", "CELL", 221, 232], ["cell", "CELL", 246, 250], ["anti-MHC class I antibodies", "GENE_OR_GENE_PRODUCT", 277, 304], ["MHC class I", "PROTEIN", 55, 66], ["CD8 + class I-dependent lymphocytes", "CELL_TYPE", 143, 178], ["CD4", "PROTEIN", 196, 199], ["class II-dependent lymphocytes", "CELL_TYPE", 202, 232], ["anti-MHC class I antibodies", "PROTEIN", 277, 304], ["-restricted lysis", "TREATMENT", 66, 83], ["cytotoxicity", "TEST", 127, 139], ["CD8", "TEST", 143, 146], ["class I-dependent lymphocytes", "PROBLEM", 149, 178], ["CD4", "TEST", 196, 199], ["dependent lymphocytes", "PROBLEM", 211, 232], ["specific cell lysis", "TREATMENT", 237, 256], ["dependent", "OBSERVATION_MODIFIER", 211, 220], ["lymphocytes", "OBSERVATION", 221, 232], ["specific cell lysis", "OBSERVATION", 237, 256]]], ["The residual lysis by CD8 + T-lymphocytes of OGC after pre-incubation with the anti-MHC class I antibody, together with the observation that lymphocytes allo-activated with MHC class I-discordant E-cells induce some specific lysis of OGC, suggest that some degree of lysis mediated by CD8 + cells is not MHC restricted.", [["CD8 + T-lymphocytes", "ANATOMY", 22, 41], ["OGC", "ANATOMY", 45, 48], ["lymphocytes", "ANATOMY", 141, 152], ["E-cells", "ANATOMY", 196, 203], ["OGC", "ANATOMY", 234, 237], ["CD8 + cells", "ANATOMY", 285, 296], ["CD8", "GENE_OR_GENE_PRODUCT", 22, 25], ["OGC", "CANCER", 45, 48], ["anti-MHC class I antibody", "GENE_OR_GENE_PRODUCT", 79, 104], ["lymphocytes", "CELL", 141, 152], ["OGC", "CANCER", 234, 237], ["CD8", "GENE_OR_GENE_PRODUCT", 285, 288], ["CD8", "PROTEIN", 22, 25], ["T-lymphocytes", "CELL_TYPE", 28, 41], ["OGC", "CELL_TYPE", 45, 48], ["anti-MHC class I antibody", "PROTEIN", 79, 104], ["lymphocytes", "CELL_TYPE", 141, 152], ["MHC class I-discordant E-cells", "CELL_LINE", 173, 203], ["OGC", "CELL_TYPE", 234, 237], ["CD8", "PROTEIN", 285, 288], ["MHC", "PROTEIN", 304, 307], ["The residual lysis", "TREATMENT", 0, 18], ["T-lymphocytes of OGC", "PROBLEM", 28, 48], ["pre-incubation", "TREATMENT", 55, 69], ["lymphocytes", "TEST", 141, 152], ["some specific lysis of OGC", "PROBLEM", 211, 237], ["lysis", "PROBLEM", 267, 272], ["residual", "OBSERVATION_MODIFIER", 4, 12], ["lysis", "OBSERVATION", 13, 18], ["lysis", "OBSERVATION", 267, 272]]], ["In previous studies with neonatal murine astrocytes, we have demonstrated that MHC class I-directed cytotoxic lymphocytes could lyse astrocytes.", [["astrocytes", "ANATOMY", 41, 51], ["cytotoxic lymphocytes", "ANATOMY", 100, 121], ["astrocytes", "ANATOMY", 133, 143], ["murine", "ORGANISM", 34, 40], ["astrocytes", "CELL", 41, 51], ["MHC class I", "GENE_OR_GENE_PRODUCT", 79, 90], ["cytotoxic lymphocytes", "CELL", 100, 121], ["astrocytes", "CELL", 133, 143], ["neonatal murine astrocytes", "CELL_TYPE", 25, 51], ["MHC class I", "PROTEIN", 79, 90], ["cytotoxic lymphocytes", "CELL_TYPE", 100, 121], ["astrocytes", "CELL_TYPE", 133, 143], ["murine", "SPECIES", 34, 40], ["neonatal murine astrocytes", "TEST", 25, 51], ["cytotoxic lymphocytes", "OBSERVATION", 100, 121]]], ["This cytotoxic effect was lost with target astrocytes from mutant animals which lacked the sensitizing MHC class I antigens (Skias et al., 1987) .", [["astrocytes", "ANATOMY", 43, 53], ["astrocytes", "CELL", 43, 53], ["astrocytes", "CELL_TYPE", 43, 53], ["MHC class I antigens", "PROTEIN", 103, 123], ["target astrocytes", "PROBLEM", 36, 53], ["mutant animals", "PROBLEM", 59, 73], ["cytotoxic effect", "OBSERVATION", 5, 21]]], ["The observed class I-restricted lysis of OGCs suggests that MHC class I molecules on OGCs could contribute to susceptibility of these cells to either antigenspecific cytotoxicity or to lysis by autoreactive cytotoxic cells (Bimbaum et al., 1984) , if expression of MHC antigens occurred in vivo, as is the case in viral infection in mice (Suzumura et al., 1986c) .DiscussionThe results of the MLC experiments indicate that alloreactive CD4 \u00f7 lymphocytes may also induce glial cell lysis.", [["OGCs", "ANATOMY", 85, 89], ["cells", "ANATOMY", 134, 139], ["autoreactive cytotoxic cells", "ANATOMY", 194, 222], ["alloreactive CD4 \u00f7 lymphocytes", "ANATOMY", 423, 453], ["glial cell", "ANATOMY", 470, 480], ["viral infection", "DISEASE", 314, 329], ["OGCs", "CANCER", 41, 45], ["MHC class I", "GENE_OR_GENE_PRODUCT", 60, 71], ["OGCs", "GENE_OR_GENE_PRODUCT", 85, 89], ["cells", "CELL", 134, 139], ["autoreactive cytotoxic cells", "CELL", 194, 222], ["MHC antigens", "GENE_OR_GENE_PRODUCT", 265, 277], ["mice", "ORGANISM", 333, 337], ["CD4", "GENE_OR_GENE_PRODUCT", 436, 439], ["glial cell", "CELL", 470, 480], ["OGCs", "CELL_TYPE", 41, 45], ["MHC class I molecules", "PROTEIN", 60, 81], ["autoreactive cytotoxic cells", "CELL_TYPE", 194, 222], ["MHC antigens", "PROTEIN", 265, 277], ["alloreactive CD4 \u00f7 lymphocytes", "CELL_TYPE", 423, 453], ["mice", "SPECIES", 333, 337], ["mice", "SPECIES", 333, 337], ["-restricted lysis of OGCs", "TREATMENT", 20, 45], ["MHC class I molecules on OGCs", "PROBLEM", 60, 89], ["these cells", "PROBLEM", 128, 139], ["antigenspecific cytotoxicity", "PROBLEM", 150, 178], ["lysis", "TREATMENT", 185, 190], ["autoreactive cytotoxic cells", "PROBLEM", 194, 222], ["MHC antigens", "PROBLEM", 265, 277], ["viral infection", "PROBLEM", 314, 329], ["the MLC experiments", "TEST", 389, 408], ["alloreactive CD4 \u00f7 lymphocytes", "PROBLEM", 423, 453], ["glial cell lysis", "TREATMENT", 470, 486], ["cytotoxic cells", "OBSERVATION", 207, 222], ["viral", "OBSERVATION_MODIFIER", 314, 319], ["infection", "OBSERVATION", 320, 329], ["alloreactive CD4", "OBSERVATION", 423, 439], ["glial cell lysis", "OBSERVATION", 470, 486]]], ["The cytotoxic effect of CD4 \u00f7 lymphocytes may have reflected lysis of class IIexpressing non-OGC cell types in the cultures, or may have resulted from the release of soluble intermediaries such as interferon-,/ or tumor necrosis factor-a.", [["CD4 \u00f7 lymphocytes", "ANATOMY", 24, 41], ["cell", "ANATOMY", 97, 101], ["cultures", "ANATOMY", 115, 123], ["tumor", "DISEASE", 214, 219], ["CD4", "GENE_OR_GENE_PRODUCT", 24, 27], ["non-OGC cell", "CELL", 89, 101], ["interferon", "GENE_OR_GENE_PRODUCT", 197, 207], ["tumor necrosis factor-a", "GENE_OR_GENE_PRODUCT", 214, 237], ["CD4 \u00f7 lymphocytes", "CELL_TYPE", 24, 41], ["class IIexpressing non-OGC cell types", "CELL_LINE", 70, 107], ["interferon", "PROTEIN", 197, 207], ["tumor necrosis factor", "PROTEIN", 214, 235], ["CD4 \u00f7 lymphocytes", "PROBLEM", 24, 41], ["lysis of class IIexpressing non-OGC cell types", "PROBLEM", 61, 107], ["the cultures", "TEST", 111, 123], ["soluble intermediaries", "PROBLEM", 166, 188], ["interferon", "TREATMENT", 197, 207], ["tumor necrosis factor", "PROBLEM", 214, 235], ["cytotoxic", "OBSERVATION_MODIFIER", 4, 13], ["effect", "OBSERVATION_MODIFIER", 14, 20], ["CD4 \u00f7 lymphocytes", "OBSERVATION", 24, 41], ["lysis", "OBSERVATION_MODIFIER", 61, 66], ["non-OGC cell types", "OBSERVATION", 89, 107], ["tumor", "OBSERVATION_MODIFIER", 214, 219], ["necrosis", "OBSERVATION", 220, 228]]], ["Despite the lack of MHC class II expression, murine OGCs are susceptible to lysis by myelin basic protein (MBP)-specific, but not purified protein derivative (PPD)-specific cytotoxic CD4 \u00f7 cells in the presence of antigen-presenting cells, which may act as intermediaries in cytotoxicity (Kawai and Zweiman, 1988) .", [["OGCs", "ANATOMY", 52, 56], ["cytotoxic CD4 \u00f7 cells", "ANATOMY", 173, 194], ["cells", "ANATOMY", 233, 238], ["MHC class II", "GENE_OR_GENE_PRODUCT", 20, 32], ["murine", "ORGANISM", 45, 51], ["OGCs", "CANCER", 52, 56], ["myelin basic protein", "GENE_OR_GENE_PRODUCT", 85, 105], ["MBP", "GENE_OR_GENE_PRODUCT", 107, 110], ["CD4 \u00f7 cells", "CELL", 183, 194], ["cells", "CELL", 233, 238], ["MHC class II", "PROTEIN", 20, 32], ["murine OGCs", "CELL_TYPE", 45, 56], ["myelin basic protein", "PROTEIN", 85, 105], ["MBP", "PROTEIN", 107, 110], ["cytotoxic CD4 \u00f7 cells", "CELL_TYPE", 173, 194], ["antigen-presenting cells", "CELL_TYPE", 214, 238], ["murine", "SPECIES", 45, 51], ["murine OGCs", "TEST", 45, 56], ["lysis", "TREATMENT", 76, 81], ["myelin basic protein", "TEST", 85, 105], ["MBP", "TEST", 107, 110], ["PPD", "TEST", 159, 162], ["specific cytotoxic CD4 \u00f7 cells", "PROBLEM", 164, 194], ["presenting cells", "PROBLEM", 222, 238], ["cytotoxic CD4 \u00f7 cells", "OBSERVATION", 173, 194]]], ["MBP-reactive CD4 \u00f7 cell lines are essential for the passive transfer of EAE (Zamvil et al., 1985) and have been isolated from peripheral blood of normal human donors (Bums et al., 1983) and MS patients (Weber and Buurman, 1988) .", [["CD4 \u00f7 cell lines", "ANATOMY", 13, 29], ["peripheral blood", "ANATOMY", 126, 142], ["EAE", "DISEASE", 72, 75], ["MBP", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD4", "GENE_OR_GENE_PRODUCT", 13, 16], ["peripheral blood", "ORGANISM_SUBSTANCE", 126, 142], ["human", "ORGANISM", 153, 158], ["donors", "ORGANISM", 159, 165], ["patients", "ORGANISM", 193, 201], ["MBP", "PROTEIN", 0, 3], ["reactive CD4 \u00f7 cell lines", "CELL_LINE", 4, 29], ["human", "SPECIES", 153, 158], ["patients", "SPECIES", 193, 201], ["human", "SPECIES", 153, 158], ["MBP", "TEST", 0, 3], ["cell lines", "TREATMENT", 19, 29], ["reactive", "OBSERVATION_MODIFIER", 4, 12], ["CD4 \u00f7 cell lines", "OBSERVATION", 13, 29], ["peripheral", "ANATOMY_MODIFIER", 126, 136], ["blood", "ANATOMY", 137, 142]]]], "87cc0af9cce74ce6cbd754eb4e38e4e2ebb652e2": [["IntroductionOn January 9, 2020, the WHO declared the detection of a new coronavirus strain never identified before in humans, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] , later shown to be the etiological agent of the respiratory disease COVID-19 (Coronavirus Disease 2019) [2] .IntroductionIn light of the elevated infectiousness, diagnosing COVID-19 at early stages of infection is crucial to immediately isolate the infected subjects from the healthy population and prevent further viral spread.", [["respiratory", "ANATOMY", 247, 258], ["acute respiratory syndrome coronavirus", "DISEASE", 140, 178], ["respiratory disease", "DISEASE", 247, 266], ["COVID-19", "CHEMICAL", 372, 380], ["infection", "DISEASE", 400, 409], ["coronavirus", "ORGANISM", 72, 83], ["humans", "ORGANISM", 118, 124], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 133, 180], ["SARS-CoV-2", "ORGANISM", 182, 192], ["humans", "SPECIES", 118, 124], ["humans", "SPECIES", 118, 124], ["severe acute respiratory syndrome coronavirus", "SPECIES", 133, 178], ["SARS-CoV-2", "SPECIES", 182, 192], ["a new coronavirus strain", "PROBLEM", 66, 90], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 133, 178], ["SARS-CoV", "TEST", 182, 190], ["the respiratory disease COVID", "PROBLEM", 243, 272], ["Coronavirus Disease", "PROBLEM", 277, 296], ["the elevated infectiousness", "PROBLEM", 332, 359], ["COVID", "TEST", 372, 377], ["infection", "PROBLEM", 400, 409], ["further viral spread", "PROBLEM", 506, 526], ["new", "OBSERVATION_MODIFIER", 68, 71], ["coronavirus", "OBSERVATION", 72, 83], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["respiratory syndrome", "OBSERVATION", 146, 166], ["respiratory disease", "OBSERVATION", 247, 266], ["elevated", "OBSERVATION_MODIFIER", 336, 344], ["infectiousness", "OBSERVATION", 345, 359], ["infection", "OBSERVATION", 400, 409], ["infected", "OBSERVATION", 448, 456], ["viral spread", "OBSERVATION", 514, 526]]], ["Although imaging plays an important role in diagnosing and evaluating COVID-19 [3, 4] , the definitive diagnosis relies on tests by real-time reverse-transcriptase-polymerase chain reaction (RT-PCR) [5, 6] .", [["reverse-transcriptase", "PROTEIN", 142, 163], ["imaging", "TEST", 9, 16], ["COVID", "TEST", 70, 75], ["tests", "TEST", 123, 128], ["polymerase chain reaction", "PROBLEM", 164, 189]]], ["However, it is currently unclear how often false negative RT-PCR results can J o u r n a l P r e -p r o o f occur.", [["PCR", "TEST", 61, 64]]], ["This issue is further complicated by the fact that the acquisition of RT-PCR findings requires several hours, whereas CT scan results can be obtained in a matter of minutes [7] .IntroductionThe RT-PCR tests performed during the Wuhan outbreak have shown various degrees of sensitivity, ranging from 37 to 71% [8, 9] , presumably due to several factors, such as throat swab adequacy, sample type, and sample acquisition time [10, 11] .", [["throat swab", "ANATOMY", 361, 372], ["sample", "ANATOMY", 400, 406], ["RT-PCR findings", "TEST", 70, 85], ["CT scan", "TEST", 118, 125], ["The RT-PCR tests", "TEST", 190, 206], ["sensitivity", "TEST", 273, 284], ["several factors", "PROBLEM", 336, 351], ["throat swab adequacy", "TEST", 361, 381], ["sample acquisition time", "TEST", 400, 423], ["presumably due to", "UNCERTAINTY", 318, 335]]], ["Currently, the WHO does not recommend the use of serological tests to diagnose patients with ongoing SARS-CoV-2 infection [12] .IntroductionOn the other hand, chest computed tomography (CT) appears to be reliable in diagnosing COVID- 19 , especially in areas with high incidence and prevalence of this disease.", [["SARS-CoV-2 infection", "DISEASE", 101, 121], ["patients", "ORGANISM", 79, 87], ["CoV-2", "ORGANISM", 106, 111], ["patients", "SPECIES", 79, 87], ["SARS-CoV-2", "SPECIES", 101, 111], ["serological tests", "TEST", 49, 66], ["ongoing SARS", "PROBLEM", 93, 105], ["CoV-2 infection", "PROBLEM", 106, 121], ["chest computed tomography", "TEST", 159, 184], ["CT", "TEST", 186, 188], ["COVID", "TEST", 227, 232], ["this disease", "PROBLEM", 297, 309], ["chest", "ANATOMY", 159, 164], ["high incidence", "OBSERVATION_MODIFIER", 264, 278], ["disease", "OBSERVATION", 302, 309]]], ["The radiographic features of infected lungs include ground-glass opacities (GGOs), multifocal patchy consolidation, and/or interstitial changes with a peripheral distribution.", [["lungs", "ANATOMY", 38, 43], ["interstitial", "ANATOMY", 123, 135], ["GGOs", "DISEASE", 76, 80], ["lungs", "ORGAN", 38, 43], ["infected lungs", "PROBLEM", 29, 43], ["ground-glass opacities", "PROBLEM", 52, 74], ["multifocal patchy consolidation", "PROBLEM", 83, 114], ["interstitial changes", "PROBLEM", 123, 143], ["a peripheral distribution", "PROBLEM", 149, 174], ["infected", "OBSERVATION_MODIFIER", 29, 37], ["lungs", "ANATOMY", 38, 43], ["ground-glass opacities", "OBSERVATION", 52, 74], ["multifocal", "OBSERVATION_MODIFIER", 83, 93], ["patchy", "OBSERVATION_MODIFIER", 94, 100], ["consolidation", "OBSERVATION", 101, 114], ["interstitial", "ANATOMY_MODIFIER", 123, 135], ["peripheral", "ANATOMY_MODIFIER", 151, 161], ["distribution", "OBSERVATION_MODIFIER", 162, 174]]], ["Noteworthy, these features can also be observed in symptomatic patients with negative RT-PCR results [13] .IntroductionIn this scenario, the largest correlation study of chest CT and RT-PCR testing, including 1,014 patients, has revealed a CT sensitivity in diagnosing COVID-19 of 97% [8] .", [["chest", "ANATOMY", 170, 175], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 215, 223], ["chest CT", "TEST", 170, 178], ["RT-PCR testing", "TEST", 183, 197], ["a CT sensitivity", "TEST", 238, 254], ["COVID", "TEST", 269, 274], ["chest", "ANATOMY", 170, 175]]], ["In another Italian study, including 158 patients, the sensitivity, specificity, and accuracy of CT for COVID-19 were 97%, 56%, and 72%, respectively [14] .IntroductionWhile some authors [15] support the use of chest CT in the screening for COVD-19 in patients, the latest Fleischner Society Statement issued on April 2020 [16] does not recommend performing imaging for medical triage of asymptomatic or in mildly symptomatic patients.", [["chest", "ANATOMY", 210, 215], ["COVD", "DISEASE", 240, 244], ["patients", "ORGANISM", 40, 48], ["chest", "ORGANISM_SUBDIVISION", 210, 215], ["patients", "ORGANISM", 251, 259], ["patients", "ORGANISM", 425, 433], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 251, 259], ["patients", "SPECIES", 425, 433], ["the sensitivity", "TEST", 50, 65], ["CT", "TEST", 96, 98], ["COVID", "TEST", 103, 108], ["chest CT", "TEST", 210, 218], ["the screening", "TEST", 222, 235], ["COVD", "TEST", 240, 244], ["performing imaging", "TEST", 346, 364], ["medical triage", "TEST", 369, 383], ["asymptomatic", "PROBLEM", 387, 399], ["mildly symptomatic patients", "PROBLEM", 406, 433], ["chest", "ANATOMY", 210, 215]]], ["Instead, they advocate the use of chest CT in COVID-19 patients with a worsening respiratory status or moderate to severe COVID-19 features regardless of RT-PCR test results.", [["chest", "ANATOMY", 34, 39], ["respiratory", "ANATOMY", 81, 92], ["COVID", "DISEASE", 122, 127], ["chest", "ORGANISM_SUBDIVISION", 34, 39], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["chest CT", "TEST", 34, 42], ["a worsening respiratory status", "PROBLEM", 69, 99], ["moderate to severe COVID", "PROBLEM", 103, 127], ["RT-PCR test", "TEST", 154, 165], ["chest", "ANATOMY", 34, 39], ["moderate", "OBSERVATION_MODIFIER", 103, 111]]], ["Furthermore, chest imaging is deemed appropriate in patients presenting with functional impairment and/or hypoxemia after recovery.", [["chest", "ANATOMY", 13, 18], ["functional impairment", "DISEASE", 77, 98], ["hypoxemia", "DISEASE", 106, 115], ["chest", "ORGAN", 13, 18], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["chest imaging", "TEST", 13, 26], ["functional impairment", "PROBLEM", 77, 98], ["hypoxemia", "PROBLEM", 106, 115], ["chest", "ANATOMY", 13, 18], ["hypoxemia", "OBSERVATION", 106, 115]]], ["In the period of time in which our study was conducted we found ourselves in a scenario were the pre-test probability of COVID-19 was high and the resources were constrained.", [["our study", "TEST", 31, 40], ["COVID", "TEST", 121, 126]]], ["The clinicians responsible for the Emergency Department (ED), in such rapidly evolving and difficult situation, felt that chest CT could help the assessment of patients suspected for COVID -19 J o u r n a l P r e -p r o o f infection.", [["chest", "ANATOMY", 122, 127], ["infection", "DISEASE", 224, 233], ["chest", "ORGAN", 122, 127], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["chest CT", "TEST", 122, 130], ["the assessment", "TEST", 142, 156], ["COVID", "TEST", 183, 188], ["infection", "PROBLEM", 224, 233], ["chest", "ANATOMY", 122, 127], ["infection", "OBSERVATION", 224, 233]]], ["In particular the low sensitivity of a single RT-PCR test and the necessity to quickly address a COVID-19 positive patient towards isolation and proper treatment in order to improve the outcome and reduce the spread of the disease drove the execution of a large number of CT scans.IntroductionOur main goal was to assess chest CT accuracy in diagnosing COVID-19 pneumonia using RT-PCR as standard of reference, according to the model developed by Ai et al. [8] .", [["chest", "ANATOMY", 321, 326], ["pneumonia", "DISEASE", 362, 371], ["patient", "ORGANISM", 115, 122], ["chest", "ORGANISM_SUBDIVISION", 321, 326], ["patient", "SPECIES", 115, 122], ["COVID-19", "SPECIES", 353, 361], ["a single RT-PCR test", "TEST", 37, 57], ["a COVID", "TEST", 95, 102], ["isolation", "TREATMENT", 131, 140], ["proper treatment", "TREATMENT", 145, 161], ["the disease", "PROBLEM", 219, 230], ["CT scans", "TEST", 272, 280], ["chest CT accuracy", "TEST", 321, 338], ["diagnosing COVID", "TEST", 342, 358], ["pneumonia", "PROBLEM", 362, 371], ["RT-PCR", "TREATMENT", 378, 384], ["low sensitivity", "OBSERVATION_MODIFIER", 18, 33], ["disease", "OBSERVATION", 223, 230], ["large", "OBSERVATION_MODIFIER", 256, 261], ["chest", "ANATOMY", 321, 326], ["pneumonia", "OBSERVATION", 362, 371]]], ["We also sought to determine the correlation between CT findings and positive RT-PCR results.Patient Population and Study DesignThis retrospective study was approved by the Institute Research Medical Ethics Committee at AOU Maggiore della Carit\u00e0, Novara, Italy; protocol number CE 123/20 Written informed consent was waived.Patient Population and Study DesignWe employed a study design similar to that published by Ai et al. (8) .", [["Patient", "SPECIES", 92, 99], ["Patient", "SPECIES", 323, 330], ["CT findings", "TEST", 52, 63], ["positive RT-PCR", "TEST", 68, 83], ["This retrospective study", "TEST", 127, 151], ["a study", "TEST", 370, 377]]], ["To this end, we enrolled a series of 773 patients admitted at the ED of our hospital from March 3 rd to April 9 th 2020, during the peak of the Italian COVID-19 epidemic.Patient Population and Study DesignThe patient inclusion criteria were as follows:Patient Population and Study Design1.", [["patients", "ORGANISM", 41, 49], ["patient", "ORGANISM", 209, 216], ["patients", "SPECIES", 41, 49], ["Patient", "SPECIES", 170, 177], ["patient", "SPECIES", 209, 216], ["Patient", "SPECIES", 252, 259], ["the Italian COVID", "TEST", 140, 157], ["epidemic", "PROBLEM", 161, 169]]], ["Clinically suspected SARS-CoV-2 infection; 2.", [["SARS-CoV-2 infection", "DISEASE", 21, 41], ["SARS-CoV-2", "SPECIES", 21, 31], ["SARS", "PROBLEM", 21, 25], ["CoV-2 infection", "PROBLEM", 26, 41], ["SARS", "OBSERVATION", 21, 25], ["CoV", "OBSERVATION_MODIFIER", 26, 29], ["infection", "OBSERVATION", 32, 41]]], ["Having performed a chest CT scan in the ED;Patient Population and Study Design3.", [["Patient", "SPECIES", 43, 50], ["a chest CT scan", "TEST", 17, 32], ["chest", "ANATOMY", 19, 24]]], ["Having undergone 1 or 2 RT-PCR assays within 7 days of the CT scan.Patient Population and Study DesignThe exclusion criteria were:Patient Population and Study Design1.", [["Patient", "SPECIES", 67, 74], ["Patient", "SPECIES", 130, 137], ["2 RT-PCR assays", "TEST", 22, 37], ["the CT scan", "TEST", 55, 66]]], ["Presence of severe motion artifacts in the CT scan; 2.", [["severe motion artifacts", "PROBLEM", 12, 35], ["the CT scan", "TEST", 39, 50], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["motion artifacts", "OBSERVATION", 19, 35]]], ["Having undergone a chest CT and an RT-PCR test with a time interval > 7 days; J o u r n a l P r e -p r o o f 3.", [["a chest CT", "TEST", 17, 27], ["an RT-PCR test", "TEST", 32, 46], ["a time interval", "TEST", 52, 67], ["chest", "ANATOMY", 19, 24]]], ["Unknown RT-PCR date.Patient Population and Study DesignIn our institution a patient was defined as clinically suspected for COVID-19 when one or more of this conditions were met: (a) presence of fever (i.e., temperature > 37.5\u00b0C), cough and dyspnea;Patient Population and Study Design(b) presence of mild symptoms and ascertained close contact with a confirmed COVID-19 patient;Patient Population and Study Design(c) one previously positive laboratory test result.", [["fever", "DISEASE", 195, 200], ["cough", "DISEASE", 231, 236], ["dyspnea", "DISEASE", 241, 248], ["patient", "ORGANISM", 76, 83], ["patient", "ORGANISM", 370, 377], ["Patient", "SPECIES", 20, 27], ["patient", "SPECIES", 76, 83], ["Patient", "SPECIES", 249, 256], ["patient", "SPECIES", 370, 377], ["Patient", "SPECIES", 378, 385], ["COVID", "TEST", 124, 129], ["fever", "PROBLEM", 195, 200], ["temperature", "TEST", 208, 219], ["cough", "PROBLEM", 231, 236], ["dyspnea", "PROBLEM", 241, 248], ["mild symptoms", "PROBLEM", 300, 313], ["fever", "OBSERVATION", 195, 200], ["mild", "OBSERVATION_MODIFIER", 300, 304]]], ["A flowchart of the study is shown in fig.1 .Patient Population and Study DesignNotably all the patients with the above conditions were examined at the presentation in our ED during the peak of the epidemic, at the time when the symptoms determined their access to the hospital, regardless to the severity and to the time of onset of the clinical signs.", [["patients", "ORGANISM", 95, 103], ["Patient", "SPECIES", 44, 51], ["patients", "SPECIES", 95, 103], ["the study", "TEST", 15, 24], ["Study", "TEST", 67, 72], ["the symptoms", "PROBLEM", 224, 236], ["the clinical signs", "PROBLEM", 333, 351]]], ["This parameters were therefore not collected in the majority of cases and not considered in the present study.Personal DataFor each patient, information such as gender, date of birth, date of the RT-PCR test and date of the chest CT were recorded.Personal DataEnrolled patients were assigned a progressive identification number (ID), which was later used to collect their personal data.", [["chest", "ANATOMY", 224, 229], ["patient", "ORGANISM", 132, 139], ["patients", "ORGANISM", 269, 277], ["patient", "SPECIES", 132, 139], ["patients", "SPECIES", 269, 277], ["the present study", "TEST", 92, 109], ["the RT-PCR test", "TEST", 192, 207], ["the chest CT", "TEST", 220, 232], ["chest", "ANATOMY", 224, 229]]], ["This procedure guaranteed anonymity, allowing non-disclosure of sensitive data.RT-PCR: Swabs and Laboratory TestsThe RT-PCR results were obtained from the patient's electronic medical records stored in our hospital information system.", [["patient", "ORGANISM", 155, 162], ["patient", "SPECIES", 155, 162], ["This procedure", "TREATMENT", 0, 14], ["RT-PCR", "TEST", 79, 85], ["Swabs", "TEST", 87, 92], ["Laboratory Tests", "TEST", 97, 113], ["The RT-PCR", "TEST", 113, 123]]], ["All these procedures are in full compliance with the WHO Guidelines [17] .CT Room Staff Organization and Decontamination TechniqueOur CT exams on patients suspected of COVID-19 were performed in the ED CT room.CT Room Staff Organization and Decontamination TechniqueDecontamination of the room was achieved by disinfecting environment surfaces with 5% NaClO.CT Room Staff Organization and Decontamination TechniqueAfter each chest CT examination, passive air exchange was performed.", [["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["Decontamination TechniqueOur CT exams", "TEST", 105, 142], ["COVID", "TEST", 168, 173], ["each chest CT examination", "TEST", 420, 445], ["passive air exchange", "TREATMENT", 447, 467], ["chest", "ANATOMY", 425, 430]]], ["Other patients arriving at the ED, not clinically suspected of COVID-19, performed the CT scanning on another device present in our Radiology Department [18] .CT Acquisition Technique and Image AnalysisAll Chest CT scans were performed during single full inspiratory breath hold in supine position on a 128-slice CT (Philips Ingenuity Core, Philips Healthcare, Netherlands).", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["COVID", "TEST", 63, 68], ["the CT scanning", "TEST", 83, 98], ["Image AnalysisAll Chest CT scans", "TEST", 188, 220], ["Chest", "ANATOMY", 206, 211]]], ["The scan technical average parameters were: tube voltage: 120 kV; tube current modulation: 226 mAs; spiral pitch factor: 1.08; collimation width 0.625, matrix 512 (mediastinal window) and 768 (lung window).", [["lung", "ANATOMY", 193, 197], ["tube", "TISSUE", 44, 48], ["lung", "ORGAN", 193, 197], ["spiral pitch factor", "PROTEIN", 100, 119], ["The scan technical average parameters", "TEST", 0, 37], ["tube voltage", "TEST", 44, 56], ["tube current modulation", "TEST", 66, 89], ["mAs", "TEST", 95, 98], ["spiral pitch factor", "TEST", 100, 119], ["collimation width", "TEST", 127, 144], ["mediastinal", "ANATOMY", 164, 175], ["lung", "ANATOMY", 193, 197]]], ["All images were reconstructed with a slice thickness of 1 mm.", [["All images", "TEST", 0, 10], ["a slice thickness", "TEST", 35, 52]]], ["For younger subjects (<40 years) tube voltage was adequately reduced to 80-100 KV and the scanner automatically adjusted the tube current modulation on the basis of the scout image in order to administer an adequate dose amount.J o u r n a l P r e -p r o o fTwo radiologists with more than 10 years of thoracic imaging experience evaluated the images in consensus, blindly to the RT-PCR results.", [["tube", "ANATOMY", 125, 129], ["thoracic", "ANATOMY", 302, 310], ["tube", "TISSUE", 33, 37], ["tube", "TISSUE", 125, 129], ["tube voltage", "TEST", 33, 45], ["the tube current modulation", "TREATMENT", 121, 148], ["the scout image", "TEST", 165, 180], ["thoracic imaging", "TEST", 302, 318], ["the images", "TEST", 340, 350], ["the RT-PCR", "TEST", 376, 386], ["tube", "OBSERVATION", 125, 129], ["thoracic", "ANATOMY", 302, 310]]], ["The patients were defined either CT-positive or CTnegative based on the presence of CT findings compatible with COVID-19 infection as defined by the STR/ACR/RSNA consensus statement [19] ; CT scans with \"typical\" or \"indeterminate\" features were considered positive, while CT scans with \"atypical\" or \"negative\" features were considered negative.Standard of referenceThe RT-PCR performed with a time interval not longer than 7 days from the chest CT was our standard of reference.", [["chest", "ANATOMY", 441, 446], ["infection", "DISEASE", 121, 130], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["CT", "TEST", 33, 35], ["CT findings", "TEST", 84, 95], ["COVID-19 infection", "PROBLEM", 112, 130], ["the STR", "TEST", 145, 152], ["CT scans", "TEST", 189, 197], ["\"indeterminate\" features", "PROBLEM", 216, 240], ["CT scans", "TEST", 273, 281], ["The RT-PCR", "TEST", 367, 377], ["the chest CT", "TEST", 437, 449], ["compatible with", "UNCERTAINTY", 96, 111], ["infection", "OBSERVATION", 121, 130], ["RSNA", "ANATOMY", 157, 161], ["indeterminate", "OBSERVATION_MODIFIER", 217, 230], ["chest", "ANATOMY", 441, 446]]], ["Several patients underwent two or more RT-PCR tests during the considered time interval.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["more RT-PCR tests", "TEST", 34, 51]]], ["The result of the one or two performed tests were considered to determine the overall RT-PCR positivity, as follows:Patient PopulationAs shown in figure 1 our original population included 1,009 patients who underwent chest CT scan in our ED due to suspected COVID-19.", [["patients", "ORGANISM", 194, 202], ["Patient", "SPECIES", 116, 123], ["patients", "SPECIES", 194, 202], ["tests", "TEST", 39, 44], ["chest CT scan", "TEST", 217, 230], ["COVID", "TEST", 258, 263], ["chest", "ANATOMY", 217, 222]]], ["We first excluded 185 patients who had not undergone an RT-PCR.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["an RT-PCR", "TEST", 53, 62]]], ["Twenty-four of the remaining patients were excluded because of severe motion artifacts, while 27 other patients were excluded because the time-interval between the chest CT and the RT-PCR assay had been longer than 7 days.", [["chest", "ANATOMY", 164, 169], ["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 103, 111], ["severe motion artifacts", "PROBLEM", 63, 86], ["the chest CT", "TEST", 160, 172], ["the RT-PCR assay", "TEST", 177, 193], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["motion artifacts", "OBSERVATION", 70, 86], ["chest", "ANATOMY", 164, 169]]], ["Thus, a total of 773 patients were available for analysis. an \"indeterminate appearance\".Radiation ExposureRadiation exposure was retrospectively evaluated in 100 patients, from 200 th to 299 th .", [["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 163, 171], ["analysis", "TEST", 49, 57], ["an \"indeterminate appearance\"", "PROBLEM", 59, 88], ["Radiation ExposureRadiation exposure", "TREATMENT", 89, 125], ["indeterminate", "OBSERVATION_MODIFIER", 63, 76]]], ["In patients weighting up to 90 kg the mean CT dose index (CTDI) volume was 8.9 +/-1.6 mGy and the mean dose length product (DLP) was 334.2 +/-33.8 mGycm.CT Diagnostic PerformanceUsing RT-PCR as reference standard (Table 2) , 419 patients were found to be true positives, while 245 patients resulted true negatives (see Fig. 4 ).", [["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 229, 237], ["patients", "ORGANISM", 281, 289], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 229, 237], ["patients", "SPECIES", 281, 289], ["the mean CT dose index", "TEST", 34, 56], ["CTDI", "TEST", 58, 62], ["volume", "TEST", 64, 70], ["the mean dose length product", "TEST", 94, 122], ["DLP", "TEST", 124, 127], ["mGycm.CT", "TEST", 147, 155], ["PCR", "TEST", 187, 190], ["true positives", "PROBLEM", 255, 269]]], ["Sixty-six patients received a positive chest CT diagnosis and a negative RT-PCR assay (FP), while 43 patients received a negative chest CT diagnosis despite testing positive for SARS-CoV-2 RNA by RT-PCR (FN).J o u r n a l P r e -p r o o fThe CT sensitivity, specificity, PPV, NPV, and accuracy for SARS- The performance of chest CT in diagnosing COVID-19 in different age and sex groups is shown in [IC 95%, 68.5-80.9]; p = 0.033).", [["chest", "ANATOMY", 323, 328], ["SARS", "DISEASE", 298, 302], ["patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 101, 109], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 178, 188], ["chest", "ORGAN", 323, 328], ["SARS-CoV-2 RNA", "RNA", 178, 192], ["FN", "PROTEIN", 204, 206], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 101, 109], ["SARS-CoV", "SPECIES", 178, 186], ["a positive chest CT", "TEST", 28, 47], ["RT-PCR assay", "TEST", 73, 85], ["a negative chest CT diagnosis", "TEST", 119, 148], ["testing", "TEST", 157, 164], ["SARS", "PROBLEM", 178, 182], ["CoV", "TEST", 183, 186], ["RT", "TEST", 196, 198], ["PCR", "TEST", 199, 202], ["The CT sensitivity", "TEST", 238, 256], ["specificity", "TEST", 258, 269], ["PPV", "TEST", 271, 274], ["NPV", "TEST", 276, 279], ["SARS", "PROBLEM", 298, 302], ["chest CT", "TEST", 323, 331], ["diagnosing COVID", "TEST", 335, 351], ["chest", "ANATOMY", 39, 44], ["chest", "ANATOMY", 130, 135], ["chest", "ANATOMY", 323, 328]]], ["Noteworthy, in the patients' group <50 years the positive rate of the RT-PCR was 46.6%, while in the group \u2265 50 years the positive rate was 64.5%.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["the RT-PCR", "TEST", 66, 76], ["the positive rate", "TEST", 118, 135]]], ["On the other hand, the positive rates in the patients' groups <60 years and \u226560 years were 57.3% and 64% respectively and no statistically significant offset was found between these categories.Analysis of FP, FN and TNOf note, 37.9% (25/66) (mean age 62.7) patients with positive CT scan and negative RT-PCR assay (Table 3) were considered to be affected by SARS-CoV-2 pneumonia by the clinicians based on clinical symptoms, epidemiological features, laboratory test results and chest CT findings.", [["SARS", "DISEASE", 358, 362], ["pneumonia", "DISEASE", 369, 378], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 257, 265], ["FN", "PROTEIN", 209, 211], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 257, 265], ["statistically significant offset", "PROBLEM", 125, 157], ["FP", "TEST", 205, 207], ["FN", "TEST", 209, 211], ["positive CT scan", "TEST", 271, 287], ["RT-PCR assay", "TEST", 301, 313], ["SARS", "PROBLEM", 358, 362], ["CoV-2 pneumonia", "PROBLEM", 363, 378], ["clinical symptoms", "PROBLEM", 406, 423], ["laboratory test", "TEST", 451, 466], ["chest CT findings", "TEST", 479, 496], ["significant", "OBSERVATION_MODIFIER", 139, 150], ["offset", "OBSERVATION", 151, 157], ["SARS", "OBSERVATION", 358, 362], ["pneumonia", "OBSERVATION", 369, 378], ["chest", "ANATOMY", 479, 484]]], ["These patients were thus isolated and treated (Fig. 5) .", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["In particular, 17/25 patients (68%) received two or more RT-PCR tests, while 8/25 (32%) performed a single nasopharyngeal swab.", [["nasopharyngeal swab", "ANATOMY", 107, 126], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["more RT-PCR tests", "TEST", 52, 69], ["a single nasopharyngeal swab", "TEST", 98, 126], ["nasopharyngeal", "ANATOMY", 107, 121], ["swab", "OBSERVATION", 122, 126]]], ["No one of these patients had the diagnosis subsequently modified, and they were isolated and treated for COVID-19Analysis of FP, FN and TNuntil the discharge (23/25) or the demise (2/25).J o u r n a l P r e -p r o o fFurthermore, 14/66 FP patients (21.2%), with a mean age of 67.3, were hospitalized but not treated for COVID-19.", [["FN", "DISEASE", 129, 131], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 239, 247], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 239, 247], ["COVID", "TEST", 105, 110], ["TNuntil", "TREATMENT", 136, 143], ["fFurthermore", "TEST", 216, 228], ["a mean age", "TEST", 262, 272], ["COVID", "TEST", 320, 325], ["one", "OBSERVATION_MODIFIER", 3, 6], ["l", "ANATOMY_MODIFIER", 199, 200]]], ["For two of them it was made a differential diagnosis of bacterial pneumonia by E.J o u r n a l P r e -p r o o fColi (Fig. 5a) , whereas a diagnosis of pulmonary thromboembolism was established in 1 patients.J o u r n a l P r e -p r o o fFinally, an empirical antibiotic treatment for community-acquired pneumonia was performed in the remaining 11 patients.J o u r n a l P r e -p r o o fWe were unable to find any clinical data for the other 27/66 patients (40.9%, mean age 56.4), most likely because they were deferred to home treatment due to the mildness of their condition or because they were admitted to other hospitals.", [["pulmonary", "ANATOMY", 151, 160], ["pneumonia", "DISEASE", 66, 75], ["pulmonary thromboembolism", "DISEASE", 151, 176], ["pneumonia", "DISEASE", 303, 312], ["pulmonary", "ORGAN", 151, 160], ["patients", "ORGANISM", 198, 206], ["patients", "ORGANISM", 347, 355], ["patients", "ORGANISM", 447, 455], ["patients", "SPECIES", 198, 206], ["patients", "SPECIES", 347, 355], ["patients", "SPECIES", 447, 455], ["bacterial pneumonia", "PROBLEM", 56, 75], ["fColi", "PROBLEM", 110, 115], ["pulmonary thromboembolism", "PROBLEM", 151, 176], ["fFinally", "PROBLEM", 236, 244], ["an empirical antibiotic treatment", "TREATMENT", 246, 279], ["community-acquired pneumonia", "PROBLEM", 284, 312], ["a l P r e -p r o o fWe", "TEST", 366, 388], ["mean age", "TEST", 464, 472], ["home treatment", "TREATMENT", 522, 536], ["bacterial", "OBSERVATION_MODIFIER", 56, 65], ["pneumonia", "OBSERVATION", 66, 75], ["pulmonary", "ANATOMY", 151, 160], ["thromboembolism", "OBSERVATION", 161, 176], ["pneumonia", "OBSERVATION", 303, 312], ["most likely", "UNCERTAINTY", 480, 491]]], ["This patients group was significantly younger than the one hospitalized but not treated for COVID-19.J o u r n a l P r e -p r o o fWe observed that 46.5% (20/43) of patients with negative chest CT scan and positive RT-PCR test (mean age 49.8) ( Table 3) showed no significant findings in the chest CT, while 16/43 (37.2%) patients of the same group (mean age 74.9) had CT chest with confounding conditions, that is chronic heart failure (CHF) (8 patients) or chronic obstructive pulmonary disease (COPD) (8 patients), (Fig. 6 ).", [["chest", "ANATOMY", 292, 297], ["chest", "ANATOMY", 372, 377], ["heart", "ANATOMY", 423, 428], ["pulmonary", "ANATOMY", 479, 488], ["chronic heart failure", "DISEASE", 415, 436], ["CHF", "DISEASE", 438, 441], ["chronic obstructive pulmonary disease", "DISEASE", 459, 496], ["COPD", "DISEASE", 498, 502], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 165, 173], ["chest", "ORGAN", 292, 297], ["patients", "ORGANISM", 322, 330], ["heart", "ORGAN", 423, 428], ["patients", "ORGANISM", 446, 454], ["pulmonary", "ORGAN", 479, 488], ["patients", "ORGANISM", 507, 515], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 322, 330], ["patients", "SPECIES", 446, 454], ["patients", "SPECIES", 507, 515], ["COVID", "TEST", 92, 97], ["negative chest CT scan", "TEST", 179, 201], ["PCR test", "TEST", 218, 226], ["mean age", "TEST", 228, 236], ["significant findings", "PROBLEM", 264, 284], ["the chest CT", "TEST", 288, 300], ["CT chest", "TEST", 369, 377], ["confounding conditions", "PROBLEM", 383, 405], ["chronic heart failure", "PROBLEM", 415, 436], ["CHF)", "PROBLEM", 438, 442], ["chronic obstructive pulmonary disease", "PROBLEM", 459, 496], ["COPD)", "PROBLEM", 498, 503], ["chest", "ANATOMY", 188, 193], ["no", "UNCERTAINTY", 261, 263], ["significant", "OBSERVATION_MODIFIER", 264, 275], ["chest", "ANATOMY", 292, 297], ["chest", "ANATOMY", 372, 377], ["chronic", "OBSERVATION_MODIFIER", 415, 422], ["heart", "ANATOMY", 423, 428], ["failure", "OBSERVATION", 429, 436], ["CHF", "OBSERVATION", 438, 441], ["chronic", "OBSERVATION_MODIFIER", 459, 466], ["obstructive", "OBSERVATION_MODIFIER", 467, 478], ["pulmonary", "ANATOMY", 479, 488], ["disease", "OBSERVATION", 489, 496], ["COPD", "OBSERVATION", 498, 502]]], ["In the 7/43 remaining patients (16.3%), with a mean age of 59 years, no confounding conditions were found in the chest CT, and the reviewing radiologists lent toward differential diagnoses.", [["chest", "ANATOMY", 113, 118], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["confounding conditions", "PROBLEM", 72, 94], ["the chest CT", "TEST", 109, 121], ["chest", "ANATOMY", 113, 118]]], ["As expected, the patients with completely negative CT scans were significantly younger than those showing confounding conditions.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["CT scans", "TEST", 51, 59], ["confounding conditions", "PROBLEM", 106, 128]]], ["No significant CT alterations were observed in 138/245 patients of the TN group (56.3%), while the remaining 107 CT scans showed pathological features which received alternative diagnoses, as shown in Table 3 .", [["TN", "DISEASE", 71, 73], ["patients", "ORGANISM", 55, 63], ["TN", "CANCER", 71, 73], ["patients", "SPECIES", 55, 63], ["significant CT alterations", "PROBLEM", 3, 29], ["the TN group", "TEST", 67, 79], ["the remaining 107 CT scans", "TEST", 95, 121], ["pathological features", "PROBLEM", 129, 150], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["alterations", "OBSERVATION", 18, 29]]], ["The patients with negative scans were significantly younger (p < 0.001) and had a higher prevalence of the female sex (p 0.032).", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Twelve TN patients (4.9%) were considered affected by COVID-19 by the clinicians and treated accordingly; noteworthy, 4 of these individuals had CT features consistent with CHF.J o u r n a l P r e -p r o o fAssuming that the 25 FP and the 12 TN patients who were hospitalized and treated for COVID-19J o u r n a l P r e -p r o o fwere positive for SARS-CoV-2, the number of FP CT scans (i.e., 66) would then decrease to 41, while the number of FN (i.e., 43) would increase to 55.", [["CHF", "DISEASE", 173, 176], ["SARS", "DISEASE", 348, 352], ["patients", "ORGANISM", 10, 18], ["individuals", "ORGANISM", 129, 140], ["patients", "ORGANISM", 245, 253], ["FN", "GENE_OR_GENE_PRODUCT", 444, 446], ["FN", "PROTEIN", 444, 446], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 245, 253], ["SARS-CoV", "SPECIES", 348, 356], ["CT features", "TEST", 145, 156], ["CHF", "PROBLEM", 173, 176], ["fAssuming", "PROBLEM", 206, 215], ["COVID", "TEST", 292, 297], ["a l P r e -p r o o", "TEST", 310, 328], ["positive", "PROBLEM", 335, 343], ["SARS", "PROBLEM", 348, 352], ["CoV", "TEST", 353, 356], ["FP CT scans", "TEST", 374, 385], ["consistent with", "UNCERTAINTY", 157, 172], ["CHF", "OBSERVATION", 173, 176]]], ["According to these assumptions combined together, the diagnostic accuracy of chest CT imaging in diagnosing COVID-19 pneumonia would slightly improve as follows: sensitivity 89% (95% CI 85.9-91.6), specificity 85% (95% CI 80.2-89), PPV 91.5% (95% CI 89.0-93.5), NPV 80.9% (76.7-84.5), and accuracy 87.6% (95% CI 85-89.8).CT Findings AnalysisAn analysis of the CT findings was also conducted by discriminating the CT findings based on the positivity or negativity of the RT-PCR results (Table 4 ).", [["chest", "ANATOMY", 77, 82], ["pneumonia", "DISEASE", 117, 126], ["chest", "ORGAN", 77, 82], ["chest CT imaging", "TEST", 77, 93], ["diagnosing COVID", "TEST", 97, 113], ["pneumonia", "PROBLEM", 117, 126], ["sensitivity", "TEST", 162, 173], ["CI", "TEST", 183, 185], ["specificity", "TEST", 198, 209], ["CI", "TEST", 219, 221], ["PPV", "TEST", 232, 235], ["CI", "TEST", 247, 249], ["NPV", "TEST", 262, 265], ["accuracy", "TEST", 289, 297], ["CI", "TEST", 309, 311], ["CT Findings", "TEST", 321, 332], ["the CT findings", "TEST", 356, 371], ["the CT findings", "TEST", 409, 424], ["the positivity", "TEST", 434, 448], ["the RT-PCR", "TEST", 466, 476], ["chest", "ANATOMY", 77, 82], ["pneumonia", "OBSERVATION", 117, 126]]], ["GGO in \u2265 3 lobes, consolidation \u2265 2 lobes, association of consolidation and GGO, bilateral alterations, crazy paving and reversed halo sign were all significantly correlated with a positive RT-PCR result (Figs.", [["lobes", "ANATOMY", 11, 16], ["lobes", "ANATOMY", 36, 41], ["GGO", "DISEASE", 0, 3], ["GGO", "DISEASE", 76, 79], ["GGO in \u2265 3 lobes", "PROBLEM", 0, 16], ["consolidation \u2265 2 lobes", "PROBLEM", 18, 41], ["consolidation", "PROBLEM", 58, 71], ["GGO", "PROBLEM", 76, 79], ["bilateral alterations", "PROBLEM", 81, 102], ["crazy paving", "PROBLEM", 104, 116], ["reversed halo sign", "PROBLEM", 121, 139], ["a positive RT-PCR result", "PROBLEM", 179, 203], ["lobes", "ANATOMY_MODIFIER", 11, 16], ["consolidation", "OBSERVATION", 18, 31], ["lobes", "ANATOMY_MODIFIER", 36, 41], ["consolidation", "OBSERVATION", 58, 71], ["GGO", "OBSERVATION", 76, 79], ["bilateral", "ANATOMY_MODIFIER", 81, 90], ["alterations", "OBSERVATION", 91, 102]]], ["Absence of consolidation, monolateral alterations and pleural effusion correlated significantly with a negative RT-PCR finding (Fig. 4) .CT Findings AnalysisNoteworthy, the presence of lymphadenopathy or pericardial effusion was not associated with either conditions.DiscussionIn our experience the chest CT specificity in diagnosing COVID-19 was significantly higher than previously reported if compared with RT/PCR which is the only reference of standard actually validated.J o u r n a l P r e -p r o o fIn their recent meta-analysis, Kim et al. [21] reported that the pooled sensitivity of chest CT in diagnosing COVID-19 is 94% [95% CI 91-96].", [["pleural effusion", "ANATOMY", 54, 70], ["pericardial", "ANATOMY", 204, 215], ["chest", "ANATOMY", 299, 304], ["chest", "ANATOMY", 593, 598], ["pleural effusion", "DISEASE", 54, 70], ["lymphadenopathy", "DISEASE", 185, 200], ["pericardial effusion", "DISEASE", 204, 224], ["pleural", "ORGAN", 54, 61], ["lymphadenopathy", "PATHOLOGICAL_FORMATION", 185, 200], ["pericardial", "ORGAN", 204, 215], ["chest", "ORGAN", 299, 304], ["chest", "ORGAN", 593, 598], ["consolidation", "PROBLEM", 11, 24], ["monolateral alterations", "PROBLEM", 26, 49], ["pleural effusion", "PROBLEM", 54, 70], ["Findings Analysis", "TEST", 140, 157], ["lymphadenopathy", "PROBLEM", 185, 200], ["pericardial effusion", "PROBLEM", 204, 224], ["the chest CT specificity", "TEST", 295, 319], ["diagnosing COVID", "TEST", 323, 339], ["RT/PCR", "TEST", 410, 416], ["chest CT", "TEST", 593, 601], ["COVID", "TEST", 616, 621], ["CI", "TEST", 637, 639], ["consolidation", "OBSERVATION", 11, 24], ["monolateral", "OBSERVATION_MODIFIER", 26, 37], ["alterations", "OBSERVATION", 38, 49], ["pleural", "ANATOMY", 54, 61], ["effusion", "OBSERVATION", 62, 70], ["lymphadenopathy", "OBSERVATION", 185, 200], ["pericardial", "ANATOMY", 204, 215], ["effusion", "OBSERVATION", 216, 224], ["chest", "ANATOMY", 299, 304], ["chest", "ANATOMY", 593, 598]]], ["In comparison, our sensitivity (90.7%) is slightly lower but still within the 95% CI.", [["our sensitivity", "TEST", 15, 30], ["slightly", "OBSERVATION_MODIFIER", 42, 50], ["lower", "OBSERVATION_MODIFIER", 51, 56]]], ["We believe that this minor discrepancy may be due to the fact that in our FN population (n=43) 20 patients showed no CT alterations, suggesting that these subjects were SARS-CoV-2 positive, as judged by RT-PCR, albeit not displaying SARS-CoV-2-induced pneumonia.", [["SARS", "DISEASE", 169, 173], ["pneumonia", "DISEASE", 252, 261], ["patients", "ORGANISM", 98, 106], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 169, 179], ["CoV-2", "ORGANISM", 238, 243], ["patients", "SPECIES", 98, 106], ["this minor discrepancy", "PROBLEM", 16, 38], ["our FN population", "TEST", 70, 87], ["CT alterations", "PROBLEM", 117, 131], ["SARS", "TEST", 169, 173], ["CoV", "TEST", 174, 177], ["RT-PCR", "TEST", 203, 209], ["SARS", "PROBLEM", 233, 237], ["CoV", "TEST", 238, 241], ["pneumonia", "PROBLEM", 252, 261], ["may be due to", "UNCERTAINTY", 39, 52], ["SARS", "OBSERVATION", 233, 237], ["pneumonia", "OBSERVATION", 252, 261]]], ["It is possible that a percentage of these patients performed the CT scan in the first two days from the symptoms onset, when the CT is commonly judged normal [22] Sixteen of the remaining 23 patients had one or more confounding pathologies.J o u r n a l P r e -p r o o fOn the other hand, our specificity was significantly higher than that reported by Kim's meta-analysis (78.8% vs. 37%, respectively).", [["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 191, 199], ["the CT scan", "TEST", 61, 72], ["the symptoms", "PROBLEM", 100, 112], ["the CT", "TEST", 125, 131], ["more confounding pathologies", "PROBLEM", 211, 239], ["our specificity", "TEST", 289, 304], ["Kim's meta-analysis", "TEST", 352, 371], ["pathologies", "OBSERVATION", 228, 239]]], ["We think that this remarkable offset may be due to three distinct reasons:J o u r n a l P r e -p r o o f1.", [["f1", "DNA", 103, 105]]], ["Several studies have reported CT scans with various and somewhat inhomogeneous findings to be consistent with COVID-19, while throughout our investigation we have been trying to be very precise and meticulous in defining the radiologic features of COVID-19, as defined by the STR/ACR/RSNA consensus statement [19] , and described in the Materials and Methods.J o u r n a l P r e -p r o o f2.", [["f2", "DNA", 388, 390], ["Several studies", "TEST", 0, 15], ["CT scans", "TEST", 30, 38], ["COVID", "TEST", 110, 115], ["COVID", "TEST", 248, 253], ["f2", "PROBLEM", 388, 390], ["RSNA", "ANATOMY", 284, 288]]], ["Since the beginning of the worldwide COVID-19 emergency, a number of studies describing the radiologic features of the disease have been published and assimilated by the international radiologic community.", [["the disease", "PROBLEM", 115, 126], ["disease", "OBSERVATION", 119, 126]]], ["While the first studies, especially those from China, were pioneering the subject, we are now starting to incorporate those experiences into our daily clinical practice, which has definitely contributed to improve our diagnostic accuracy.J o u r n a l P r e -p r o o f3.", [["f3", "DNA", 267, 269], ["the first studies", "TEST", 6, 23]]], ["Notoriously, the accuracy of one test is dependent on pre-test probability, and our investigation was conducted during the Italian COVID-19 epidemic, when the probability of this condition was obviously very high.J o u r n a l P r e -p r o o fEven though Raptis et al. in their recent literature review [23] were skeptical about a study [24] reporting high CT specificity, we believe our findings to be genuinely true and that they reflect the real clinical experience, especially in light of the fact that our population included numerous noninfectious diseases, such as CHF, COPD, and cancer.", [["cancer", "ANATOMY", 587, 593], ["noninfectious diseases", "DISEASE", 540, 562], ["CHF", "DISEASE", 572, 575], ["COPD", "DISEASE", 577, 581], ["cancer", "DISEASE", 587, 593], ["cancer", "CANCER", 587, 593], ["one test", "TEST", 29, 37], ["our investigation", "TEST", 80, 97], ["the Italian COVID", "TEST", 119, 136], ["this condition", "PROBLEM", 174, 188], ["fEven", "PROBLEM", 242, 247], ["a study", "TEST", 329, 336], ["high CT specificity", "PROBLEM", 352, 371], ["numerous noninfectious diseases", "PROBLEM", 531, 562], ["CHF", "PROBLEM", 572, 575], ["COPD", "PROBLEM", 577, 581], ["cancer", "PROBLEM", 587, 593], ["numerous", "OBSERVATION_MODIFIER", 531, 539], ["noninfectious", "OBSERVATION", 540, 553], ["CHF", "OBSERVATION", 572, 575], ["COPD", "OBSERVATION", 577, 581], ["cancer", "OBSERVATION", 587, 593]]], ["In addition, as specified above, our readers used objective criteria to define a positive CT examination and developed their experience through direct examination and literature review.J o u r n a l P r e -p r o o fWe failed to reproduce the findings by Ai et al. [8] , who reported higher PPV and accuracy of chest CT scan in patients younger than 60 years.", [["chest", "ORGANISM_SUBDIVISION", 310, 315], ["patients", "ORGANISM", 327, 335], ["patients", "SPECIES", 327, 335], ["a positive CT examination", "TEST", 79, 104], ["direct examination", "TEST", 144, 162], ["literature review", "TEST", 167, 184], ["fWe", "PROBLEM", 214, 217], ["chest CT scan", "TEST", 310, 323], ["chest", "ANATOMY", 310, 315]]], ["Conversely, we found a significantly lower sensitivity and a significantly higher specificity in patients younger than 50 years.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["a significantly lower sensitivity", "PROBLEM", 21, 54]]], ["We explain these results by the presence of a higher number of CT scans without any parenchymal or mediastinal alteration in the younger group, which, conversely, displayed a lower incidence of confounding pathologies such as COPD and heart failure.", [["parenchymal", "ANATOMY", 84, 95], ["mediastinal", "ANATOMY", 99, 110], ["heart", "ANATOMY", 235, 240], ["COPD", "DISEASE", 226, 230], ["heart failure", "DISEASE", 235, 248], ["heart", "ORGAN", 235, 240], ["CT scans", "TEST", 63, 71], ["any parenchymal or mediastinal alteration", "PROBLEM", 80, 121], ["confounding pathologies", "PROBLEM", 194, 217], ["COPD", "PROBLEM", 226, 230], ["heart failure", "PROBLEM", 235, 248], ["parenchymal", "ANATOMY_MODIFIER", 84, 95], ["mediastinal", "ANATOMY", 99, 110], ["alteration", "OBSERVATION", 111, 121], ["lower incidence", "OBSERVATION_MODIFIER", 175, 190], ["pathologies", "OBSERVATION", 206, 217], ["COPD", "OBSERVATION", 226, 230], ["heart", "ANATOMY", 235, 240], ["failure", "OBSERVATION", 241, 248]]], ["It is also possible that this results, especially the higher specificity, are due to the lower percentage of positive RT-PCR rate in the patients <50 years, as explained by Leeflang et al [25] .J o u r n a l P r e -p r o o fIn our experience, CT findings of COVID-19 pneumonia (GGOs, consolidations, multilobar and bilateral involvement, crazy paving, reversed halo sign) largely overlapped those described in the recent literature [3] , [19] .", [["multilobar", "ANATOMY", 300, 310], ["pneumonia", "DISEASE", 267, 276], ["GGOs", "DISEASE", 278, 282], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["CT findings", "TEST", 243, 254], ["COVID", "TEST", 258, 263], ["pneumonia", "PROBLEM", 267, 276], ["GGOs", "PROBLEM", 278, 282], ["consolidations", "PROBLEM", 284, 298], ["multilobar and bilateral involvement", "PROBLEM", 300, 336], ["reversed halo sign", "PROBLEM", 352, 370], ["pneumonia", "OBSERVATION", 267, 276], ["consolidations", "OBSERVATION", 284, 298], ["multilobar", "OBSERVATION_MODIFIER", 300, 310], ["bilateral", "ANATOMY_MODIFIER", 315, 324]]], ["However we experienced that CT signs of CHF and pulmonary edema largely overlap with those of COVID-19 pneumonia.", [["pulmonary", "ANATOMY", 48, 57], ["CHF", "DISEASE", 40, 43], ["pulmonary edema", "DISEASE", 48, 63], ["pneumonia", "DISEASE", 103, 112], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 48, 63], ["CT signs", "TEST", 28, 36], ["CHF", "PROBLEM", 40, 43], ["pulmonary edema", "PROBLEM", 48, 63], ["COVID", "TEST", 94, 99], ["pneumonia", "PROBLEM", 103, 112], ["CHF", "OBSERVATION", 40, 43], ["pulmonary", "ANATOMY", 48, 57], ["edema", "OBSERVATION", 58, 63], ["pneumonia", "OBSERVATION", 103, 112]]], ["In the subgroup of 51 patients with CHF CT sensitivity dropped to 61.9%.", [["CHF", "DISEASE", 36, 39], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["CHF CT sensitivity", "TEST", 36, 54], ["CHF", "OBSERVATION", 36, 39]]], ["We believe that the radiologist should be extremely careful in the differential diagnosis, possibly stating that Sars-CoV-2 infection cannot be excluded in the most dubious cases.J o u r n a l P r e -p r o o fWe trust that, given the supposed FN rate of the RT-PCR , could be correct to consider the CT FP and TN patients treated for COVID-19 as affected by the disease.", [["infection", "DISEASE", 124, 133], ["Sars-CoV-2", "ORGANISM", 113, 123], ["patients", "ORGANISM", 313, 321], ["FN", "PROTEIN", 243, 245], ["patients", "SPECIES", 313, 321], ["Sars-CoV-2 infection", "PROBLEM", 113, 133], ["the RT-PCR", "TEST", 254, 264], ["the CT FP", "TEST", 296, 305], ["COVID", "TEST", 334, 339], ["the disease", "PROBLEM", 358, 369], ["infection", "OBSERVATION", 124, 133], ["cannot be excluded", "UNCERTAINTY", 134, 152], ["disease", "OBSERVATION", 362, 369]]], ["If our assumptions are true, the CT J o u r n a l P r e -p r o o f scan sensitivity for COVID-19 pneumonia drops to 89%, while the specificity increases to 85%.", [["pneumonia", "DISEASE", 97, 106], ["the CT", "TEST", 29, 35], ["a l P r e -p r o o f scan sensitivity", "TEST", 46, 83], ["COVID", "TEST", 88, 93], ["pneumonia", "PROBLEM", 97, 106], ["pneumonia", "OBSERVATION", 97, 106]]], ["While these results seem to support the hypothesis by Radpour et al. [26] that, in highly infected communities chest CT imaging may be a superior diagnostic tool compared to RT-PCR testing, we must consider that the additional benefit of CT scan as a diagnostic tool for COVID-19 in the general population is still to be proven, and that its execution is not exempt from significant risks such as radiation exposure and the risk of infection for other patients or staff in the Radiology department.J o u r n a l P r e -p r o o fMoreover, the hazard that a non-COVID-19 patient may end up in a COVID-19 dedicated department because of a FP CT scan and be therefore infected cannot be overlooked.J o u r n a l P r e -p r o o fEven if in our investigation the specificity was considerably higher than previously reported case studies in a general population the RT-PCR, despite the low sensitivity, remains the only gold standard validated globallyJ o u r n a l P r e -p r o o fAs an alternative we believe that developing a \"composed gold standard\" according to the model utilized in pulmonary thromboembolism [27] could be clinically relevant.", [["pulmonary", "ANATOMY", 1082, 1091], ["infection", "DISEASE", 432, 441], ["pulmonary thromboembolism", "DISEASE", 1082, 1107], ["patients", "ORGANISM", 452, 460], ["patient", "ORGANISM", 569, 576], ["pulmonary", "ORGAN", 1082, 1091], ["patients", "SPECIES", 452, 460], ["patient", "SPECIES", 569, 576], ["chest CT imaging", "TEST", 111, 127], ["RT-PCR testing", "TEST", 174, 188], ["CT scan", "TEST", 238, 245], ["a diagnostic tool", "TEST", 249, 266], ["COVID", "TEST", 271, 276], ["radiation exposure", "TREATMENT", 397, 415], ["infection", "PROBLEM", 432, 441], ["a FP CT scan", "TEST", 634, 646], ["infected", "PROBLEM", 664, 672], ["our investigation", "TEST", 735, 752], ["the RT-PCR", "TEST", 855, 865], ["the low sensitivity", "PROBLEM", 875, 894], ["pulmonary thromboembolism", "PROBLEM", 1082, 1107], ["chest", "ANATOMY", 111, 116], ["infection", "OBSERVATION", 432, 441], ["infected", "OBSERVATION", 664, 672], ["pulmonary", "ANATOMY", 1082, 1091], ["thromboembolism", "OBSERVATION", 1092, 1107]]], ["The new reference should be based upon clinical adjudication relying on repeat swabs, contact with patients with ascertained COVID-19, clinical and laboratory features, chest radiographs, and CT scans.", [["swabs", "ANATOMY", 79, 84], ["chest", "ANATOMY", 169, 174], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["repeat swabs", "TEST", 72, 84], ["laboratory features", "TEST", 148, 167], ["chest radiographs", "TEST", 169, 186], ["CT scans", "TEST", 192, 200], ["chest", "ANATOMY", 169, 174]]], ["On the other hand, this could introduce some incorporation bias, since the evaluated tests are part of the reference standard, and this may expand the measured accuracy of these tests, as pointed out by Watson et al. [28] .J o u r n a l P r e -p r o o fFurther research and consensus along these lines are obviously needed.J o u r n a l P r e -p r o o fOur study has several limitations.", [["the evaluated tests", "TEST", 71, 90], ["these tests", "TEST", 172, 183], ["fFurther research", "TEST", 252, 269], ["these lines", "TREATMENT", 290, 301], ["fOur study", "TEST", 352, 362], ["incorporation bias", "OBSERVATION", 45, 63]]], ["The first is that our analysis used a single RT-PCR test as the reference standard in the large majority of patients, while this is considered suboptimal given the fact that repeated RT-PCR are undoubtedly more accurate [28] .", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["our analysis", "TEST", 18, 30], ["a single RT-PCR test", "TEST", 36, 56], ["repeated RT-PCR", "TEST", 174, 189], ["large", "OBSERVATION_MODIFIER", 90, 95]]], ["A second limitation is that lung involvement has been quantified only via the number of affected lobes: this may fail to assess the actual percentage of affected parenchyma as predictor of outcome.", [["lung", "ANATOMY", 28, 32], ["lobes", "ANATOMY", 97, 102], ["parenchyma", "ANATOMY", 162, 172], ["lung", "ORGAN", 28, 32], ["lobes", "ORGAN", 97, 102], ["parenchyma", "TISSUE", 162, 172], ["lung involvement", "PROBLEM", 28, 44], ["affected parenchyma", "PROBLEM", 153, 172], ["lung", "ANATOMY", 28, 32], ["involvement", "OBSERVATION", 33, 44]]], ["A third limitation is the retrospective nature of the study, during which patients presented autonomously to the ED with the J o u r n a l P r e -p r o o f consequent impossibility to collect the time interval between the onset of the clinical signs and the chest CT in the majority of cases.", [["chest", "ANATOMY", 258, 263], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["the study", "TEST", 50, 59], ["the clinical signs", "TEST", 231, 249], ["the chest CT", "TEST", 254, 266], ["chest", "ANATOMY", 258, 263]]], ["Finally our results could be largely determined by the epidemic context in which pre-test probability of Covid-19 pneumonia is very high.ConclusionChest CT scan has a high sensitivity and supposedly a consistently higher specificity than whatAcknowledgementsThe authors would like to give a special thanks to Leonardo Mammana for his help in database construction and organization.", [["pneumonia", "DISEASE", 114, 123], ["Covid-19", "ORGANISM", 105, 113], ["Covid-19", "SPECIES", 105, 113], ["Covid", "TEST", 105, 110], ["pneumonia", "PROBLEM", 114, 123], ["ConclusionChest CT scan", "TEST", 137, 160], ["a high sensitivity", "PROBLEM", 165, 183], ["pneumonia", "OBSERVATION", 114, 123]]], ["The authors would also like to thank Fabio Falaschi for his help in editing and counselling.FundingNo funding has been released for this research.", [["No", "UNCERTAINTY", 99, 101], ["funding", "OBSERVATION", 102, 109]]], ["This study was conducted by voluntary contribution of the authors using technology belonging to Universit\u00e0 del Piemonte Orientale and Ospedale Maggiore della Carit\u00e0-Novara, ItalyFundingCompliance with Ethical Standards This retrospective study is in compliance with the guidelines issued by the Institute Research Medical Ethics Committee at AOU Maggiore della Carit\u00e0, Novara, Italy, and with the declaration of Helsinki.", [["This study", "TEST", 0, 10], ["Universit\u00e0 del Piemonte Orientale", "TREATMENT", 96, 129], ["Ospedale Maggiore della Carit\u00e0", "TREATMENT", 134, 164], ["Ethical Standards", "TREATMENT", 201, 218], ["This retrospective study", "TEST", 219, 243]]], ["Written informed consent was waived.Guarantor:The scientific guarantor of this publication is Prof. Alessandro Carriero.Conflict of Interest:The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.Statistics and Biometry:One of the authors, Ferruccio Aquilini, has significant statistical expertise.Statistics and Biometry:6.", [["significant", "OBSERVATION_MODIFIER", 364, 375]]], ["Informed Consent: Written informed consent was not required for this study because this research was retrospective and did not altered the treatment or the life of the patients in any way.", [["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["this study", "TEST", 64, 74]]], ["Enrolled patients were assigned a progressive identification number (ID), which was later used to collect their personal data.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["This procedure guaranteed anonymity, allowing non-disclosure of sensitive data.Ethical Approval:Institutional Review Board approval was not required because this research was retrospective and did not altered the treatment or the life of the patients in any way.", [["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 242, 250], ["This procedure", "TREATMENT", 0, 14]]], ["Enrolled patients were assigned a progressive identification number (ID), which was later used to collect their personal data.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["This procedure guaranteed anonymity, allowing non-disclosure of sensitive data.Study subjects or cohorts overlap:This study subjects or cohorts have never been previously reported.", [["This procedure", "TREATMENT", 0, 14], ["This study", "TEST", 113, 123]]]], "PMC7414258": [["IntroductionHuman norovirus (HuNV) is a non-enveloped, positive single-stranded RNA virus [1].", [["norovirus", "DISEASE", 18, 27], ["IntroductionHuman norovirus", "ORGANISM", 0, 27], ["HuNV", "SPECIES", 29, 33], ["IntroductionHuman norovirus", "PROBLEM", 0, 27], ["a non-enveloped, positive single-stranded RNA virus", "PROBLEM", 38, 89]]], ["Recently, noroviruses have been classified into at least 10 genogroups (GI-GX) on the basis of the amino acid sequence diversity of the viral VP1 protein [2].", [["amino acid", "CHEMICAL", 99, 109], ["amino acid", "CHEMICAL", 99, 109], ["noroviruses", "ORGANISM", 10, 21], ["GI-GX", "GENE_OR_GENE_PRODUCT", 72, 77], ["amino acid", "AMINO_ACID", 99, 109], ["viral VP1 protein", "PROTEIN", 136, 153], ["noroviruses", "PROBLEM", 10, 21], ["the amino acid sequence", "TREATMENT", 95, 118], ["the viral VP1 protein", "TEST", 132, 153], ["noroviruses", "OBSERVATION", 10, 21], ["viral VP1", "OBSERVATION", 136, 145]]], ["Viruses in the GI, GII, GIV, GVIII and GIX genogroups can infect humans and are a major cause of acute epidemic viral gastroenteritis worldwide [2].", [["viral gastroenteritis", "DISEASE", 112, 133], ["GI", "ORGANISM_SUBDIVISION", 15, 17], ["GIV", "GENE_OR_GENE_PRODUCT", 24, 27], ["GVIII", "GENE_OR_GENE_PRODUCT", 29, 34], ["GIX", "GENE_OR_GENE_PRODUCT", 39, 42], ["humans", "ORGANISM", 65, 71], ["humans", "SPECIES", 65, 71], ["humans", "SPECIES", 65, 71], ["Viruses", "PROBLEM", 0, 7], ["GIV", "PROBLEM", 24, 27], ["GVIII", "TREATMENT", 29, 34], ["GIX genogroups", "PROBLEM", 39, 53], ["acute epidemic viral gastroenteritis", "PROBLEM", 97, 133], ["GI", "ANATOMY", 15, 17], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["epidemic", "OBSERVATION_MODIFIER", 103, 111], ["viral gastroenteritis", "OBSERVATION", 112, 133]]], ["It is estimated that noroviruses are responsible for 699 million gastroenteritis cases per year [3] and 200,000 deaths in children under 5 years of age in developing countries [4].", [["noroviruses", "DISEASE", 21, 32], ["gastroenteritis", "DISEASE", 65, 80], ["deaths", "DISEASE", 112, 118], ["children", "ORGANISM", 122, 130], ["children", "SPECIES", 122, 130], ["noroviruses", "PROBLEM", 21, 32], ["noroviruses", "OBSERVATION", 21, 32]]], ["Although norovirus gastroenteritis is usually self-limiting, it has been recognized as an emerging burden in immunocompromised populations, particularly transplant recipients [5, 6].", [["norovirus gastroenteritis", "DISEASE", 9, 34], ["recipients", "ORGANISM", 164, 174], ["norovirus gastroenteritis", "PROBLEM", 9, 34], ["immunocompromised populations", "PROBLEM", 109, 138], ["transplant recipients", "TREATMENT", 153, 174], ["norovirus", "OBSERVATION", 9, 18], ["self-limiting", "OBSERVATION_MODIFIER", 46, 59], ["immunocompromised populations", "OBSERVATION", 109, 138]]], ["However, research into HuNV infection has been hampered by the lack of availability of robust experimental models sustaining viral infection.", [["infection", "DISEASE", 28, 37], ["viral infection", "DISEASE", 125, 140], ["HuNV", "GENE_OR_GENE_PRODUCT", 23, 27], ["HuNV", "SPECIES", 23, 27], ["research into HuNV infection", "PROBLEM", 9, 37], ["viral infection", "PROBLEM", 125, 140], ["infection", "OBSERVATION", 28, 37], ["viral", "OBSERVATION_MODIFIER", 125, 130], ["infection", "OBSERVATION", 131, 140]]], ["Murine norovirus (MNV), which is capable of replicating in both cell culture and small-animal models, shares similar traits with HuNV in structural and genetic features and has thus been widely used as a surrogate model [7, 8].", [["cell culture", "ANATOMY", 64, 76], ["Murine norovirus", "ORGANISM", 0, 16], ["MNV", "ORGANISM", 18, 21], ["cell culture", "CELL", 64, 76], ["HuNV", "GENE_OR_GENE_PRODUCT", 129, 133], ["Murine", "SPECIES", 0, 6], ["Murine norovirus", "SPECIES", 0, 16], ["MNV", "SPECIES", 18, 21], ["Murine norovirus", "PROBLEM", 0, 16], ["both cell culture", "TEST", 59, 76], ["norovirus", "OBSERVATION", 7, 16], ["both cell", "OBSERVATION", 59, 68], ["small", "OBSERVATION_MODIFIER", 81, 86]]], ["To date, no vaccine or specific antiviral treatment is available, and clinical management is restricted to supportive care and oral rehydration.", [["oral", "ANATOMY", 127, 131], ["oral", "ORGANISM_SUBDIVISION", 127, 131], ["vaccine", "TREATMENT", 12, 19], ["specific antiviral treatment", "TREATMENT", 23, 51], ["clinical management", "TREATMENT", 70, 89], ["supportive care", "TREATMENT", 107, 122], ["oral rehydration", "TREATMENT", 127, 143]]], ["Thus, the development of specific antiviral drugs for norovirus infection is urgently needed.IntroductionPotential inhibitors of noroviruses have been identified, and some of these have demonstrated efficacy in experimental models.", [["norovirus infection", "DISEASE", 54, 73], ["noroviruses", "DISEASE", 129, 140], ["norovirus", "ORGANISM", 54, 63], ["noroviruses", "ORGANISM", 129, 140], ["norovirus", "SPECIES", 54, 63], ["specific antiviral drugs", "TREATMENT", 25, 49], ["norovirus infection", "PROBLEM", 54, 73], ["Potential inhibitors of noroviruses", "PROBLEM", 105, 140], ["antiviral drugs", "OBSERVATION", 34, 49], ["noroviruses", "OBSERVATION", 129, 140]]], ["Ribavirin has been extensively studied and exhibits broad antiviral activity against multiple viruses, including hepatitis C virus (HCV) [9], hemorrhagic fever virus [10], hepatitis E virus [11, 12], and norovirus [13].", [["Ribavirin", "CHEMICAL", 0, 9], ["hepatitis C", "DISEASE", 113, 124], ["hemorrhagic fever", "DISEASE", 142, 159], ["hepatitis E", "DISEASE", 172, 183], ["norovirus", "DISEASE", 204, 213], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["hepatitis C virus", "ORGANISM", 113, 130], ["HCV) [9], hemorrhagic fever virus", "ORGANISM", 132, 165], ["hepatitis E virus", "ORGANISM", 172, 189], ["hepatitis C virus", "SPECIES", 113, 130], ["hemorrhagic fever virus", "SPECIES", 142, 165], ["hepatitis E virus", "SPECIES", 172, 189], ["hepatitis C virus", "SPECIES", 113, 130], ["HCV", "SPECIES", 132, 135], ["hemorrhagic fever virus", "SPECIES", 142, 165], ["hepatitis E virus", "SPECIES", 172, 189], ["Ribavirin", "TREATMENT", 0, 9], ["multiple viruses", "PROBLEM", 85, 101], ["hepatitis C virus (HCV)", "PROBLEM", 113, 136], ["hemorrhagic fever virus", "PROBLEM", 142, 165], ["hepatitis E virus", "PROBLEM", 172, 189], ["norovirus", "PROBLEM", 204, 213], ["broad", "OBSERVATION_MODIFIER", 52, 57], ["antiviral activity", "OBSERVATION", 58, 76], ["viruses", "OBSERVATION", 94, 101]]], ["In a clinical study, ribavirin treatment resulted in complete viral clearance in a subset of norovirus-infected patients, but treatment failure occurred in two cases [14].", [["ribavirin", "CHEMICAL", 21, 30], ["norovirus-infected", "DISEASE", 93, 111], ["ribavirin", "CHEMICAL", 21, 30], ["ribavirin", "SIMPLE_CHEMICAL", 21, 30], ["norovirus", "ORGANISM", 93, 102], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["a clinical study", "TEST", 3, 19], ["ribavirin treatment", "TREATMENT", 21, 40], ["complete viral clearance", "PROBLEM", 53, 77], ["norovirus", "PROBLEM", 93, 102], ["treatment failure", "PROBLEM", 126, 143], ["viral clearance", "OBSERVATION", 62, 77], ["norovirus", "OBSERVATION", 93, 102], ["infected", "OBSERVATION_MODIFIER", 103, 111]]], ["We demonstrated previously that mycophenolic acid (MPA), a potent inhibitor of IMP dehydrogenase (IMPDH), can inhibit norovirus replication in cell culture [15].", [["cell", "ANATOMY", 143, 147], ["mycophenolic acid", "CHEMICAL", 32, 49], ["MPA", "CHEMICAL", 51, 54], ["IMP", "CHEMICAL", 79, 82], ["mycophenolic acid", "CHEMICAL", 32, 49], ["MPA", "CHEMICAL", 51, 54], ["IMP", "CHEMICAL", 79, 82], ["mycophenolic acid", "SIMPLE_CHEMICAL", 32, 49], ["MPA", "SIMPLE_CHEMICAL", 51, 54], ["IMP dehydrogenase", "GENE_OR_GENE_PRODUCT", 79, 96], ["IMPDH", "GENE_OR_GENE_PRODUCT", 98, 103], ["norovirus", "ORGANISM", 118, 127], ["cell", "CELL", 143, 147], ["IMP dehydrogenase", "PROTEIN", 79, 96], ["IMPDH", "PROTEIN", 98, 103], ["norovirus", "SPECIES", 118, 127], ["mycophenolic acid (MPA)", "TREATMENT", 32, 55], ["a potent inhibitor", "TREATMENT", 57, 75], ["IMP dehydrogenase (IMPDH)", "PROBLEM", 79, 104], ["norovirus replication", "PROBLEM", 118, 139], ["cell culture", "TEST", 143, 155]]], ["Favipiravir, also known as T-705, has been approved for the treatment of influenza in Japan and has been repositioned to treat patients with Ebola virus infection [16, 17].", [["Favipiravir", "CHEMICAL", 0, 11], ["T-705", "CHEMICAL", 27, 32], ["influenza", "DISEASE", 73, 82], ["Ebola virus infection", "DISEASE", 141, 162], ["Favipiravir", "CHEMICAL", 0, 11], ["T-705", "CHEMICAL", 27, 32], ["Favipiravir", "SIMPLE_CHEMICAL", 0, 11], ["T-705", "GENE_OR_GENE_PRODUCT", 27, 32], ["patients", "ORGANISM", 127, 135], ["Ebola virus", "ORGANISM", 141, 152], ["patients", "SPECIES", 127, 135], ["Ebola virus", "SPECIES", 141, 152], ["T-705", "SPECIES", 27, 32], ["Ebola virus", "SPECIES", 141, 152], ["Favipiravir", "TREATMENT", 0, 11], ["influenza", "PROBLEM", 73, 82], ["Ebola virus infection", "PROBLEM", 141, 162]]], ["It has been shown to be effective against noroviruses, but the treatment can induce mutagenesis in mice and in patients, challenging the application of favipiravir for treating chronic norovirus infection [18].IntroductionRecently, 2\u2019-fluoro-2\u2019-deoxycytidine (2\u2019-FdC), also known as 2\u2019-deoxy-2\u2019-fluorocytidine, has been reported to exert broad antiviral activity against HCV, Lassa virus, Crimean-Congo hemorrhagic fever virus, and bunyaviruses [19\u201322].", [["noroviruses", "DISEASE", 42, 53], ["favipiravir", "CHEMICAL", 152, 163], ["chronic norovirus infection", "DISEASE", 177, 204], ["2\u2019-fluoro-2\u2019-deoxycytidine", "CHEMICAL", 232, 258], ["2\u2019-FdC", "CHEMICAL", 260, 266], ["2\u2019-deoxy-2\u2019-fluorocytidine", "CHEMICAL", 283, 309], ["Lassa virus", "DISEASE", 376, 387], ["Crimean-Congo hemorrhagic fever", "DISEASE", 389, 420], ["favipiravir", "CHEMICAL", 152, 163], ["2\u2019-fluoro-2\u2019-deoxycytidine", "CHEMICAL", 232, 258], ["2\u2019-FdC", "CHEMICAL", 260, 266], ["2\u2019-deoxy-2\u2019-fluorocytidine", "CHEMICAL", 283, 309], ["mice", "ORGANISM", 99, 103], ["patients", "ORGANISM", 111, 119], ["favipiravir", "SIMPLE_CHEMICAL", 152, 163], ["2\u2019-fluoro-2\u2019-deoxycytidine", "SIMPLE_CHEMICAL", 232, 258], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 260, 266], ["2\u2019-deoxy-2\u2019-fluorocytidine", "SIMPLE_CHEMICAL", 283, 309], ["HCV", "ORGANISM", 371, 374], ["Lassa virus", "ORGANISM", 376, 387], ["Crimean-Congo hemorrhagic fever virus", "ORGANISM", 389, 426], ["mice", "SPECIES", 99, 103], ["patients", "SPECIES", 111, 119], ["Lassa virus", "SPECIES", 376, 387], ["Congo hemorrhagic fever virus", "SPECIES", 397, 426], ["mice", "SPECIES", 99, 103], ["HCV", "SPECIES", 371, 374], ["Lassa virus", "SPECIES", 376, 387], ["Crimean-Congo hemorrhagic fever virus", "SPECIES", 389, 426], ["noroviruses", "PROBLEM", 42, 53], ["favipiravir", "TREATMENT", 152, 163], ["chronic norovirus infection", "PROBLEM", 177, 204], ["IntroductionRecently", "TEST", 210, 230], ["fluoro", "TREATMENT", 235, 241], ["deoxycytidine (2\u2019-FdC)", "TREATMENT", 245, 267], ["deoxy", "TREATMENT", 286, 291], ["fluorocytidine", "TREATMENT", 295, 309], ["HCV", "PROBLEM", 371, 374], ["Lassa virus", "PROBLEM", 376, 387], ["Crimean", "TEST", 389, 396], ["Congo hemorrhagic fever virus", "PROBLEM", 397, 426], ["bunyaviruses", "TEST", 432, 444], ["shown to be", "UNCERTAINTY", 12, 23], ["effective", "OBSERVATION_MODIFIER", 24, 33], ["chronic", "OBSERVATION_MODIFIER", 177, 184], ["norovirus", "OBSERVATION", 185, 194]]], ["Given the success of 2\u2019-FdC against the abovementioned viruses, we aimed to investigate the potential antiviral activity of this compound against MNV replication.Reagents ::: Materials and methods2\u2019-Fluoro-2\u2019-deoxycytidine was purchased from Biosynth Carbosynth and dissolved in dimethyl sulfoxide (DMSO, Sigma, Zwijndrecht, The Netherlands).", [["2\u2019-FdC", "CHEMICAL", 21, 27], ["methods2\u2019-Fluoro-2\u2019-deoxycytidine", "CHEMICAL", 189, 222], ["Biosynth Carbosynth", "CHEMICAL", 242, 261], ["dimethyl sulfoxide", "CHEMICAL", 279, 297], ["DMSO", "CHEMICAL", 299, 303], ["2\u2019-FdC", "CHEMICAL", 21, 27], ["methods2\u2019-Fluoro-2\u2019-deoxycytidine", "CHEMICAL", 189, 222], ["dimethyl sulfoxide", "CHEMICAL", 279, 297], ["DMSO", "CHEMICAL", 299, 303], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 21, 27], ["MNV", "ORGANISM", 146, 149], ["methods2\u2019-Fluoro-2\u2019-deoxycytidine", "SIMPLE_CHEMICAL", 189, 222], ["Biosynth Carbosynth", "SIMPLE_CHEMICAL", 242, 261], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 279, 297], ["DMSO", "SIMPLE_CHEMICAL", 299, 303], ["MNV", "SPECIES", 146, 149], ["2\u2019-FdC", "TREATMENT", 21, 27], ["the abovementioned viruses", "PROBLEM", 36, 62], ["MNV replication", "TREATMENT", 146, 161], ["Materials", "TEST", 175, 184], ["methods2\u2019-Fluoro", "TREATMENT", 189, 205], ["deoxycytidine", "TREATMENT", 209, 222], ["Biosynth Carbosynth", "TREATMENT", 242, 261], ["dimethyl sulfoxide (DMSO", "TREATMENT", 279, 303], ["viruses", "OBSERVATION", 55, 62], ["antiviral activity", "OBSERVATION", 102, 120]]], ["MPA (Sigma), ribavirin (Bio-Connect BV), T705 (BioVision), cytidine triphosphate (CTP; Sigma), guanosine triphosphate (GTP; Sigma), human IFN-\u03b1 (Thermo Scientific, The Netherlands) and JAK inhibitor 1 (Santa Cruz Biotechnology, USA) were used.", [["MPA", "CHEMICAL", 0, 3], ["ribavirin", "CHEMICAL", 13, 22], ["cytidine triphosphate", "CHEMICAL", 59, 80], ["CTP", "CHEMICAL", 82, 85], ["guanosine triphosphate", "CHEMICAL", 95, 117], ["GTP", "CHEMICAL", 119, 122], ["MPA", "CHEMICAL", 0, 3], ["ribavirin", "CHEMICAL", 13, 22], ["T705", "CHEMICAL", 41, 45], ["cytidine triphosphate", "CHEMICAL", 59, 80], ["CTP", "CHEMICAL", 82, 85], ["guanosine triphosphate", "CHEMICAL", 95, 117], ["GTP", "CHEMICAL", 119, 122], ["MPA", "SIMPLE_CHEMICAL", 0, 3], ["Sigma", "SIMPLE_CHEMICAL", 5, 10], ["ribavirin", "SIMPLE_CHEMICAL", 13, 22], ["T705", "SIMPLE_CHEMICAL", 41, 45], ["cytidine triphosphate", "SIMPLE_CHEMICAL", 59, 80], ["CTP", "SIMPLE_CHEMICAL", 82, 85], ["Sigma", "SIMPLE_CHEMICAL", 87, 92], ["guanosine triphosphate", "SIMPLE_CHEMICAL", 95, 117], ["GTP", "SIMPLE_CHEMICAL", 119, 122], ["human", "ORGANISM", 132, 137], ["JAK", "GENE_OR_GENE_PRODUCT", 185, 188], ["IFN", "PROTEIN", 138, 141], ["JAK", "PROTEIN", 185, 188], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["MPA (Sigma)", "TREATMENT", 0, 11], ["ribavirin (Bio-Connect BV)", "TREATMENT", 13, 39], ["T705 (BioVision)", "TREATMENT", 41, 57], ["cytidine triphosphate (CTP", "TREATMENT", 59, 85], ["guanosine triphosphate (GTP", "TREATMENT", 95, 122], ["human IFN", "TREATMENT", 132, 141], ["JAK inhibitor", "TREATMENT", 185, 198]]], ["A rabbit polyclonal antiserum against MNV NS1/2 [23] was kindly provided by Prof. Vernon K. Ward (School of Biomedical Sciences, University of Otago, New Zealand). \u03b2-actin antibody (#sc-47778) was purchased from Santa Cruz Biotechnology.", [["#sc-47778", "CHEMICAL", 182, 191], ["rabbit", "ORGANISM", 2, 8], ["MNV NS1", "ORGANISM", 38, 45], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 164, 171], ["MNV NS1", "PROTEIN", 38, 45], ["\u03b2-actin antibody", "PROTEIN", 164, 180], ["Santa Cruz Biotechnology", "PROTEIN", 212, 236], ["rabbit", "SPECIES", 2, 8], ["rabbit", "SPECIES", 2, 8], ["A rabbit polyclonal antiserum", "TEST", 0, 29], ["MNV NS1", "TEST", 38, 45], ["\u03b2-actin antibody", "TEST", 164, 180], ["sc", "TEST", 183, 185]]], ["IRDye\u00ae 800CW-conjugated goat anti-rabbit and goat anti-mouse IgGs (Li-Cor Bioscience, Lincoln, USA) were used as secondary antibodies, as appropriate.Cells and viruses ::: Materials and methodsRAW264.7 and J774A.1 were cultured in Dulbecco\u2019s modified Eagle\u2019s medium (DMEM; Lonza Verviers, Belgium) supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (FCS; Hyclone, Logan, UT, USA) and 100 \u03bcg of streptomycin, and 100 IU of penicillin per mL.", [["Cells", "ANATOMY", 150, 155], ["RAW264.7", "ANATOMY", 193, 201], ["J774A.1", "ANATOMY", 206, 213], ["fetal calf serum", "ANATOMY", 347, 363], ["IRDye\u00ae 800CW", "CHEMICAL", 0, 12], ["streptomycin", "CHEMICAL", 409, 421], ["penicillin", "CHEMICAL", 437, 447], ["streptomycin", "CHEMICAL", 409, 421], ["penicillin", "CHEMICAL", 437, 447], ["IRDye\u00ae", "SIMPLE_CHEMICAL", 0, 6], ["800CW", "SIMPLE_CHEMICAL", 7, 12], ["goat", "ORGANISM", 24, 28], ["Cells", "CELL", 150, 155], ["RAW264.7", "CELL", 193, 201], ["J774A.1", "CELL", 206, 213], ["calf", "ORGANISM", 353, 357], ["serum", "ORGANISM_SUBSTANCE", 358, 363], ["FCS", "ORGANISM_SUBSTANCE", 365, 368], ["Hyclone", "ORGANISM_SUBSTANCE", 370, 377], ["streptomycin", "SIMPLE_CHEMICAL", 409, 421], ["penicillin", "SIMPLE_CHEMICAL", 437, 447], ["IRDye\u00ae 800CW-conjugated goat anti-rabbit and goat anti-mouse IgGs", "PROTEIN", 0, 65], ["secondary antibodies", "PROTEIN", 113, 133], ["RAW264.7", "CELL_LINE", 193, 201], ["J774A.1", "CELL_LINE", 206, 213], ["goat", "SPECIES", 24, 28], ["anti-rabbit", "SPECIES", 29, 40], ["goat", "SPECIES", 45, 49], ["anti-mouse", "SPECIES", 50, 60], ["calf", "SPECIES", 353, 357], ["goat", "SPECIES", 24, 28], ["anti-rabbit", "SPECIES", 29, 40], ["goat", "SPECIES", 45, 49], ["IRDye\u00ae", "TEST", 0, 6], ["conjugated goat anti-rabbit", "TREATMENT", 13, 40], ["goat anti-mouse IgGs", "TREATMENT", 45, 65], ["J774A.1", "TEST", 206, 213], ["Dulbecco", "TEST", 231, 239], ["Lonza Verviers", "TREATMENT", 273, 287], ["heat", "TEST", 330, 334], ["fetal calf serum", "TEST", 347, 363], ["FCS", "TEST", 365, 368], ["Hyclone", "TEST", 370, 377], ["streptomycin", "TREATMENT", 409, 421], ["penicillin", "TREATMENT", 437, 447], ["viruses", "OBSERVATION", 160, 167], ["fetal calf", "ANATOMY", 347, 357]]], ["The murine norovirus strain MNV-1 (MNV-1.CW1), the acutely cleared strain MNVCW3, and the persistent strain MNVCR6 were produced by consecutively inoculating the virus (kindly provided by Prof. Herbert Virgin, Department of Pathology and Immunology, Washington University School of Medicine) onto RAW264.7 cells [24].", [["RAW264.7 cells", "ANATOMY", 297, 311], ["murine", "ORGANISM", 4, 10], ["norovirus strain", "ORGANISM", 11, 27], ["MNV-1", "ORGANISM", 28, 33], ["MNV-1.CW1", "ORGANISM", 35, 44], ["MNVCR6", "GENE_OR_GENE_PRODUCT", 108, 114], ["RAW264.7 cells", "CELL", 297, 311], ["RAW264.7 cells", "CELL_LINE", 297, 311], ["murine", "SPECIES", 4, 10], ["MNV-1", "SPECIES", 28, 33], ["murine norovirus strain MNV-1", "SPECIES", 4, 33], ["MNVCR6", "SPECIES", 108, 114], ["The murine norovirus strain MNV", "TEST", 0, 31], ["MNV", "TEST", 35, 38], ["the acutely cleared strain MNVCW3", "PROBLEM", 47, 80], ["the persistent strain MNVCR6", "PROBLEM", 86, 114], ["norovirus", "OBSERVATION", 11, 20], ["persistent", "OBSERVATION_MODIFIER", 90, 100]]], ["Human Huh7 hepatocellular carcinoma cells harboring a genotype 1 HuNV replicon (HG23) were kindly provided by Dr. Kyeong-Ok Chang (Kansas State University) [25].", [["Huh7 hepatocellular carcinoma cells", "ANATOMY", 6, 41], ["hepatocellular carcinoma", "DISEASE", 11, 35], ["Human", "ORGANISM", 0, 5], ["Huh7 hepatocellular carcinoma cells", "CELL", 6, 41], ["Human Huh7 hepatocellular carcinoma cells", "CELL_LINE", 0, 41], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human Huh7 hepatocellular carcinoma cells", "TREATMENT", 0, 41], ["a genotype 1 HuNV replicon", "TREATMENT", 52, 78], ["hepatocellular carcinoma", "OBSERVATION", 11, 35]]], ["A neomycin resistance gene was engineered into ORF2, conferring HG23 resistance to neomycin.", [["neomycin", "CHEMICAL", 2, 10], ["neomycin", "CHEMICAL", 83, 91], ["neomycin", "CHEMICAL", 2, 10], ["neomycin", "CHEMICAL", 83, 91], ["neomycin", "SIMPLE_CHEMICAL", 2, 10], ["ORF2", "GENE_OR_GENE_PRODUCT", 47, 51], ["HG23", "GENE_OR_GENE_PRODUCT", 64, 68], ["neomycin", "SIMPLE_CHEMICAL", 83, 91], ["neomycin resistance gene", "DNA", 2, 26], ["ORF2", "DNA", 47, 51], ["HG23", "DNA", 64, 68], ["A neomycin resistance gene", "TREATMENT", 0, 26], ["neomycin", "TREATMENT", 83, 91], ["neomycin resistance", "OBSERVATION", 2, 21]]], ["Gentamicin (G418; Gibco) was added to HG23 culture medium at 0.5 mg/mL for selection before experimentation.Tcid50 ::: Materials and methodsMNV was quantified using a 50% tissue culture infectious dose (TCID50) assay.", [["tissue", "ANATOMY", 171, 177], ["Gentamicin", "CHEMICAL", 0, 10], ["G418", "CHEMICAL", 12, 16], ["HG23", "CHEMICAL", 38, 42], ["Gentamicin", "CHEMICAL", 0, 10], ["G418", "CHEMICAL", 12, 16], ["Gentamicin", "SIMPLE_CHEMICAL", 0, 10], ["G418", "SIMPLE_CHEMICAL", 12, 16], ["Gibco", "ORGANISM_SUBSTANCE", 18, 23], ["MNV", "ORGANISM", 140, 143], ["tissue", "TISSUE", 171, 177], ["MNV", "SPECIES", 140, 143], ["Gentamicin", "TREATMENT", 0, 10], ["Gibco)", "TREATMENT", 18, 24], ["HG23 culture medium", "TREATMENT", 38, 57], ["methodsMNV", "TEST", 133, 143], ["a 50% tissue culture", "TREATMENT", 165, 185]]], ["Briefly, tenfold dilutions of MNV were inoculated onto RAW264.7 cells grown in a 96-well tissue culture plate at 1,000 cells/well.", [["RAW264.7 cells", "ANATOMY", 55, 69], ["tissue", "ANATOMY", 89, 95], ["cells", "ANATOMY", 119, 124], ["MNV", "ORGANISM", 30, 33], ["RAW264.7 cells", "CELL", 55, 69], ["cells", "CELL", 119, 124], ["RAW264.7 cells", "CELL_LINE", 55, 69], ["MNV", "SPECIES", 30, 33], ["tenfold dilutions of MNV", "PROBLEM", 9, 33], ["RAW264.7 cells", "TEST", 55, 69]]], ["The plate was incubated at 37\u00b0C for another 5 days, and each well was examined under a light microscope for a cytopathic effect (CPE).", [["a light microscope", "TEST", 85, 103], ["a cytopathic effect", "PROBLEM", 108, 127], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["The TCID50 was calculated by using the Reed-Muench method.Antiviral assay ::: Materials and methodsThe antiviral assay was initiated by inoculating RAW264.7 or J774A.1 cells with MNV at a multiplicity of infection (MOI) of 1.", [["RAW264.7", "ANATOMY", 148, 156], ["1 cells", "ANATOMY", 166, 173], ["infection", "DISEASE", 204, 213], ["RAW264.7", "CELL", 148, 156], ["1 cells", "CELL", 166, 173], ["MNV", "ORGANISM", 179, 182], ["RAW264.7", "CELL_LINE", 148, 156], ["The TCID50", "TREATMENT", 0, 10], ["the Reed-Muench method", "TREATMENT", 35, 57], ["The antiviral assay", "TEST", 99, 118], ["MNV", "PROBLEM", 179, 182], ["infection", "PROBLEM", 204, 213], ["antiviral assay", "OBSERVATION", 103, 118], ["infection", "OBSERVATION", 204, 213]]], ["After 1 h of infection, cells were washed twice with phosphate-buffered saline (PBS) to remove free virus particles and then treated with the indicated compounds.", [["cells", "ANATOMY", 24, 29], ["infection", "DISEASE", 13, 22], ["phosphate", "CHEMICAL", 53, 62], ["phosphate", "CHEMICAL", 53, 62], ["cells", "CELL", 24, 29], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 53, 78], ["PBS", "SIMPLE_CHEMICAL", 80, 83], ["infection", "PROBLEM", 13, 22], ["phosphate-buffered saline (PBS", "TREATMENT", 53, 83], ["free virus particles", "TREATMENT", 95, 115], ["infection", "OBSERVATION", 13, 22]]], ["For combination assays, RAW264.7 cells were infected with the virus for 1 h, and the medium was replaced with medium containing 2\u2019-FdC, MPA, ribavirin, or T705, alone or in combination, at the indicated concentrations.", [["RAW264.7 cells", "ANATOMY", 24, 38], ["2\u2019-FdC", "CHEMICAL", 128, 134], ["MPA", "CHEMICAL", 136, 139], ["ribavirin", "CHEMICAL", 141, 150], ["T705", "CHEMICAL", 155, 159], ["2\u2019-FdC", "CHEMICAL", 128, 134], ["MPA", "CHEMICAL", 136, 139], ["ribavirin", "CHEMICAL", 141, 150], ["T705", "CHEMICAL", 155, 159], ["RAW264.7 cells", "CELL", 24, 38], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 128, 134], ["MPA", "SIMPLE_CHEMICAL", 136, 139], ["ribavirin", "SIMPLE_CHEMICAL", 141, 150], ["T705", "SIMPLE_CHEMICAL", 155, 159], ["RAW264.7 cells", "CELL_LINE", 24, 38], ["combination assays", "TEST", 4, 22], ["RAW264.7 cells", "PROBLEM", 24, 38], ["the virus", "PROBLEM", 58, 67], ["FdC", "TREATMENT", 131, 134], ["MPA", "TREATMENT", 136, 139], ["ribavirin", "TREATMENT", 141, 150], ["T705", "TREATMENT", 155, 159]]], ["After 20 h of treatment, total RNA, protein and the supernatant samples were collected and further analyzed by qRT-PCR, western blot and TCID50 assay, respectively.qRT-PCR ::: Materials and methodsTotal RNA was isolated using a Macherey NucleoSpin RNA II Kit (Bioke, Leiden, The Netherlands) and quantified using a NanoDrop ND-1000 spectrophotometer (Wilmington, DE, USA). cDNA was synthesized from 500 ng of RNA using a cDNA synthesis kit (TaKaRa Bio, Inc., Shiga, Japan).", [["supernatant samples", "ANATOMY", 52, 71], ["cDNA", "DNA", 373, 377], ["treatment", "TREATMENT", 14, 23], ["total RNA", "TREATMENT", 25, 34], ["the supernatant samples", "TEST", 48, 71], ["qRT", "TEST", 111, 114], ["PCR", "TEST", 115, 118], ["western blot", "TEST", 120, 132], ["TCID50 assay", "TEST", 137, 149], ["PCR", "TEST", 168, 171], ["a NanoDrop ND", "TREATMENT", 313, 326], ["a cDNA synthesis kit", "TREATMENT", 419, 439], ["TaKaRa Bio", "TREATMENT", 441, 451]]], ["The cDNA of all target genes was quantified by SYBR-Green-based (Applied Biosystems) real-time PCR on a StepOnePlusTM System (Thermo Fisher Scientific LifeSciences) according to the manufacturer\u2019s instructions.", [["cDNA", "DNA", 4, 8], ["target genes", "DNA", 16, 28], ["The cDNA", "TEST", 0, 8], ["SYBR", "TEST", 47, 51], ["a StepOnePlusTM System", "TREATMENT", 102, 124]]], ["Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and murine GAPDH genes were used as reference genes to normalize gene expression.", [["glyceraldehyde-3-phosphate", "CHEMICAL", 6, 32], ["glyceraldehyde-3-phosphate", "CHEMICAL", 6, 32], ["Human", "ORGANISM", 0, 5], ["glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 6, 46], ["GAPDH", "GENE_OR_GENE_PRODUCT", 48, 53], ["murine", "ORGANISM", 59, 65], ["GAPDH", "GENE_OR_GENE_PRODUCT", 66, 71], ["Human glyceraldehyde-3-phosphate dehydrogenase", "PROTEIN", 0, 46], ["GAPDH", "PROTEIN", 48, 53], ["murine GAPDH genes", "DNA", 59, 77], ["Human", "SPECIES", 0, 5], ["murine", "SPECIES", 59, 65], ["Human", "SPECIES", 0, 5], ["Human glyceraldehyde", "TREATMENT", 0, 20], ["phosphate dehydrogenase (GAPDH)", "TREATMENT", 23, 54], ["murine GAPDH genes", "TREATMENT", 59, 77]]], ["The relative expression of the target gene was calculated as 2-\u0394\u0394CT, where \u0394\u0394CT = \u0394CTsample - \u0394CTcontrol (\u0394CT = CT[target gene] - CT[GAPDH]).", [["target gene", "DNA", 31, 42], ["\u0394\u0394CT", "TEST", 75, 79], ["\u0394CTsample", "TEST", 82, 91], ["\u0394CT", "TEST", 106, 109], ["CT", "TEST", 112, 114]]], ["All primer sequences are listed in Supplementary Table 1.Western blot ::: Materials and methodsCultured cells were lysed in Laemmli sample buffer containing 0.1 M DTT, heated for 5 min at 95 \u00b0C, and loaded onto a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel.", [["cells", "ANATOMY", 104, 109], ["sodium dodecyl sulfate", "CHEMICAL", 217, 239], ["SDS-PAGE", "CHEMICAL", 276, 284], ["DTT", "CHEMICAL", 163, 166], ["sodium dodecyl sulfate", "CHEMICAL", 217, 239], ["polyacrylamide", "CHEMICAL", 240, 254], ["cells", "CELL", 104, 109], ["DTT", "SIMPLE_CHEMICAL", 163, 166], ["sodium dodecyl sulfate polyacrylamide", "SIMPLE_CHEMICAL", 217, 254], ["primer sequences", "DNA", 4, 20], ["All primer sequences", "TEST", 0, 20], ["methodsCultured cells", "TREATMENT", 88, 109], ["Laemmli sample buffer", "TREATMENT", 124, 145], ["a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis", "TREATMENT", 211, 274]]], ["After electrophoresis, the proteins were electrophoretically transferred to a polyvinylidene difluoride (PVDF) membrane (pore size, 0.45 \u03bcM; Invitrogen) for 2 h with an electric current of 250 mA.", [["membrane", "ANATOMY", 111, 119], ["pore", "ANATOMY", 121, 125], ["polyvinylidene difluoride", "CHEMICAL", 78, 103], ["PVDF", "CHEMICAL", 105, 109], ["electrophoresis", "TEST", 6, 21], ["a polyvinylidene difluoride (PVDF) membrane (pore size", "TREATMENT", 76, 130], ["Invitrogen", "TREATMENT", 141, 151]]], ["Subsequently, the membrane was blocked with a mixture of 2.5 mL of blocking buffer (Odyssey) and 2.5 mL of PBS containing 0.05% Tween 20 for 1 h, followed by overnight incubation with primary antibodies (1:1000) at 4 \u00b0C. The membrane was washed three times and then incubated with IRDye-conjugated secondary antibody (1:5000) for 1 h.", [["membrane", "ANATOMY", 18, 26], ["membrane", "ANATOMY", 225, 233], ["Tween 20", "CHEMICAL", 128, 136], ["IRDye", "CHEMICAL", 281, 286], ["membrane", "CELLULAR_COMPONENT", 18, 26], ["membrane", "CELLULAR_COMPONENT", 225, 233], ["IRDye", "SIMPLE_CHEMICAL", 281, 286], ["primary antibodies", "PROTEIN", 184, 202], ["IRDye-conjugated secondary antibody", "PROTEIN", 281, 316], ["blocking buffer (Odyssey)", "TREATMENT", 67, 92], ["PBS containing", "TREATMENT", 107, 121], ["primary antibodies", "TREATMENT", 184, 202], ["IRDye-conjugated secondary antibody", "TREATMENT", 281, 316], ["membrane", "OBSERVATION_MODIFIER", 225, 233]]], ["After washing three times, protein bands were detected using an Odyssey 3.0 Infrared Imaging System (Li-Cor Biosciences).Confocal fluorescence microscopy ::: Materials and methodsRAW264.7 or J774A.1 cells infected with MNV-1 at an MOI of 1 for 1 h, and the culture medium was replaced by medium containing different concentrations of 2\u2019-FdC in an 8-well chamber (cat. no. 80826; ibidi GmbH) for 20 h.", [["RAW264.7", "ANATOMY", 179, 187], ["1 cells", "ANATOMY", 197, 204], ["2\u2019-FdC", "CHEMICAL", 334, 340], ["2\u2019-FdC", "CHEMICAL", 334, 340], ["RAW264.7", "CELL", 179, 187], ["J774A.", "CELL", 191, 197], ["1 cells", "CELL", 197, 204], ["MNV-1", "ORGANISM", 219, 224], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 334, 340], ["RAW264.7", "CELL_LINE", 179, 187], ["MNV-1", "SPECIES", 219, 224], ["protein bands", "TEST", 27, 40], ["Infrared Imaging System", "TEST", 76, 99], ["Confocal fluorescence microscopy", "TEST", 121, 153], ["MNV", "TEST", 219, 222], ["the culture medium", "TEST", 253, 271]]], ["The cells were fixed with 4% paraformaldehyde in PBS, permeablized with 0.2% Triton X-100, blocked with 5% skim milk for 1 h, reacted with rabbit polyclonal antiserum against MNV NS1/2, and stained with 4\u2019,6-diamidino-2-phenylindole (DAPI).", [["cells", "ANATOMY", 4, 9], ["milk", "ANATOMY", 112, 116], ["Triton X-100", "CHEMICAL", 77, 89], ["4\u2019,6-diamidino-2-phenylindole", "CHEMICAL", 203, 232], ["paraformaldehyde", "CHEMICAL", 29, 45], ["4\u2019,6-diamidino-2-phenylindole", "CHEMICAL", 203, 232], ["DAPI", "CHEMICAL", 234, 238], ["cells", "CELL", 4, 9], ["paraformaldehyde", "SIMPLE_CHEMICAL", 29, 45], ["PBS", "SIMPLE_CHEMICAL", 49, 52], ["Triton X-100", "SIMPLE_CHEMICAL", 77, 89], ["milk", "ORGANISM_SUBSTANCE", 112, 116], ["rabbit", "ORGANISM", 139, 145], ["4\u2019,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 203, 232], ["DAPI", "SIMPLE_CHEMICAL", 234, 238], ["MNV NS1/2", "PROTEIN", 175, 184], ["rabbit", "SPECIES", 139, 145], ["rabbit", "SPECIES", 139, 145], ["4% paraformaldehyde in PBS", "TREATMENT", 26, 52], ["5% skim milk", "TREATMENT", 104, 116], ["rabbit polyclonal antiserum", "TEST", 139, 166], ["NS1", "TEST", 179, 182], ["diamidino", "TEST", 208, 217]]], ["Secondary antibody anti-rabbit IgG (H+L), F(ab\u2019)2 fragment (Alexa Fluor\u00ae 488 conjugate) was used.", [["Alexa Fluor\u00ae 488 conjugate", "SIMPLE_CHEMICAL", 60, 86], ["antibody anti-rabbit IgG", "PROTEIN", 10, 34], ["H+L", "PROTEIN", 36, 39], ["Alexa Fluor\u00ae 488 conjugate", "PROTEIN", 60, 86], ["anti-rabbit", "SPECIES", 19, 30], ["anti-rabbit", "SPECIES", 19, 30], ["H+L", "SPECIES", 36, 39], ["Secondary antibody anti-rabbit IgG", "TEST", 0, 34], ["F(ab\u2019)", "TREATMENT", 42, 48], ["fragment (Alexa Fluor\u00ae 488 conjugate", "TREATMENT", 50, 86], ["antibody", "OBSERVATION", 10, 18], ["anti-rabbit IgG", "OBSERVATION", 19, 34]]], ["Imaging was performed on a Leica SP5 confocal microscopy using a 63x oil objective.IC50 and CC50 calculation ::: Materials and methodsThe 50% inhibitory concentration (IC50) value and 50% cytotoxic concentration (CC50) were calculated using the formula Y\u00bcBottom \u00fe (Top-Bottom)/ (1 \u00fe 10^((LogIC50-X)*HillSlope)) using GraphPad Prism 5 software (GraphPad Prism 5; GraphPad Software Inc., La Jolla, CA, USA).MTT assay ::: Materials and methodsCells were seeded into 96-well tissue culture plates, and cell viability was assessed by adding 10 mM 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (Sigma, Zwijndrecht, The Netherlands).", [["Cells", "ANATOMY", 440, 445], ["tissue", "ANATOMY", 471, 477], ["cell", "ANATOMY", 498, 502], ["3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide", "CHEMICAL", 542, 606], ["MTT", "CHEMICAL", 405, 408], ["3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide", "CHEMICAL", 542, 606], ["MTT", "CHEMICAL", 608, 611], ["Cells", "CELL", 440, 445], ["cell", "CELL", 498, 502], ["3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide", "SIMPLE_CHEMICAL", 542, 606], ["MTT", "SIMPLE_CHEMICAL", 608, 611], ["Imaging", "TEST", 0, 7], ["IC50", "TEST", 83, 87], ["CC50 calculation", "TEST", 92, 108], ["methods", "TREATMENT", 127, 134], ["value", "TEST", 174, 179], ["50% cytotoxic concentration", "TREATMENT", 184, 211], ["the formula Y\u00bcBottom", "TEST", 241, 261], ["IC50", "TEST", 291, 295], ["Prism", "TEST", 326, 331], ["Prism", "TEST", 353, 358], ["GraphPad", "TEST", 362, 370], ["Software", "TEST", 371, 379], ["MTT assay", "TEST", 405, 414], ["Cells", "TEST", 440, 445], ["tissue culture plates", "TEST", 471, 492], ["cell viability", "TEST", 498, 512], ["dimethyl", "TREATMENT", 549, 557], ["thiazolyl", "TREATMENT", 560, 569], ["diphenyl", "TREATMENT", 575, 583], ["tetrazolium bromide", "TREATMENT", 587, 606]]], ["After 3 h, the medium was replaced with 100 \u03bcL of DMSO and was incubated at 37\u00b0C for 50 min.", [["DMSO", "CHEMICAL", 50, 54], ["DMSO", "CHEMICAL", 50, 54], ["DMSO", "SIMPLE_CHEMICAL", 50, 54], ["DMSO", "TREATMENT", 50, 54]]], ["The absorbance at 490 nm was recorded using a microplate absorbance reader (Bio-Rad, CA, USA).Statistical analysis ::: Materials and methodsData are presented as the mean \u00b1 SEM.", [["The absorbance", "TEST", 0, 14], ["a microplate absorbance", "TEST", 44, 67], ["methodsData", "TEST", 133, 144], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["Comparisons between groups were performed using the Mann-Whitney test in GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA).", [["Prism", "TEST", 82, 87], ["GraphPad Software", "TEST", 93, 110]]], ["Differences were considered significant at a P-value less than 0.05.Results and discussionTo test the potential anti-norovirus activity of 2\u2019-FdC, we used the murine norovirus as a surrogate model.", [["2\u2019-FdC", "CHEMICAL", 139, 145], ["2\u2019-FdC", "CHEMICAL", 139, 145], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 139, 145], ["murine", "ORGANISM", 159, 165], ["norovirus", "ORGANISM", 166, 175], ["murine", "SPECIES", 159, 165], ["a P-value", "TEST", 43, 52], ["the murine norovirus", "TREATMENT", 155, 175], ["a surrogate model", "TREATMENT", 179, 196]]], ["We found that 2\u2019-FdC significantly decreased the viral RNA and NS1/2 protein expression of MNV-1 in RAW264.7 cells, a murine macrophage cell line that is susceptible to MNV propagation (Fig. 1A and B).", [["RAW264.7 cells", "ANATOMY", 100, 114], ["macrophage cell line", "ANATOMY", 125, 145], ["2\u2019-FdC", "CHEMICAL", 14, 20], ["2\u2019-FdC", "CHEMICAL", 14, 20], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 14, 20], ["NS1/2", "GENE_OR_GENE_PRODUCT", 63, 68], ["MNV-1", "GENE_OR_GENE_PRODUCT", 91, 96], ["RAW264.7 cells", "CELL", 100, 114], ["murine", "ORGANISM", 118, 124], ["macrophage cell line", "CELL", 125, 145], ["MNV", "ORGANISM", 169, 172], ["B", "GENE_OR_GENE_PRODUCT", 198, 199], ["viral RNA", "RNA", 49, 58], ["NS1", "PROTEIN", 63, 66], ["RAW264.7 cells", "CELL_LINE", 100, 114], ["murine macrophage cell line", "CELL_LINE", 118, 145], ["murine", "SPECIES", 118, 124], ["MNV-1", "SPECIES", 91, 96], ["MNV", "SPECIES", 169, 172], ["the viral RNA", "TEST", 45, 58], ["NS1", "TEST", 63, 66], ["MNV", "TEST", 91, 94], ["a murine macrophage cell line", "TREATMENT", 116, 145], ["viral RNA", "OBSERVATION", 49, 58], ["RAW264.7 cells", "OBSERVATION", 100, 114], ["macrophage cell line", "OBSERVATION", 125, 145], ["MNV propagation", "OBSERVATION", 169, 184]]], ["The inhibitory effect of this compound was confirmed, with decreased viral NS1/2 expression observable by confocal fluorescence microscopy (Fig. 1C).", [["NS1/2", "GENE_OR_GENE_PRODUCT", 75, 80], ["NS1", "PROTEIN", 75, 78], ["this compound", "PROBLEM", 25, 38], ["decreased viral NS1/2 expression", "PROBLEM", 59, 91], ["confocal fluorescence microscopy", "TEST", 106, 138], ["decreased", "OBSERVATION_MODIFIER", 59, 68], ["viral NS1", "OBSERVATION", 69, 78]]], ["Moreover, the viral titer was found to decrease after treatment with 100 \u00b5M 2\u2019-FdC (Fig. 1D).", [["2\u2019-FdC", "CHEMICAL", 76, 82], ["2\u2019-FdC", "CHEMICAL", 76, 82], ["\u2019-FdC", "SIMPLE_CHEMICAL", 77, 82], ["the viral titer", "TEST", 10, 25], ["treatment", "TREATMENT", 54, 63], ["viral titer", "OBSERVATION", 14, 25], ["decrease", "OBSERVATION_MODIFIER", 39, 47]]], ["To further examine the antiviral effects, another murine macrophage cell line, J774A.1, was used, and a similar inhibitory effect of 2\u2019-FdC on MNV-1 replication was observed, with decreased viral RNA and NS1/2 protein expression (Supplementary Fig. 1).Results and discussionWith 2\u2019-FdC emerging as a potential anti-MNV candidate, we further evaluated its antiviral effect on two other MNV strains with distinct biological characteristics, the acutely cleared strain MNVCW3 and the persistent strain MNVCR6.", [["macrophage cell line", "ANATOMY", 57, 77], ["J774A.1", "ANATOMY", 79, 86], ["2\u2019-FdC", "CHEMICAL", 133, 139], ["2\u2019-FdC", "CHEMICAL", 133, 139], ["2\u2019-FdC", "CHEMICAL", 279, 285], ["murine", "ORGANISM", 50, 56], ["macrophage cell line", "CELL", 57, 77], ["J774A.1", "CELL", 79, 86], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 133, 139], ["MNV-1", "GENE_OR_GENE_PRODUCT", 143, 148], ["NS1/2", "GENE_OR_GENE_PRODUCT", 204, 209], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 279, 285], ["anti-MNV", "CANCER", 310, 318], ["MNV", "ORGANISM", 385, 388], ["murine macrophage cell line", "CELL_LINE", 50, 77], ["J774A.1", "CELL_LINE", 79, 86], ["viral RNA", "RNA", 190, 199], ["NS1", "PROTEIN", 204, 207], ["murine", "SPECIES", 50, 56], ["MNV-1", "SPECIES", 143, 148], ["MNV", "SPECIES", 385, 388], ["the antiviral effects", "TREATMENT", 19, 40], ["another murine macrophage cell line", "TREATMENT", 42, 77], ["MNV", "TREATMENT", 143, 146], ["decreased viral RNA", "PROBLEM", 180, 199], ["NS1/2 protein expression", "TREATMENT", 204, 228], ["Supplementary Fig", "TREATMENT", 230, 247], ["the acutely cleared strain MNVCW3", "PROBLEM", 439, 472], ["the persistent strain MNVCR6", "PROBLEM", 477, 505], ["macrophage cell line", "OBSERVATION", 57, 77], ["viral RNA", "OBSERVATION", 190, 199], ["persistent", "OBSERVATION_MODIFIER", 481, 491]]], ["Notably, 2\u2019-FdC inhibited viral RNA replication and protein expression of both viral strains (Fig. 1E and F).", [["2\u2019-FdC", "CHEMICAL", 9, 15], ["2\u2019-FdC", "CHEMICAL", 9, 15], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 9, 15], ["FdC", "PROTEIN", 12, 15], ["viral RNA replication", "TREATMENT", 26, 47], ["both viral strains", "PROBLEM", 74, 92], ["viral RNA replication", "OBSERVATION", 26, 47], ["viral strains", "OBSERVATION", 79, 92]]], ["In addition, the IC50 value of 2\u2019-FdC against MNV-1 replication in RAW264.7 cells was 20.92 \u00b5M (Fig. 1G), and the CC50 of 2\u2019-FdC in RAW264.7 cells was 1.768 mM (Fig. 1G).", [["RAW264.7 cells", "ANATOMY", 67, 81], ["RAW264.7 cells", "ANATOMY", 132, 146], ["2\u2019-FdC", "CHEMICAL", 31, 37], ["2\u2019-FdC", "CHEMICAL", 122, 128], ["2\u2019-FdC", "CHEMICAL", 31, 37], ["2\u2019-FdC", "CHEMICAL", 122, 128], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 31, 37], ["MNV-1", "GENE_OR_GENE_PRODUCT", 46, 51], ["RAW264.7 cells", "CELL", 67, 81], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 122, 128], ["RAW264.7 cells", "CELL", 132, 146], ["RAW264.7 cells", "CELL_LINE", 67, 81], ["FdC", "PROTEIN", 125, 128], ["RAW264.7 cells", "CELL_LINE", 132, 146], ["MNV-1", "SPECIES", 46, 51], ["the IC50 value", "TEST", 13, 27], ["MNV", "TEST", 46, 49], ["RAW264.7 cells", "TEST", 67, 81], ["\u00b5M", "TEST", 92, 94], ["Fig.", "TEST", 96, 100], ["the CC50", "TEST", 110, 118], ["RAW264.7 cells", "TEST", 132, 146], ["RAW264.7 cells", "OBSERVATION", 67, 81], ["RAW264.7 cells", "OBSERVATION", 132, 146]]], ["Moreover, we tested the antiviral effect of 2\u2019-FdC on HuNV by using HG23 cells harboring an HuNV replicon and found moderate inhibition of viral replication (Supplementary Fig. 2).Results and discussionNucleoside analogues have been reported to induce an antiviral interferon response [13, 26].", [["HG23 cells", "ANATOMY", 68, 78], ["2\u2019-FdC", "CHEMICAL", 44, 50], ["Nucleoside", "CHEMICAL", 202, 212], ["2\u2019-FdC", "CHEMICAL", 44, 50], ["Nucleoside", "CHEMICAL", 202, 212], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 44, 50], ["HuNV", "SIMPLE_CHEMICAL", 54, 58], ["HG23 cells", "CELL", 68, 78], ["Nucleoside analogues", "SIMPLE_CHEMICAL", 202, 222], ["HG23 cells", "CELL_LINE", 68, 78], ["interferon", "PROTEIN", 265, 275], ["HuNV", "SPECIES", 92, 96], ["HuNV", "TREATMENT", 54, 58], ["HG23 cells", "TREATMENT", 68, 78], ["an HuNV replicon", "TREATMENT", 89, 105], ["viral replication", "TREATMENT", 139, 156], ["Supplementary Fig", "TREATMENT", 158, 175], ["Nucleoside analogues", "TREATMENT", 202, 222], ["an antiviral interferon response", "TREATMENT", 252, 284], ["moderate", "OBSERVATION_MODIFIER", 116, 124], ["inhibition", "OBSERVATION_MODIFIER", 125, 135], ["viral replication", "OBSERVATION", 139, 156]]], ["Interferon-stimulated genes (ISGs) are considered the ultimate effectors against viral infection, but we found that 2\u2019-FdC treatment did not significantly increase ISG expression (Supplementary Fig. 3A), and inhibition of viral RNA production by 2\u2019-FdC was not affected by treatment with a JAK inhibitor (Supplementary Fig. 3B), suggesting that the antiviral effect of 2\u2019-FdC does not require ISG induction.", [["viral infection", "DISEASE", 81, 96], ["2\u2019-FdC", "CHEMICAL", 116, 122], ["2\u2019-FdC", "CHEMICAL", 246, 252], ["2\u2019-FdC", "CHEMICAL", 369, 375], ["2\u2019-FdC", "CHEMICAL", 116, 122], ["2\u2019-FdC", "CHEMICAL", 246, 252], ["2\u2019-FdC", "CHEMICAL", 369, 375], ["Interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 0, 27], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 116, 122], ["ISG", "GENE_OR_GENE_PRODUCT", 164, 167], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 246, 252], ["JAK", "GENE_OR_GENE_PRODUCT", 290, 293], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 369, 375], ["ISG", "GENE_OR_GENE_PRODUCT", 393, 396], ["Interferon-stimulated genes", "DNA", 0, 27], ["ISGs", "DNA", 29, 33], ["ISG", "PROTEIN", 164, 167], ["viral RNA", "RNA", 222, 231], ["JAK", "PROTEIN", 290, 293], ["Interferon", "TREATMENT", 0, 10], ["viral infection", "PROBLEM", 81, 96], ["FdC treatment", "TREATMENT", 119, 132], ["viral RNA production", "PROBLEM", 222, 242], ["a JAK inhibitor", "TREATMENT", 288, 303], ["the antiviral effect", "TREATMENT", 345, 365], ["ISG induction", "TREATMENT", 393, 406], ["infection", "OBSERVATION", 87, 96], ["viral RNA", "OBSERVATION", 222, 231]]], ["Theoretically, nucleoside analogues exert potential antiviral activity because they bind to the viral RNA polymerase active site to impede viral replication.", [["nucleoside", "CHEMICAL", 15, 25], ["nucleoside", "CHEMICAL", 15, 25], ["nucleoside analogues", "SIMPLE_CHEMICAL", 15, 35], ["viral RNA polymerase active site", "DNA", 96, 128], ["nucleoside analogues", "TREATMENT", 15, 35], ["potential antiviral activity", "TREATMENT", 42, 70], ["the viral RNA polymerase active site", "PROBLEM", 92, 128], ["viral replication", "TREATMENT", 139, 156], ["antiviral activity", "OBSERVATION", 52, 70], ["viral replication", "OBSERVATION", 139, 156]]], ["Since 2\u2019-FdC is an analogue of cytidine and fluorine is isosteric with a hydroxyl group, chemical conversion of 2\u2019-FdC to the corresponding 2\u2019-FdC-triphosphate (FdCTP) results in a compound with antiviral activity against HCV, possibly targeting the viral NS5B enzyme [20].", [["2\u2019-FdC", "CHEMICAL", 6, 12], ["cytidine", "CHEMICAL", 31, 39], ["fluorine", "CHEMICAL", 44, 52], ["hydroxyl", "CHEMICAL", 73, 81], ["2\u2019-FdC", "CHEMICAL", 112, 118], ["2\u2019-FdC-triphosphate", "CHEMICAL", 140, 159], ["FdCTP", "CHEMICAL", 161, 166], ["2\u2019-FdC", "CHEMICAL", 6, 12], ["cytidine", "CHEMICAL", 31, 39], ["fluorine", "CHEMICAL", 44, 52], ["hydroxyl", "CHEMICAL", 73, 81], ["2\u2019-FdC", "CHEMICAL", 112, 118], ["2\u2019-FdC-triphosphate", "CHEMICAL", 140, 159], ["FdCTP", "CHEMICAL", 161, 166], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 6, 12], ["cytidine", "SIMPLE_CHEMICAL", 31, 39], ["fluorine", "SIMPLE_CHEMICAL", 44, 52], ["hydroxyl", "SIMPLE_CHEMICAL", 73, 81], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 112, 118], ["2\u2019-FdC-triphosphate", "SIMPLE_CHEMICAL", 140, 159], ["FdCTP", "SIMPLE_CHEMICAL", 161, 166], ["HCV", "ORGANISM", 222, 225], ["viral NS5B enzyme", "PROTEIN", 250, 267], ["HCV", "SPECIES", 222, 225], ["cytidine and fluorine", "TREATMENT", 31, 52], ["a hydroxyl group", "TREATMENT", 71, 87], ["chemical conversion", "TREATMENT", 89, 108], ["antiviral activity", "TREATMENT", 195, 213], ["HCV", "PROBLEM", 222, 225], ["the viral NS5B enzyme", "TEST", 246, 267]]], ["Thus, we performed a competition assay by using CTP and GTP, which showed that CTP partially reversed the inhibitory effects of 2\u2019-FdC on MNV replication, as reflected in viral RNA and protein levels (Fig. 2A and B) as well as the viral titers (Fig. 2D).", [["CTP", "CHEMICAL", 48, 51], ["GTP", "CHEMICAL", 56, 59], ["CTP", "CHEMICAL", 79, 82], ["2\u2019-FdC", "CHEMICAL", 128, 134], ["CTP", "CHEMICAL", 48, 51], ["GTP", "CHEMICAL", 56, 59], ["CTP", "CHEMICAL", 79, 82], ["2\u2019-FdC", "CHEMICAL", 128, 134], ["CTP", "SIMPLE_CHEMICAL", 48, 51], ["GTP", "SIMPLE_CHEMICAL", 56, 59], ["CTP", "SIMPLE_CHEMICAL", 79, 82], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 128, 134], ["MNV", "ORGANISM", 138, 141], ["2A", "GENE_OR_GENE_PRODUCT", 206, 208], ["B", "GENE_OR_GENE_PRODUCT", 213, 214], ["viral RNA", "RNA", 171, 180], ["B", "PROTEIN", 213, 214], ["MNV", "SPECIES", 138, 141], ["a competition assay", "TEST", 19, 38], ["CTP and GTP", "TEST", 48, 59], ["CTP", "TEST", 79, 82], ["MNV replication", "TREATMENT", 138, 153], ["viral RNA", "TEST", 171, 180], ["protein levels", "TEST", 185, 199], ["the viral titers", "TEST", 227, 243], ["MNV replication", "OBSERVATION", 138, 153], ["viral RNA", "OBSERVATION", 171, 180]]], ["In contrast, no significant effect of GTP on 2\u2019-FdC-mediated inhibition of viral replication was observed (Fig. 2C and D).", [["GTP", "CHEMICAL", 38, 41], ["2\u2019-FdC", "CHEMICAL", 45, 51], ["GTP", "CHEMICAL", 38, 41], ["2\u2019-FdC", "CHEMICAL", 45, 51], ["GTP", "SIMPLE_CHEMICAL", 38, 41], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 45, 51], ["FdC", "PROTEIN", 48, 51], ["GTP", "PROBLEM", 38, 41], ["viral replication", "TREATMENT", 75, 92], ["no", "UNCERTAINTY", 13, 15], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["effect", "OBSERVATION_MODIFIER", 28, 34], ["viral replication", "OBSERVATION", 75, 92]]], ["Interestingly, we found that both CTP and GTP decreased the viral RNA level and NS1/2 protein expression (Fig. 2A-D).", [["CTP", "CHEMICAL", 34, 37], ["GTP", "CHEMICAL", 42, 45], ["2A-D", "CHEMICAL", 111, 115], ["CTP", "CHEMICAL", 34, 37], ["GTP", "CHEMICAL", 42, 45], ["CTP", "SIMPLE_CHEMICAL", 34, 37], ["GTP", "SIMPLE_CHEMICAL", 42, 45], ["NS1/2", "GENE_OR_GENE_PRODUCT", 80, 85], ["2A-D", "GENE_OR_GENE_PRODUCT", 111, 115], ["NS1", "PROTEIN", 80, 83], ["both CTP", "TEST", 29, 37], ["GTP", "TEST", 42, 45], ["the viral RNA level", "TEST", 56, 75], ["NS1", "TEST", 80, 83], ["GTP decreased", "OBSERVATION", 42, 55], ["viral RNA", "OBSERVATION", 60, 69]]], ["It has been shown that MNV infection can induce viperin transcription in RAW264.7 cells [27], and viperin can convert CTP into 3\u2019-deoxy-3\u2019,4\u2019-didehydro-CTP (ddhCTP), which acts as a chain terminator of RNA-dependent RNA-polymerases and inhibits replication of Zika virus [28].", [["RAW264.7 cells", "ANATOMY", 73, 87], ["infection", "DISEASE", 27, 36], ["viperin", "CHEMICAL", 98, 105], ["CTP", "CHEMICAL", 118, 121], ["3\u2019-deoxy-3\u2019,4\u2019-didehydro-CTP", "CHEMICAL", 127, 155], ["ddhCTP", "CHEMICAL", 157, 163], ["CTP", "CHEMICAL", 118, 121], ["3\u2019-deoxy-3\u2019,4\u2019-didehydro-CTP", "CHEMICAL", 127, 155], ["ddhCTP", "CHEMICAL", 157, 163], ["MNV", "ORGANISM", 23, 26], ["viperin", "GENE_OR_GENE_PRODUCT", 48, 55], ["RAW264.7 cells", "CELL", 73, 87], ["viperin", "SIMPLE_CHEMICAL", 98, 105], ["CTP", "SIMPLE_CHEMICAL", 118, 121], ["3\u2019-deoxy-3\u2019,4\u2019-didehydro-CTP", "SIMPLE_CHEMICAL", 127, 155], ["ddhCTP", "SIMPLE_CHEMICAL", 157, 163], ["Zika virus", "ORGANISM", 260, 270], ["viperin", "PROTEIN", 48, 55], ["RAW264.7 cells", "CELL_LINE", 73, 87], ["ddhCTP", "PROTEIN", 157, 163], ["RNA-dependent RNA-polymerases", "PROTEIN", 202, 231], ["MNV", "SPECIES", 23, 26], ["Zika virus", "SPECIES", 260, 270], ["MNV infection", "PROBLEM", 23, 36], ["viperin transcription", "TEST", 48, 69], ["viperin", "TREATMENT", 98, 105], ["CTP", "TEST", 118, 121], ["deoxy", "TEST", 130, 135], ["CTP (ddhCTP)", "PROBLEM", 152, 164], ["dependent RNA-polymerases", "PROBLEM", 206, 231], ["Zika virus", "PROBLEM", 260, 270], ["MNV", "OBSERVATION_MODIFIER", 23, 26], ["infection", "OBSERVATION", 27, 36]]], ["Moreover, exogenous CTP/GTP might complete with the endogenous CTP/GTP for MNV replication [29].", [["CTP", "CHEMICAL", 20, 23], ["GTP", "CHEMICAL", 24, 27], ["CTP", "CHEMICAL", 63, 66], ["GTP", "CHEMICAL", 67, 70], ["CTP", "CHEMICAL", 20, 23], ["GTP", "CHEMICAL", 24, 27], ["CTP", "CHEMICAL", 63, 66], ["GTP", "CHEMICAL", 67, 70], ["CTP", "SIMPLE_CHEMICAL", 20, 23], ["GTP", "SIMPLE_CHEMICAL", 24, 27], ["CTP", "SIMPLE_CHEMICAL", 63, 66], ["GTP", "SIMPLE_CHEMICAL", 67, 70], ["exogenous CTP/GTP", "TREATMENT", 10, 27], ["the endogenous CTP", "TEST", 48, 66], ["MNV replication", "TREATMENT", 75, 90]]], ["These results suggest a potential mechanism of action of 2\u2019-FdC against MNV, and it needs to be investigated whether 2\u2019-FdC exerts anti-MNV activity by targeting the viral replicase.Results and discussionSince MPA, ribavirin, and T705 have been reported to have anti-norovirus activity, a combined treatment using 2\u2019-FdC together with these compounds might be envisaged.", [["2\u2019-FdC", "CHEMICAL", 57, 63], ["2\u2019-FdC", "CHEMICAL", 117, 123], ["MPA", "CHEMICAL", 210, 213], ["ribavirin", "CHEMICAL", 215, 224], ["T705", "CHEMICAL", 230, 234], ["2\u2019-FdC", "CHEMICAL", 314, 320], ["2\u2019-FdC", "CHEMICAL", 57, 63], ["2\u2019-FdC", "CHEMICAL", 117, 123], ["MPA", "CHEMICAL", 210, 213], ["ribavirin", "CHEMICAL", 215, 224], ["T705", "CHEMICAL", 230, 234], ["2\u2019-FdC", "CHEMICAL", 314, 320], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 57, 63], ["MNV", "ORGANISM", 72, 75], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 117, 123], ["anti-MNV", "GENE_OR_GENE_PRODUCT", 131, 139], ["MPA", "SIMPLE_CHEMICAL", 210, 213], ["ribavirin", "SIMPLE_CHEMICAL", 215, 224], ["T705", "SIMPLE_CHEMICAL", 230, 234], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 314, 320], ["FdC", "PROTEIN", 120, 123], ["anti-MNV", "PROTEIN", 131, 139], ["viral replicase", "PROTEIN", 166, 181], ["MNV", "SPECIES", 72, 75], ["the viral replicase", "PROBLEM", 162, 181], ["MPA", "TREATMENT", 210, 213], ["ribavirin", "TREATMENT", 215, 224], ["anti-norovirus activity", "PROBLEM", 262, 285], ["a combined treatment", "TREATMENT", 287, 307], ["2\u2019-FdC", "TREATMENT", 314, 320], ["these compounds", "TREATMENT", 335, 350], ["viral replicase", "OBSERVATION", 166, 181]]], ["To achieve better antiviral efficacy, we evaluated the combined antiviral effects of 2\u2019-FdC with MPA by mathematical modeling using MacSynergy [30].", [["2\u2019-FdC", "CHEMICAL", 85, 91], ["MPA", "CHEMICAL", 97, 100], ["2\u2019-FdC", "CHEMICAL", 85, 91], ["MPA", "CHEMICAL", 97, 100], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 85, 91], ["MPA", "SIMPLE_CHEMICAL", 97, 100], ["MPA", "TREATMENT", 97, 100]]], ["Surprisingly, the results showed a moderate synergistic antiviral effect (36.57 \u00b5M2%), which is greater than either 2\u2019-FdC or MPA alone (Fig. 3A).", [["MPA", "CHEMICAL", 126, 129], ["2\u2019-FdC", "CHEMICAL", 116, 122], ["MPA", "CHEMICAL", 126, 129], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 116, 122], ["MPA", "SIMPLE_CHEMICAL", 126, 129], ["a moderate synergistic antiviral effect", "PROBLEM", 33, 72], ["moderate", "OBSERVATION_MODIFIER", 35, 43], ["synergistic", "OBSERVATION_MODIFIER", 44, 55], ["antiviral effect", "OBSERVATION", 56, 72], ["greater", "OBSERVATION_MODIFIER", 96, 103]]], ["Similar synergistic antiviral effects were observed when combining 2\u2019-FdC with ribavirin (99.18 \u00b5M2%) or T705 (112.47 \u00b5M2%) (Fig. 3B and C).", [["2\u2019-FdC", "CHEMICAL", 67, 73], ["ribavirin", "CHEMICAL", 79, 88], ["2\u2019-FdC", "CHEMICAL", 67, 73], ["ribavirin", "CHEMICAL", 79, 88], ["T705", "CHEMICAL", 105, 109], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 67, 73], ["ribavirin", "SIMPLE_CHEMICAL", 79, 88], ["Similar synergistic antiviral effects", "PROBLEM", 0, 37], ["ribavirin", "TREATMENT", 79, 88], ["synergistic", "OBSERVATION_MODIFIER", 8, 19], ["antiviral effects", "OBSERVATION", 20, 37]]], ["To confirm the predicted synergistic antiviral effects, we measured viral protein expression and viral titers by using high concentrations of the antivirals without major cytotoxicity (Fig. 3F).", [["the predicted synergistic antiviral effects", "PROBLEM", 11, 54], ["viral protein expression", "PROBLEM", 68, 92], ["viral titers", "TEST", 97, 109], ["the antivirals", "TREATMENT", 142, 156], ["synergistic", "OBSERVATION_MODIFIER", 25, 36], ["antiviral effects", "OBSERVATION", 37, 54]]], ["As shown in Fig. 3D and E, the viral NS1/2 protein expression and viral titers were further decreased when the antivirals were used in combination, supporting the synergistic antiviral effects of 2\u2019-FdC with MPA, ribavirin, or T705 against MNV replication.Results and discussionDespite their wide clinical application, the potential side effects or unintended off-target effects of nucleoside analogues should be considered.", [["2\u2019-FdC", "CHEMICAL", 196, 202], ["MPA", "CHEMICAL", 208, 211], ["ribavirin", "CHEMICAL", 213, 222], ["T705", "CHEMICAL", 227, 231], ["nucleoside", "CHEMICAL", 382, 392], ["2\u2019-FdC", "CHEMICAL", 196, 202], ["MPA", "CHEMICAL", 208, 211], ["ribavirin", "CHEMICAL", 213, 222], ["T705", "CHEMICAL", 227, 231], ["nucleoside", "CHEMICAL", 382, 392], ["NS1/2", "GENE_OR_GENE_PRODUCT", 37, 42], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 196, 202], ["MPA", "SIMPLE_CHEMICAL", 208, 211], ["ribavirin", "SIMPLE_CHEMICAL", 213, 222], ["T705", "SIMPLE_CHEMICAL", 227, 231], ["MNV", "ORGANISM", 240, 243], ["nucleoside analogues", "SIMPLE_CHEMICAL", 382, 402], ["viral NS1/2 protein", "PROTEIN", 31, 50], ["MNV", "SPECIES", 240, 243], ["the viral NS1", "TEST", 27, 40], ["viral titers", "PROBLEM", 66, 78], ["the antivirals", "TREATMENT", 107, 121], ["the synergistic antiviral effects", "TREATMENT", 159, 192], ["MPA", "TREATMENT", 208, 211], ["ribavirin", "TREATMENT", 213, 222], ["T705", "TREATMENT", 227, 231], ["nucleoside analogues", "TREATMENT", 382, 402], ["viral titers", "OBSERVATION", 66, 78]]], ["Induction of mutagenesis by T705 treatment in patients has raised questions for treating chronic norovirus infections [18].", [["T705", "CHEMICAL", 28, 32], ["norovirus infections", "DISEASE", 97, 117], ["T705", "SIMPLE_CHEMICAL", 28, 32], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["mutagenesis", "TREATMENT", 13, 24], ["T705 treatment", "TREATMENT", 28, 42], ["chronic norovirus infections", "PROBLEM", 89, 117]]], ["Previous studies have reported that 2\u2019-FdC exhibits delayed toxicity after prolonged exposure, and no adverse clinical effects were observed in rats and woodchucks after 90 days of treatment [20].", [["2\u2019-FdC", "CHEMICAL", 36, 42], ["toxicity", "DISEASE", 60, 68], ["2\u2019-FdC", "CHEMICAL", 36, 42], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 36, 42], ["rats", "ORGANISM", 144, 148], ["rats", "SPECIES", 144, 148], ["Previous studies", "TEST", 0, 16], ["delayed toxicity", "PROBLEM", 52, 68], ["adverse clinical effects", "PROBLEM", 102, 126], ["treatment", "TREATMENT", 181, 190]]], ["Several derivatives of 2\u2019-FdC have shown promise as anti-HCV drugs with progress to clinical trials [31, 32].", [["2\u2019-FdC", "CHEMICAL", 23, 29], ["2\u2019-FdC", "CHEMICAL", 23, 29], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 23, 29], ["Several derivatives", "TREATMENT", 0, 19], ["anti-HCV drugs", "TREATMENT", 52, 66]]], ["However, due to their potential mitochondrial toxicity, the long-term adverse effects of treatment with 2\u2019-deoxynucleoside analogues remains a concern [33].", [["mitochondrial", "ANATOMY", 32, 45], ["mitochondrial toxicity", "DISEASE", 32, 54], ["2\u2019-deoxynucleoside", "CHEMICAL", 104, 122], ["2\u2019-deoxynucleoside", "CHEMICAL", 104, 122], ["mitochondrial", "CELLULAR_COMPONENT", 32, 45], ["2\u2019-deoxynucleoside analogues", "SIMPLE_CHEMICAL", 104, 132], ["mitochondrial toxicity", "PROBLEM", 32, 54], ["treatment", "TREATMENT", 89, 98], ["deoxynucleoside analogues", "TREATMENT", 107, 132], ["mitochondrial toxicity", "OBSERVATION", 32, 54], ["long-term", "OBSERVATION_MODIFIER", 60, 69]]], ["Thus, although 2\u2019-FdC is an interesting antiviral compound, its potential adverse effects as well as its combination with other compounds should be carefully evaluated in future studies.Results and discussionIn conclusion, 2\u2019-FdC exerts potent anti-MNV effects in macrophages.", [["macrophages", "ANATOMY", 264, 275], ["2\u2019-FdC", "CHEMICAL", 15, 21], ["2\u2019-FdC", "CHEMICAL", 223, 229], ["2\u2019-FdC", "CHEMICAL", 15, 21], ["2\u2019-FdC", "CHEMICAL", 223, 229], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 15, 21], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 223, 229], ["anti-MNV", "CANCER", 244, 252], ["macrophages", "CELL", 264, 275], ["macrophages", "CELL_TYPE", 264, 275], ["an interesting antiviral compound", "PROBLEM", 25, 58], ["future studies", "TEST", 171, 185], ["antiviral compound", "OBSERVATION", 40, 58], ["macrophages", "OBSERVATION", 264, 275]]], ["Importantly, 2\u2019-FdC acts synergistically with the well-known antivirals, including MPA, ribavirin, and T705.", [["2\u2019-FdC", "CHEMICAL", 13, 19], ["MPA", "CHEMICAL", 83, 86], ["ribavirin", "CHEMICAL", 88, 97], ["T705", "CHEMICAL", 103, 107], ["2\u2019-FdC", "CHEMICAL", 13, 19], ["MPA", "CHEMICAL", 83, 86], ["ribavirin", "CHEMICAL", 88, 97], ["T705", "CHEMICAL", 103, 107], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 13, 19], ["MPA", "SIMPLE_CHEMICAL", 83, 86], ["ribavirin", "SIMPLE_CHEMICAL", 88, 97], ["T705", "SIMPLE_CHEMICAL", 103, 107], ["antivirals", "TREATMENT", 61, 71], ["MPA", "TREATMENT", 83, 86], ["ribavirin", "TREATMENT", 88, 97]]], ["Although further studies are still required for evaluation of the antiviral effects of 2\u2019-FdC or its derivatives against HuNV infection in robust models, our results suggest that 2\u2019-FdC can serve as a potential backbone for anti-norovirus drug design.", [["2\u2019-FdC", "CHEMICAL", 87, 93], ["HuNV infection", "DISEASE", 121, 135], ["2\u2019-FdC", "CHEMICAL", 179, 185], ["2\u2019-FdC", "CHEMICAL", 87, 93], ["2\u2019-FdC", "CHEMICAL", 179, 185], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 87, 93], ["HuNV", "SIMPLE_CHEMICAL", 121, 125], ["2\u2019-FdC", "SIMPLE_CHEMICAL", 179, 185], ["anti-norovirus", "SIMPLE_CHEMICAL", 224, 238], ["HuNV", "SPECIES", 121, 125], ["further studies", "TEST", 9, 24], ["evaluation", "TEST", 48, 58], ["the antiviral effects", "PROBLEM", 62, 83], ["2\u2019-FdC", "TREATMENT", 87, 93], ["its derivatives", "TREATMENT", 97, 112], ["HuNV infection", "PROBLEM", 121, 135], ["a potential backbone", "TREATMENT", 199, 219], ["anti-norovirus drug design", "TREATMENT", 224, 250], ["infection", "OBSERVATION", 126, 135]]]], "PMC7489049": [["What Do Past Outbreaks Reveal? ::: IntroductionInfection may transfer via air from one person to another and becomeepidemic.6 Although it is accepted that theairborne route exists, its attributed contribution to the spread ofinfectious diseases is less certain.7 For example,tuberculosis (TB) is transmitted person-to-person by the airborneroute via small particle aerosols measuring 1 to 5 \u03bcm,sufficiently small that they remain aloft in the air.8 In 1966, aboard the Navy ship U.S.S. Richard E.Byrd, 45.5% of the at-risk crew members (140 out of 308) unfortunatelybecame infected with TB.", [["tuberculosis", "DISEASE", 275, 287], ["TB", "DISEASE", 289, 291], ["TB", "DISEASE", 587, 589], ["person", "SPECIES", 87, 93], ["person", "SPECIES", 308, 314], ["person", "SPECIES", 318, 324], ["the spread ofinfectious diseases", "PROBLEM", 212, 244], ["tuberculosis", "PROBLEM", 275, 287], ["TB", "PROBLEM", 587, 589], ["tuberculosis", "OBSERVATION", 275, 287], ["small", "OBSERVATION_MODIFIER", 407, 412], ["air", "OBSERVATION", 443, 446], ["infected", "OBSERVATION", 573, 581], ["TB", "OBSERVATION", 587, 589]]], ["In this episode, air recirculation on theship was implicated as the primary amplification pathway ofinfection.9 In 1972, Ehrenkranz reported 21healthcare staff who developed latent TB infections out of 60 formerlytuberculin-negative personnel.", [["TB infections", "DISEASE", 181, 194], ["formerlytuberculin", "CHEMICAL", 205, 223], ["formerlytuberculin", "SIMPLE_CHEMICAL", 205, 223], ["air recirculation on theship", "PROBLEM", 17, 45], ["the primary amplification pathway ofinfection", "PROBLEM", 64, 109], ["latent TB infections", "PROBLEM", 174, 194], ["air recirculation", "OBSERVATION", 17, 34], ["latent", "OBSERVATION_MODIFIER", 174, 180], ["TB", "OBSERVATION_MODIFIER", 181, 183], ["infections", "OBSERVATION", 184, 194]]], ["Ten of these 21 staff had little or nodirect contact with the patient with TB, and the authors concludedthat they likely had been infected by the spread ofMycobacterium tuberculosis through anunbalanced air conditioning system which was found by smoke stick toallow air from patients\u2019 room to enter the hallway, and thissystem lacked a \u201chigh-efficiency filter\u201d (80% orgreater).7,10 During 1983\u20131984, 6employees of the emergency department of Parkland Memorial Hospital(Dallas, TX) developed active TB.", [["TB", "DISEASE", 75, 77], ["Mycobacterium tuberculosis", "DISEASE", 155, 181], ["TB", "DISEASE", 498, 500], ["patient", "ORGANISM", 62, 69], ["Mycobacterium tuberculosis", "ORGANISM", 155, 181], ["patients", "ORGANISM", 275, 283], ["patient", "SPECIES", 62, 69], ["Mycobacterium tuberculosis", "SPECIES", 155, 181], ["patients", "SPECIES", 275, 283], ["Mycobacterium tuberculosis", "SPECIES", 155, 181], ["TB", "PROBLEM", 75, 77], ["Mycobacterium tuberculosis", "PROBLEM", 155, 181], ["anunbalanced air conditioning system", "TREATMENT", 190, 226], ["active TB", "PROBLEM", 491, 500], ["Mycobacterium tuberculosis", "OBSERVATION", 155, 181], ["air conditioning", "OBSERVATION", 203, 219], ["efficiency filter", "OBSERVATION", 342, 359], ["active", "OBSERVATION_MODIFIER", 491, 497], ["TB", "OBSERVATION", 498, 500]]], ["One of the reasons that led to theoutbreak of TB was the lack of adequate filtration ofthe 60% recirculated air which could not remove tubercle bacilli inthe emergency department.11 Prior to 1994, it wasrecommended that isolation rooms for patients known or suspected ofactive TB disease should have had a minimum total of 6 air changes perhour (ACH), at least 2 of which with outdoor air.12\u221214 In the updated 1994 guidelines, the CDCrecommended that, wherever feasible, air flow rates be increased to 12air changes per hour with recirculating air in the room through fixed,monitored high efficiency particulate air (HEPA) filtration orportable air cleaners.15What Do Past Outbreaks Reveal? ::: IntroductionReviews of other environmental parameters in healthcare facilities exist,such as Memarzadeh (2012) on the effect of temperature and relativehumidity on pathogen viability.16 Another reviewspecifically targeted thermal comfort in hospitals, concluding thatwhile it is almost impossible to satisfy every occupant, there arecertain engineering tools and numerical techniques that can beutilized to improve the design and operation of the hospital.17 Most recently, a review of scientific evidence onhospital buildings studied the temperature, relative humidity, andventilation system.", [["TB", "DISEASE", 46, 48], ["TB", "DISEASE", 277, 279], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 240, 248], ["TB", "PROBLEM", 46, 48], ["suspected ofactive TB disease", "PROBLEM", 258, 287], ["6 air changes", "PROBLEM", 323, 336], ["air flow rates", "TEST", 471, 485], ["pathogen viability", "PROBLEM", 859, 877], ["numerical techniques", "TREATMENT", 1058, 1078], ["the temperature", "TEST", 1230, 1245], ["andventilation system", "TREATMENT", 1266, 1287], ["TB", "OBSERVATION", 46, 48], ["recirculated air", "OBSERVATION", 95, 111], ["TB", "OBSERVATION", 277, 279], ["outdoor air", "OBSERVATION", 377, 388], ["air", "OBSERVATION", 544, 547], ["air cleaners", "OBSERVATION", 645, 657]]], ["It briefly mentioned the filtration systems;however, recirculation was not considered.18Focus of the Current Paper ::: IntroductionThe current state of healthcare ventilation management stems from twocomplementary schools of thought around minimizing both recirculationof indoor air and energy demands.", [["the filtration systems", "TEST", 21, 43], ["healthcare ventilation management", "TREATMENT", 152, 185], ["not considered", "UNCERTAINTY", 71, 85]]], ["Various studies demonstrate theimportance of the airborne route of infection transmission in thehospital setting.19 On one hand, it seemsunreasonable to allow recirculation of return air into patient careenvironments.", [["infection", "DISEASE", 67, 76], ["patient", "ORGANISM", 192, 199], ["patient", "SPECIES", 192, 199], ["Various studies", "TEST", 0, 15], ["infection transmission", "PROBLEM", 67, 89], ["infection", "OBSERVATION", 67, 76]]], ["On the other hand, it seems reasonable to take advantageof the energy in the return air to dilute contamination through airrecirculation, while ensuring that the return air is clean andcomfortable.", [["dilute contamination through airrecirculation", "PROBLEM", 91, 136], ["air", "OBSERVATION", 169, 172], ["clean", "OBSERVATION", 176, 181]]], ["With recent advancements in technology, the latter canalso be achieved via energy recovery techniques, and recirculation isno longer the sole option.", [["no longer", "UNCERTAINTY", 123, 132]]], ["However, these techniques are not always afeasible and affordable retrofit response to the emergence ofCOVID-19, especially in existing facilities while replacing thefiltration system, and altering the air distribution system could bemore convenient.", [["the emergence ofCOVID", "TEST", 87, 108], ["thefiltration system", "TREATMENT", 163, 183], ["altering the air distribution system", "PROBLEM", 189, 225], ["air distribution", "OBSERVATION", 202, 218]]], ["Perhaps, a natural question is, to what extent cannew approaches in air filtration/recirculation improve the health andsafety of patients and the front-line medical personnel?", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["air filtration", "TREATMENT", 68, 82], ["air filtration", "OBSERVATION", 68, 82]]], ["Theseapproaches bring about this literature review on the issue of airfiltration and recirculation in healthcare facilities.", [["airfiltration", "PROBLEM", 67, 80]]], ["In the presentwork, we will first briefly discuss the theoretical background ofinterconnections between air filtration and recirculation.", [["air filtration", "TREATMENT", 104, 118], ["air filtration", "OBSERVATION", 104, 118]]], ["Next, theprocess of identifying relevant publications, followed by assessingtheir methodology, will be explained, and evidence for air filtrationand air recirculation and potential interconnections will bereviewed.Theoretical BackgroundThe true effect of air filtration and air recirculation on the temporal andspatial distributions of contaminants indoors is a very difficultproblem\u2014one that does not have an analytical solution and iscomputationally very expensive.", [["air filtrationand air recirculation", "PROBLEM", 131, 166], ["air filtration", "PROBLEM", 255, 269], ["air recirculation", "PROBLEM", 274, 291], ["an analytical solution", "TREATMENT", 407, 429], ["true", "OBSERVATION_MODIFIER", 240, 244], ["effect", "OBSERVATION_MODIFIER", 245, 251], ["air filtration", "OBSERVATION", 255, 269], ["air recirculation", "OBSERVATION", 274, 291], ["temporal", "OBSERVATION_MODIFIER", 299, 307], ["contaminants indoors", "OBSERVATION", 336, 356]]], ["However, one could set aside the spatialterm by assuming that contamination is uniformly distributed throughout thespace.", [["contamination", "OBSERVATION", 62, 75], ["uniformly", "OBSERVATION_MODIFIER", 79, 88], ["distributed", "OBSERVATION_MODIFIER", 89, 100]]], ["This so-called well-mixed assumption is a useful simplification thatis often used in the field.20,21 Taking the room as a large controlvolume, one could derive the differentialequation1where V is thevolume of the room, C is contaminant concentration as afunction of time, Cs is contaminantconcentration at the supply air inlet, Qs andQr are supply and return flow rates, andS is a source of contamination in the room (Figure 1).", [["Cs", "CHEMICAL", 272, 274], ["Cs", "CHEMICAL", 272, 274], ["C", "SIMPLE_CHEMICAL", 219, 220], ["Cs", "SIMPLE_CHEMICAL", 272, 274], ["Qs", "SIMPLE_CHEMICAL", 328, 330], ["Qr", "SIMPLE_CHEMICAL", 334, 336], ["return flow rates", "TEST", 352, 369], ["air inlet", "OBSERVATION", 317, 326]]], ["Without a loss ofgenerality, let us assume that the supply and return flow rates areidentical, Qs = Qr =Q. It is noteworthy that for pressurized spaces(i.e., operating rooms (OR), AIIRs) this assumption is not valid.", [["a loss ofgenerality", "PROBLEM", 8, 27], ["return flow rates", "TEST", 63, 80], ["loss", "OBSERVATION", 10, 14]]], ["Ingeneral, eq 1 is a lineardifferential equation with an exponential solution.", [["an exponential solution", "TREATMENT", 54, 77], ["exponential", "OBSERVATION_MODIFIER", 57, 68]]], ["For example, eq 1 shows an exponential decay for asingle release of contaminant.", [["an exponential decay", "PROBLEM", 24, 44], ["contaminant", "PROBLEM", 68, 79], ["contaminant", "OBSERVATION", 68, 79]]], ["One can argue that the efficiency of thefilter changes with time, which will turn eq 1 into a nonlinear problem that must be solvednumerically.22Theoretical BackgroundMoreover, the concentration at the supply air inlet can be writtenas2where \u03b1 is the percentageof outside air mixed with return air, Cout iscontaminant concentration in the outside environment, and \u03b7 is filterefficiency.", [["thefilter changes", "PROBLEM", 37, 54], ["filterefficiency", "PROBLEM", 369, 385], ["air inlet", "OBSERVATION", 209, 218], ["return air", "OBSERVATION", 287, 297]]], ["For the scope of this work, Cout canbe assumed as zero, as one does not expect to have COVID concentrations atthe outside air intake location.", [["COVID", "CHEMICAL", 87, 92], ["COVID", "SIMPLE_CHEMICAL", 87, 92], ["COVID concentrations", "PROBLEM", 87, 107], ["air intake", "OBSERVATION", 122, 132]]], ["In essence, \u03b1 represents therecirculation in the system where \u03b1 = 100% shows a full recirculationsystem and \u03b1 = 0% shows a one-pass (i.e., no recirculation) system.Combining eq 1 and eq2, and moving V to theright-hand side of the equation, we willhave3where theterm is the space ventilation rate that is oftenreferred to as air changes per hour (ACH).", [["eq 1", "GENE_OR_GENE_PRODUCT", 174, 178], ["eq2", "GENE_OR_GENE_PRODUCT", 183, 186], ["\u03b1", "PROTEIN", 12, 13], ["eq2", "DNA", 183, 186], ["a full recirculationsystem", "TEST", 77, 103], ["the space ventilation rate", "TREATMENT", 269, 295]]], ["To show the effect of filtrationagainst increasing the ratio of outside air, eq 3 was solved for different values of \u03b1(10% to 100%) and \u03b7 ranging from MERV 12 (70% efficiency for 0.3\u03bcm) to HEPA (99.97% efficiency for 0.3 \u03bcm).", [["filtrationagainst", "PROBLEM", 22, 39], ["\u03b7", "TEST", 136, 137], ["MERV", "TEST", 151, 155], ["HEPA", "TEST", 189, 193]]], ["To compare differentcases, a time index (T) was defined as the amount of timeit takes for the concentration of the contaminant to decay to 0.001 initialrelease value.", [["amount", "OBSERVATION_MODIFIER", 63, 69]]], ["The shorter the time index, the more efficient theventilation system is in removing contamination from the space.", [["contamination", "OBSERVATION", 84, 97]]], ["Resultsshowed that for low filter efficiencies T reducedsignificantly by introducing more outside air (\u03b1 on thex-axis), but HEPA filters can clean the space suchthat T became insensitive to the portion of outside air(Figure 2).Theoretical BackgroundAnother interesting interaction between the filtration and recirculationsystems is that filters with higher efficiencies create a pressure dropacross the filter, leading to lower supply airflowrates.23,24 This process is more profound for fibrous media thatare frequently used for HVAC air filtration.25,26 Theliterature suggests that the pressure drop across the air filter is linearlyrelated to filter efficiency.27,28 Further, for a constant fan power,pressure drop is inversely related to flow rate squared.29 Therefore, for a room with a fixed volume and fanpower:4The combination of eq 3 and eq 4 was solved to obtain the coupled effect ofair filtration and recirculation.", [["low filter efficiencies", "PROBLEM", 23, 46], ["HEPA filters", "TREATMENT", 124, 136], ["the filtration", "TREATMENT", 289, 303], ["recirculationsystems", "TREATMENT", 308, 328], ["higher efficiencies", "PROBLEM", 350, 369], ["a pressure dropacross the filter", "TREATMENT", 377, 409], ["lower supply airflowrates", "PROBLEM", 422, 447], ["fibrous media thatare", "TREATMENT", 488, 509], ["HVAC air filtration", "TREATMENT", 530, 549], ["the pressure drop", "PROBLEM", 584, 601], ["the air filter", "TREATMENT", 609, 623], ["a constant fan power", "TREATMENT", 683, 703], ["pressure drop", "PROBLEM", 704, 717], ["flow rate", "TEST", 742, 751], ["a fixed volume and fanpower", "TREATMENT", 790, 817], ["ofair filtration", "TREATMENT", 892, 908], ["low", "OBSERVATION_MODIFIER", 23, 26], ["filter efficiencies", "OBSERVATION", 27, 46], ["filtration", "OBSERVATION", 293, 303], ["higher efficiencies", "OBSERVATION", 350, 369], ["pressure", "OBSERVATION_MODIFIER", 379, 387], ["filter", "OBSERVATION", 403, 409], ["lower", "OBSERVATION_MODIFIER", 422, 427], ["supply airflowrates", "OBSERVATION", 428, 447], ["more profound", "OBSERVATION_MODIFIER", 470, 483], ["air filtration", "OBSERVATION", 535, 549], ["pressure", "OBSERVATION_MODIFIER", 588, 596], ["drop", "OBSERVATION_MODIFIER", 597, 601], ["air filter", "OBSERVATION", 613, 623], ["filter efficiency", "OBSERVATION", 646, 663]]], ["As shown in Figure 3, considering the impact of higher filterefficiency on the recirculation flow rate can result in significant increasein the cleaning time index (T).", [["higher filterefficiency", "PROBLEM", 48, 71], ["the recirculation flow rate", "TEST", 75, 102], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["increasein", "OBSERVATION_MODIFIER", 129, 139]]], ["It must be noted that thereare several other filtration mechanisms that produce less significantpressure drops compared to fibrous filter media,30 yetthe coupled effect seems to deserve great consideration when increasingfilter efficiency without changing fan power.MethodIn Phase I of this systematic literature review, related academic databases,and codes and guidelines by relevant organizations have been identified.", [["several other filtration mechanisms", "PROBLEM", 31, 66], ["less significantpressure drops", "PROBLEM", 80, 110], ["fibrous filter media", "TREATMENT", 123, 143], ["increasingfilter efficiency", "PROBLEM", 211, 238], ["academic databases", "TEST", 329, 347], ["fibrous filter", "OBSERVATION", 123, 137]]], ["Table 1 shows theresults of the initial search of the key terms with a separate focus on airfiltration and air recirculation in healthcare facilities.", [["airfiltration", "TREATMENT", 89, 102], ["air recirculation", "OBSERVATION", 107, 124]]], ["Next, theresearch team looked for duplicated outcomes from these databases.", [["these databases", "TEST", 59, 74]]], ["The first round ofsource selection resulted in 394 publications.MethodOnly peer-reviewed documents, available in English, were selected for furtherreview.", [["394 publications", "OBSERVATION", 47, 63]]], ["Next, these publications were independently reviewed by two expertsfor relevance to the topic of this literature review, that is, the effect ofair filtration and air recirculation on the spread of pathogenic agents inthe hospital.", [["air recirculation", "PROBLEM", 162, 179], ["air recirculation", "OBSERVATION", 162, 179]]], ["The inclusion criteria were as follows: availability inEnglish (390 documents), peer reviewed conference or journal articles (307documents), a focus on the building mechanical ventilation (178 documents).Finally, only those publications with either original results or rigorousreview papers were included for the final review (91 documents).", [["the building mechanical ventilation", "TREATMENT", 152, 187]]], ["Figure 4 illustrates the systematicreview method.MethodIn Phase II of document identification, guidelines from relevant organizationssuch as the Facility Guide Institute (FGI), The American Society of Heating,Refrigerating and Air-Conditioning Engineers (ASHRAE), The American HospitalAssociation (AHA), the American Society of Healthcare Engineers (ASHE), andthe Center for Disease Control (CDC) were included.", [["Disease Control (CDC)", "PROBLEM", 375, 396]]], ["Guidelines fromregulatory bodies from across the globe were also included, contingent uponthe availability of the documents in English.", [["globe", "ANATOMY", 49, 54]]], ["This study reviews 20 codes,guideline, standards, and handbooks pertaining to ventilation in healthcarefacilities.MethodFurther, the level of evidence was evaluated based on the methodology in thearticles (Table 2).", [["This study", "TEST", 0, 10], ["ventilation", "TREATMENT", 78, 89]]], ["To that end,the publications were categorized in five levels based on the methodologyrigor based on Preferred Reporting Items for Systematic Reviews andMeta-Analyses (PRISMA) recommendations.", [["Systematic Reviews", "TEST", 130, 148]]], ["Also, Figure 5 shows the distribution ofpublications with original data based on the methodology employed.Air Filtration ::: Codes, Guidelines, and StandardsAs it relates to air filtration, ASHRAE recognizes five different spacesin a typical in-patient hospital facility: (1) surgery and criticalcare spaces including operating rooms (ORs), inpatient and ambulatorydiagnostic and therapeutic radiology, and inpatient delivery rooms;(2) inpatient nursing including airborne infection isolation rooms(AIIRs), intermediate, critical, and intensive care units; (3)protective environment rooms, or rooms that are intended to protect ahigh-risk immunocompromised patient from human and environmentalairborne pathogens; (4) laboratories and procedure rooms andassociated semirestricted spaces; and (5) all other service,administrative, food preparation, and laundry, and storagespaces.32 It must be noted that in the mostrecent version (2017), ASHRAE Standard 170 offers design parametersfor in-patient facilities, out-patient facilities, and nursing homes.However, the above categories and the associated requirements arestill very similar for these three facility types.", [["infection", "DISEASE", 473, 482], ["patient", "ORGANISM", 245, 252], ["patient", "ORGANISM", 657, 664], ["human", "ORGANISM", 670, 675], ["patient", "ORGANISM", 988, 995], ["patient", "ORGANISM", 1012, 1019], ["patient", "SPECIES", 245, 252], ["patient", "SPECIES", 657, 664], ["human", "SPECIES", 670, 675], ["patient", "SPECIES", 988, 995], ["patient", "SPECIES", 1012, 1019], ["human", "SPECIES", 670, 675], ["the distribution ofpublications", "PROBLEM", 21, 52], ["original data", "TEST", 58, 71], ["StandardsAs", "TREATMENT", 148, 159], ["air filtration", "PROBLEM", 174, 188], ["surgery", "TREATMENT", 276, 283], ["human and environmentalairborne pathogens", "PROBLEM", 670, 711], ["administrative, food preparation", "TREATMENT", 813, 845], ["laundry", "TREATMENT", 851, 858], ["air filtration", "OBSERVATION", 174, 188]]], ["Specifically,filtration and air recirculation requirements for inpatientfacilities, where a COVID patient is likely hospitalized, have notchanged compared to the previous version.", [["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["air recirculation requirements", "PROBLEM", 28, 58], ["filtration", "OBSERVATION", 13, 23], ["air recirculation", "OBSERVATION", 28, 45]]], ["Moreover, in the olderversions of Standard 170, ORs are classified based on the type ofsurgery in Group A (minor surgery), Group B (procedures that requireintravenous sedation), and Group C (procedures that requiregeneral/regional block anesthesia).", [["minor surgery", "TREATMENT", 107, 120], ["Group B (procedures", "TREATMENT", 123, 142], ["requireintravenous sedation", "TREATMENT", 148, 175], ["Group C (procedures", "TREATMENT", 182, 201], ["requiregeneral/regional block anesthesia", "TREATMENT", 207, 247]]], ["Table 3shows the minimum filtration and air recirculation requirements forthese spaces based on the various standards reviewed in this work.", [["the minimum filtration", "TREATMENT", 13, 35], ["air recirculation requirements forthese spaces", "TREATMENT", 40, 86], ["air recirculation", "OBSERVATION", 40, 57]]], ["Thefiltration rating is reported in the minimum efficiency reportingvalue (MERV) rating, that is, the lowest point of filter efficiency inremoving three different size ranges of 0.3\u20131.0 \u03bcm,1.0\u20133.0 \u03bcm, and 3.0\u201310.0 \u03bcm.34 MERV-equivalent efficiencies are reported for thenon-US standards.Air Filtration ::: Codes, Guidelines, and StandardsNinomura et al. (2001) provided the first edition of the\u201cGuidelines for Design and Construction of Hospital and HealthCare Facilities\u201d that the Facility Guidelines Institute (FGI)supported.35 These guidelines required theprotective environment rooms (i.e., dedicated to immunocompromisedpatients) to be equipped with HEPA filters with a 99.97% efficiencyfor particles larger than 0.3 \u03bcm.35 Forproduct protection in pharmacies, laminar flow with a nonhydroscopicfilter at 99.97% removal efficiency should be designed.", [["Thefiltration rating", "TEST", 0, 20], ["filter efficiency", "PROBLEM", 118, 135], ["MERV", "TEST", 220, 224], ["HEPA filters", "TREATMENT", 654, 666], ["Forproduct protection", "TREATMENT", 727, 748], ["a nonhydroscopicfilter", "TREATMENT", 782, 804], ["removal efficiency", "TREATMENT", 815, 833], ["filter efficiency", "OBSERVATION", 118, 135], ["different", "OBSERVATION_MODIFIER", 153, 162], ["size", "OBSERVATION_MODIFIER", 163, 167], ["ranges", "OBSERVATION_MODIFIER", 168, 174], ["laminar flow", "OBSERVATION", 764, 776]]], ["The committeeon operating room environment of the American College of Surgeonsadvised the use of HEPA filters as standards for all operating rooms,to help prevent surgical site infections.36 Whentwo banks of filters are necessary as with areas for inpatient care,and protective environment rooms, the first filter should be on theupstream of air conditioning equipment and the second filter should bedownstream of fans or blowers.", [["site", "ANATOMY", 172, 176], ["infections", "DISEASE", 177, 187], ["HEPA filters", "TREATMENT", 97, 109], ["all operating rooms", "TREATMENT", 127, 146], ["surgical site infections", "PROBLEM", 163, 187], ["filters", "TREATMENT", 208, 215], ["inpatient care", "TREATMENT", 248, 262], ["the first filter", "TREATMENT", 297, 313], ["air conditioning equipment", "TREATMENT", 342, 368], ["the second filter", "TREATMENT", 373, 390], ["infections", "OBSERVATION", 177, 187]]], ["Hoods that are used to processradioactive or infectious materials should be equipped with HEPAfilters.", [["infectious materials", "TREATMENT", 45, 65], ["HEPAfilters", "TREATMENT", 90, 101]]], ["When designing a filtration system, it is important to makesure that no stagnation or short-circuiting of air flowhappens.35Air Filtration ::: Codes, Guidelines, and StandardsPatients on airborne precautions for possible aerosolizing infectionsshall be placed in hospital rooms with HEPA filters to reduce theirrisk of cross-contamination.37,38 The AmericanInstitute of Architects (AIA) and the CDC recommend that for AirborneInfection Isolation Rooms (AIIRs), the exhaust air should be directlydischarged to the outside or filtered prior to recirculation usingin-duct HEPA filters.39,40 The exhaust should be atleast 25 feet away from public areas.", [["Patients", "ORGANISM", 175, 183], ["Patients", "SPECIES", 175, 183], ["a filtration system", "TREATMENT", 15, 34], ["stagnation", "PROBLEM", 72, 82], ["short-circuiting of air flowhappens", "PROBLEM", 86, 121], ["airborne precautions", "TREATMENT", 187, 207], ["aerosolizing infectionsshall", "PROBLEM", 221, 249], ["HEPA filters", "TREATMENT", 283, 295], ["cross-contamination", "PROBLEM", 319, 338], ["recirculation usingin-duct HEPA filters", "TREATMENT", 542, 581], ["air flowhappens", "OBSERVATION", 106, 121], ["Air Filtration", "OBSERVATION", 124, 138], ["cross-contamination", "OBSERVATION", 319, 338], ["duct", "ANATOMY", 564, 568], ["HEPA filters", "OBSERVATION", 569, 581], ["exhaust", "OBSERVATION", 592, 599]]], ["In case a good location forexhaust cannot be met, HEPA filters can be installed in the dischargeduct upstream of the exhaust fan to clean the air.41 It must be noted that adding a HEPA filter to an existing system isnot recommended as it can cause friction in the airstream that leadsto delivering less-than-designed amounts of air to the room (i.e.,pressure drops).41 Therefore, if the installationof in-duct HEPA filters is not feasible, a recirculating HEPA filterunit should be added.", [["duct", "MULTI-TISSUE_STRUCTURE", 405, 409], ["HEPA filters", "TREATMENT", 50, 62], ["a HEPA filter", "TREATMENT", 178, 191], ["friction in the airstream", "PROBLEM", 248, 273], ["pressure drops", "TREATMENT", 350, 364], ["the installationof in-duct HEPA filters", "TREATMENT", 383, 422], ["a recirculating HEPA filterunit", "TREATMENT", 440, 471], ["air", "OBSERVATION", 142, 145], ["friction", "OBSERVATION", 248, 256], ["duct", "ANATOMY", 405, 409]]], ["They are available as wall, floor, and ceilingmounted types.", [["wall", "ANATOMY", 22, 26], ["floor", "ANATOMY", 28, 33], ["wall", "TISSUE", 22, 26]]], ["The wall and ceiling units are less obstructive to theairflow, while the floor units are easier to service.40Air Filtration ::: Codes, Guidelines, and StandardsThe Australian guideline for design of isolation room by the VictorianAdvisory Committee on Infection Control requires the supply or exhaustair to be filtered at their maximum pressure drop.42 For class P or positive pressure room, the air change rate shouldbe kept at 12 ACH with supply air HEPA filtration.43 The state of California requires that manufacturers specify filterefficiency and that specified rooms have filters with specificfiltration efficiency based on ASHRAE Standards.44Table 3 shows filtration andair recirculation requirements for several key spaces in the hospitalinformed by English et al.45 and Betz et al.46 Filter efficiencies for other countries areconverted into the MERV rating system.45\u221247Air Recirculation ::: Codes, Guidelines, and StandardsGuidelines for Design and Construction of Hospital and Health CareFacilities note there should be no recirculation of air within soiledworkrooms or soiled holding areas, ETO-sterilizer rooms, soiled ordecontamination rooms, clean workrooms, food preparation centers,ware-washing, soiled linen (sorting and storage) rooms, soiled linen,and trash chute rooms and janitor\u2019s closets.35 No recirculation of air is allowed in operating rooms, deliveryrooms, recovery rooms, or rooms with odor problems.48 CDC recommends placing patients who have infections which may betransmitted by small particle aerosols in rooms without airrecirculation.49 The state of Texasrecommends not allowing recirculation in operating rooms and deliveryrooms.", [["wall", "ANATOMY", 4, 8], ["theairflow", "DISEASE", 51, 61], ["Infection", "DISEASE", 252, 261], ["ETO-sterilizer", "CHEMICAL", 1103, 1117], ["infections", "DISEASE", 1473, 1483], ["wall", "MULTI-TISSUE_STRUCTURE", 4, 8], ["patients", "ORGANISM", 1455, 1463], ["patients", "SPECIES", 1455, 1463], ["The wall and ceiling units", "TREATMENT", 0, 26], ["less obstructive", "PROBLEM", 31, 47], ["design of isolation room", "TREATMENT", 189, 213], ["Infection Control", "TREATMENT", 252, 269], ["exhaustair", "TREATMENT", 293, 303], ["positive pressure room", "TREATMENT", 368, 390], ["the air change rate", "TEST", 392, 411], ["air HEPA filtration", "TREATMENT", 448, 467], ["specificfiltration efficiency", "PROBLEM", 591, 620], ["filtration andair recirculation requirements", "TREATMENT", 663, 707], ["Filter efficiencies", "TREATMENT", 793, 812], ["soiled linen", "TREATMENT", 1213, 1225], ["soiled linen", "TREATMENT", 1255, 1267], ["recirculation of air", "PROBLEM", 1318, 1338], ["odor problems", "PROBLEM", 1415, 1428], ["infections", "PROBLEM", 1473, 1483], ["airrecirculation", "PROBLEM", 1552, 1568], ["wall", "ANATOMY_MODIFIER", 4, 8], ["ceiling units", "OBSERVATION", 13, 26], ["less", "OBSERVATION_MODIFIER", 31, 35], ["obstructive", "OBSERVATION", 36, 47], ["Air Filtration", "OBSERVATION", 109, 123], ["Infection", "OBSERVATION", 252, 261], ["air change", "OBSERVATION", 396, 406], ["air HEPA filtration", "OBSERVATION", 448, 467], ["Filter efficiencies", "OBSERVATION", 793, 812], ["recirculation", "OBSERVATION_MODIFIER", 1318, 1331], ["air", "OBSERVATION", 1335, 1338], ["infections", "OBSERVATION", 1473, 1483], ["small", "OBSERVATION_MODIFIER", 1511, 1516], ["particle aerosols", "OBSERVATION", 1517, 1534]]], ["If recirculation is necessary to increase the air changes perhour, filters of MERV 17 or higher (HEPA filters) shall beused.50 These recommendations result inethical challenges to performing prospective controlled trials.", [["the air changes", "PROBLEM", 42, 57], ["MERV", "TEST", 78, 82], ["higher (HEPA filters)", "TREATMENT", 89, 110], ["prospective controlled trials", "TREATMENT", 191, 220], ["air changes", "OBSERVATION", 46, 57]]], ["Hence,there is a dearth of high quality studies that prospectively examinethe effect of recirculation on disease spread in the hospitalsetting.37,51 Before recent pharmacologicaladvancements, anesthetic gases were at risk of combustion, andrecirculation of air was prohibited by both federal and stateregulations.45Air Recirculation ::: Codes, Guidelines, and StandardsA very important note pertaining to the COVID-19 outbreak is that manyhealthcare facilities, especially those in more populated states(e.g., New York, California), have rapidly surpassed their capacityfor isolation rooms.", [["high quality studies", "PROBLEM", 27, 47], ["disease spread", "PROBLEM", 105, 119], ["recent pharmacologicaladvancements", "TREATMENT", 156, 190], ["anesthetic gases", "TEST", 192, 208], ["combustion", "PROBLEM", 225, 235], ["andrecirculation of air", "PROBLEM", 237, 260], ["recirculation", "OBSERVATION_MODIFIER", 88, 101], ["combustion", "OBSERVATION", 225, 235], ["air", "OBSERVATION", 257, 260], ["Air Recirculation", "OBSERVATION", 315, 332]]], ["This means that new admissions must be placed inintensive care units (ICUs) or general patient rooms where far lessstringent air filtration schemes are required by codes.", [["patient", "ORGANISM", 87, 94], ["patient", "SPECIES", 87, 94], ["lessstringent air filtration schemes", "TREATMENT", 111, 147], ["air filtration", "OBSERVATION", 125, 139]]], ["Awareness mustbe raised that such practices may exacerbate the spread of virus inthe room and other adjoining spaces (i.e., hallways), and thepotential to reconfigure air and pressure flows to increase safetycapacity should be evaluated.52Epidemic Task Force Guidance ::: Codes, Guidelines, and StandardsSince the beginning of the COVID-19 pandemic, several organizations suchas the World Health Organization, U.S. Federal Government, and StateJurisdictions have established taskforces to assess various aspect ofthe pandemic such as emergency medical services, health inequalities,and healthcare preparedness.", [["virus", "PROBLEM", 73, 78], ["pressure flows", "TEST", 175, 189], ["increase safetycapacity", "PROBLEM", 193, 216], ["the COVID", "TEST", 327, 336], ["pressure flows", "OBSERVATION", 175, 189]]], ["The one taskforce related to hospitalventilation design has been established by ASHRAE.", [["ASHRAE", "PROTEIN", 80, 86], ["hospitalventilation design", "TREATMENT", 29, 55]]], ["Among otherconsiderations, ASHRAE recommends increasing filtration level (ifpossible), minimizing air recirculation, maintaining 40\u201360%relative humidity, and utilizing portable HEPA filtration and anteroomunits.", [["increasing filtration level", "PROBLEM", 45, 72], ["portable HEPA filtration", "TREATMENT", 168, 192], ["anteroomunits", "TREATMENT", 197, 210], ["air recirculation", "OBSERVATION", 98, 115]]], ["Further, ASHRAE proposes five options of airflow alteration tothe patient room before hosting a COVID case (Figure6).", [["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["a COVID case (Figure6)", "TREATMENT", 94, 116]]], ["It must be noted thatfiltration and recirculation are central to these air distributionschemes.", [["these air distributionschemes", "PROBLEM", 65, 94], ["central", "OBSERVATION_MODIFIER", 54, 61], ["air distributionschemes", "OBSERVATION", 71, 94]]], ["In the case of no filtration (i.e., option 2), air must bedischarged at least 25 feet away from any building opening andentrance.Filtration in Operating Room (OR) ::: Filtration in Healthcare FacilitiesHigh efficiency filters have been widely used in operating rooms toreduce the risk of surgical site infection.64,65 TheSARS-CoV-2 pandemic has brought to light an abundance of relevantpublications pertaining to filtration in the OR.", [["site", "ANATOMY", 297, 301], ["infection", "DISEASE", 302, 311], ["filtration", "PROBLEM", 18, 28], ["High efficiency filters", "TREATMENT", 202, 225], ["surgical site infection", "PROBLEM", 288, 311], ["TheSARS", "TEST", 318, 325], ["CoV", "TEST", 326, 329], ["pandemic", "PROBLEM", 332, 340], ["relevantpublications", "PROBLEM", 378, 398], ["filtration", "TREATMENT", 413, 423], ["no", "UNCERTAINTY", 15, 17], ["filtration", "OBSERVATION", 18, 28], ["efficiency filters", "OBSERVATION", 207, 225], ["surgical site", "OBSERVATION", 288, 301], ["infection", "OBSERVATION", 302, 311]]], ["For example, duringan HVAC system operations audit of 20 operating rooms in 10 differenthospitals in the Hellenic Republic, the most common problems were poormaintenance of filters and nonexistent of air exhaust filters.66 Another study compared freestanding HEPA filterunits placed inside the OR to a novel portable anteroom system withHEPA unit (PAS-HEPA) that is placed outside the OR, near the mainentrance.67 It was found that with thePAS-HEPA system, experimental smoke plumes were observed movingdownward and toward the main entry door.", [["anteroom system withHEPA unit", "DNA", 317, 346], ["filters", "TREATMENT", 173, 180], ["air exhaust filters", "TREATMENT", 200, 219], ["Another study", "TEST", 223, 236], ["freestanding HEPA filterunits", "TREATMENT", 246, 275], ["PAS-HEPA", "TREATMENT", 348, 356], ["thePAS", "TEST", 437, 443], ["Hellenic Republic", "ANATOMY", 105, 122], ["filters", "OBSERVATION", 173, 180], ["air", "OBSERVATION", 200, 203], ["exhaust filters", "OBSERVATION", 204, 219], ["smoke plumes", "OBSERVATION", 470, 482]]], ["However, when freestandingHEPA units were placed on the patient bed inside the OR, smoke plumeswere moving vertically upward toward the breathing zone of the ORpersonnel.", [["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["freestandingHEPA units", "TREATMENT", 14, 36]]], ["These findings suggest that PAS-HEPA systems can be adoptedwhen coping with surgical patients during an airborne pandemic.Al-waked (2010) investigated the steady state operation of a laminarflow system (LAF) using HEPA filters that was centrally located in theOR ceiling, using computational fluid dynamics (CFD), and resultsindicated their effectiveness in minimizing the spread of contaminantsand providing thermal comfort.68Filtration in Operating Room (OR) ::: Filtration in Healthcare FacilitiesOne major difference between the OR design and that for the AIIR is theuse of laminar airflow systems.", [["PAS", "SIMPLE_CHEMICAL", 28, 31], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["PAS", "TEST", 28, 31], ["an airborne pandemic", "PROBLEM", 101, 121], ["a laminarflow system (LAF", "TREATMENT", 181, 206], ["HEPA filters", "TREATMENT", 214, 226], ["computational fluid dynamics", "TEST", 278, 306], ["thermal comfort", "TREATMENT", 409, 424], ["laminar airflow systems", "PROBLEM", 578, 601], ["laminar airflow", "OBSERVATION", 578, 593]]], ["The laminar flow system provides aunidirectional flow,36 and it must not be confusedwith cleaned air.69 The HEPA filtration plays anoutstanding role in the efficiency of laminar flow systems, as itassures the cleanliness of the supply air prior to pouring it on theOR bed.70\u221272 The laminar air flow combined with HEPAfilters can bring the contamination level down and is recommended forORs and immunocompromised patient rooms.37,73\u221278 It must be noted that a true laminar flowsystem is not achievable, as hospital personnel and equipmentmovements often disturb airflow patterns.7Filtration in Operating Room (OR) ::: Filtration in Healthcare FacilitiesIn a study by Sheretz et al. (1987), the use of whole-wall HEPAfiltration units with horizontal laminar flow (LAF) in patient roomsreduced the number of Aspergillus organisms in theair to 0.009 colony-forming units/m3, which wassignificantly lower than in all other areas of the hospital.78 However, Sadrizadeh et al. (2016) showed thathorizontal laminar flow systems, even when equipped with HEPA filters,lose efficiency due to the movement of medical staff andequipment.79Filtration in Operating Room (OR) ::: Filtration in Healthcare FacilitiesThe Surgical Infection Society recently published guidance on deliveringsurgical care to SARS-CoV-2 patients.", [["laminar", "ANATOMY", 4, 11], ["laminar", "ANATOMY", 748, 755], ["HEPAfilters", "CHEMICAL", 313, 324], ["37,73\u221278", "CHEMICAL", 426, 434], ["SARS", "DISEASE", 1288, 1292], ["patient", "ORGANISM", 412, 419], ["patient", "ORGANISM", 770, 777], ["SARS-CoV-2", "ORGANISM", 1288, 1298], ["patients", "ORGANISM", 1299, 1307], ["patient", "SPECIES", 412, 419], ["patient", "SPECIES", 770, 777], ["patients", "SPECIES", 1299, 1307], ["SARS-CoV", "SPECIES", 1288, 1296], ["aunidirectional flow", "TEST", 33, 53], ["The HEPA filtration", "TREATMENT", 104, 123], ["laminar flow systems", "TEST", 170, 190], ["The laminar air flow", "TEST", 278, 298], ["HEPAfilters", "TREATMENT", 313, 324], ["the contamination level", "TEST", 335, 358], ["a true laminar flowsystem", "PROBLEM", 457, 482], ["whole-wall HEPAfiltration units", "TREATMENT", 700, 731], ["horizontal laminar flow (LAF", "TREATMENT", 737, 765], ["Aspergillus organisms", "PROBLEM", 805, 826], ["thathorizontal laminar flow systems", "PROBLEM", 984, 1019], ["HEPA filters", "TREATMENT", 1045, 1057], ["lose efficiency", "PROBLEM", 1058, 1073], ["laminar", "ANATOMY_MODIFIER", 4, 11], ["flow system", "OBSERVATION", 12, 23], ["air", "OBSERVATION", 97, 100], ["HEPA filtration", "OBSERVATION", 108, 123], ["laminar flow", "OBSERVATION", 170, 182], ["air", "OBSERVATION", 235, 238], ["laminar", "OBSERVATION_MODIFIER", 282, 289], ["air flow", "OBSERVATION", 290, 298], ["laminar", "OBSERVATION_MODIFIER", 464, 471], ["flowsystem", "OBSERVATION", 472, 482], ["laminar flow", "OBSERVATION", 748, 760], ["Aspergillus organisms", "OBSERVATION", 805, 826], ["m3", "ANATOMY", 867, 869], ["laminar flow", "OBSERVATION", 999, 1011], ["Surgical Infection", "OBSERVATION", 1203, 1221]]], ["They recommended the use of anegatively pressurized OR, should one be available.", [["anegatively pressurized", "TREATMENT", 28, 51]]], ["Facilities thatlack negative pressure ORs shall equip a room with a HEPA filter forsurgical purposes.", [["a HEPA filter forsurgical purposes", "TREATMENT", 66, 100]]], ["Also, the guidance requires a geographicalseparation (including the supply room) between the OR dedicated toCOVID-19 patients and the rest of the surgical suite.", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125]]], ["No particularmention of air recirculation was found in the guidance.80Filtration in AIIRs ::: Filtration in Healthcare FacilitiesResearch on 2519 burn patients provided strong evidence that single-bedisolation rooms in combination with air filtration substantiallyreduced the incidence of infection with Gram-negative bacteria.53 Another study measured the efficiency of isolationrooms with and without anteroom and with and without care providertraffic.", [["burn", "DISEASE", 146, 150], ["infection", "DISEASE", 289, 298], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["air recirculation", "PROBLEM", 24, 41], ["single-bedisolation rooms", "TREATMENT", 190, 215], ["air filtration", "TREATMENT", 236, 250], ["infection", "PROBLEM", 289, 298], ["Gram-negative bacteria", "PROBLEM", 304, 326], ["Another study", "TEST", 330, 343], ["care providertraffic", "TREATMENT", 433, 453], ["air recirculation", "OBSERVATION", 24, 41], ["air filtration", "OBSERVATION", 236, 250], ["infection", "OBSERVATION", 289, 298], ["negative bacteria", "OBSERVATION", 309, 326]]], ["Two micrometer aerosol particles that were dyed withfluorescent dye were released inside three isolation rooms that wereequipped with HEPA filters.", [["Two micrometer aerosol particles", "TREATMENT", 0, 32], ["HEPA filters", "TREATMENT", 134, 146], ["HEPA filters", "OBSERVATION", 134, 146]]], ["The negative pressure and HEPA filtrationwas effective in containing more than 99% of the aerosols.81 The experiments were repeated for differentprovider traffic levels (i.e., no pass, one pass, and three pass) andresults revealed over 99.7% containment of aerosols under all threeconditions, providing a 5 min stay inside the AII unit.", [["HEPA filtrationwas", "TREATMENT", 26, 44], ["the AII unit", "TREATMENT", 323, 335], ["negative", "OBSERVATION", 4, 12], ["pressure", "OBSERVATION_MODIFIER", 13, 21]]], ["This isparticularly important as it relates to providing care to the COVID-19patients in AIIRs.Filtration in AIIRs ::: Filtration in Healthcare FacilitiesMarier and colleagues (1993) investigated a novelfiltration\u2013ventilation system to recirculate AIIR air throughan Ultra-Low Penetration Air (99.9995% efficiency for 0.12 \u03bcmparticles) filter and return the clean air into the adjacent anteroom.This system partially contributed to establishing the negativepressurization in the AIIR.", [["AIIRs", "CANCER", 89, 94], ["a novelfiltration\u2013ventilation system", "TREATMENT", 196, 232], ["Low Penetration Air", "PROBLEM", 273, 292], ["filter", "TREATMENT", 336, 342], ["clean air", "OBSERVATION", 358, 367]]], ["The concentration of particles reduced to30% of the baseline (fan off) when the system worked on the low mode,and up to 2% of the baseline for the high mode.82Filtration in Protective Environment (PE) ::: Filtration in Healthcare FacilitiesBone marrow transplant (BMT) units in the University of Minnesotahospital, built in 1986, had three different filters: 1, rough filter40% (ASHRAE 52\u201376); 2, 95% bag filter (ASHRAE 52\u201376);and 3, HEPA final filters.83 Other rooms in thehospital had the same filters, with the exception of HEPA filtration.By mapping particle concentrations to the level of filtration andoccupancy level in the room, it was found that the number of smallparticles (0.3\u20130.5 \u03bcm) was a function of the filtration,and that the number of large particles (>5 \u03bcm) was a functionof the occupancy level.", [["Bone marrow", "ANATOMY", 240, 251], ["Bone marrow", "MULTI-TISSUE_STRUCTURE", 240, 251], ["The concentration of particles", "TREATMENT", 0, 30], ["Bone marrow transplant (BMT)", "TREATMENT", 240, 268], ["ASHRAE", "TEST", 379, 385], ["bag filter", "TEST", 401, 411], ["ASHRAE", "TEST", 413, 419], ["HEPA final filters", "TREATMENT", 434, 452], ["HEPA filtration", "TREATMENT", 527, 542], ["smallparticles", "TEST", 669, 683], ["the filtration", "TREATMENT", 715, 729], ["large particles", "PROBLEM", 753, 768], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["particles", "OBSERVATION_MODIFIER", 21, 30], ["reduced", "OBSERVATION_MODIFIER", 31, 38], ["PE", "OBSERVATION", 197, 199], ["Bone marrow", "ANATOMY", 240, 251], ["HEPA", "ANATOMY", 527, 531], ["filtration", "OBSERVATION", 532, 542], ["filtration", "OBSERVATION", 719, 729], ["large", "OBSERVATION_MODIFIER", 753, 758], ["particles", "OBSERVATION_MODIFIER", 759, 768]]], ["Compared to the rooms without HEPA filters,the count of small particles (0.3\u20130.5 \u03bcm) wassubstantially lower for BMT units equipped with HEPA filter.", [["HEPA filters", "TREATMENT", 30, 42], ["the count", "TEST", 43, 52], ["small particles", "PROBLEM", 56, 71], ["BMT units", "TREATMENT", 112, 121], ["HEPA filter", "TREATMENT", 136, 147], ["filters", "OBSERVATION", 35, 42], ["small", "OBSERVATION_MODIFIER", 56, 61], ["particles", "OBSERVATION_MODIFIER", 62, 71], ["HEPA filter", "OBSERVATION", 136, 147]]], ["(2002) also showed that HEPA filters made a significant reductionin the number of HAIs in highly immunocompromised patients.77 The incident of nosocomialAspergillus infection was 10 times lower whenthe BMT patient was placed in a room with HEPA filtration and laminarairflow.78 Passweg et al. (1998) also foundthat HEPA filters reduced contamination and increased the survival ofBMT and leukemia patients.54Filtration in Protective Environment (PE) ::: Filtration in Healthcare FacilitiesDuring a four-year period, in two hematology wards and a BMT unit, therewere 64 cases of invasive nosocomial Aspergillus.", [["ofBMT", "ANATOMY", 377, 382], ["leukemia", "ANATOMY", 387, 395], ["HAIs", "DISEASE", 82, 86], ["Aspergillus infection", "DISEASE", 153, 174], ["leukemia", "DISEASE", 387, 395], ["nosocomial Aspergillus", "DISEASE", 586, 608], ["patients", "ORGANISM", 115, 123], ["patient", "ORGANISM", 206, 213], ["ofBMT", "CANCER", 377, 382], ["leukemia", "CANCER", 387, 395], ["patients", "ORGANISM", 396, 404], ["patients", "SPECIES", 115, 123], ["patient", "SPECIES", 206, 213], ["patients", "SPECIES", 396, 404], ["HEPA filters", "TREATMENT", 24, 36], ["HAIs", "PROBLEM", 82, 86], ["nosocomialAspergillus infection", "PROBLEM", 143, 174], ["HEPA filtration", "TREATMENT", 240, 255], ["laminarairflow", "TREATMENT", 260, 274], ["HEPA filters", "TREATMENT", 315, 327], ["the survival ofBMT", "TREATMENT", 364, 382], ["leukemia patients", "PROBLEM", 387, 404], ["invasive nosocomial Aspergillus", "PROBLEM", 577, 608], ["HEPA filters", "OBSERVATION", 24, 36], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["reductionin", "OBSERVATION_MODIFIER", 56, 67], ["number", "OBSERVATION_MODIFIER", 72, 78], ["HAIs", "OBSERVATION_MODIFIER", 82, 86], ["highly", "OBSERVATION_MODIFIER", 90, 96], ["immunocompromised", "OBSERVATION", 97, 114], ["nosocomial", "OBSERVATION_MODIFIER", 143, 153], ["Aspergillus infection", "OBSERVATION", 153, 174], ["increased", "OBSERVATION_MODIFIER", 354, 363], ["survival ofBMT", "OBSERVATION", 368, 382], ["leukemia", "OBSERVATION", 387, 395], ["PE", "OBSERVATION", 445, 447], ["invasive", "OBSERVATION_MODIFIER", 577, 585], ["nosocomial Aspergillus", "OBSERVATION", 586, 608]]], ["Therooms were equipped with HEPA filters and/or laminar air flow (LAF)systems.", [["HEPA filters", "TREATMENT", 28, 40], ["HEPA filters", "OBSERVATION", 28, 40], ["laminar", "ANATOMY_MODIFIER", 48, 55], ["air flow", "OBSERVATION", 56, 64]]], ["Air and surface samples were collected to measure the levelof fungal contamination bimonthly during this period.", [["surface samples", "ANATOMY", 8, 23], ["surface samples", "ORGANISM_SUBSTANCE", 8, 23], ["Air and surface samples", "TEST", 0, 23], ["the levelof fungal contamination", "PROBLEM", 50, 82], ["surface", "OBSERVATION_MODIFIER", 8, 15], ["fungal contamination", "OBSERVATION", 62, 82]]], ["Results showedno fungi in air or surface in the rooms equipped with HEPA-LAF,73 consistent with the findings of otherinvestigators.78,84,85Table 4 presents a summary ofpublications on air filtration with a brief discussion of the employedmethod.Portable HEPA Filters ::: Filtration in Healthcare FacilitiesHEPA filters can reduce the fungal spore and pathogencounts.73,86,87 HEPAfilters are usually placed in the HVAC system.88 Itis better to locate the HEPA filter at the point of air discharge tothe room rather than at the discharge of the fan.89\u221291 This is because the ductwork system from thefan discharge to the room outlet could be contaminated due tomaintenance or construction.92 Portable HEPA unitscan be used if this practice is not feasible.", [["surface", "ANATOMY", 33, 40], ["spore", "ANATOMY", 341, 346], ["89\u221291", "CHEMICAL", 547, 552], ["thefan", "CHEMICAL", 594, 600], ["fungi in air", "PROBLEM", 17, 29], ["HEPA-LAF", "TEST", 68, 76], ["air filtration", "TREATMENT", 184, 198], ["the employedmethod", "TREATMENT", 226, 244], ["Filtration", "TREATMENT", 271, 281], ["Healthcare FacilitiesHEPA filters", "TREATMENT", 285, 318], ["the fungal spore", "PROBLEM", 330, 346], ["pathogencounts", "PROBLEM", 351, 365], ["HEPAfilters", "TREATMENT", 375, 386], ["the HEPA filter", "TREATMENT", 450, 465], ["the ductwork system", "PROBLEM", 569, 588], ["Portable HEPA unitscan", "TEST", 689, 711], ["no", "UNCERTAINTY", 14, 16], ["fungi", "OBSERVATION", 17, 22], ["air", "OBSERVATION", 26, 29], ["surface", "OBSERVATION_MODIFIER", 33, 40], ["consistent with", "UNCERTAINTY", 80, 95], ["air filtration", "OBSERVATION", 184, 198], ["fungal spore", "OBSERVATION", 334, 346], ["HVAC system", "ANATOMY", 413, 424], ["HEPA", "ANATOMY", 454, 458], ["filter", "OBSERVATION", 459, 465], ["air discharge", "OBSERVATION", 482, 495], ["fan", "ANATOMY", 543, 546]]], ["Portable HEPA filtersare capable of increasing the effective ACH, removing particles, andreducing the risk of transmission in general wards when there are notenough isolation wards as is the case with the COVID-19pandemic8,39,89,93\u221295 (Table 5).Portable HEPA Filters ::: Filtration in Healthcare FacilitiesMiller et al. (1996) investigated the effectiveness of portable airfilters (PAFs) and ceiling mounted air filters (CMAFs) for controllingTB exposure.", [["TB", "DISEASE", 443, 445], ["ACH", "SIMPLE_CHEMICAL", 61, 64], ["the COVID", "TEST", 201, 210], ["portable airfilters (PAFs", "TREATMENT", 361, 386], ["ceiling mounted air filters (CMAFs)", "TREATMENT", 392, 427], ["controllingTB exposure", "PROBLEM", 432, 454], ["increasing", "OBSERVATION_MODIFIER", 36, 46], ["air filters", "OBSERVATION", 408, 419]]], ["CMAFs were shown to be more advantageous over PAFs due totheir elevated inlet and the buoyant nature of the dropletnuclei.62 Qian and colleagues tested theperformance of portable HEPA filters, such as their effect on theairflow pattern, using both smoke visualization and computersimulation.", [["CMAFs", "SIMPLE_CHEMICAL", 0, 5], ["PAFs", "SIMPLE_CHEMICAL", 46, 50], ["dropletnuclei", "CANCER", 108, 121], ["totheir elevated inlet", "PROBLEM", 55, 77], ["portable HEPA filters", "TREATMENT", 170, 191], ["computersimulation", "TREATMENT", 272, 290], ["elevated inlet", "OBSERVATION", 63, 77], ["buoyant nature", "OBSERVATION_MODIFIER", 86, 100]]], ["They found that having portable HEPA filters with strongair supply could bring a global airflow mixing by interacting with theairflow pattern.93 One study found, on average, a75% reduction in MRSA surface contamination when portable HEPA filterwas placed inside three different patient rooms.96While the portable unit did make a significant change in overallairflow patterns, the final outcome (i.e., surface decontamination)did not change by changing the location of the HEPA unit.", [["surface", "ANATOMY", 197, 204], ["surface", "ANATOMY", 401, 408], ["patient", "ORGANISM", 278, 285], ["HEPA unit", "DNA", 472, 481], ["MRSA", "SPECIES", 192, 196], ["patient", "SPECIES", 278, 285], ["portable HEPA filters", "TREATMENT", 23, 44], ["strongair supply", "TREATMENT", 50, 66], ["a global airflow mixing", "PROBLEM", 79, 102], ["One study", "TEST", 145, 154], ["MRSA surface contamination", "PROBLEM", 192, 218], ["portable HEPA filterwas", "TREATMENT", 224, 247], ["a significant change in overallairflow patterns", "PROBLEM", 327, 374], ["surface decontamination", "TREATMENT", 401, 424], ["the HEPA unit", "TREATMENT", 468, 481], ["global", "OBSERVATION_MODIFIER", 81, 87], ["airflow", "OBSERVATION", 88, 95], ["MRSA surface", "OBSERVATION", 192, 204], ["significant", "OBSERVATION_MODIFIER", 329, 340], ["change", "OBSERVATION", 341, 347], ["HEPA", "ANATOMY", 472, 476]]], ["Casagrandeand Piller (2020) demonstrated that the change in the global patternsof air movement due to a portable HEPA unit can be positivelyharnessed.", [["HEPA unit", "DNA", 113, 122], ["the change", "PROBLEM", 46, 56], ["the global patternsof air movement", "PROBLEM", 60, 94], ["a portable HEPA unit", "TREATMENT", 102, 122], ["change", "OBSERVATION_MODIFIER", 50, 56], ["air movement", "OBSERVATION", 82, 94]]], ["By placing the portable HEPA unit next to theinstrumentation table in the OR, an invisible air curtain was createdaround the instrument table that reduced the risk of instrumentcontamination up to 75%.97 Another investigationassessed the impact of 48 portable HEPA filter units on the invasiveAspergillosis (IA) incidence.", [["instrumentcontamination", "DISEASE", 167, 190], ["invasiveAspergillosis", "DISEASE", 285, 306], ["IA", "DISEASE", 308, 310], ["HEPA unit", "DNA", 24, 33], ["an invisible air curtain", "PROBLEM", 78, 102], ["instrumentcontamination", "TEST", 167, 190], ["48 portable HEPA filter units", "TREATMENT", 248, 277], ["air curtain", "OBSERVATION", 91, 102]]], ["Portable HEPAfilters nearly halved the IA incidence ratio.", [["Portable HEPAfilters", "TEST", 0, 20]]], ["The costs of HEPAfiltration were negligible compared to the significant decrease in therates of IA infection.88 Nevertheless, portableHEPA filters can be noisy, and bring physical obstruction for airflowin the room.39 A more recent study assessed theperformance of a portable air purifier (filter efficiency notspecified) in a pediatric hospital setting.", [["IA", "CHEMICAL", 96, 98], ["infection", "DISEASE", 99, 108], ["obstruction", "DISEASE", 180, 191], ["HEPAfiltration", "TREATMENT", 13, 27], ["IA infection", "PROBLEM", 96, 108], ["portableHEPA filters", "TREATMENT", 126, 146], ["physical obstruction", "PROBLEM", 171, 191], ["A more recent study", "TEST", 218, 237], ["a portable air purifier (filter efficiency", "TREATMENT", 265, 307], ["significant", "OBSERVATION_MODIFIER", 60, 71], ["decrease", "OBSERVATION_MODIFIER", 72, 80], ["IA", "OBSERVATION_MODIFIER", 96, 98], ["infection", "OBSERVATION", 99, 108], ["obstruction", "OBSERVATION", 180, 191]]], ["A total of 562 patientsdiagnosed with infectious or noninfectious respiratory distress wereincluded in this study in pre- and post-cohorts.", [["respiratory", "ANATOMY", 66, 77], ["respiratory distress", "DISEASE", 66, 86], ["infectious", "PROBLEM", 38, 48], ["noninfectious respiratory distress", "PROBLEM", 52, 86], ["this study", "TEST", 103, 113], ["infectious", "OBSERVATION", 38, 48], ["noninfectious", "OBSERVATION_MODIFIER", 52, 65], ["respiratory distress", "OBSERVATION", 66, 86]]], ["Results showed thatthe rate of using invasive patient ventilation (i.e., intubation) wasreduced 30%, and the average hospitalization time declined from 0.7days to 0.4 days upon placing the portable air purifier in therooms,98 though these differences did notachieve statistical significance.", [["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["invasive patient ventilation", "TREATMENT", 37, 65], ["intubation", "TREATMENT", 73, 83], ["the portable air purifier", "TEST", 185, 210]]], ["Further, clinical details were notprovided to allow a better understanding of potential differences inspecific clinical outcomes such as healthcare associated pneumonias,so it is difficult to understand these changes.Other Air Treatment Methods ::: Filtration in Healthcare FacilitiesWhile filtration is critical in maintaining the quality of hospital air,filters themselves can shelter viable organisms and hence sometimessupport their growth.99\u2212101 Therefore, thedevice itself can become the source ofcontamination.102\u2212107 In an investigation of three sealants withdifferent active antimicrobial compounds, only two of them reduced thefungal regrowth.108 Some of the air microorganismsare compatible with the antimicrobial agents applied on them.109 On the other hand, Foarde et al. (2001) foundthat filters did not become the source of microbial growth as long aspolyacrylate copolymer antimicrobial agents containing zinc oxide andborates were used under normal conditions.110 Itwas also reported that antimicrobial agents were not effective incurbing fungal reproduction on dust-loaded filters, while chemicallycoated filters had slightly higher than 60% efficiency.111 This area of research has remained fairlycontroversial where there are not enough studies to support (orimpugn) the use of antimicrobial agents on airfilters.20,112 Specific to the coronavirusoutbreak, rigorous research must be conducted to characterize theviability and reproduction of the virus on the filters.", [["pneumonias", "DISEASE", 159, 169], ["zinc oxide", "CHEMICAL", 921, 931], ["zinc oxide", "CHEMICAL", 921, 931], ["aspolyacrylate copolymer antimicrobial agents", "SIMPLE_CHEMICAL", 864, 909], ["zinc oxide andborates", "SIMPLE_CHEMICAL", 921, 942], ["orimpugn", "SIMPLE_CHEMICAL", 1277, 1285], ["healthcare associated pneumonias", "PROBLEM", 137, 169], ["thedevice", "TREATMENT", 462, 471], ["the source ofcontamination", "PROBLEM", 490, 516], ["active antimicrobial compounds", "TREATMENT", 577, 607], ["them reduced thefungal regrowth", "PROBLEM", 621, 652], ["the air microorganismsare", "PROBLEM", 665, 690], ["the antimicrobial agents", "TREATMENT", 707, 731], ["microbial growth", "PROBLEM", 839, 855], ["long aspolyacrylate copolymer antimicrobial agents", "TREATMENT", 859, 909], ["zinc oxide andborates", "TREATMENT", 921, 942], ["antimicrobial agents", "TREATMENT", 1006, 1026], ["fungal reproduction", "PROBLEM", 1056, 1075], ["dust-loaded filters", "TREATMENT", 1079, 1098], ["chemicallycoated filters", "TREATMENT", 1106, 1130], ["antimicrobial agents", "TREATMENT", 1298, 1318], ["airfilters", "TREATMENT", 1322, 1332], ["the virus", "PROBLEM", 1462, 1471], ["the filters", "TREATMENT", 1475, 1486], ["pneumonias", "OBSERVATION", 159, 169], ["Air Treatment", "OBSERVATION", 223, 236], ["active", "OBSERVATION_MODIFIER", 577, 583], ["antimicrobial compounds", "OBSERVATION", 584, 607], ["reduced", "OBSERVATION_MODIFIER", 626, 633], ["thefungal regrowth", "OBSERVATION", 634, 652], ["air microorganismsare", "OBSERVATION", 669, 690], ["compatible with", "UNCERTAINTY", 691, 706], ["antimicrobial agents", "OBSERVATION", 711, 731], ["normal conditions", "OBSERVATION", 959, 976], ["slightly", "OBSERVATION_MODIFIER", 1135, 1143], ["higher", "OBSERVATION_MODIFIER", 1144, 1150], ["virus", "OBSERVATION", 1466, 1471]]], ["Bergeron and colleagues (2007)designed a novel mobile air treatment unit to both remove airborneparticles and destruct microorganism by use of electrostatic captureand nonthermal plasma reactors.107 Nonthermalplasma reactors ensure that no microorganisms were stored in thesystem and eventually released into the air.", [["plasma", "ORGANISM_SUBSTANCE", 179, 185], ["a novel mobile air treatment", "TREATMENT", 39, 67], ["airborneparticles", "TREATMENT", 88, 105], ["electrostatic captureand nonthermal plasma reactors", "TREATMENT", 143, 194], ["Nonthermalplasma reactors", "TREATMENT", 199, 224], ["microorganisms", "PROBLEM", 240, 254], ["air", "OBSERVATION", 313, 316]]], ["Their efficiency forremoving biological airborne contamination at the speed of 1.5 m/s wasreported greater than 99% for a wide range of microorganisms.113Other Air Treatment Methods ::: Filtration in Healthcare FacilitiesThe combination of filtration and disinfection has been recommended byCDC, NIOSH, and ASHRAE as a complementary air cleaning approach to theroom air conditioning system.12,15,114 For example, the combination of ultravioletgermicidal irradiation (UVGI) lamps and filtration was most effectivein removing and killing pathogens like Aspergillusspp. andStaphylococci.91,115 Ryanet al. found that installation of UVGI in the HVAC systems equippedwith 95% filter efficiency helped reduce ventilator-associatedpneumonia and tracheal colonization.116 Anothermore recent work studied the effectiveness of UVGI when used inventilation ducts.", [["tracheal", "ANATOMY", 738, 746], ["inventilation ducts", "ANATOMY", 832, 851], ["12,15,114", "CHEMICAL", 390, 399], ["Aspergillusspp", "CHEMICAL", 551, 565], ["UVGI", "CHEMICAL", 629, 633], ["UVGI", "CHEMICAL", 817, 821], ["tracheal", "ORGAN", 738, 746], ["UVGI", "SIMPLE_CHEMICAL", 817, 821], ["inventilation ducts", "MULTI-TISSUE_STRUCTURE", 832, 851], ["biological airborne contamination", "PROBLEM", 29, 62], ["filtration", "TREATMENT", 240, 250], ["disinfection", "TREATMENT", 255, 267], ["a complementary air cleaning approach", "TREATMENT", 317, 354], ["ultravioletgermicidal irradiation (UVGI) lamps", "TREATMENT", 432, 478], ["filtration", "TREATMENT", 483, 493], ["killing pathogens", "PROBLEM", 528, 545], ["Aspergillusspp", "PROBLEM", 551, 565], ["UVGI in the HVAC systems", "TREATMENT", 629, 653], ["ventilator", "TREATMENT", 703, 713], ["associatedpneumonia", "PROBLEM", 714, 733], ["tracheal colonization", "PROBLEM", 738, 759], ["inventilation ducts", "PROBLEM", 832, 851], ["efficiency", "OBSERVATION_MODIFIER", 6, 16], ["airborne contamination", "OBSERVATION", 40, 62], ["filtration", "OBSERVATION", 240, 250], ["ultravioletgermicidal irradiation", "OBSERVATION", 432, 465], ["tracheal", "ANATOMY", 738, 746], ["colonization", "OBSERVATION", 747, 759], ["ducts", "ANATOMY", 846, 851]]], ["Results showed the UVGI inactivated nearly all themicroorganisms in the ductwork when the air velocity was 3.0 m/s.However, an increase in air velocity (6.0 m/s) led to insufficientexposure of bacteria to irradiation, and thus only 80% inactivationwas found for S. enterica and S.epidermidis.117 Interested readersmay find further useful discussions in a review article published byMemarzadeh and colleagues on the application of the UVGI technology inhealthcare settings.118Recirculation in Healthcare FacilitiesWaiting for a contaminant to decay naturally in the building is a slow process.Hence, engineering alternatives like mixing indoor air with the outside airand recirculating it back to the room and pressurization control areutilized.", [["S. enterica", "ORGANISM", 262, 273], ["S.epidermidis", "SIMPLE_CHEMICAL", 278, 291], ["UVGI", "DNA", 19, 23], ["S. enterica", "SPECIES", 262, 273], ["S. enterica", "SPECIES", 262, 273], ["the air velocity", "TEST", 86, 102], ["an increase in air velocity", "PROBLEM", 124, 151], ["bacteria", "PROBLEM", 193, 201], ["irradiation", "TREATMENT", 205, 216], ["S. enterica and S.epidermidis", "PROBLEM", 262, 291], ["a slow process", "PROBLEM", 577, 591], ["pressurization control areutilized", "TREATMENT", 709, 743], ["air velocity", "OBSERVATION", 90, 102], ["increase", "OBSERVATION_MODIFIER", 127, 135], ["air velocity", "OBSERVATION", 139, 151], ["bacteria", "OBSERVATION", 193, 201], ["enterica", "OBSERVATION", 265, 273], ["Recirculation", "OBSERVATION_MODIFIER", 475, 488]]], ["There are two types of general air systems: (1) single pass and(2) recirculating.119 The single pass air system suppliesair from the outdoors, and after passing through the room air it is thenexhausted 100% back to the outdoor environment.", [["two", "OBSERVATION_MODIFIER", 10, 13], ["types", "OBSERVATION_MODIFIER", 14, 19], ["air systems", "OBSERVATION", 31, 42], ["air system", "OBSERVATION", 101, 111]]], ["This system does not,however, take advantage of the embodied energy required for heating/coolingof discharged air.", [["heating/coolingof discharged air", "TREATMENT", 81, 113]]], ["In the recirculating system, however, a limited portionof the air is exhausted to the outdoors and replaced by fresh air.120 Recirculating systems are typically designed forsignificantly larger flow rates compared to single pass systems as theyutilize the power of contaminant dilution.", [["a limited portionof the air", "PROBLEM", 38, 65], ["larger flow rates", "PROBLEM", 187, 204], ["recirculating system", "ANATOMY", 7, 27], ["air", "OBSERVATION", 62, 65], ["fresh air", "OBSERVATION", 111, 120], ["larger", "OBSERVATION_MODIFIER", 187, 193], ["flow", "OBSERVATION", 194, 198], ["contaminant dilution", "OBSERVATION", 265, 285]]], ["Recirculation could be used aslong as air is filtered through high efficiency filters or is cleaned bydisinfection techniques.121 Recirculation of air can beproblematic under two conditions: (1) when it leads to the delivery ofinsufficient fresh air, and consequently excessive CO2 exposure,or (2) when the return air is not properly filtered.122For most patient-care areas, there are two filters in central HVAC systems.The outside air is filtered through the first bank filter to remove largerparticles (1\u20135 \u03bcm).", [["CO2", "CHEMICAL", 278, 281], ["CO2", "CHEMICAL", 278, 281], ["CO2", "SIMPLE_CHEMICAL", 278, 281], ["patient", "ORGANISM", 355, 362], ["largerparticles", "PROTEIN", 489, 504], ["patient", "SPECIES", 355, 362], ["Recirculation", "TREATMENT", 0, 13], ["high efficiency filters", "TREATMENT", 62, 85], ["cleaned bydisinfection techniques", "TREATMENT", 92, 125], ["excessive CO2 exposure", "PROBLEM", 268, 290], ["two filters in central HVAC systems", "TREATMENT", 385, 420], ["the first bank filter", "TREATMENT", 457, 478], ["high efficiency", "OBSERVATION_MODIFIER", 62, 77], ["filters", "OBSERVATION", 78, 85], ["air", "OBSERVATION", 147, 150], ["air", "OBSERVATION", 246, 249], ["excessive", "OBSERVATION_MODIFIER", 268, 277], ["CO2 exposure", "OBSERVATION", 278, 290], ["air", "OBSERVATION", 314, 317], ["two filters", "OBSERVATION", 385, 396], ["central", "ANATOMY_MODIFIER", 400, 407], ["HVAC", "ANATOMY", 408, 412], ["air", "OBSERVATION", 433, 436]]], ["The incoming air then mixes with therecirculated air and is reconditioned for temperature and humidity andeventually passes through the second filter in the air handlingunit.35,123Recirculation in Healthcare FacilitiesUlrich (1974) studied two neurosurgical operating rooms at St. Mary\u2019sHospital in Rochester, Minnesota, during surgical procedures.", [["humidity", "TREATMENT", 94, 102], ["the second filter", "TREATMENT", 132, 149], ["surgical procedures", "TREATMENT", 328, 347], ["air", "OBSERVATION", 13, 16], ["air", "OBSERVATION", 49, 52], ["second filter", "OBSERVATION", 136, 149], ["air handlingunit", "OBSERVATION", 157, 173]]], ["Air andsurface samples were taken to determine bacterial counts.", [["andsurface samples", "ANATOMY", 4, 22], ["Air andsurface samples", "TEST", 0, 22], ["bacterial counts", "TEST", 47, 63]]], ["Results for bothrooms demonstrated that recirculation of air along with filtration reducedthe number of bacteria inside the OR when compared to 100% fresh air.124 Woods et al. (1986) studied two operating rooms in MaryMedical Center in Ames, Iowa, and data were recorded from two existing HVACsettings.", [["recirculation of air", "PROBLEM", 40, 60], ["filtration", "TREATMENT", 72, 82], ["bacteria", "PROBLEM", 104, 112], ["recirculation", "OBSERVATION_MODIFIER", 40, 53], ["air", "OBSERVATION", 57, 60], ["bacteria", "OBSERVATION_MODIFIER", 104, 112]]], ["In the first OR, the system performed 12 air changes per hour with100% outdoor air and only one filter.", [["one filter", "TREATMENT", 92, 102], ["filter", "OBSERVATION", 96, 102]]], ["In the second operating room, thesystem performed 17 air changes per hour with 20% from the outdoor (i.e.,3.5 ACH) and two filters.", [["two filters", "TREATMENT", 119, 130]]], ["Although the percentage of outdoor air in thesecond operating room was lower than the first room, computer simulationsand field measurements showed a reduction in particulate matterconcentrations, indicating the usefulness of air recirculation andfiltration.125Recirculation in Healthcare FacilitiesResearch has shown that air recirculation should only be used in the hospitalsetting in conjunction with adequate air filtration.", [["computer simulationsand field measurements", "TEST", 98, 140], ["a reduction in particulate matterconcentrations", "PROBLEM", 148, 195], ["air recirculation andfiltration", "PROBLEM", 226, 257], ["air recirculation", "TREATMENT", 323, 340], ["adequate air filtration", "TREATMENT", 404, 427], ["percentage", "OBSERVATION_MODIFIER", 13, 23], ["outdoor air", "OBSERVATION", 27, 38], ["reduction", "OBSERVATION_MODIFIER", 150, 159], ["particulate matterconcentrations", "OBSERVATION", 163, 195], ["air recirculation", "OBSERVATION", 226, 243], ["air recirculation", "OBSERVATION", 323, 340], ["air filtration", "OBSERVATION", 413, 427]]], ["The distribution ofparticles were studied in a patient room of a Brazilian hospital that wasventilated with a split system that recirculated air inside the room withoutdoor air, but without filtration.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["a split system", "TREATMENT", 108, 122], ["filtration", "PROBLEM", 190, 200], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["air", "OBSERVATION", 141, 144], ["without", "UNCERTAINTY", 182, 189], ["filtration", "OBSERVATION", 190, 200]]], ["Results showed that small particlesfollowed the path of the air and remained suspended in the room due to airrecirculation inside the room.", [["small", "OBSERVATION_MODIFIER", 20, 25], ["particlesfollowed", "OBSERVATION", 26, 43], ["air", "OBSERVATION", 60, 63]]], ["Hence, pure recirculation can increase therisk of contamination due to random particle movements, and it may alsoresult in significant particle deposition onto surfaces.126 The placement of inlet and outlet filters is also important, as the HVACsystem can cause different recirculation patterns in theroom.127,128Practical ImplicationsThere is substantial evidence (Level 2 publications) that contaminated air canresult in disease spread, and that the combination of air filtration andrecirculation can reduce this risk.", [["contamination", "PROBLEM", 50, 63], ["random particle movements", "PROBLEM", 71, 96], ["significant particle deposition onto surfaces", "PROBLEM", 123, 168], ["The placement of inlet and outlet filters", "TREATMENT", 173, 214], ["substantial evidence (Level 2 publications", "PROBLEM", 344, 386], ["contaminated air canresult in disease spread", "PROBLEM", 393, 437], ["air filtration andrecirculation", "TREATMENT", 467, 498], ["recirculation", "OBSERVATION", 12, 25], ["particle movements", "OBSERVATION", 78, 96], ["significant", "OBSERVATION_MODIFIER", 123, 134], ["particle deposition", "OBSERVATION", 135, 154], ["inlet", "OBSERVATION_MODIFIER", 190, 195], ["outlet filters", "OBSERVATION", 200, 214], ["recirculation patterns", "OBSERVATION", 272, 294], ["substantial", "OBSERVATION_MODIFIER", 344, 355], ["air canresult", "OBSERVATION", 406, 419], ["air filtration", "OBSERVATION", 467, 481]]], ["Observational and animal studies suggestthat air recirculation alone may result in the airborne transmission ofpathogens.129\u2212131 The experimental setup is mostly designed forextreme cases to prove the airborne route, which is far from realistic inthe healthcare setting.", [["animal studies", "TEST", 18, 32], ["air recirculation", "PROBLEM", 45, 62], ["the airborne transmission ofpathogens", "PROBLEM", 83, 120], ["air recirculation", "OBSERVATION", 45, 62]]], ["There are a few outstanding findings from theliterature that can be used to minimize the adverse impact of the SARS-CoV-2virus on medical personnel who spend many hours of their time inside thehospital as well as reduce risk of nosocomial infections.1.The combination ofHEPA filtration and air recirculation has been shown to beextremely effective in many space functions such as ORs,AIIRs, and PEs.", [["SARS", "DISEASE", 111, 115], ["nosocomial infections", "DISEASE", 228, 249], ["CoV-2virus", "ORGANISM", 116, 126], ["ofHEPA", "SIMPLE_CHEMICAL", 268, 274], ["SARS-CoV-2virus", "SPECIES", 111, 126], ["nosocomial infections", "PROBLEM", 228, 249], ["The combination ofHEPA filtration", "TREATMENT", 252, 285], ["air recirculation", "TREATMENT", 290, 307], ["PEs", "PROBLEM", 395, 398], ["few", "OBSERVATION_MODIFIER", 12, 15], ["nosocomial", "OBSERVATION_MODIFIER", 228, 238], ["infections", "OBSERVATION", 239, 249], ["air recirculation", "OBSERVATION", 290, 307], ["effective", "OBSERVATION_MODIFIER", 338, 347]]], ["These systems clean air by simultaneouslyremoving (i.e., filtering) and diluting (throughrecirculation) contaminants from the space.", [["diluting (throughrecirculation) contaminants from the space", "PROBLEM", 72, 131], ["clean", "OBSERVATION_MODIFIER", 14, 19], ["air", "OBSERVATION", 20, 23], ["space", "ANATOMY", 126, 131]]], ["They haveshown significant reduction in the number of bacterialcolonies, and surrogate particulate matters previousstudies, and they are expected to show a similarefficiency for the COVID-19 pandemic.", [["COVID-19", "SPECIES", 182, 190], ["bacterialcolonies", "PROBLEM", 54, 71], ["the COVID", "TEST", 178, 187], ["pandemic", "PROBLEM", 191, 199], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["reduction", "OBSERVATION_MODIFIER", 27, 36], ["number", "OBSERVATION_MODIFIER", 44, 50]]], ["The role of airdistribution systems in buildings during an outbreak hasbeen the subject of previousresearch.132,133A findingthat is worthy of reiteration is from Streifel andcolleagues (1995) that showed HEPA filters are remarkablyefficient in capturing submicron particles.83 The SARS-CoV-2 virus is shown to havea diameter less than 1 \u03bcm.", [["SARS", "DISEASE", 281, 285], ["SARS-CoV-2 virus", "ORGANISM", 281, 297], ["CoV-2 virus", "SPECIES", 286, 297], ["SARS-CoV-2 virus", "SPECIES", 281, 297], ["airdistribution systems", "PROBLEM", 12, 35], ["HEPA filters", "TREATMENT", 204, 216], ["The SARS", "TEST", 277, 285], ["CoV", "TEST", 286, 289], ["HEPA filters", "OBSERVATION", 204, 216], ["submicron particles", "OBSERVATION", 254, 273], ["diameter", "OBSERVATION_MODIFIER", 316, 324]]], ["This further suggeststhat HEPA filters will be effective tools to mitigatehospital spread, as noted in a recent review on thepotential airborne route of the SARS-CoV-2 transmission inhospitals.1342.Thecoronavirus outbreak has severely hit the healthcaresettings.", [["SARS", "DISEASE", 157, 161], ["Thecoronavirus", "CHEMICAL", 198, 212], ["HEPA filters", "TREATMENT", 26, 38], ["the SARS", "TEST", 153, 161], ["severely hit the healthcaresettings", "PROBLEM", 226, 261], ["severely", "OBSERVATION_MODIFIER", 226, 234], ["hit", "OBSERVATION", 235, 238]]], ["Notably, in hospitals in the epicenter of thepandemic during the spring of 2020 (New York, Connecticut,and Boston), the surge capacity exceeded standard roomconfigurations and SARS-CoV-2 positive patients wereplaced in general patient wards and converted ICUs withoutnegative pressure capacity.", [["patients", "ORGANISM", 196, 204], ["patient", "ORGANISM", 227, 234], ["patients", "SPECIES", 196, 204], ["patient", "SPECIES", 227, 234], ["the surge capacity", "TEST", 116, 134], ["SARS", "TEST", 176, 180], ["CoV", "TEST", 181, 184]]], ["These spaces likely frequentlylack sufficient filtration requirements, ventilationrates, and negative pressurization capacity.", [["ventilationrates", "TREATMENT", 71, 87], ["likely", "UNCERTAINTY", 13, 19], ["frequentlylack", "OBSERVATION_MODIFIER", 20, 34], ["sufficient", "OBSERVATION_MODIFIER", 35, 45], ["filtration", "OBSERVATION", 46, 56], ["pressurization capacity", "OBSERVATION", 102, 125]]], ["Therefore,one short-term solution seems to be substituting theexisting filter in those rooms with higher efficiencyfilters (i.e., HEPA filters).", [["one short-term solution", "TREATMENT", 10, 33], ["theexisting filter", "TREATMENT", 59, 77], ["higher efficiencyfilters", "PROBLEM", 98, 122], ["HEPA filters", "TREATMENT", 130, 142], ["filter", "OBSERVATION", 71, 77], ["higher efficiencyfilters", "OBSERVATION", 98, 122], ["HEPA filters", "OBSERVATION", 130, 142]]], ["Though this seems like alogical decision at the first glance, it may result inunfavorable outcomes such as increasing the pressure dropwhen replacing a lower rate filter with HEPAfilters.29,135 When thepressure drop increases and the fan speed remainsconstant, the amount of air supplied to the space willdecrease.", [["the pressure dropwhen", "TREATMENT", 118, 139], ["a lower rate filter", "TREATMENT", 150, 169], ["HEPAfilters", "TREATMENT", 175, 186], ["thepressure drop", "PROBLEM", 199, 215], ["pressure", "OBSERVATION_MODIFIER", 122, 130], ["lower", "OBSERVATION_MODIFIER", 152, 157], ["rate filter", "OBSERVATION", 158, 169], ["amount", "OBSERVATION_MODIFIER", 265, 271], ["air", "OBSERVATION", 275, 278]]], ["This can result in an imbalanced system that canincrease the distribution to spreaddisease.3.PortableHEPA filter systems have been shown to be anothereffective tool in reducing viral load.", [["an imbalanced system", "PROBLEM", 19, 39], ["spreaddisease", "PROBLEM", 77, 90], ["PortableHEPA filter systems", "TREATMENT", 93, 120], ["reducing viral load", "PROBLEM", 168, 187], ["imbalanced", "OBSERVATION", 22, 32], ["distribution", "OBSERVATION_MODIFIER", 61, 73], ["viral load", "OBSERVATION", 177, 187]]], ["Another innovativedesign is to place a portable HEPA filter that dischargesair into a portable plastic anteroom right at theentrance.82 Such a system, alsorecommended by the ASHRAE epidemic task force, can cleanthe air inside the patient room, while creating negativepressure with respect to the plastic anteroom.", [["patient", "ORGANISM", 230, 237], ["patient", "SPECIES", 230, 237], ["a portable HEPA filter", "TREATMENT", 37, 59], ["a portable plastic anteroom right at theentrance", "TREATMENT", 84, 132], ["right", "ANATOMY_MODIFIER", 112, 117]]], ["Therefore,both virus removal and containment may beachieved.", [["both virus removal", "TREATMENT", 10, 28], ["containment", "TREATMENT", 33, 44], ["virus removal", "OBSERVATION", 15, 28]]]], "055543ff5e0e0aa6403554e1bff5e996eb5a0ed2": [["Pentraxins, c-reactive proteins and serum amyloid proteins.", [["serum", "ANATOMY", 36, 41], ["Pentraxins", "CHEMICAL", 0, 10], ["Pentraxins", "GENE_OR_GENE_PRODUCT", 0, 10], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["amyloid", "GENE_OR_GENE_PRODUCT", 42, 49], ["Pentraxins", "PROTEIN", 0, 10], ["c-reactive proteins", "PROTEIN", 12, 31], ["serum amyloid proteins", "PROTEIN", 36, 58], ["Pentraxins", "TREATMENT", 0, 10], ["c-reactive proteins", "TEST", 12, 31], ["serum amyloid proteins", "TEST", 36, 58]]], ["The basicsLiving organisms have to be prepared to face external aggressions such as injuries or pathogen invasions.", [["injuries", "DISEASE", 84, 92], ["The basicsLiving organisms", "PROBLEM", 0, 26], ["injuries", "PROBLEM", 84, 92], ["pathogen invasions", "PROBLEM", 96, 114], ["pathogen", "OBSERVATION_MODIFIER", 96, 104], ["invasions", "OBSERVATION", 105, 114]]], ["One of the arms of the host defensive response is the activation of the so called acute phase response (APR) that includes the production of inflammatory cytokines and a number of proteins such as c-reactive proteins (CRPs), serum amyloid proteins (SAA, SAP) and pentraxins (PTX).", [["serum", "ANATOMY", 225, 230], ["PTX", "CHEMICAL", 275, 278], ["pentraxins", "CHEMICAL", 263, 273], ["PTX", "CHEMICAL", 275, 278], ["c-reactive proteins", "GENE_OR_GENE_PRODUCT", 197, 216], ["CRPs", "GENE_OR_GENE_PRODUCT", 218, 222], ["serum amyloid proteins", "GENE_OR_GENE_PRODUCT", 225, 247], ["SAA", "GENE_OR_GENE_PRODUCT", 249, 252], ["SAP", "GENE_OR_GENE_PRODUCT", 254, 257], ["pentraxins", "GENE_OR_GENE_PRODUCT", 263, 273], ["PTX", "SIMPLE_CHEMICAL", 275, 278], ["inflammatory cytokines", "PROTEIN", 141, 163], ["c-reactive proteins", "PROTEIN", 197, 216], ["CRPs", "PROTEIN", 218, 222], ["serum amyloid proteins", "PROTEIN", 225, 247], ["SAA", "PROTEIN", 249, 252], ["SAP", "PROTEIN", 254, 257], ["acute phase response", "PROBLEM", 82, 102], ["inflammatory cytokines", "PROBLEM", 141, 163], ["c-reactive proteins", "TEST", 197, 216], ["CRPs", "TEST", 218, 222], ["serum amyloid proteins", "TEST", 225, 247], ["SAA", "TEST", 249, 252], ["SAP", "TEST", 254, 257], ["pentraxins (PTX)", "PROBLEM", 263, 279], ["host", "OBSERVATION_MODIFIER", 23, 27], ["defensive response", "OBSERVATION", 28, 46], ["inflammatory cytokines", "OBSERVATION", 141, 163]]], ["Those are collectively termed acute phase proteins (APP).", [["acute phase proteins", "GENE_OR_GENE_PRODUCT", 30, 50], ["APP", "GENE_OR_GENE_PRODUCT", 52, 55], ["acute phase proteins", "PROTEIN", 30, 50], ["APP", "PROTEIN", 52, 55], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["phase", "OBSERVATION_MODIFIER", 36, 41]]], ["APP are present in all animal groups studied, from arthropods to vertebrates [1, 2] .", [["APP", "GENE_OR_GENE_PRODUCT", 0, 3], ["APP", "PROTEIN", 0, 3]]], ["Nonetheless, most of the research on APP has been conducted on mammalian models.Pentraxins, c-reactive proteins and serum amyloid proteins.", [["serum", "ANATOMY", 116, 121], ["Pentraxins", "CHEMICAL", 80, 90], ["APP", "GENE_OR_GENE_PRODUCT", 37, 40], ["Pentraxins", "GENE_OR_GENE_PRODUCT", 80, 90], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["amyloid", "GENE_OR_GENE_PRODUCT", 122, 129], ["APP", "PROTEIN", 37, 40], ["Pentraxins", "PROTEIN", 80, 90], ["c-reactive proteins", "PROTEIN", 92, 111], ["serum amyloid proteins", "PROTEIN", 116, 138], ["Pentraxins", "TREATMENT", 80, 90], ["c-reactive proteins", "TEST", 92, 111], ["serum amyloid proteins", "TEST", 116, 138]]], ["The basicsCRP are classified into the short pentraxins group.", [["pentraxins", "CHEMICAL", 44, 54], ["basicsCRP", "GENE_OR_GENE_PRODUCT", 4, 13], ["pentraxins", "GENE_OR_GENE_PRODUCT", 44, 54], ["basicsCRP", "PROTEIN", 4, 13], ["short", "OBSERVATION_MODIFIER", 38, 43]]], ["They were identified as proteins around 25-kDa synthesized in the liver.", [["liver", "ANATOMY", 66, 71], ["liver", "ORGAN", 66, 71], ["proteins", "TEST", 24, 32], ["liver", "ANATOMY", 66, 71]]], ["CRP blood levels rise notably in patients undergoing inflammatory response to a number of disease conditions, including cancer [3, 4] .", [["blood", "ANATOMY", 4, 9], ["cancer", "ANATOMY", 120, 126], ["cancer", "DISEASE", 120, 126], ["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["patients", "ORGANISM", 33, 41], ["cancer", "CANCER", 120, 126], ["CRP", "PROTEIN", 0, 3], ["patients", "SPECIES", 33, 41], ["CRP blood levels", "TEST", 0, 16], ["inflammatory response", "PROBLEM", 53, 74], ["disease conditions", "PROBLEM", 90, 108], ["cancer", "PROBLEM", 120, 126], ["inflammatory response", "OBSERVATION", 53, 74], ["disease", "OBSERVATION", 90, 97], ["cancer", "OBSERVATION", 120, 126]]], ["Human CRP tends to form pentameric structures [1] .", [["Human", "ORGANISM", 0, 5], ["CRP", "GENE_OR_GENE_PRODUCT", 6, 9], ["CRP", "PROTEIN", 6, 9], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human CRP", "TEST", 0, 9]]], ["It is currently accepted that the balance between monomeric CRP and pentameric CRP states determines its functionality [5] [6] [7] .Pentraxins, c-reactive proteins and serum amyloid proteins.", [["serum", "ANATOMY", 168, 173], ["Pentraxins", "CHEMICAL", 132, 142], ["CRP", "GENE_OR_GENE_PRODUCT", 60, 63], ["CRP", "GENE_OR_GENE_PRODUCT", 79, 82], ["Pentraxins", "GENE_OR_GENE_PRODUCT", 132, 142], ["serum", "ORGANISM_SUBSTANCE", 168, 173], ["amyloid", "GENE_OR_GENE_PRODUCT", 174, 181], ["CRP", "PROTEIN", 60, 63], ["pentameric CRP states", "PROTEIN", 68, 89], ["Pentraxins", "PROTEIN", 132, 142], ["c-reactive proteins", "PROTEIN", 144, 163], ["serum amyloid proteins", "PROTEIN", 168, 190], ["monomeric CRP", "TEST", 50, 63], ["pentameric CRP", "TEST", 68, 82], ["Pentraxins", "TREATMENT", 132, 142], ["c-reactive proteins", "TEST", 144, 163], ["serum amyloid proteins", "TEST", 168, 190]]], ["The basicsSerum amyloid A (SAA) and serum amyloid P (SAP) are also released to circulation in correlation with antimicrobial and anti-inflammatory activity [8, 9] .", [["serum", "ANATOMY", 36, 41], ["basicsSerum amyloid A", "GENE_OR_GENE_PRODUCT", 4, 25], ["SAA", "GENE_OR_GENE_PRODUCT", 27, 30], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["amyloid P", "GENE_OR_GENE_PRODUCT", 42, 51], ["SAP", "GENE_OR_GENE_PRODUCT", 53, 56], ["basicsSerum amyloid A", "PROTEIN", 4, 25], ["SAA", "PROTEIN", 27, 30], ["SAP", "PROTEIN", 53, 56], ["serum amyloid P (SAP)", "PROBLEM", 36, 57], ["antimicrobial and anti-inflammatory activity", "TREATMENT", 111, 155], ["amyloid", "OBSERVATION", 16, 23]]], ["Both proteins are often found in amyloid deposits such as in atherosclerosis disease [10, 11] .", [["atherosclerosis", "DISEASE", 61, 76], ["amyloid deposits", "PROBLEM", 33, 49], ["atherosclerosis disease", "PROBLEM", 61, 84], ["amyloid deposits", "OBSERVATION", 33, 49], ["atherosclerosis", "OBSERVATION", 61, 76]]], ["CRP and SAP are known to interact with the complement component C1q which results in the activation of the complement cascade [12] .Pentraxins, c-reactive proteins and serum amyloid proteins.", [["serum", "ANATOMY", 168, 173], ["Pentraxins", "CHEMICAL", 132, 142], ["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["SAP", "GENE_OR_GENE_PRODUCT", 8, 11], ["C1q", "GENE_OR_GENE_PRODUCT", 64, 67], ["Pentraxins", "GENE_OR_GENE_PRODUCT", 132, 142], ["serum", "ORGANISM_SUBSTANCE", 168, 173], ["amyloid", "GENE_OR_GENE_PRODUCT", 174, 181], ["CRP", "PROTEIN", 0, 3], ["SAP", "PROTEIN", 8, 11], ["complement component", "PROTEIN", 43, 63], ["C1q", "PROTEIN", 64, 67], ["Pentraxins", "PROTEIN", 132, 142], ["c-reactive proteins", "PROTEIN", 144, 163], ["serum amyloid proteins", "PROTEIN", 168, 190], ["CRP", "TEST", 0, 3], ["SAP", "PROBLEM", 8, 11], ["Pentraxins", "TREATMENT", 132, 142], ["c-reactive proteins", "TEST", 144, 163], ["serum amyloid proteins", "TEST", 168, 190]]], ["The basicsPTX are larger proteins (\u224840-kDa) that form multimeric structures [3, 13] .", [["PTX", "CHEMICAL", 10, 13], ["PTX", "CHEMICAL", 10, 13], ["PTX", "SIMPLE_CHEMICAL", 10, 13], ["The basicsPTX", "TEST", 0, 13], ["larger proteins", "PROBLEM", 18, 33], ["larger", "OBSERVATION_MODIFIER", 18, 24]]], ["PTX production by various cell types is stimulated by microbial infection [14] .", [["cell", "ANATOMY", 26, 30], ["PTX", "CHEMICAL", 0, 3], ["infection", "DISEASE", 64, 73], ["PTX", "CHEMICAL", 0, 3], ["PTX", "SIMPLE_CHEMICAL", 0, 3], ["cell", "CELL", 26, 30], ["PTX production", "PROBLEM", 0, 14], ["various cell types", "PROBLEM", 18, 36], ["microbial infection", "PROBLEM", 54, 73], ["various cell types", "OBSERVATION", 18, 36]]], ["PTX are normally stored in blood cells such as neutrophils ready to be released after challenge with the bacterial or viral pathogen [15] .", [["blood cells", "ANATOMY", 27, 38], ["neutrophils", "ANATOMY", 47, 58], ["PTX", "CHEMICAL", 0, 3], ["PTX", "CHEMICAL", 0, 3], ["PTX", "SIMPLE_CHEMICAL", 0, 3], ["blood cells", "CELL", 27, 38], ["neutrophils", "CELL", 47, 58], ["blood cells", "CELL_TYPE", 27, 38], ["neutrophils", "CELL_TYPE", 47, 58], ["PTX", "PROBLEM", 0, 3], ["blood cells", "TEST", 27, 38], ["the bacterial or viral pathogen", "PROBLEM", 101, 132]]], ["Pentraxin 3 (PTX3) is regarded as the most prominent member of the pentraxin superfamily, with dramatic increase in blood levels upon bacterial and viral infections [13, 16] .", [["blood", "ANATOMY", 116, 121], ["bacterial and viral infections", "DISEASE", 134, 164], ["Pentraxin 3", "GENE_OR_GENE_PRODUCT", 0, 11], ["PTX3", "GENE_OR_GENE_PRODUCT", 13, 17], ["pentraxin", "GENE_OR_GENE_PRODUCT", 67, 76], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["Pentraxin 3", "PROTEIN", 0, 11], ["PTX3", "PROTEIN", 13, 17], ["pentraxin superfamily", "PROTEIN", 67, 88], ["Pentraxin", "TREATMENT", 0, 9], ["the pentraxin superfamily", "TREATMENT", 63, 88], ["dramatic increase in blood levels", "PROBLEM", 95, 128], ["bacterial and viral infections", "PROBLEM", 134, 164], ["dramatic", "OBSERVATION_MODIFIER", 95, 103], ["increase", "OBSERVATION_MODIFIER", 104, 112], ["bacterial", "OBSERVATION_MODIFIER", 134, 143], ["viral infections", "OBSERVATION", 148, 164]]], ["PTX3 is involved in a number of functions in immunity and inflammation [17] .Pentraxins, c-reactive proteins and serum amyloid proteins.", [["serum", "ANATOMY", 113, 118], ["inflammation", "DISEASE", 58, 70], ["Pentraxins", "CHEMICAL", 77, 87], ["PTX3", "GENE_OR_GENE_PRODUCT", 0, 4], ["Pentraxins", "GENE_OR_GENE_PRODUCT", 77, 87], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["amyloid", "GENE_OR_GENE_PRODUCT", 119, 126], ["PTX3", "PROTEIN", 0, 4], ["Pentraxins", "PROTEIN", 77, 87], ["c-reactive proteins", "PROTEIN", 89, 108], ["serum amyloid proteins", "PROTEIN", 113, 135], ["PTX3", "PROBLEM", 0, 4], ["inflammation", "PROBLEM", 58, 70], ["Pentraxins", "TREATMENT", 77, 87], ["c-reactive proteins", "TEST", 89, 108], ["serum amyloid proteins", "TEST", 113, 135], ["number", "OBSERVATION_MODIFIER", 22, 28]]], ["The basicsSeveral aspects of the APP regarding to inflammation-related disorders have been reviewed by others [3, 11, 13, 18, 19] .", [["inflammation", "DISEASE", 50, 62], ["APP", "GENE_OR_GENE_PRODUCT", 33, 36], ["APP", "PROTEIN", 33, 36], ["inflammation", "PROBLEM", 50, 62], ["related disorders", "PROBLEM", 63, 80], ["inflammation", "OBSERVATION", 50, 62]]], ["Here the focus will be set on the response to invading viruses, discussing how the presence of APP in blood and other specific tissues may be altered after viral infection, in association with an enhancement of the host innate immune response.", [["blood", "ANATOMY", 102, 107], ["tissues", "ANATOMY", 127, 134], ["viral infection", "DISEASE", 156, 171], ["APP", "GENE_OR_GENE_PRODUCT", 95, 98], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["tissues", "TISSUE", 127, 134], ["APP", "PROTEIN", 95, 98], ["invading viruses", "PROBLEM", 46, 62], ["APP in blood and other specific tissues", "PROBLEM", 95, 134], ["viral infection", "PROBLEM", 156, 171], ["viral", "OBSERVATION_MODIFIER", 156, 161], ["infection", "OBSERVATION", 162, 171], ["host innate immune response", "OBSERVATION", 215, 242]]], ["The differential modulation of CRP, PTX and SAP upon microbial challenge makes those proteins ideal markers for disease prognosis and discrimination between bacterial and viral etiology.", [["PTX", "CHEMICAL", 36, 39], ["PTX", "CHEMICAL", 36, 39], ["CRP", "GENE_OR_GENE_PRODUCT", 31, 34], ["PTX", "SIMPLE_CHEMICAL", 36, 39], ["SAP", "GENE_OR_GENE_PRODUCT", 44, 47], ["CRP", "PROTEIN", 31, 34], ["SAP", "PROTEIN", 44, 47], ["CRP", "TEST", 31, 34], ["PTX", "PROBLEM", 36, 39], ["SAP", "PROBLEM", 44, 47], ["microbial challenge", "TREATMENT", 53, 72], ["disease prognosis", "PROBLEM", 112, 129], ["bacterial", "PROBLEM", 157, 166], ["CRP", "OBSERVATION_MODIFIER", 31, 34], ["viral", "OBSERVATION_MODIFIER", 171, 176]]], ["Furthermore, changes in APP expression after the administration of antiviral drugs and vaccines have been observed, suggesting the possible use of APP as reporters of the efficacy of antiviral treatments.Pentraxins, c-reactive proteins and serum amyloid proteins.", [["serum", "ANATOMY", 240, 245], ["Pentraxins", "CHEMICAL", 204, 214], ["APP", "GENE_OR_GENE_PRODUCT", 24, 27], ["APP", "GENE_OR_GENE_PRODUCT", 147, 150], ["Pentraxins", "GENE_OR_GENE_PRODUCT", 204, 214], ["serum", "ORGANISM_SUBSTANCE", 240, 245], ["amyloid", "GENE_OR_GENE_PRODUCT", 246, 253], ["APP", "PROTEIN", 24, 27], ["APP", "PROTEIN", 147, 150], ["Pentraxins", "PROTEIN", 204, 214], ["c-reactive proteins", "PROTEIN", 216, 235], ["serum amyloid proteins", "PROTEIN", 240, 262], ["antiviral drugs", "TREATMENT", 67, 82], ["vaccines", "TREATMENT", 87, 95], ["antiviral treatments", "TREATMENT", 183, 203], ["Pentraxins", "TREATMENT", 204, 214], ["c-reactive proteins", "TEST", 216, 235], ["serum amyloid proteins", "TEST", 240, 262]]], ["The basicsin virus-infected organisms.", [["basicsin virus", "ORGANISM", 4, 18], ["The basicsin virus", "TEST", 0, 18], ["infected organisms", "PROBLEM", 19, 37], ["infected organisms", "OBSERVATION", 19, 37]]], ["Representative examples of APP modulation during virus infection have been summarized in Table 1 .Influenza and other respiratory virusesConsistent correlations between disease progression and elevated levels of APP have been reported In viral diseases affecting the respiratory tract.", [["respiratory tract", "ANATOMY", 267, 284], ["infection", "DISEASE", 55, 64], ["Influenza", "DISEASE", 98, 107], ["respiratory viruses", "DISEASE", 118, 137], ["viral diseases affecting the respiratory tract", "DISEASE", 238, 284], ["APP", "GENE_OR_GENE_PRODUCT", 27, 30], ["APP", "GENE_OR_GENE_PRODUCT", 212, 215], ["respiratory tract", "ORGANISM_SUBDIVISION", 267, 284], ["APP", "PROTEIN", 27, 30], ["APP", "PROTEIN", 212, 215], ["Influenza", "SPECIES", 98, 107], ["APP modulation", "PROBLEM", 27, 41], ["virus infection", "PROBLEM", 49, 64], ["Influenza", "PROBLEM", 98, 107], ["other respiratory viruses", "PROBLEM", 112, 137], ["disease progression", "PROBLEM", 169, 188], ["elevated levels of APP", "PROBLEM", 193, 215], ["viral diseases affecting the respiratory tract", "PROBLEM", 238, 284], ["respiratory viruses", "OBSERVATION", 118, 137], ["viral diseases", "OBSERVATION", 238, 252], ["respiratory tract", "ANATOMY", 267, 284]]], ["Increased APP concentrations in serum of organisms infected with viruses causing respiratory illness can reach the hundredsthousand-fold over healthy samples [27] .", [["serum", "ANATOMY", 32, 37], ["respiratory", "ANATOMY", 81, 92], ["samples", "ANATOMY", 150, 157], ["respiratory illness", "DISEASE", 81, 100], ["APP", "GENE_OR_GENE_PRODUCT", 10, 13], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["APP", "PROTEIN", 10, 13], ["Increased APP concentrations in serum of organisms", "PROBLEM", 0, 50], ["viruses", "PROBLEM", 65, 72], ["respiratory illness", "PROBLEM", 81, 100], ["concentrations", "OBSERVATION_MODIFIER", 14, 28]]], ["Increased levels of CRP have been found in patients infected with the most virulent types of influenza A virus.", [["influenza A virus", "DISEASE", 93, 110], ["CRP", "GENE_OR_GENE_PRODUCT", 20, 23], ["patients", "ORGANISM", 43, 51], ["influenza A virus", "ORGANISM", 93, 110], ["CRP", "PROTEIN", 20, 23], ["patients", "SPECIES", 43, 51], ["influenza A virus", "SPECIES", 93, 110], ["influenza A virus", "SPECIES", 93, 110], ["Increased levels of CRP", "PROBLEM", 0, 23], ["influenza A virus", "PROBLEM", 93, 110], ["infected", "OBSERVATION", 52, 60], ["most virulent", "OBSERVATION_MODIFIER", 70, 83], ["influenza", "OBSERVATION", 93, 102]]], ["Thus, human influenza disease outcome has been associated with enhanced production of CRP, with the highest CRP levels correlating with the more severe symptoms and even mortality [20, 21, 24] .", [["influenza disease", "DISEASE", 12, 29], ["human", "ORGANISM", 6, 11], ["CRP", "GENE_OR_GENE_PRODUCT", 86, 89], ["CRP", "GENE_OR_GENE_PRODUCT", 108, 111], ["CRP", "PROTEIN", 86, 89], ["CRP", "PROTEIN", 108, 111], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 6, 11], ["human influenza disease outcome", "PROBLEM", 6, 37], ["enhanced production of CRP", "PROBLEM", 63, 89], ["the highest CRP levels", "TEST", 96, 118], ["the more severe symptoms", "PROBLEM", 136, 160], ["influenza", "OBSERVATION", 12, 21]]], ["CRP induction may vary amongst different avian influenza A virus subtypes: H7N9 is a more powerful inductor of CRP and cytokine production than the H1N1 subtype [23] .", [["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["avian", "ORGANISM", 41, 46], ["influenza A virus", "ORGANISM", 47, 64], ["H7N9", "ORGANISM", 75, 79], ["CRP", "GENE_OR_GENE_PRODUCT", 111, 114], ["CRP", "PROTEIN", 0, 3], ["CRP", "PROTEIN", 111, 114], ["cytokine", "PROTEIN", 119, 127], ["avian influenza A virus", "SPECIES", 41, 64], ["A virus", "SPECIES", 57, 64], ["H7N9", "SPECIES", 75, 79], ["CRP induction", "TEST", 0, 13], ["H7N9", "PROBLEM", 75, 79], ["CRP", "TEST", 111, 114], ["cytokine production", "PROBLEM", 119, 138], ["the H1N1 subtype", "PROBLEM", 144, 160]]], ["In fact, the highly pathogenic influenza A H7N9 subtype induces high serum levels of CRP that are associated with a fatal clinical outcome [22] .Influenza and other respiratory virusesPTX3 has shown good correlation with the duration of fever in children with respiratory tract infection [29] , although it does not seem that PTX3 by its own could be regarded as a good reference for confirming a viral cause.", [["serum", "ANATOMY", 69, 74], ["respiratory tract", "ANATOMY", 260, 277], ["Influenza", "DISEASE", 145, 154], ["fever", "DISEASE", 237, 242], ["respiratory tract infection", "DISEASE", 260, 287], ["influenza A H7N9", "ORGANISM", 31, 47], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["CRP", "GENE_OR_GENE_PRODUCT", 85, 88], ["children", "ORGANISM", 246, 254], ["respiratory tract", "ORGANISM", 260, 277], ["PTX3", "GENE_OR_GENE_PRODUCT", 326, 330], ["CRP", "PROTEIN", 85, 88], ["PTX3", "PROTEIN", 326, 330], ["influenza A H7N9", "SPECIES", 31, 47], ["Influenza", "SPECIES", 145, 154], ["children", "SPECIES", 246, 254], ["the highly pathogenic influenza A H7N9 subtype", "PROBLEM", 9, 55], ["high serum levels of CRP", "PROBLEM", 64, 88], ["a fatal clinical outcome", "PROBLEM", 114, 138], ["Influenza", "PROBLEM", 145, 154], ["other respiratory virusesPTX3", "TEST", 159, 188], ["fever", "PROBLEM", 237, 242], ["respiratory tract infection", "PROBLEM", 260, 287], ["a viral cause", "PROBLEM", 395, 408], ["highly", "OBSERVATION_MODIFIER", 13, 19], ["pathogenic", "OBSERVATION_MODIFIER", 20, 30], ["influenza", "OBSERVATION", 31, 40], ["respiratory tract", "ANATOMY", 260, 277]]], ["In a recent study, a combined data analysis of CRP, SAA and PTX3 became the best predictor of severe respiratory disease in hospitalized children [57] .Influenza and other respiratory virusesIn influenza virus infected mice SAA concentration in serum rises several-hundred fold in three days [27] .", [["respiratory", "ANATOMY", 101, 112], ["serum", "ANATOMY", 245, 250], ["respiratory disease", "DISEASE", 101, 120], ["Influenza", "DISEASE", 152, 161], ["respiratory viruses", "DISEASE", 172, 191], ["influenza virus infected", "DISEASE", 194, 218], ["CRP", "GENE_OR_GENE_PRODUCT", 47, 50], ["SAA", "GENE_OR_GENE_PRODUCT", 52, 55], ["PTX3", "GENE_OR_GENE_PRODUCT", 60, 64], ["children", "ORGANISM", 137, 145], ["influenza virus", "ORGANISM", 194, 209], ["mice", "ORGANISM", 219, 223], ["SAA", "GENE_OR_GENE_PRODUCT", 224, 227], ["serum", "ORGANISM_SUBSTANCE", 245, 250], ["CRP", "PROTEIN", 47, 50], ["SAA", "PROTEIN", 52, 55], ["PTX3", "PROTEIN", 60, 64], ["SAA", "PROTEIN", 224, 227], ["children", "SPECIES", 137, 145], ["Influenza", "SPECIES", 152, 161], ["influenza virus", "SPECIES", 194, 209], ["mice", "SPECIES", 219, 223], ["mice", "SPECIES", 219, 223], ["a recent study", "TEST", 3, 17], ["a combined data analysis", "TEST", 19, 43], ["CRP", "TEST", 47, 50], ["SAA", "TEST", 52, 55], ["severe respiratory disease", "PROBLEM", 94, 120], ["Influenza", "PROBLEM", 152, 161], ["other respiratory viruses", "PROBLEM", 166, 191], ["influenza virus infected", "PROBLEM", 194, 218], ["SAA concentration", "TEST", 224, 241], ["serum rises", "TEST", 245, 256], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["respiratory disease", "OBSERVATION", 101, 120], ["respiratory viruses", "OBSERVATION", 172, 191], ["influenza virus", "OBSERVATION", 194, 209]]], ["In other species changes in acute phase protein levels are not so dramatic: CRP and SAA increments of 3-fold and 20-fold, respectively, have been reported in pigs infected with swine influenza [33, 58] .", [["swine influenza", "DISEASE", 177, 192], ["CRP", "GENE_OR_GENE_PRODUCT", 76, 79], ["SAA", "GENE_OR_GENE_PRODUCT", 84, 87], ["pigs", "ORGANISM", 158, 162], ["swine influenza", "ORGANISM", 177, 192], ["CRP", "PROTEIN", 76, 79], ["SAA", "PROTEIN", 84, 87], ["pigs", "SPECIES", 158, 162], ["swine influenza", "SPECIES", 177, 192], ["pigs", "SPECIES", 158, 162], ["swine", "SPECIES", 177, 182], ["acute phase protein levels", "TEST", 28, 54], ["CRP", "TEST", 76, 79], ["SAA increments", "TEST", 84, 98], ["species", "OBSERVATION", 9, 16], ["acute", "OBSERVATION_MODIFIER", 28, 33]]], ["Overall, there is a good correlation between severity of disease and CRP serum concentrations after infection with swine influenza virus [58] .", [["serum", "ANATOMY", 73, 78], ["infection", "DISEASE", 100, 109], ["swine influenza virus", "DISEASE", 115, 136], ["CRP", "GENE_OR_GENE_PRODUCT", 69, 72], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["swine influenza virus", "ORGANISM", 115, 136], ["CRP", "PROTEIN", 69, 72], ["swine influenza virus", "SPECIES", 115, 136], ["swine influenza virus", "SPECIES", 115, 136], ["disease", "PROBLEM", 57, 64], ["CRP serum concentrations", "PROBLEM", 69, 93], ["infection", "PROBLEM", 100, 109], ["swine influenza virus", "PROBLEM", 115, 136], ["good", "OBSERVATION_MODIFIER", 20, 24], ["disease", "OBSERVATION", 57, 64]]], ["SAA was demonstrated to be a useful reporter of disease development in pigs co-infected with viral and bacterial pathogens [59] .", [["viral and bacterial pathogens", "DISEASE", 93, 122], ["SAA", "GENE_OR_GENE_PRODUCT", 0, 3], ["pigs", "ORGANISM", 71, 75], ["SAA", "PROTEIN", 0, 3], ["pigs", "SPECIES", 71, 75], ["pigs", "SPECIES", 71, 75], ["disease development", "PROBLEM", 48, 67], ["viral and bacterial pathogens", "PROBLEM", 93, 122], ["disease", "OBSERVATION", 48, 55], ["bacterial", "OBSERVATION_MODIFIER", 103, 112]]], ["In particular, SAA serum levels appear to be the best indicators of disease progression in swine influenza cases [32] .Influenza and other respiratory virusesThe infection of the respiratory tract may trigger the up-regulation of APP expression in lungs and bronchi.", [["serum", "ANATOMY", 19, 24], ["respiratory tract", "ANATOMY", 179, 196], ["lungs", "ANATOMY", 248, 253], ["bronchi", "ANATOMY", 258, 265], ["influenza", "DISEASE", 97, 106], ["Influenza", "DISEASE", 119, 128], ["respiratory viruses", "DISEASE", 139, 158], ["infection of the respiratory tract", "DISEASE", 162, 196], ["SAA", "GENE_OR_GENE_PRODUCT", 15, 18], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["respiratory tract", "ORGANISM_SUBDIVISION", 179, 196], ["APP", "GENE_OR_GENE_PRODUCT", 230, 233], ["lungs", "ORGAN", 248, 253], ["bronchi", "MULTI-TISSUE_STRUCTURE", 258, 265], ["SAA", "PROTEIN", 15, 18], ["APP", "PROTEIN", 230, 233], ["swine", "SPECIES", 91, 96], ["Influenza", "SPECIES", 119, 128], ["swine", "SPECIES", 91, 96], ["SAA serum levels", "TEST", 15, 31], ["disease progression in swine influenza cases", "PROBLEM", 68, 112], ["Influenza", "PROBLEM", 119, 128], ["other respiratory viruses", "PROBLEM", 133, 158], ["The infection of the respiratory tract", "PROBLEM", 158, 196], ["APP expression in lungs and bronchi", "PROBLEM", 230, 265], ["disease", "OBSERVATION", 68, 75], ["respiratory viruses", "OBSERVATION", 139, 158], ["infection", "OBSERVATION", 162, 171], ["respiratory tract", "ANATOMY", 179, 196], ["up-regulation", "OBSERVATION_MODIFIER", 213, 226], ["lungs", "ANATOMY", 248, 253], ["bronchi", "ANATOMY", 258, 265]]], ["Such extrahepatic upregulation of SAA has also been reported in porcine reproductive and respiratory syndrome virus (PRRSV)-infected pig, particularly in the lungs [35] .", [["extrahepatic", "ANATOMY", 5, 17], ["lungs", "ANATOMY", 158, 163], ["porcine reproductive and respiratory syndrome virus (PRRSV)-infected", "DISEASE", 64, 132], ["extrahepatic", "MULTI-TISSUE_STRUCTURE", 5, 17], ["SAA", "GENE_OR_GENE_PRODUCT", 34, 37], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 64, 115], ["PRRSV", "ORGANISM", 117, 122], ["pig", "ORGANISM", 133, 136], ["lungs", "ORGAN", 158, 163], ["SAA", "PROTEIN", 34, 37], ["PRRSV", "SPECIES", 117, 122], ["pig", "SPECIES", 133, 136], ["PRRSV", "SPECIES", 117, 122], ["pig", "SPECIES", 133, 136], ["Such extrahepatic upregulation of SAA", "PROBLEM", 0, 37], ["respiratory syndrome virus", "PROBLEM", 89, 115], ["infected pig", "PROBLEM", 124, 136], ["extrahepatic", "ANATOMY", 5, 17], ["upregulation", "OBSERVATION", 18, 30], ["SAA", "OBSERVATION", 34, 37], ["respiratory syndrome", "OBSERVATION", 89, 109], ["infected", "OBSERVATION_MODIFIER", 124, 132], ["pig", "OBSERVATION_MODIFIER", 133, 136], ["lungs", "ANATOMY", 158, 163]]], ["Infection with pandemic influenza viruses causes increased levels of SAA in other non-human hosts [26] .", [["influenza viruses", "DISEASE", 24, 41], ["SAA", "GENE_OR_GENE_PRODUCT", 69, 72], ["SAA", "PROTEIN", 69, 72], ["pandemic influenza viruses", "SPECIES", 15, 41], ["Infection", "PROBLEM", 0, 9], ["pandemic influenza viruses", "PROBLEM", 15, 41], ["increased levels of SAA", "PROBLEM", 49, 72], ["pandemic", "OBSERVATION_MODIFIER", 15, 23], ["influenza viruses", "OBSERVATION", 24, 41]]], ["SAA plays a part in the host response to equine influenza, with SAA concentrations peaking during the acute phase of the disease [34] , in good correlation with the appearance of clinical signs.", [["influenza", "DISEASE", 48, 57], ["SAA", "GENE_OR_GENE_PRODUCT", 0, 3], ["equine", "ORGANISM", 41, 47], ["SAA", "GENE_OR_GENE_PRODUCT", 64, 67], ["SAA", "PROTEIN", 0, 3], ["SAA", "PROTEIN", 64, 67], ["equine influenza", "PROBLEM", 41, 57], ["SAA concentrations", "PROBLEM", 64, 82], ["the disease", "PROBLEM", 117, 128], ["clinical signs", "TEST", 179, 193]]], ["This observation can be applied to veterinary practice where elevated concentrations of SAA may serve as a marker of respiratory viral infection in cattle [36, 37] .Persistent and latent viral infectionsA phenomenon termed acute phase response would be expected to develop in a different fashion in long term viral diseases compared to acute viral infections.", [["respiratory viral infection", "DISEASE", 117, 144], ["viral infections", "DISEASE", 187, 203], ["viral diseases", "DISEASE", 309, 323], ["viral infections", "DISEASE", 342, 358], ["SAA", "GENE_OR_GENE_PRODUCT", 88, 91], ["SAA", "PROTEIN", 88, 91], ["cattle", "SPECIES", 148, 154], ["cattle", "SPECIES", 148, 154], ["elevated concentrations of SAA", "PROBLEM", 61, 91], ["respiratory viral infection", "PROBLEM", 117, 144], ["Persistent and latent viral infections", "PROBLEM", 165, 203], ["A phenomenon termed acute phase response", "PROBLEM", 203, 243], ["long term viral diseases", "PROBLEM", 299, 323], ["acute viral infections", "PROBLEM", 336, 358], ["latent", "OBSERVATION_MODIFIER", 180, 186], ["viral", "OBSERVATION_MODIFIER", 187, 192], ["infections", "OBSERVATION", 193, 203], ["acute", "OBSERVATION_MODIFIER", 223, 228], ["phase", "OBSERVATION_MODIFIER", 229, 234], ["long term", "OBSERVATION_MODIFIER", 299, 308], ["viral diseases", "OBSERVATION", 309, 323], ["acute", "OBSERVATION_MODIFIER", 336, 341], ["viral", "OBSERVATION_MODIFIER", 342, 347], ["infections", "OBSERVATION", 348, 358]]], ["Hepatitis are amongst the most prevalent chronic viral infections in humans.", [["Hepatitis", "DISEASE", 0, 9], ["viral infections", "DISEASE", 49, 65], ["humans", "ORGANISM", 69, 75], ["humans", "SPECIES", 69, 75], ["humans", "SPECIES", 69, 75], ["Hepatitis", "PROBLEM", 0, 9], ["chronic viral infections in humans", "PROBLEM", 41, 75], ["most prevalent", "OBSERVATION_MODIFIER", 26, 40], ["chronic", "OBSERVATION_MODIFIER", 41, 48], ["viral", "OBSERVATION_MODIFIER", 49, 54], ["infections", "OBSERVATION", 55, 65]]], ["Hepatitis B and C viruses target the liver, that is the main producer of CRP and serum amyloid proteins as discussed above [60] .", [["liver", "ANATOMY", 37, 42], ["serum", "ANATOMY", 81, 86], ["Hepatitis B", "DISEASE", 0, 11], ["Hepatitis B and C viruses", "ORGANISM", 0, 25], ["liver", "ORGAN", 37, 42], ["CRP", "GENE_OR_GENE_PRODUCT", 73, 76], ["serum", "ORGANISM_SUBSTANCE", 81, 86], ["amyloid proteins", "GENE_OR_GENE_PRODUCT", 87, 103], ["CRP", "PROTEIN", 73, 76], ["serum amyloid proteins", "PROTEIN", 81, 103], ["Hepatitis B", "SPECIES", 0, 11], ["Hepatitis B and C viruses", "PROBLEM", 0, 25], ["CRP", "TEST", 73, 76], ["serum amyloid proteins", "TEST", 81, 103], ["liver", "ANATOMY", 37, 42]]], ["Thus, it is not surprising that patients undergoing chronic hepatitis C infection showed higher levels of CRPs than healthy individuals [40] .", [["chronic hepatitis C infection", "DISEASE", 52, 81], ["patients", "ORGANISM", 32, 40], ["chronic hepatitis C", "ORGANISM", 52, 71], ["CRPs", "GENE_OR_GENE_PRODUCT", 106, 110], ["CRPs", "PROTEIN", 106, 110], ["patients", "SPECIES", 32, 40], ["chronic hepatitis C infection", "PROBLEM", 52, 81], ["higher levels of CRPs", "PROBLEM", 89, 110], ["chronic", "OBSERVATION_MODIFIER", 52, 59], ["hepatitis", "OBSERVATION", 60, 69]]], ["Similarly, high levels of CRP have been reported in chronic hepatitis B patients in association to liver damage [38, 39] .", [["liver", "ANATOMY", 99, 104], ["chronic hepatitis B", "DISEASE", 52, 71], ["liver damage", "DISEASE", 99, 111], ["CRP", "GENE_OR_GENE_PRODUCT", 26, 29], ["hepatitis B", "ORGANISM", 60, 71], ["patients", "ORGANISM", 72, 80], ["liver", "ORGAN", 99, 104], ["CRP", "PROTEIN", 26, 29], ["patients", "SPECIES", 72, 80], ["hepatitis B", "SPECIES", 60, 71], ["high levels of CRP", "PROBLEM", 11, 29], ["chronic hepatitis B patients", "PROBLEM", 52, 80], ["liver damage", "PROBLEM", 99, 111], ["high", "OBSERVATION_MODIFIER", 11, 15], ["chronic", "OBSERVATION_MODIFIER", 52, 59], ["hepatitis", "OBSERVATION", 60, 69], ["liver", "ANATOMY", 99, 104]]], ["In fact, CRP is considered to be a useful predictor of mortality in hepatitis B infected individuals suffering from cirrhosis [61] .", [["hepatitis B infected", "DISEASE", 68, 88], ["cirrhosis", "DISEASE", 116, 125], ["CRP", "GENE_OR_GENE_PRODUCT", 9, 12], ["hepatitis B", "ORGANISM", 68, 79], ["CRP", "PROTEIN", 9, 12], ["hepatitis B", "SPECIES", 68, 79], ["CRP", "TEST", 9, 12], ["hepatitis B infected individuals", "PROBLEM", 68, 100], ["cirrhosis", "PROBLEM", 116, 125], ["hepatitis", "OBSERVATION", 68, 77], ["cirrhosis", "OBSERVATION", 116, 125]]], ["In the same way, elevated plasma levels of PTX3 are considered to be a risk factor of developing liver carcinoma in HCV patients [41] .Persistent and latent viral infectionsRetroviruses such as human immunodeficiency virus (HIV) have a well-known capacity for establishing long lasting infections in the body [62] .", [["plasma", "ANATOMY", 26, 32], ["liver carcinoma", "ANATOMY", 97, 112], ["body", "ANATOMY", 304, 308], ["liver carcinoma", "DISEASE", 97, 112], ["HCV", "DISEASE", 116, 119], ["viral infections", "DISEASE", 157, 173], ["human immunodeficiency virus (HIV)", "DISEASE", 194, 228], ["infections", "DISEASE", 286, 296], ["plasma", "ORGANISM_SUBSTANCE", 26, 32], ["PTX3", "GENE_OR_GENE_PRODUCT", 43, 47], ["liver carcinoma", "CANCER", 97, 112], ["HCV", "ORGANISM", 116, 119], ["patients", "ORGANISM", 120, 128], ["Retroviruses", "ORGANISM", 173, 185], ["human immunodeficiency virus", "ORGANISM", 194, 222], ["HIV", "ORGANISM", 224, 227], ["body", "ORGANISM_SUBDIVISION", 304, 308], ["PTX3", "PROTEIN", 43, 47], ["patients", "SPECIES", 120, 128], ["human immunodeficiency virus (HIV", "SPECIES", 194, 227], ["HCV", "SPECIES", 116, 119], ["human immunodeficiency virus", "SPECIES", 194, 222], ["HIV", "SPECIES", 224, 227], ["elevated plasma levels", "PROBLEM", 17, 39], ["PTX3", "PROBLEM", 43, 47], ["developing liver carcinoma", "PROBLEM", 86, 112], ["Persistent and latent viral infectionsRetroviruses", "PROBLEM", 135, 185], ["human immunodeficiency virus", "PROBLEM", 194, 222], ["a well-known capacity", "PROBLEM", 234, 255], ["long lasting infections in the body", "PROBLEM", 273, 308], ["elevated", "OBSERVATION", 17, 25], ["liver", "ANATOMY", 97, 102], ["carcinoma", "OBSERVATION", 103, 112], ["latent", "OBSERVATION_MODIFIER", 150, 156], ["viral", "OBSERVATION_MODIFIER", 157, 162], ["infections", "OBSERVATION", 163, 173], ["long lasting", "OBSERVATION_MODIFIER", 273, 285], ["infections", "OBSERVATION", 286, 296], ["body", "ANATOMY", 304, 308]]], ["HIV-exposed infants show elevated CRP levels and other inflammatory markers like interleukin 6 (il6) [44] .", [["HIV", "ORGANISM", 0, 3], ["infants", "ORGANISM", 12, 19], ["CRP", "GENE_OR_GENE_PRODUCT", 34, 37], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 81, 94], ["il6", "GENE_OR_GENE_PRODUCT", 96, 99], ["CRP", "PROTEIN", 34, 37], ["inflammatory markers", "PROTEIN", 55, 75], ["interleukin 6", "PROTEIN", 81, 94], ["il6", "PROTEIN", 96, 99], ["HIV", "SPECIES", 0, 3], ["infants", "SPECIES", 12, 19], ["HIV", "SPECIES", 0, 3], ["HIV", "PROBLEM", 0, 3], ["elevated CRP levels", "PROBLEM", 25, 44], ["other inflammatory markers", "PROBLEM", 49, 75], ["interleukin", "TEST", 81, 92], ["elevated", "OBSERVATION_MODIFIER", 25, 33], ["CRP levels", "OBSERVATION_MODIFIER", 34, 44], ["inflammatory", "OBSERVATION_MODIFIER", 55, 67]]], ["A persistently high level of CRP in patients receiving antiretroviral therapy is associated with disease progression and a higher probability of clinical failure [43, 45] .", [["CRP", "GENE_OR_GENE_PRODUCT", 29, 32], ["patients", "ORGANISM", 36, 44], ["CRP", "PROTEIN", 29, 32], ["patients", "SPECIES", 36, 44], ["A persistently high level of CRP", "PROBLEM", 0, 32], ["antiretroviral therapy", "TREATMENT", 55, 77], ["disease progression", "PROBLEM", 97, 116], ["clinical failure", "PROBLEM", 145, 161], ["persistently", "OBSERVATION_MODIFIER", 2, 14], ["high", "OBSERVATION_MODIFIER", 15, 19], ["failure", "OBSERVATION", 154, 161]]], ["This up-regulation of APP upon retrovirus infection has been reported in other species as well.", [["retrovirus infection", "DISEASE", 31, 51], ["APP", "GENE_OR_GENE_PRODUCT", 22, 25], ["retrovirus", "ORGANISM", 31, 41], ["APP", "PROTEIN", 22, 25], ["APP upon retrovirus infection", "PROBLEM", 22, 51], ["retrovirus infection", "OBSERVATION", 31, 51]]], ["In feline immunodeficiency virus (FIV)-infected cats determination of SAP concentrations in plasma is complementary to the measurements of viral RNA levels when predicting disease progression [46] .Persistent and latent viral infectionsMany viruses are known to persist in the host's nervous system [55, 56] where they establish a latent infection.", [["plasma", "ANATOMY", 92, 98], ["nervous system", "ANATOMY", 284, 298], ["feline immunodeficiency virus (FIV)-infected", "DISEASE", 3, 47], ["viral infections", "DISEASE", 220, 236], ["infection", "DISEASE", 338, 347], ["feline immunodeficiency virus", "ORGANISM", 3, 32], ["FIV", "ORGANISM", 34, 37], ["cats", "ORGANISM", 48, 52], ["SAP", "GENE_OR_GENE_PRODUCT", 70, 73], ["plasma", "ORGANISM_SUBSTANCE", 92, 98], ["nervous system", "ANATOMICAL_SYSTEM", 284, 298], ["SAP", "PROTEIN", 70, 73], ["viral RNA", "RNA", 139, 148], ["feline immunodeficiency virus", "SPECIES", 3, 32], ["cats", "SPECIES", 48, 52], ["feline immunodeficiency virus", "SPECIES", 3, 32], ["FIV", "SPECIES", 34, 37], ["feline immunodeficiency virus", "PROBLEM", 3, 32], ["SAP concentrations in plasma", "PROBLEM", 70, 98], ["viral RNA levels", "TEST", 139, 155], ["predicting disease progression", "PROBLEM", 161, 191], ["Persistent and latent viral infections", "PROBLEM", 198, 236], ["Many viruses", "PROBLEM", 236, 248], ["a latent infection", "PROBLEM", 329, 347], ["feline immunodeficiency virus", "OBSERVATION", 3, 32], ["viral RNA", "OBSERVATION", 139, 148], ["latent", "OBSERVATION_MODIFIER", 213, 219], ["viral", "OBSERVATION_MODIFIER", 220, 225], ["infections", "OBSERVATION", 226, 236], ["viruses", "OBSERVATION", 241, 248], ["latent", "OBSERVATION_MODIFIER", 331, 337], ["infection", "OBSERVATION", 338, 347]]], ["Aujeszky's disease (pseudorabies) is a pathology of pigs caused by a herpes virus resulting in neurological signs that can be fatal [63] .", [["neurological", "ANATOMY", 95, 107], ["Aujeszky's disease", "DISEASE", 0, 18], ["pseudorabies", "DISEASE", 20, 32], ["herpes virus", "DISEASE", 69, 81], ["neurological signs", "DISEASE", 95, 113], ["Aujeszky", "ORGANISM", 0, 8], ["pseudorabies", "ORGANISM", 20, 32], ["pigs", "ORGANISM", 52, 56], ["herpes virus", "ORGANISM", 69, 81], ["Aujeszky", "SPECIES", 0, 8], ["pseudorabies", "SPECIES", 20, 32], ["pigs", "SPECIES", 52, 56], ["herpes virus", "SPECIES", 69, 81], ["Aujeszky", "SPECIES", 0, 8], ["pseudorabies", "SPECIES", 20, 32], ["pigs", "SPECIES", 52, 56], ["herpes virus", "SPECIES", 69, 81], ["Aujeszky's disease", "PROBLEM", 0, 18], ["pseudorabies", "PROBLEM", 20, 32], ["a pathology of pigs", "PROBLEM", 37, 56], ["a herpes virus", "PROBLEM", 67, 81], ["neurological signs", "PROBLEM", 95, 113], ["disease", "OBSERVATION", 11, 18]]], ["The clinical outcome of pseudorabies virus infection in a mouse model is determined by the acute inflammatory response after infection, with high levels of CRP and il6 produced in several tissues [47] .Other viral infectionsA number of systemic infections are caused by arthropod-borne viruses with significant impact on human health.", [["tissues", "ANATOMY", 188, 195], ["pseudorabies virus infection", "DISEASE", 24, 52], ["infection", "DISEASE", 125, 134], ["viral infections", "DISEASE", 208, 224], ["systemic infections", "DISEASE", 236, 255], ["pseudorabies virus", "ORGANISM", 24, 42], ["mouse", "ORGANISM", 58, 63], ["CRP", "GENE_OR_GENE_PRODUCT", 156, 159], ["il6", "GENE_OR_GENE_PRODUCT", 164, 167], ["tissues", "TISSUE", 188, 195], ["human", "ORGANISM", 321, 326], ["CRP", "PROTEIN", 156, 159], ["il6", "PROTEIN", 164, 167], ["pseudorabies virus", "SPECIES", 24, 42], ["mouse", "SPECIES", 58, 63], ["human", "SPECIES", 321, 326], ["pseudorabies virus", "SPECIES", 24, 42], ["mouse", "SPECIES", 58, 63], ["human", "SPECIES", 321, 326], ["pseudorabies virus infection", "PROBLEM", 24, 52], ["the acute inflammatory response", "PROBLEM", 87, 118], ["infection", "PROBLEM", 125, 134], ["CRP", "TEST", 156, 159], ["Other viral infections", "PROBLEM", 202, 224], ["systemic infections", "PROBLEM", 236, 255], ["arthropod-borne viruses", "PROBLEM", 270, 293], ["pseudorabies virus infection", "OBSERVATION", 24, 52], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["inflammatory", "OBSERVATION_MODIFIER", 97, 109], ["infection", "OBSERVATION", 125, 134], ["viral", "OBSERVATION_MODIFIER", 208, 213], ["infections", "OBSERVATION", 214, 224], ["number", "OBSERVATION_MODIFIER", 226, 232], ["systemic", "OBSERVATION_MODIFIER", 236, 244], ["infections", "OBSERVATION", 245, 255]]], ["In severe hemorrhagic cases of dengue CRP levels are elevated as well as some inflammatory cytokines including il6 [48, 49, 64] .", [["hemorrhagic", "DISEASE", 10, 21], ["dengue", "DISEASE", 31, 37], ["CRP", "GENE_OR_GENE_PRODUCT", 38, 41], ["il6", "GENE_OR_GENE_PRODUCT", 111, 114], ["CRP", "PROTEIN", 38, 41], ["inflammatory cytokines", "PROTEIN", 78, 100], ["il6", "PROTEIN", 111, 114], ["dengue", "SPECIES", 31, 37], ["severe hemorrhagic cases", "PROBLEM", 3, 27], ["dengue CRP levels", "TEST", 31, 48], ["elevated", "PROBLEM", 53, 61], ["some inflammatory cytokines", "PROBLEM", 73, 100], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["hemorrhagic", "OBSERVATION_MODIFIER", 10, 21], ["dengue CRP", "OBSERVATION", 31, 41], ["elevated", "OBSERVATION_MODIFIER", 53, 61], ["some", "OBSERVATION_MODIFIER", 73, 77], ["inflammatory", "OBSERVATION_MODIFIER", 78, 90]]], ["However, other authors refer to PTX3 as a more reliable indicator of dengue disease severity [50] .", [["dengue", "DISEASE", 69, 75], ["PTX3", "GENE_OR_GENE_PRODUCT", 32, 36], ["PTX3", "PROTEIN", 32, 36], ["dengue", "SPECIES", 69, 75], ["dengue disease severity", "PROBLEM", 69, 92]]], ["The inflammatory response after chikungunya virus (CHIKV) infection is associated to higher amounts of PTX3 in patients [18] .", [["chikungunya virus (CHIKV) infection", "DISEASE", 32, 67], ["chikungunya virus", "ORGANISM", 32, 49], ["CHIKV", "ORGANISM", 51, 56], ["PTX3", "GENE_OR_GENE_PRODUCT", 103, 107], ["patients", "ORGANISM", 111, 119], ["PTX3", "PROTEIN", 103, 107], ["chikungunya virus (CHIKV", "SPECIES", 32, 56], ["patients", "SPECIES", 111, 119], ["chikungunya virus", "SPECIES", 32, 49], ["CHIKV", "SPECIES", 51, 56], ["The inflammatory response", "PROBLEM", 0, 25], ["chikungunya virus (CHIKV) infection", "PROBLEM", 32, 67], ["inflammatory", "OBSERVATION_MODIFIER", 4, 16], ["chikungunya virus", "OBSERVATION", 32, 49]]], ["In acute infections with rodent-borne hantaviruses, disease severity and duration of hospital stays can be inferred from high plasma levels of PTX3 and the appearance of hemorrhagic fever symptoms [51, 52] .Avian and fish virusesLike mammals, birds possess an innate immune system as the first barrier of defense against pathogens [65] .", [["plasma", "ANATOMY", 126, 132], ["infections", "DISEASE", 9, 19], ["rodent-borne hantaviruses", "DISEASE", 25, 50], ["hemorrhagic fever", "DISEASE", 170, 187], ["hantaviruses", "ORGANISM", 38, 50], ["plasma", "ORGANISM_SUBSTANCE", 126, 132], ["PTX3", "GENE_OR_GENE_PRODUCT", 143, 147], ["Avian", "ORGANISM", 207, 212], ["fish virusesLike mammals", "ORGANISM", 217, 241], ["birds", "ORGANISM", 243, 248], ["PTX3", "PROTEIN", 143, 147], ["rodent", "SPECIES", 25, 31], ["Avian", "SPECIES", 207, 212], ["acute infections", "PROBLEM", 3, 19], ["rodent-borne hantaviruses", "PROBLEM", 25, 50], ["disease severity", "PROBLEM", 52, 68], ["high plasma levels of PTX3", "PROBLEM", 121, 147], ["hemorrhagic fever symptoms", "PROBLEM", 170, 196], ["an innate immune system", "TREATMENT", 257, 280], ["acute", "OBSERVATION_MODIFIER", 3, 8], ["infections", "OBSERVATION", 9, 19], ["hemorrhagic", "OBSERVATION_MODIFIER", 170, 181], ["fish viruses", "OBSERVATION", 217, 229]]], ["Therefore, birds are capable of mounting a rapid response upon viral infection [66] .", [["viral infection", "DISEASE", 63, 78], ["birds", "ORGANISM", 11, 16], ["viral infection", "PROBLEM", 63, 78], ["viral infection", "OBSERVATION", 63, 78]]], ["The magnitude of the response may vary among species: avian H5N1 influenza virus causes a rapid elevation of SAA levels in chicken but not in ducks [53] , which may explain the lesser mortality rates and less severe disease in ducks compared to chicken.", [["influenza virus", "DISEASE", 65, 80], ["avian H5N1 influenza virus", "ORGANISM", 54, 80], ["SAA", "GENE_OR_GENE_PRODUCT", 109, 112], ["chicken", "ORGANISM", 123, 130], ["ducks", "ORGANISM", 142, 147], ["ducks", "ORGANISM", 227, 232], ["chicken", "ORGANISM", 245, 252], ["SAA", "PROTEIN", 109, 112], ["avian H5N1 influenza virus", "SPECIES", 54, 80], ["chicken", "SPECIES", 123, 130], ["ducks", "SPECIES", 142, 147], ["ducks", "SPECIES", 227, 232], ["chicken", "SPECIES", 245, 252], ["H5N1 influenza virus", "SPECIES", 60, 80], ["chicken", "SPECIES", 123, 130], ["ducks", "SPECIES", 227, 232], ["chicken", "SPECIES", 245, 252], ["avian H5N1 influenza virus", "PROBLEM", 54, 80], ["a rapid elevation of SAA levels", "PROBLEM", 88, 119], ["the lesser mortality rates", "PROBLEM", 173, 199], ["less severe disease in ducks", "PROBLEM", 204, 232], ["rapid", "OBSERVATION_MODIFIER", 90, 95], ["elevation", "OBSERVATION_MODIFIER", 96, 105], ["lesser", "OBSERVATION_MODIFIER", 177, 183], ["less", "OBSERVATION_MODIFIER", 204, 208], ["severe", "OBSERVATION_MODIFIER", 209, 215], ["disease", "OBSERVATION", 216, 223]]], ["Other viral pathogens of birds can also change APP patterns, like infectious bursal disease virus (IBDV) inducing a 20-fold increase change of PTX3 in infected chickens [54] .", [["infectious bursal disease", "DISEASE", 66, 91], ["IBDV", "DISEASE", 99, 103], ["birds", "ORGANISM", 25, 30], ["APP", "GENE_OR_GENE_PRODUCT", 47, 50], ["infectious bursal disease virus", "ORGANISM", 66, 97], ["IBDV", "ORGANISM", 99, 103], ["PTX3", "GENE_OR_GENE_PRODUCT", 143, 147], ["chickens", "ORGANISM", 160, 168], ["APP", "PROTEIN", 47, 50], ["PTX3", "PROTEIN", 143, 147], ["infectious bursal disease virus", "SPECIES", 66, 97], ["chickens", "SPECIES", 160, 168], ["infectious bursal disease virus", "SPECIES", 66, 97], ["IBDV", "SPECIES", 99, 103], ["chickens", "SPECIES", 160, 168], ["Other viral pathogens of birds", "PROBLEM", 0, 30], ["APP patterns", "TEST", 47, 59], ["infectious bursal disease virus", "PROBLEM", 66, 97], ["PTX3", "PROBLEM", 143, 147], ["infectious", "OBSERVATION_MODIFIER", 66, 76]]], ["The previous reports suggest that APP response to viral challenge is common in poultry.Avian and fish virusesWith a more primitive adaptive immunity, fish are considered to rely heavily on the innate immune response.", [["APP", "GENE_OR_GENE_PRODUCT", 34, 37], ["Avian", "ORGANISM", 87, 92], ["fish", "ORGANISM", 97, 101], ["fish", "ORGANISM", 150, 154], ["APP", "PROTEIN", 34, 37], ["Avian", "SPECIES", 87, 92], ["viral challenge", "TREATMENT", 50, 65]]], ["In fact, some of the APP like CRP are multigene families in fish [67] .", [["APP", "GENE_OR_GENE_PRODUCT", 21, 24], ["CRP", "GENE_OR_GENE_PRODUCT", 30, 33], ["APP", "PROTEIN", 21, 24], ["CRP", "PROTEIN", 30, 33], ["CRP", "TEST", 30, 33]]], ["Although our current knowledge of APP role in fish viral diseases is still limited, the relevance of CRP and SAA in various antimicrobial defense functions has been recognized [4, 68] .", [["viral diseases", "DISEASE", 51, 65], ["APP", "GENE_OR_GENE_PRODUCT", 34, 37], ["fish", "ORGANISM", 46, 50], ["CRP", "GENE_OR_GENE_PRODUCT", 101, 104], ["SAA", "GENE_OR_GENE_PRODUCT", 109, 112], ["APP", "PROTEIN", 34, 37], ["CRP", "PROTEIN", 101, 104], ["SAA", "PROTEIN", 109, 112], ["fish viral diseases", "PROBLEM", 46, 65], ["CRP", "TEST", 101, 104], ["SAA", "TEST", 109, 112]]], ["Two important viruses affecting fish farming, viral hemorrhagic septicemia virus (VHSV) and spring viremia of carp virus (SVCV) have been shown to alter crp gene expression in zebrafish where significant up-regulation of mRNA expression of crp gene isoforms has been observed in zebrafish 2 days after infection with VHSV and SVCV [55] .", [["viral hemorrhagic septicemia", "DISEASE", 46, 74], ["viremia", "DISEASE", 99, 106], ["infection", "DISEASE", 302, 311], ["fish", "ORGANISM_SUBDIVISION", 32, 36], ["viral hemorrhagic septicemia virus", "ORGANISM", 46, 80], ["VHSV", "ORGANISM", 82, 86], ["carp virus", "ORGANISM", 110, 120], ["crp", "GENE_OR_GENE_PRODUCT", 153, 156], ["zebrafish", "ORGANISM", 176, 185], ["crp", "GENE_OR_GENE_PRODUCT", 240, 243], ["zebrafish", "ORGANISM", 279, 288], ["VHSV", "ORGANISM", 317, 321], ["crp gene", "DNA", 153, 161], ["crp gene isoforms", "PROTEIN", 240, 257], ["viral hemorrhagic septicemia virus", "SPECIES", 46, 80], ["VHSV", "SPECIES", 82, 86], ["carp virus", "SPECIES", 110, 120], ["zebrafish", "SPECIES", 279, 288], ["VHSV", "SPECIES", 317, 321], ["viral hemorrhagic septicemia virus", "SPECIES", 46, 80], ["VHSV", "SPECIES", 82, 86], ["carp virus", "SPECIES", 110, 120], ["SVCV", "SPECIES", 122, 126], ["VHSV", "SPECIES", 317, 321], ["SVCV", "SPECIES", 326, 330], ["viral hemorrhagic septicemia virus", "PROBLEM", 46, 80], ["VHSV", "PROBLEM", 82, 86], ["spring viremia of carp virus", "PROBLEM", 92, 120], ["mRNA expression of crp gene isoforms", "PROBLEM", 221, 257], ["infection", "PROBLEM", 302, 311], ["VHSV", "PROBLEM", 317, 321], ["viruses", "OBSERVATION", 14, 21], ["viral", "OBSERVATION_MODIFIER", 46, 51], ["hemorrhagic", "OBSERVATION_MODIFIER", 52, 63], ["septicemia", "OBSERVATION", 64, 74], ["carp virus", "OBSERVATION", 110, 120]]], ["In parallel, the transcriptional activation of crp gene promoters by histone methylation was shown to increase from day 1 to day 5 postinfection with SVCV [69] .", [["crp", "GENE_OR_GENE_PRODUCT", 47, 50], ["histone", "GENE_OR_GENE_PRODUCT", 69, 76], ["crp gene promoters", "DNA", 47, 65], ["histone", "PROTEIN", 69, 76], ["SVCV", "SPECIES", 150, 154], ["crp gene promoters", "TREATMENT", 47, 65]]], ["At the protein level, proteomic analysis of blood from SVCV-infected zebrafish revealed a peak of isoforms crp2 and crp5 expression at 24 hpi, returning rapidly to basal levels [55] .", [["blood", "ANATOMY", 44, 49], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["SVCV", "GENE_OR_GENE_PRODUCT", 55, 59], ["zebrafish", "ORGANISM", 69, 78], ["crp2", "GENE_OR_GENE_PRODUCT", 107, 111], ["crp5", "GENE_OR_GENE_PRODUCT", 116, 120], ["crp2", "PROTEIN", 107, 111], ["crp5", "PROTEIN", 116, 120], ["zebrafish", "SPECIES", 69, 78], ["the protein level", "TEST", 3, 20], ["proteomic analysis", "TEST", 22, 40], ["blood", "TEST", 44, 49], ["SVCV", "TEST", 55, 59], ["infected zebrafish", "PROBLEM", 60, 78], ["a peak of isoforms crp2", "PROBLEM", 88, 111], ["basal levels", "TEST", 164, 176]]], ["A similar response has been observed in carp infected with the herpesvirus CyHV, with a peak of serum concentrations of CRP already at 24 hpi that declined after day 5 [70] .Avian and fish virusesRock bream SAP profiles are also modulated after iridovirus infection with a peak of SAP levels in the liver of infected fish detected at 3 days post-infection [71, 72] .", [["serum", "ANATOMY", 96, 101], ["liver", "ANATOMY", 299, 304], ["infection", "DISEASE", 256, 265], ["carp", "ORGANISM", 40, 44], ["herpesvirus", "ORGANISM", 63, 74], ["CyHV", "ORGANISM", 75, 79], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["CRP", "GENE_OR_GENE_PRODUCT", 120, 123], ["Avian", "ORGANISM", 174, 179], ["fish viruses", "ORGANISM", 184, 196], ["bream", "ORGANISM", 201, 206], ["SAP", "GENE_OR_GENE_PRODUCT", 207, 210], ["SAP", "GENE_OR_GENE_PRODUCT", 281, 284], ["liver", "ORGAN", 299, 304], ["fish", "ORGANISM", 317, 321], ["CRP", "PROTEIN", 120, 123], ["SAP", "PROTEIN", 207, 210], ["SAP", "PROTEIN", 281, 284], ["carp", "SPECIES", 40, 44], ["Avian", "SPECIES", 174, 179], ["Rock bream", "SPECIES", 196, 206], ["the herpesvirus CyHV", "PROBLEM", 59, 79], ["a peak of serum concentrations", "PROBLEM", 86, 116], ["CRP", "TEST", 120, 123], ["Rock bream SAP profiles", "TEST", 196, 219], ["iridovirus infection", "PROBLEM", 245, 265], ["SAP levels", "TEST", 281, 291], ["infected fish", "PROBLEM", 308, 321], ["carp", "OBSERVATION_MODIFIER", 40, 44], ["infected", "OBSERVATION", 45, 53], ["herpesvirus CyHV", "OBSERVATION", 63, 79], ["peak", "OBSERVATION_MODIFIER", 88, 92], ["fish viruses", "OBSERVATION", 184, 196], ["iridovirus", "OBSERVATION_MODIFIER", 245, 255], ["infection", "OBSERVATION", 256, 265], ["peak", "OBSERVATION_MODIFIER", 273, 277], ["SAP levels", "OBSERVATION", 281, 291], ["liver", "ANATOMY", 299, 304], ["infected fish", "OBSERVATION", 308, 321]]], ["Taken together, the aforementioned findings highlight the involvement of APP in a rapid antiviral response in teleost fish.Avian and fish virusesThe use of APP as therapeutic agents in fish is an attractive possibility supported by some experimental evidence.", [["APP", "GENE_OR_GENE_PRODUCT", 73, 76], ["teleost", "ORGANISM", 110, 117], ["fish", "ORGANISM_SUBDIVISION", 118, 122], ["Avian", "ORGANISM", 123, 128], ["fish viruses", "ORGANISM", 133, 145], ["APP", "GENE_OR_GENE_PRODUCT", 156, 159], ["fish", "ORGANISM", 185, 189], ["APP", "PROTEIN", 73, 76], ["APP", "PROTEIN", 156, 159], ["Avian", "SPECIES", 123, 128], ["APP as therapeutic agents", "TREATMENT", 156, 181], ["rapid", "OBSERVATION_MODIFIER", 82, 87], ["antiviral response", "OBSERVATION", 88, 106], ["fish viruses", "OBSERVATION", 133, 145]]], ["CRP and SAP have the potential to become wide range antimicrobial compounds, due to their ability to restrict bacterial and viral replication [55, 68] .", [["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["SAP", "GENE_OR_GENE_PRODUCT", 8, 11], ["CRP", "PROTEIN", 0, 3], ["SAP", "PROTEIN", 8, 11], ["CRP", "TEST", 0, 3], ["SAP", "PROBLEM", 8, 11], ["wide range antimicrobial compounds", "PROBLEM", 41, 75], ["bacterial and viral replication", "PROBLEM", 110, 141]]], ["The intraperitoneal administration of recombinant SAP has been shown to protect carp from iridovirus disease [68] .", [["intraperitoneal", "ANATOMY", 4, 19], ["iridovirus disease", "DISEASE", 90, 108], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 19], ["SAP", "GENE_OR_GENE_PRODUCT", 50, 53], ["carp", "ORGANISM", 80, 84], ["SAP", "PROTEIN", 50, 53], ["carp", "SPECIES", 80, 84], ["The intraperitoneal administration", "TREATMENT", 0, 34], ["recombinant SAP", "TREATMENT", 38, 53], ["iridovirus disease", "PROBLEM", 90, 108], ["intraperitoneal", "ANATOMY", 4, 19], ["iridovirus disease", "OBSERVATION", 90, 108]]], ["Whether the cost-efficacy of the therapeutic use of recombinant APP would meet the requirements of the fish farming industry is a matter of debate.APP response to vaccinationThe administration of antiviral vaccines can induce changes in the profile of pentraxins ( Table 2 ), but often the magnitude of the response is smaller than the response to the corresponding virus infection.", [["infection", "DISEASE", 372, 381], ["APP", "GENE_OR_GENE_PRODUCT", 64, 67], ["APP", "GENE_OR_GENE_PRODUCT", 147, 150], ["pentraxins", "GENE_OR_GENE_PRODUCT", 252, 262], ["Table 2", "GENE_OR_GENE_PRODUCT", 265, 272], ["recombinant APP", "PROTEIN", 52, 67], ["APP", "PROTEIN", 147, 150], ["pentraxins", "PROTEIN", 252, 262], ["recombinant APP", "TREATMENT", 52, 67], ["vaccination", "TREATMENT", 163, 174], ["antiviral vaccines", "TREATMENT", 196, 214], ["the corresponding virus infection", "PROBLEM", 348, 381], ["smaller", "OBSERVATION_MODIFIER", 319, 326], ["virus infection", "OBSERVATION", 366, 381]]], ["That is the case of the influenza virus vaccine where CRP response to vaccination is normally weak [77] .", [["influenza", "DISEASE", 24, 33], ["influenza virus", "ORGANISM", 24, 39], ["CRP", "GENE_OR_GENE_PRODUCT", 54, 57], ["CRP", "PROTEIN", 54, 57], ["influenza virus vaccine", "SPECIES", 24, 47], ["the influenza virus vaccine", "TREATMENT", 20, 47], ["CRP response", "TEST", 54, 66]]], ["Nevertheless, a number of studies have explored the potential of measuring the changes in APP levels to assess the protective efficacy of a given vaccine.", [["APP", "GENE_OR_GENE_PRODUCT", 90, 93], ["APP", "PROTEIN", 90, 93], ["APP levels", "TEST", 90, 100], ["a given vaccine", "TREATMENT", 138, 153]]], ["On this respect, it is important to note that the correlation between CRP levels and the efficacy of the vaccine may vary depending on host conditions, particularly age.", [["CRP", "GENE_OR_GENE_PRODUCT", 70, 73], ["CRP", "PROTEIN", 70, 73], ["CRP levels", "TEST", 70, 80], ["the vaccine", "TREATMENT", 101, 112]]], ["Elder patients respond to herpes zoster vaccination with lower levels of CRP, which has been taken as an indication of vaccine failure [74] .", [["herpes zoster", "DISEASE", 26, 39], ["patients", "ORGANISM", 6, 14], ["herpes zoster", "ORGANISM", 26, 39], ["CRP", "GENE_OR_GENE_PRODUCT", 73, 76], ["CRP", "PROTEIN", 73, 76], ["patients", "SPECIES", 6, 14], ["herpes zoster vaccination", "TREATMENT", 26, 51], ["CRP", "TEST", 73, 76], ["vaccine failure", "PROBLEM", 119, 134]]], ["A similar age-dependent behavior occurs in HIV-infected patients where inflammatory markers correlation with mortality is different among infants and adults [44] .", [["HIV-infected", "DISEASE", 43, 55], ["HIV", "ORGANISM", 43, 46], ["patients", "ORGANISM", 56, 64], ["infants", "ORGANISM", 138, 145], ["HIV", "SPECIES", 43, 46], ["patients", "SPECIES", 56, 64], ["infants", "SPECIES", 138, 145], ["HIV", "SPECIES", 43, 46], ["A similar age-dependent behavior", "PROBLEM", 0, 32], ["infected", "OBSERVATION_MODIFIER", 47, 55], ["inflammatory", "OBSERVATION_MODIFIER", 71, 83]]], ["Serum concentrations of CRP during HIV infection can be associated with viral loads and therefore with the efficacy of a therapeutic vaccine [78] .", [["Serum", "ANATOMY", 0, 5], ["HIV infection", "DISEASE", 35, 48], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["CRP", "GENE_OR_GENE_PRODUCT", 24, 27], ["HIV", "ORGANISM", 35, 38], ["CRP", "PROTEIN", 24, 27], ["HIV", "SPECIES", 35, 38], ["HIV", "SPECIES", 35, 38], ["Serum concentrations", "TEST", 0, 20], ["CRP", "TEST", 24, 27], ["HIV infection", "PROBLEM", 35, 48], ["viral loads", "PROBLEM", 72, 83], ["a therapeutic vaccine", "TREATMENT", 119, 140], ["infection", "OBSERVATION", 39, 48]]], ["A similar situation is observed in non-human species: the CRP response of mice to influenza virus vaccination is also affected by age, with neonatal mice showing higher CRP levels than adult individuals [25] .APP response to vaccinationAdjuvants are substances added to vaccines to boost the host immune response.", [["influenza", "DISEASE", 82, 91], ["CRP", "GENE_OR_GENE_PRODUCT", 58, 61], ["mice", "ORGANISM", 74, 78], ["influenza virus", "ORGANISM", 82, 97], ["mice", "ORGANISM", 149, 153], ["CRP", "GENE_OR_GENE_PRODUCT", 169, 172], ["APP", "GENE_OR_GENE_PRODUCT", 209, 212], ["CRP", "PROTEIN", 58, 61], ["CRP", "PROTEIN", 169, 172], ["APP", "PROTEIN", 209, 212], ["mice", "SPECIES", 74, 78], ["influenza virus", "SPECIES", 82, 97], ["mice", "SPECIES", 149, 153], ["mice", "SPECIES", 74, 78], ["influenza virus", "SPECIES", 82, 97], ["mice", "SPECIES", 149, 153], ["A similar situation", "PROBLEM", 0, 19], ["non-human species", "PROBLEM", 35, 52], ["the CRP", "TEST", 54, 61], ["influenza virus vaccination", "TREATMENT", 82, 109], ["higher CRP levels", "PROBLEM", 162, 179], ["vaccinationAdjuvants", "TREATMENT", 225, 245], ["vaccines", "TREATMENT", 270, 278]]], ["Thus, adjuvants may become important factors influencing the APP response to vaccination.", [["APP", "GENE_OR_GENE_PRODUCT", 61, 64], ["APP", "PROTEIN", 61, 64], ["adjuvants", "TREATMENT", 6, 15], ["vaccination", "TREATMENT", 77, 88]]], ["In rabbits, the responses associated with acute phase proteins can be either positive or negative depending of the vaccine/adjuvant combination [79] .", [["rabbits", "ORGANISM", 3, 10], ["acute phase proteins", "PROTEIN", 42, 62], ["rabbits", "SPECIES", 3, 10], ["rabbits", "SPECIES", 3, 10], ["acute phase proteins", "PROBLEM", 42, 62], ["the vaccine/adjuvant combination", "TREATMENT", 111, 143]]], ["In fact, some adjuvant formulations by their own can lead to a rapid increase of CRP levels (that later return to basal levels) after injection, which is considered a sign of acute inflammation caused by vaccination [75] .", [["inflammation", "DISEASE", 181, 193], ["CRP", "GENE_OR_GENE_PRODUCT", 81, 84], ["CRP", "PROTEIN", 81, 84], ["some adjuvant formulations", "TREATMENT", 9, 35], ["a rapid increase of CRP levels", "PROBLEM", 61, 91], ["injection", "TREATMENT", 134, 143], ["acute inflammation", "PROBLEM", 175, 193], ["rapid", "OBSERVATION_MODIFIER", 63, 68], ["increase", "OBSERVATION_MODIFIER", 69, 77], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["inflammation", "OBSERVATION", 181, 193]]], ["A commercial vaccine against two viral diseases of dogs (Nobivac \u00ae ) induced only a 2-fold increase in serum levels of CRP [73] that went in parallel to increasing antibody titers against canine distemper virus and canine parvovirus.", [["serum", "ANATOMY", 103, 108], ["viral diseases", "DISEASE", 33, 47], ["Nobivac \u00ae", "CHEMICAL", 57, 66], ["canine parvovirus", "DISEASE", 215, 232], ["dogs", "ORGANISM", 51, 55], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["CRP", "GENE_OR_GENE_PRODUCT", 119, 122], ["canine distemper virus", "ORGANISM", 188, 210], ["canine parvovirus", "ORGANISM", 215, 232], ["CRP", "PROTEIN", 119, 122], ["dogs", "SPECIES", 51, 55], ["canine distemper virus", "SPECIES", 188, 210], ["canine parvovirus", "SPECIES", 215, 232], ["canine distemper virus", "SPECIES", 188, 210], ["canine parvovirus", "SPECIES", 215, 232], ["A commercial vaccine", "TREATMENT", 0, 20], ["two viral diseases of dogs", "PROBLEM", 29, 55], ["a 2-fold increase", "PROBLEM", 82, 99], ["serum levels", "TEST", 103, 115], ["CRP", "TEST", 119, 122], ["increasing antibody titers", "PROBLEM", 153, 179], ["canine distemper virus", "PROBLEM", 188, 210], ["canine parvovirus", "PROBLEM", 215, 232], ["distemper virus", "OBSERVATION", 195, 210]]], ["The work of Romiszewski and colleagues suggested that CRP profiles could be a reliable measure of the efficacy of vaccines for dogs.APP response to vaccinationRegarding non-mammalian hosts, SAA has been proposed as a candidate marker of vaccine efficacy in poultry.", [["CRP", "GENE_OR_GENE_PRODUCT", 54, 57], ["dogs", "ORGANISM", 127, 131], ["APP", "GENE_OR_GENE_PRODUCT", 132, 135], ["SAA", "GENE_OR_GENE_PRODUCT", 190, 193], ["CRP", "PROTEIN", 54, 57], ["APP", "PROTEIN", 132, 135], ["SAA", "PROTEIN", 190, 193], ["dogs", "SPECIES", 127, 131], ["poultry", "SPECIES", 257, 264], ["CRP profiles", "TEST", 54, 66], ["vaccines", "TREATMENT", 114, 122], ["dogs", "PROBLEM", 127, 131], ["vaccination", "TREATMENT", 148, 159]]], ["Chickens vaccinated against Newcastle disease virus showed SAA increased \u22483-fold in correlation with higher antibody titers [76] .The antiviral activity of APPsAt present it is widely recognized the capacity of APP to limit viral replication and spread within the host, functioning as part of an early defense response before the induction of a specific antibody response against the pathogen.", [["Newcastle disease", "DISEASE", 28, 45], ["APPsAt", "CHEMICAL", 156, 162], ["Chickens", "ORGANISM", 0, 8], ["Newcastle disease virus", "ORGANISM", 28, 51], ["SAA", "GENE_OR_GENE_PRODUCT", 59, 62], ["APPsAt", "SIMPLE_CHEMICAL", 156, 162], ["APP", "GENE_OR_GENE_PRODUCT", 211, 214], ["SAA", "PROTEIN", 59, 62], ["APP", "PROTEIN", 211, 214], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["Newcastle disease virus", "SPECIES", 28, 51], ["Chickens", "TREATMENT", 0, 8], ["Newcastle disease virus", "PROBLEM", 28, 51], ["SAA", "PROBLEM", 59, 62], ["higher antibody titers", "TEST", 101, 123], ["The antiviral activity of APPsAt", "TREATMENT", 130, 162], ["viral replication", "TREATMENT", 224, 241], ["the pathogen", "PROBLEM", 380, 392], ["antiviral activity", "OBSERVATION", 134, 152]]], ["The several ways APP could affect viral replication are discussed in the following sections.Direct inhibition through binding to the virus particleThe mechanism of action most widely reported for the antiviral activity of APP is based on their capacity to attach to the virus particles and subsequently block virus-cell interaction.", [["sections", "ANATOMY", 83, 91], ["cell", "ANATOMY", 315, 319], ["APP", "GENE_OR_GENE_PRODUCT", 17, 20], ["APP", "GENE_OR_GENE_PRODUCT", 222, 225], ["cell", "CELL", 315, 319], ["APP", "PROTEIN", 17, 20], ["APP", "PROTEIN", 222, 225], ["viral replication", "TREATMENT", 34, 51], ["Direct inhibition through binding", "PROBLEM", 92, 125], ["the virus particles", "PROBLEM", 266, 285], ["viral replication", "OBSERVATION", 34, 51]]], ["Human PTX3 and SAP binding to influenza virus inhibits virus-induced hemagglutination [30] .", [["Human", "ORGANISM", 0, 5], ["PTX3", "GENE_OR_GENE_PRODUCT", 6, 10], ["SAP", "GENE_OR_GENE_PRODUCT", 15, 18], ["influenza virus", "ORGANISM", 30, 45], ["PTX3", "PROTEIN", 6, 10], ["SAP", "PROTEIN", 15, 18], ["Human", "SPECIES", 0, 5], ["influenza virus", "SPECIES", 30, 45], ["Human", "SPECIES", 0, 5], ["Human PTX3", "PROBLEM", 0, 10], ["SAP binding", "PROBLEM", 15, 26], ["influenza virus inhibits virus", "PROBLEM", 30, 60], ["induced hemagglutination", "PROBLEM", 61, 85]]], ["Interestingly, PTX3 and SAP can bind to virus-infected cells but not to uninfected cells, which suggest a selective effect of PTX and SAP during viral infection [28] .", [["cells", "ANATOMY", 55, 60], ["cells", "ANATOMY", 83, 88], ["PTX", "CHEMICAL", 126, 129], ["viral infection", "DISEASE", 145, 160], ["PTX", "CHEMICAL", 126, 129], ["PTX3", "GENE_OR_GENE_PRODUCT", 15, 19], ["SAP", "GENE_OR_GENE_PRODUCT", 24, 27], ["cells", "CELL", 55, 60], ["cells", "CELL", 83, 88], ["PTX", "SIMPLE_CHEMICAL", 126, 129], ["SAP", "GENE_OR_GENE_PRODUCT", 134, 137], ["PTX3", "PROTEIN", 15, 19], ["SAP", "PROTEIN", 24, 27], ["virus-infected cells", "CELL_TYPE", 40, 60], ["uninfected cells", "CELL_TYPE", 72, 88], ["SAP", "PROTEIN", 134, 137], ["PTX3", "PROBLEM", 15, 19], ["SAP", "PROBLEM", 24, 27], ["virus", "PROBLEM", 40, 45], ["infected cells", "PROBLEM", 46, 60], ["uninfected cells", "PROBLEM", 72, 88], ["PTX", "PROBLEM", 126, 129], ["SAP during viral infection", "PROBLEM", 134, 160], ["infected cells", "OBSERVATION", 46, 60], ["selective", "OBSERVATION_MODIFIER", 106, 115], ["effect", "OBSERVATION_MODIFIER", 116, 122], ["PTX", "OBSERVATION", 126, 129], ["SAP", "OBSERVATION_MODIFIER", 134, 137], ["viral", "OBSERVATION_MODIFIER", 145, 150], ["infection", "OBSERVATION", 151, 160]]], ["By analyzing influenza A virus mutants resistant to the inhibitory effect of PTX3, the amino acid residues in the hemagglutinin (HA) responsible of the virus sensitivity to PTX3 were identified [31] , providing further evidence of the recognition of HA by PTX3 in mice.", [["amino acid", "CHEMICAL", 87, 97], ["amino acid", "CHEMICAL", 87, 97], ["influenza A virus", "ORGANISM", 13, 30], ["PTX3", "GENE_OR_GENE_PRODUCT", 77, 81], ["amino acid", "AMINO_ACID", 87, 97], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 114, 127], ["PTX3", "GENE_OR_GENE_PRODUCT", 173, 177], ["HA", "GENE_OR_GENE_PRODUCT", 250, 252], ["PTX3", "GENE_OR_GENE_PRODUCT", 256, 260], ["mice", "ORGANISM", 264, 268], ["PTX3", "PROTEIN", 77, 81], ["hemagglutinin", "PROTEIN", 114, 127], ["HA", "PROTEIN", 129, 131], ["PTX3", "PROTEIN", 173, 177], ["PTX3", "PROTEIN", 256, 260], ["influenza A virus", "SPECIES", 13, 30], ["mice", "SPECIES", 264, 268], ["influenza A virus", "SPECIES", 13, 30], ["mice", "SPECIES", 264, 268], ["analyzing influenza A virus mutants", "PROBLEM", 3, 38], ["PTX3", "TREATMENT", 77, 81], ["the amino acid residues", "TREATMENT", 83, 106], ["the hemagglutinin (HA)", "PROBLEM", 110, 132], ["the virus sensitivity", "PROBLEM", 148, 169], ["PTX3", "TEST", 173, 177], ["HA", "PROBLEM", 250, 252]]], ["Treatment of influenza virus-infected mice with human PTX3 has been successful in reducing viral loads and increasing survival on the infected animals [30] , hinting the potential therapeutic application of pentraxins.", [["influenza virus-infected", "DISEASE", 13, 37], ["pentraxins", "CHEMICAL", 207, 217], ["pentraxins", "CHEMICAL", 207, 217], ["influenza virus", "ORGANISM", 13, 28], ["mice", "ORGANISM", 38, 42], ["human", "ORGANISM", 48, 53], ["PTX3", "GENE_OR_GENE_PRODUCT", 54, 58], ["pentraxins", "SIMPLE_CHEMICAL", 207, 217], ["human PTX3", "PROTEIN", 48, 58], ["influenza virus-", "SPECIES", 13, 29], ["mice", "SPECIES", 38, 42], ["human", "SPECIES", 48, 53], ["mice", "SPECIES", 38, 42], ["human", "SPECIES", 48, 53], ["influenza virus", "PROBLEM", 13, 28], ["human PTX3", "TREATMENT", 48, 58], ["viral loads", "PROBLEM", 91, 102], ["pentraxins", "TREATMENT", 207, 217], ["influenza virus", "OBSERVATION", 13, 28], ["viral loads", "OBSERVATION", 91, 102]]], ["In recent years the use of recombinant PTX as antiviral drugs has emerged as a distinct possibility.", [["PTX", "CHEMICAL", 39, 42], ["PTX", "CHEMICAL", 39, 42], ["PTX", "SIMPLE_CHEMICAL", 39, 42], ["recombinant PTX", "TREATMENT", 27, 42], ["antiviral drugs", "TREATMENT", 46, 61]]], ["On this respect, Han and colleagues demonstrated the protective effect of intranasal administration of recombinant PTX3 against murine coronavirus [42] .Direct inhibition through binding to the virus particleIn the aforementioned study the gene knockout technology was applied to the investigation of the antiviral response of pentraxins, showing higher susceptibility to mouse hepatitis coronavirus MHV in PTX3-deficient mice [42] .", [["pentraxins", "CHEMICAL", 327, 337], ["hepatitis coronavirus", "DISEASE", 378, 399], ["pentraxins", "CHEMICAL", 327, 337], ["PTX3", "GENE_OR_GENE_PRODUCT", 115, 119], ["murine coronavirus", "ORGANISM", 128, 146], ["pentraxins", "GENE_OR_GENE_PRODUCT", 327, 337], ["mouse hepatitis coronavirus MHV", "ORGANISM", 372, 403], ["PTX3", "GENE_OR_GENE_PRODUCT", 407, 411], ["mice", "ORGANISM", 422, 426], ["recombinant PTX3", "PROTEIN", 103, 119], ["PTX3", "PROTEIN", 407, 411], ["murine", "SPECIES", 128, 134], ["mouse", "SPECIES", 372, 377], ["hepatitis coronavirus MHV", "SPECIES", 378, 403], ["mice", "SPECIES", 422, 426], ["murine coronavirus", "SPECIES", 128, 146], ["mouse hepatitis coronavirus MHV", "SPECIES", 372, 403], ["mice", "SPECIES", 422, 426], ["intranasal administration", "TREATMENT", 74, 99], ["murine coronavirus", "PROBLEM", 128, 146], ["Direct inhibition through binding", "PROBLEM", 153, 186], ["the gene knockout technology", "TREATMENT", 236, 264], ["pentraxins", "TREATMENT", 327, 337], ["higher susceptibility to mouse hepatitis coronavirus MHV", "PROBLEM", 347, 403]]], ["Moreover, the observation that PTX3 could bind MHV particles in vitro prompted an in vivo study where mice were treated with recombinant PTX3, achieving a better clearance of the virus in the lung.", [["lung", "ANATOMY", 192, 196], ["PTX3", "GENE_OR_GENE_PRODUCT", 31, 35], ["MHV particles", "ORGANISM", 47, 60], ["mice", "ORGANISM", 102, 106], ["PTX3", "GENE_OR_GENE_PRODUCT", 137, 141], ["lung", "ORGAN", 192, 196], ["PTX3", "PROTEIN", 31, 35], ["recombinant PTX3", "PROTEIN", 125, 141], ["mice", "SPECIES", 102, 106], ["MHV", "SPECIES", 47, 50], ["mice", "SPECIES", 102, 106], ["an in vivo study", "TEST", 79, 95], ["recombinant PTX3", "TREATMENT", 125, 141], ["the virus in the lung", "PROBLEM", 175, 196], ["virus", "OBSERVATION", 179, 184], ["lung", "ANATOMY", 192, 196]]], ["SAP binding to influenza virus HA results in the inhibition of infection in mice, with higher survival observed after intranasal administration of SAP [80] .", [["infection", "DISEASE", 63, 72], ["SAP", "GENE_OR_GENE_PRODUCT", 0, 3], ["influenza virus HA", "ORGANISM", 15, 33], ["mice", "ORGANISM", 76, 80], ["SAP", "PROTEIN", 0, 3], ["influenza virus", "SPECIES", 15, 30], ["mice", "SPECIES", 76, 80], ["influenza virus", "SPECIES", 15, 30], ["mice", "SPECIES", 76, 80], ["SAP binding", "PROBLEM", 0, 11], ["influenza virus HA", "PROBLEM", 15, 33], ["infection", "PROBLEM", 63, 72], ["infection", "OBSERVATION", 63, 72]]], ["Likewise the anti-hepatitis activity of SAA is associated with its inhibitory effect on the HCV entry through binding of SAA to the virus particles [81] .", [["SAA", "CHEMICAL", 40, 43], ["SAA", "GENE_OR_GENE_PRODUCT", 40, 43], ["HCV", "ORGANISM", 92, 95], ["SAA", "GENE_OR_GENE_PRODUCT", 121, 124], ["SAA", "PROTEIN", 40, 43], ["SAA", "PROTEIN", 121, 124], ["HCV", "SPECIES", 92, 95], ["the anti-hepatitis activity of SAA", "PROBLEM", 9, 43], ["its inhibitory effect", "PROBLEM", 63, 84], ["anti-hepatitis activity", "OBSERVATION", 13, 36]]], ["A follow up study corroborated that SAA protected cells from HCV infection, blocking a step prior to virus entry into the cell [82] .", [["cells", "ANATOMY", 50, 55], ["cell", "ANATOMY", 122, 126], ["SAA", "CHEMICAL", 36, 39], ["HCV infection", "DISEASE", 61, 74], ["SAA", "GENE_OR_GENE_PRODUCT", 36, 39], ["cells", "CELL", 50, 55], ["HCV", "ORGANISM", 61, 64], ["cell", "CELL", 122, 126], ["SAA", "PROTEIN", 36, 39], ["HCV", "SPECIES", 61, 64], ["A follow up study", "TEST", 0, 17], ["SAA protected cells", "PROBLEM", 36, 55], ["HCV infection", "PROBLEM", 61, 74], ["HCV", "OBSERVATION_MODIFIER", 61, 64], ["infection", "OBSERVATION", 65, 74]]], ["It is worth to mention that the binding of APP to the virus particle does not always end up with the inhibition of viral replication.", [["APP", "GENE_OR_GENE_PRODUCT", 43, 46], ["APP", "PROTEIN", 43, 46], ["viral replication", "TREATMENT", 115, 132], ["viral replication", "OBSERVATION", 115, 132]]], ["On the contrary, PTX3 binding to Ross River virus seems to facilitate virus entry into the cell [14] .", [["cell", "ANATOMY", 91, 95], ["PTX3", "GENE_OR_GENE_PRODUCT", 17, 21], ["Ross River virus", "ORGANISM", 33, 49], ["cell", "CELL", 91, 95], ["PTX3", "PROTEIN", 17, 21], ["Ross River virus", "SPECIES", 33, 49], ["PTX3 binding", "PROBLEM", 17, 29], ["Ross River virus", "PROBLEM", 33, 49]]], ["Another instance of a \"pro-viral\" action of APP, porcine SAA has been reported to have an enhancing effect on PRRSV replication in vitro [35] .", [["APP", "GENE_OR_GENE_PRODUCT", 44, 47], ["porcine", "ORGANISM", 49, 56], ["SAA", "GENE_OR_GENE_PRODUCT", 57, 60], ["PRRSV", "ORGANISM", 110, 115], ["APP", "PROTEIN", 44, 47], ["porcine SAA", "PROTEIN", 49, 60], ["PRRSV", "SPECIES", 110, 115], ["an enhancing effect", "PROBLEM", 87, 106], ["PRRSV replication", "TREATMENT", 110, 127], ["enhancing", "OBSERVATION_MODIFIER", 90, 99]]], ["Why pentraxins can both inhibit and enhance viral replication is not fully understood.", [["pentraxins", "CHEMICAL", 4, 14], ["pentraxins", "GENE_OR_GENE_PRODUCT", 4, 14], ["pentraxins", "TREATMENT", 4, 14]]], ["While the in vitro antiviral effects of pentraxins are often related to their virus binding capacity, the in vivo effect of APP on viral infectivity is usually mediated by the activation if the innate immune system and interferon pathways [83] .", [["pentraxins", "CHEMICAL", 40, 50], ["pentraxins", "CHEMICAL", 40, 50], ["pentraxins", "SIMPLE_CHEMICAL", 40, 50], ["APP", "GENE_OR_GENE_PRODUCT", 124, 127], ["APP", "PROTEIN", 124, 127], ["interferon", "PROTEIN", 219, 229], ["pentraxins", "TREATMENT", 40, 50], ["their virus binding capacity", "PROBLEM", 72, 100], ["viral infectivity", "PROBLEM", 131, 148], ["interferon pathways", "TEST", 219, 238]]], ["That can lead to a discrepancy between in vitro and in vivo roles of pentraxins.Binding of CRP to cell membranes and induction of autophagyBinding of CRP to the cell membrane can impair subsequent virus attachment and entry into the cell.", [["cell membranes", "ANATOMY", 98, 112], ["cell membrane", "ANATOMY", 161, 174], ["cell", "ANATOMY", 233, 237], ["pentraxins", "CHEMICAL", 69, 79], ["pentraxins", "GENE_OR_GENE_PRODUCT", 69, 79], ["CRP", "GENE_OR_GENE_PRODUCT", 91, 94], ["cell membranes", "CELLULAR_COMPONENT", 98, 112], ["CRP", "GENE_OR_GENE_PRODUCT", 150, 153], ["cell membrane", "CELLULAR_COMPONENT", 161, 174], ["cell", "CELL", 233, 237], ["pentraxins", "PROTEIN", 69, 79], ["CRP", "PROTEIN", 91, 94], ["CRP", "PROTEIN", 150, 153], ["a discrepancy between in vitro", "PROBLEM", 17, 47], ["pentraxins", "TREATMENT", 69, 79], ["CRP", "TEST", 91, 94], ["cell membranes", "TREATMENT", 98, 112], ["induction of autophagy", "TREATMENT", 117, 139], ["CRP", "TEST", 150, 153], ["subsequent virus attachment", "PROBLEM", 186, 213], ["cell membranes", "OBSERVATION", 98, 112], ["cell membrane", "OBSERVATION", 161, 174], ["virus", "OBSERVATION", 197, 202], ["cell", "ANATOMY", 233, 237]]], ["The binding seems to be dependent on the affinity of CRP for cholesterol-rich lipid rafts on the cell membrane [6] .", [["lipid rafts", "ANATOMY", 78, 89], ["cell membrane", "ANATOMY", 97, 110], ["cholesterol", "CHEMICAL", 61, 72], ["cholesterol", "CHEMICAL", 61, 72], ["CRP", "GENE_OR_GENE_PRODUCT", 53, 56], ["cholesterol", "SIMPLE_CHEMICAL", 61, 72], ["lipid rafts", "CELLULAR_COMPONENT", 78, 89], ["cell membrane", "CELLULAR_COMPONENT", 97, 110], ["CRP", "PROTEIN", 53, 56], ["CRP", "TEST", 53, 56], ["cholesterol", "TEST", 61, 72], ["lipid rafts", "OBSERVATION", 78, 89], ["cell membrane", "OBSERVATION", 97, 110]]], ["That would explain the antiviral activity of zebrafish CRP against SVCV [56] .", [["zebrafish", "ORGANISM", 45, 54], ["CRP", "GENE_OR_GENE_PRODUCT", 55, 58], ["zebrafish CRP", "PROTEIN", 45, 58], ["zebrafish", "SPECIES", 45, 54], ["SVCV", "SPECIES", 67, 71], ["zebrafish CRP", "TEST", 45, 58]]], ["Human CRP binds rapidly to activated monocytes in a calcium-dependent way, but such binding does not last long: CRP quickly detaches and the cells go back to basal condition [5] .Binding of CRP to cell membranes and induction of autophagyThe antiviral action of APP can be also linked to the activation of autophagy.", [["monocytes", "ANATOMY", 37, 46], ["cells", "ANATOMY", 141, 146], ["cell membranes", "ANATOMY", 197, 211], ["calcium", "CHEMICAL", 52, 59], ["calcium", "CHEMICAL", 52, 59], ["Human", "ORGANISM", 0, 5], ["CRP", "GENE_OR_GENE_PRODUCT", 6, 9], ["monocytes", "CELL", 37, 46], ["calcium", "SIMPLE_CHEMICAL", 52, 59], ["CRP", "GENE_OR_GENE_PRODUCT", 112, 115], ["cells", "CELL", 141, 146], ["CRP", "GENE_OR_GENE_PRODUCT", 190, 193], ["cell membranes", "CELLULAR_COMPONENT", 197, 211], ["APP", "GENE_OR_GENE_PRODUCT", 262, 265], ["CRP", "PROTEIN", 6, 9], ["activated monocytes", "CELL_TYPE", 27, 46], ["CRP", "PROTEIN", 112, 115], ["CRP", "PROTEIN", 190, 193], ["APP", "PROTEIN", 262, 265], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human CRP binds", "PROBLEM", 0, 15], ["activated monocytes", "PROBLEM", 27, 46], ["a calcium", "TEST", 50, 59], ["such binding", "PROBLEM", 79, 91], ["CRP", "TEST", 112, 115], ["the cells", "PROBLEM", 137, 146], ["CRP", "TEST", 190, 193], ["cell membranes", "TREATMENT", 197, 211], ["induction of autophagy", "TREATMENT", 216, 238], ["The antiviral action of APP", "TREATMENT", 238, 265], ["cell membranes", "OBSERVATION", 197, 211]]], ["Autophagy is a defensive mechanism of the cell that allows the removal of intracellular microbial pathogens [84] .", [["cell", "ANATOMY", 42, 46], ["intracellular", "ANATOMY", 74, 87], ["cell", "CELL", 42, 46], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 74, 87], ["a defensive mechanism of the cell", "PROBLEM", 13, 46], ["the removal", "TREATMENT", 59, 70], ["intracellular microbial pathogens", "PROBLEM", 74, 107], ["cell", "OBSERVATION", 42, 46]]], ["Disruption of the cell membrane by CRP would trigger the formation of the autophagic vesicles as part of the cell defense mechanism [85, 86] .", [["cell membrane", "ANATOMY", 18, 31], ["autophagic vesicles", "ANATOMY", 74, 93], ["cell", "ANATOMY", 109, 113], ["cell membrane", "CELLULAR_COMPONENT", 18, 31], ["CRP", "GENE_OR_GENE_PRODUCT", 35, 38], ["autophagic vesicles", "CELLULAR_COMPONENT", 74, 93], ["cell", "CELL", 109, 113], ["CRP", "PROTEIN", 35, 38], ["Disruption of the cell membrane", "PROBLEM", 0, 31], ["CRP", "TEST", 35, 38], ["the autophagic vesicles", "PROBLEM", 70, 93], ["the cell defense mechanism", "TEST", 105, 131], ["cell membrane", "OBSERVATION", 18, 31], ["autophagic vesicles", "OBSERVATION", 74, 93]]], ["Evidence of the relationship between up-regulation of CRP and autophagy has been reported.", [["CRP", "GENE_OR_GENE_PRODUCT", 54, 57], ["CRP", "PROTEIN", 54, 57], ["CRP", "TEST", 54, 57]]], ["In renal cell carcinoma there is a correlation between expression of CRP and ATG9B, a protein involved in autophagy [87] .", [["renal cell carcinoma", "ANATOMY", 3, 23], ["renal cell carcinoma", "DISEASE", 3, 23], ["renal cell carcinoma", "CANCER", 3, 23], ["CRP", "GENE_OR_GENE_PRODUCT", 69, 72], ["ATG9B", "GENE_OR_GENE_PRODUCT", 77, 82], ["CRP", "PROTEIN", 69, 72], ["ATG9B", "PROTEIN", 77, 82], ["renal cell carcinoma", "PROBLEM", 3, 23], ["CRP", "TEST", 69, 72], ["ATG9B", "TEST", 77, 82], ["a protein", "TEST", 84, 93], ["renal", "ANATOMY", 3, 8], ["cell carcinoma", "OBSERVATION", 9, 23]]], ["At present there are some research gaps on the relationship between CRP and autophagy in virus-infected cells that will have to be addressed in the future.Modulation of the innate immune response by APPThe innate immune system serves as a rapid first wave of defense against invading pathogens [86] .", [["cells", "ANATOMY", 104, 109], ["CRP", "GENE_OR_GENE_PRODUCT", 68, 71], ["cells", "CELL", 104, 109], ["APPThe", "GENE_OR_GENE_PRODUCT", 199, 205], ["CRP", "PROTEIN", 68, 71], ["virus-infected cells", "CELL_TYPE", 89, 109], ["some research gaps", "PROBLEM", 21, 39], ["CRP", "TEST", 68, 71], ["autophagy in virus", "PROBLEM", 76, 94], ["infected cells", "PROBLEM", 95, 109], ["invading pathogens", "PROBLEM", 275, 293], ["some", "OBSERVATION_MODIFIER", 21, 25], ["research", "OBSERVATION_MODIFIER", 26, 34], ["gaps", "OBSERVATION", 35, 39], ["infected cells", "OBSERVATION", 95, 109]]], ["The immunomodulatory role of APP and their interaction with innate immune cells has been reported [14, 88] .", [["immune cells", "ANATOMY", 67, 79], ["APP", "GENE_OR_GENE_PRODUCT", 29, 32], ["innate immune cells", "CELL", 60, 79], ["APP", "PROTEIN", 29, 32], ["innate immune cells", "CELL_TYPE", 60, 79], ["innate immune cells", "TREATMENT", 60, 79]]], ["Human CRP interferes with the migration of macrophages, raising the suggestion that CRP may assist to recruit macrophages in the site of tissue injury [89] .", [["macrophages", "ANATOMY", 43, 54], ["macrophages", "ANATOMY", 110, 121], ["site", "ANATOMY", 129, 133], ["tissue", "ANATOMY", 137, 143], ["Human", "ORGANISM", 0, 5], ["CRP", "GENE_OR_GENE_PRODUCT", 6, 9], ["macrophages", "CELL", 43, 54], ["CRP", "GENE_OR_GENE_PRODUCT", 84, 87], ["macrophages", "CELL", 110, 121], ["tissue", "TISSUE", 137, 143], ["CRP", "PROTEIN", 6, 9], ["macrophages", "CELL_TYPE", 43, 54], ["CRP", "PROTEIN", 84, 87], ["macrophages", "CELL_TYPE", 110, 121], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human CRP", "TEST", 0, 9], ["the migration of macrophages", "TREATMENT", 26, 54], ["CRP", "TEST", 84, 87], ["tissue injury", "PROBLEM", 137, 150], ["macrophages", "OBSERVATION", 43, 54], ["macrophages", "OBSERVATION", 110, 121], ["tissue", "ANATOMY", 137, 143], ["injury", "OBSERVATION", 144, 150]]], ["Monomeric CRP binding to lipid rafts stimulates production of pro-inflammatory cytokines [6, 56] .", [["lipid rafts", "ANATOMY", 25, 36], ["CRP", "GENE_OR_GENE_PRODUCT", 10, 13], ["CRP", "PROTEIN", 10, 13], ["pro-inflammatory cytokines", "PROTEIN", 62, 88], ["Monomeric CRP binding", "PROBLEM", 0, 21], ["lipid rafts", "TEST", 25, 36], ["pro-inflammatory cytokines", "TEST", 62, 88]]], ["Likewise, CRP binding to cell membranes also activates the complement cascade through C1q [5] .Modulation of the innate immune response by APPSerum amyloid proteins also have a regulatory activity on innate immunity and inflammatory cytokines as well [90] .", [["cell membranes", "ANATOMY", 25, 39], ["CRP", "GENE_OR_GENE_PRODUCT", 10, 13], ["cell membranes", "CELLULAR_COMPONENT", 25, 39], ["C1q", "GENE_OR_GENE_PRODUCT", 86, 89], ["APPSerum amyloid proteins", "GENE_OR_GENE_PRODUCT", 139, 164], ["CRP", "PROTEIN", 10, 13], ["C1q", "PROTEIN", 86, 89], ["APPSerum amyloid proteins", "PROTEIN", 139, 164], ["inflammatory cytokines", "PROTEIN", 220, 242], ["CRP binding to cell membranes", "PROBLEM", 10, 39], ["APPSerum amyloid proteins", "PROBLEM", 139, 164], ["inflammatory cytokines", "PROBLEM", 220, 242], ["cell membranes", "OBSERVATION", 25, 39], ["activity", "OBSERVATION_MODIFIER", 188, 196], ["inflammatory", "OBSERVATION_MODIFIER", 220, 232]]], ["Production of SAA in the liver has a triggering effect on the cytokine response to microbial infections, although its antiviral activity seems to be restricted to HCV [8] .", [["liver", "ANATOMY", 25, 30], ["infections", "DISEASE", 93, 103], ["SAA", "GENE_OR_GENE_PRODUCT", 14, 17], ["liver", "ORGAN", 25, 30], ["SAA", "PROTEIN", 14, 17], ["cytokine", "PROTEIN", 62, 70], ["HCV", "SPECIES", 163, 166], ["Production of SAA in the liver", "PROBLEM", 0, 30], ["microbial infections", "PROBLEM", 83, 103], ["HCV", "PROBLEM", 163, 166], ["SAA", "OBSERVATION", 14, 17], ["liver", "ANATOMY", 25, 30], ["microbial", "OBSERVATION_MODIFIER", 83, 92], ["infections", "OBSERVATION", 93, 103]]], ["As discussed earlier, a close connection between il6 expression and CRP production has been established in fish and mammals [15, 55, 91] .APP as biomarkers of antiviral treatment efficacyThe measurements of circulating levels of cytokines and APP as well as the characterization of patterns associated to each specific disease condition have been regarded as very useful tools to assist diagnosis of infectious diseases differentiating bacterial from viral origin of the disease [15, 92, 93] .", [["infectious diseases", "DISEASE", 400, 419], ["il6", "GENE_OR_GENE_PRODUCT", 49, 52], ["CRP", "GENE_OR_GENE_PRODUCT", 68, 71], ["fish", "ORGANISM_SUBDIVISION", 107, 111], ["APP", "GENE_OR_GENE_PRODUCT", 138, 141], ["APP", "GENE_OR_GENE_PRODUCT", 243, 246], ["il6", "PROTEIN", 49, 52], ["CRP", "PROTEIN", 68, 71], ["APP", "PROTEIN", 138, 141], ["cytokines", "PROTEIN", 229, 238], ["APP", "PROTEIN", 243, 246], ["a close connection between il6 expression", "TREATMENT", 22, 63], ["CRP production", "TEST", 68, 82], ["antiviral treatment efficacy", "TREATMENT", 159, 187], ["cytokines and APP", "TREATMENT", 229, 246], ["the characterization", "TEST", 258, 278], ["each specific disease condition", "PROBLEM", 305, 336], ["infectious diseases", "PROBLEM", 400, 419], ["the disease", "PROBLEM", 467, 478], ["infectious", "OBSERVATION_MODIFIER", 400, 410], ["viral origin", "OBSERVATION", 451, 463]]], ["Particularly, measurements of serum CRP levels have been recommended to distinguish between bacterial and viral diseases [94, 95] in those pathologies resulting in febrile condition in children [96] .", [["serum", "ANATOMY", 30, 35], ["bacterial and viral diseases", "DISEASE", 92, 120], ["febrile condition", "DISEASE", 164, 181], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["CRP", "GENE_OR_GENE_PRODUCT", 36, 39], ["children", "ORGANISM", 185, 193], ["CRP", "PROTEIN", 36, 39], ["children", "SPECIES", 185, 193], ["serum CRP levels", "TEST", 30, 46], ["bacterial and viral diseases", "PROBLEM", 92, 120], ["those pathologies", "PROBLEM", 133, 150], ["febrile condition", "PROBLEM", 164, 181], ["viral diseases", "OBSERVATION", 106, 120], ["febrile", "OBSERVATION_MODIFIER", 164, 171]]], ["Immunoassay tests for myxovirus A (MxA) and CRP were the bases of a clinical diagnostic protocol to determine the bacterial or viral etiology of acute respiratory infections [97] .", [["respiratory", "ANATOMY", 151, 162], ["acute respiratory infections", "DISEASE", 145, 173], ["myxovirus A", "GENE_OR_GENE_PRODUCT", 22, 33], ["MxA", "GENE_OR_GENE_PRODUCT", 35, 38], ["CRP", "GENE_OR_GENE_PRODUCT", 44, 47], ["myxovirus A", "PROTEIN", 22, 33], ["MxA", "PROTEIN", 35, 38], ["CRP", "PROTEIN", 44, 47], ["Immunoassay tests", "TEST", 0, 17], ["myxovirus A (MxA)", "TEST", 22, 39], ["CRP", "TEST", 44, 47], ["a clinical diagnostic protocol", "TEST", 66, 96], ["the bacterial", "PROBLEM", 110, 123], ["acute respiratory infections", "PROBLEM", 145, 173], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["respiratory infections", "OBSERVATION", 151, 173]]], ["Higher blood levels of CRP can be used to differentiate between bacterial and viral gastrointestinal infection [98, 99] and therefore avoiding unnecessary antibiotic therapy.", [["blood", "ANATOMY", 7, 12], ["gastrointestinal", "ANATOMY", 84, 100], ["bacterial and viral gastrointestinal infection", "DISEASE", 64, 110], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["CRP", "GENE_OR_GENE_PRODUCT", 23, 26], ["gastrointestinal", "ORGAN", 84, 100], ["CRP", "PROTEIN", 23, 26], ["Higher blood levels", "TEST", 0, 19], ["CRP", "TEST", 23, 26], ["bacterial and viral gastrointestinal infection", "PROBLEM", 64, 110], ["unnecessary antibiotic therapy", "TREATMENT", 143, 173], ["viral", "OBSERVATION_MODIFIER", 78, 83], ["gastrointestinal", "ANATOMY", 84, 100], ["infection", "OBSERVATION", 101, 110]]], ["Combined high levels of both CRP and SAA are indicative of bacterial infection in cases on infectious mononucleosis, while elevated SAA (only) points to a viral infection [100] .", [["bacterial infection", "DISEASE", 59, 78], ["infectious mononucleosis", "DISEASE", 91, 115], ["viral infection", "DISEASE", 155, 170], ["CRP", "GENE_OR_GENE_PRODUCT", 29, 32], ["SAA", "GENE_OR_GENE_PRODUCT", 37, 40], ["SAA", "GENE_OR_GENE_PRODUCT", 132, 135], ["CRP", "PROTEIN", 29, 32], ["SAA", "PROTEIN", 37, 40], ["SAA", "PROTEIN", 132, 135], ["Combined high levels of both CRP and SAA", "PROBLEM", 0, 40], ["bacterial infection", "PROBLEM", 59, 78], ["infectious mononucleosis", "PROBLEM", 91, 115], ["elevated SAA", "PROBLEM", 123, 135], ["a viral infection", "PROBLEM", 153, 170], ["indicative of", "UNCERTAINTY", 45, 58], ["bacterial", "OBSERVATION_MODIFIER", 59, 68], ["infection", "OBSERVATION", 69, 78], ["infectious", "OBSERVATION_MODIFIER", 91, 101], ["viral", "OBSERVATION_MODIFIER", 155, 160], ["infection", "OBSERVATION", 161, 170]]], ["In addition to the identification of a bacterial or viral origin of a disease the determination of CRP concentrations has been shown to distinguish between viral (dengue) and protozoan (malaria)-infected patients with very similar clinical signs [101] .APP as biomarkers of antiviral treatment efficacyIn a rare case of APP analysis applied to the differential diagnostic of two viruses in a respiratory infection, the analysis of CRP profiles has contributed to validate a diagnostic of influenza virus infection, ruling out rhinovirus infection [102] .APP as biomarkers of antiviral treatment efficacySeveral studies have stressed the utility of APP as biomarkers of disease.", [["respiratory", "ANATOMY", 392, 403], ["viral (dengue) and protozoan (malaria)-infected", "DISEASE", 156, 203], ["respiratory infection", "DISEASE", 392, 413], ["influenza virus infection", "DISEASE", 488, 513], ["rhinovirus infection", "DISEASE", 526, 546], ["CRP", "GENE_OR_GENE_PRODUCT", 99, 102], ["patients", "ORGANISM", 204, 212], ["APP", "GENE_OR_GENE_PRODUCT", 320, 323], ["CRP", "GENE_OR_GENE_PRODUCT", 431, 434], ["influenza virus", "ORGANISM", 488, 503], ["rhinovirus", "ORGANISM", 526, 536], ["APP", "GENE_OR_GENE_PRODUCT", 648, 651], ["CRP", "PROTEIN", 99, 102], ["APP", "PROTEIN", 320, 323], ["CRP", "PROTEIN", 431, 434], ["APP", "PROTEIN", 648, 651], ["patients", "SPECIES", 204, 212], ["influenza virus", "SPECIES", 488, 503], ["dengue", "SPECIES", 163, 169], ["influenza virus", "SPECIES", 488, 503], ["a bacterial", "PROBLEM", 37, 48], ["a disease", "PROBLEM", 68, 77], ["CRP concentrations", "PROBLEM", 99, 117], ["viral (dengue)", "PROBLEM", 156, 170], ["protozoan (malaria)", "PROBLEM", 175, 194], ["antiviral treatment efficacy", "TREATMENT", 274, 302], ["APP analysis", "TEST", 320, 332], ["two viruses", "PROBLEM", 375, 386], ["a respiratory infection", "PROBLEM", 390, 413], ["the analysis", "TEST", 415, 427], ["CRP profiles", "TEST", 431, 443], ["influenza virus infection", "PROBLEM", 488, 513], ["rhinovirus infection", "PROBLEM", 526, 546], ["antiviral treatment efficacy", "TREATMENT", 575, 603], ["Several studies", "TEST", 603, 618], ["disease", "PROBLEM", 669, 676], ["bacterial", "OBSERVATION_MODIFIER", 39, 48], ["viral origin", "OBSERVATION", 52, 64], ["disease", "OBSERVATION", 70, 77], ["respiratory", "ANATOMY", 392, 403], ["infection", "OBSERVATION", 404, 413], ["disease", "OBSERVATION", 669, 676]]], ["Consequently, the determination of APP levels in virus-infected patients has been established as an instrument to evaluate the efficacy of antiviral drugs.", [["APP", "GENE_OR_GENE_PRODUCT", 35, 38], ["patients", "ORGANISM", 64, 72], ["APP", "PROTEIN", 35, 38], ["patients", "SPECIES", 64, 72], ["APP levels", "TEST", 35, 45], ["virus", "PROBLEM", 49, 54], ["an instrument", "TEST", 97, 110], ["antiviral drugs", "TREATMENT", 139, 154]]], ["For instance, reduced CRP levels are good indicators of the efficacy of interferon-ribavirin combined therapy in HCV-infected patients [40] .", [["interferon-ribavirin", "CHEMICAL", 72, 92], ["HCV-infected", "DISEASE", 113, 125], ["ribavirin", "CHEMICAL", 83, 92], ["CRP", "GENE_OR_GENE_PRODUCT", 22, 25], ["ribavirin", "SIMPLE_CHEMICAL", 83, 92], ["HCV", "ORGANISM", 113, 116], ["patients", "ORGANISM", 126, 134], ["CRP", "PROTEIN", 22, 25], ["interferon", "PROTEIN", 72, 82], ["patients", "SPECIES", 126, 134], ["HCV", "SPECIES", 113, 116], ["reduced CRP levels", "PROBLEM", 14, 32], ["interferon", "TREATMENT", 72, 82], ["ribavirin combined therapy", "TREATMENT", 83, 109], ["HCV", "PROBLEM", 113, 116]]], ["SAA and CRP concentrations are elevated in cats receiving interferon therapy against feline immunodeficiency virus and feline leukemia virus.", [["interferon", "CHEMICAL", 58, 68], ["feline immunodeficiency virus", "DISEASE", 85, 114], ["feline leukemia virus", "DISEASE", 119, 140], ["SAA", "GENE_OR_GENE_PRODUCT", 0, 3], ["CRP", "GENE_OR_GENE_PRODUCT", 8, 11], ["cats", "ORGANISM", 43, 47], ["feline immunodeficiency virus", "ORGANISM", 85, 114], ["feline leukemia virus", "ORGANISM", 119, 140], ["SAA", "PROTEIN", 0, 3], ["CRP", "PROTEIN", 8, 11], ["interferon", "PROTEIN", 58, 68], ["cats", "SPECIES", 43, 47], ["feline immunodeficiency virus", "SPECIES", 85, 114], ["feline leukemia virus", "SPECIES", 119, 140], ["feline immunodeficiency virus", "SPECIES", 85, 114], ["feline leukemia virus", "SPECIES", 119, 140], ["SAA", "TEST", 0, 3], ["CRP concentrations", "TEST", 8, 26], ["elevated in cats", "PROBLEM", 31, 47], ["interferon therapy", "TREATMENT", 58, 76], ["feline immunodeficiency virus", "PROBLEM", 85, 114], ["feline leukemia virus", "PROBLEM", 119, 140], ["elevated", "OBSERVATION_MODIFIER", 31, 39], ["feline leukemia virus", "OBSERVATION", 119, 140]]], ["In that model SAA/CRP levels can be taken as evidence of the innate immune system being activated by the antiviral treatment [103] .", [["SAA", "GENE_OR_GENE_PRODUCT", 14, 17], ["CRP", "GENE_OR_GENE_PRODUCT", 18, 21], ["SAA", "PROTEIN", 14, 17], ["CRP", "PROTEIN", 18, 21], ["CRP levels", "TEST", 18, 28], ["the innate immune system", "TREATMENT", 57, 81], ["the antiviral treatment", "TREATMENT", 101, 124]]], ["In mice, on the other hand, lower levels of SAA in serum are associated with the inhibition of influenza virus replication in oseltamivir-treated individuals [27] .APP as biomarkers of antiviral treatment efficacyDue to their rapid increase after infection, high CRP levels can be used as an early marker of viral disease in fish, before the outcome of the symptoms.", [["serum", "ANATOMY", 51, 56], ["oseltamivir", "CHEMICAL", 126, 137], ["infection", "DISEASE", 247, 256], ["viral disease", "DISEASE", 308, 321], ["oseltamivir", "CHEMICAL", 126, 137], ["mice", "ORGANISM", 3, 7], ["SAA", "GENE_OR_GENE_PRODUCT", 44, 47], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["influenza virus", "ORGANISM", 95, 110], ["oseltamivir", "SIMPLE_CHEMICAL", 126, 137], ["APP", "GENE_OR_GENE_PRODUCT", 164, 167], ["CRP", "GENE_OR_GENE_PRODUCT", 263, 266], ["fish", "ORGANISM", 325, 329], ["SAA", "PROTEIN", 44, 47], ["APP", "PROTEIN", 164, 167], ["CRP", "PROTEIN", 263, 266], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["influenza virus", "SPECIES", 95, 110], ["lower levels of SAA in serum", "PROBLEM", 28, 56], ["influenza virus replication", "TREATMENT", 95, 122], ["oseltamivir", "TREATMENT", 126, 137], ["antiviral treatment efficacy", "TREATMENT", 185, 213], ["infection", "PROBLEM", 247, 256], ["high CRP levels", "PROBLEM", 258, 273], ["viral disease", "PROBLEM", 308, 321], ["the symptoms", "PROBLEM", 353, 365], ["rapid", "OBSERVATION_MODIFIER", 226, 231], ["increase", "OBSERVATION_MODIFIER", 232, 240], ["infection", "OBSERVATION", 247, 256], ["viral disease", "OBSERVATION", 308, 321]]], ["However, they could not be used for differential diagnosis, since both viral and bacterial infections induce the upregulation of crp expression in fish [68, 72, 104, 105] .ConclusionsDespite the intensive research conducted on APP in the past decade we are only beginning to understand all the functions played by APP in virus-infected organisms.", [["viral and bacterial infections", "DISEASE", 71, 101], ["crp", "GENE_OR_GENE_PRODUCT", 129, 132], ["APP", "GENE_OR_GENE_PRODUCT", 227, 230], ["APP", "GENE_OR_GENE_PRODUCT", 314, 317], ["crp", "DNA", 129, 132], ["APP", "PROTEIN", 227, 230], ["APP", "PROTEIN", 314, 317], ["both viral and bacterial infections", "PROBLEM", 66, 101], ["crp expression", "TEST", 129, 143], ["infected organisms", "PROBLEM", 327, 345], ["bacterial infections", "OBSERVATION", 81, 101]]], ["It is now evident that APP are key components of the antimicrobial response, very often involved directly or indirectly in the inhibition of viral replication and spread within the host.", [["APP", "GENE_OR_GENE_PRODUCT", 23, 26], ["APP", "PROTEIN", 23, 26], ["viral replication", "PROBLEM", 141, 158], ["antimicrobial response", "OBSERVATION", 53, 75], ["viral replication", "OBSERVATION", 141, 158]]], ["We have managed to get some insight into their range of antiviral activities but many open questions remain: is the APP stimulation sufficient to provide a primary protection against viral pathogenesis?", [["APP", "GENE_OR_GENE_PRODUCT", 116, 119], ["APP", "PROTEIN", 116, 119], ["antiviral activities", "TREATMENT", 56, 76], ["a primary protection", "TREATMENT", 154, 174], ["viral pathogenesis", "PROBLEM", 183, 201]]], ["Can the innate immune system be \"trained\" to keep a memory of the APP response?", [["APP", "GENE_OR_GENE_PRODUCT", 66, 69], ["APP", "PROTEIN", 66, 69]]], ["Thus, active research is needed to assess the full potential of APP as therapeutic agents for viral diseases as well as biomarkers of the efficacy of antiviral treatments.ConclusionsSeveral final conclusions can be drawn from the body of knowledge in the field: 1 CRP expression is up-regulated in a broad range of human virus infections.", [["viral diseases", "DISEASE", 94, 108], ["human virus infections", "DISEASE", 315, 337], ["APP", "GENE_OR_GENE_PRODUCT", 64, 67], ["CRP", "GENE_OR_GENE_PRODUCT", 264, 267], ["human", "ORGANISM", 315, 320], ["APP", "PROTEIN", 64, 67], ["CRP", "PROTEIN", 264, 267], ["human", "SPECIES", 315, 320], ["human virus", "SPECIES", 315, 326], ["APP", "TREATMENT", 64, 67], ["therapeutic agents", "TREATMENT", 71, 89], ["viral diseases", "PROBLEM", 94, 108], ["antiviral treatments", "TREATMENT", 150, 170], ["CRP expression", "TEST", 264, 278], ["human virus infections", "PROBLEM", 315, 337], ["virus infections", "OBSERVATION", 321, 337]]], ["2 In non-human hosts serum amyloid proteins (SAA, SAP) are the main APP altered after viral infection.", [["serum", "ANATOMY", 21, 26], ["viral infection", "DISEASE", 86, 101], ["non-human", "ORGANISM", 5, 14], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["amyloid proteins", "GENE_OR_GENE_PRODUCT", 27, 43], ["SAA", "GENE_OR_GENE_PRODUCT", 45, 48], ["SAP", "GENE_OR_GENE_PRODUCT", 50, 53], ["APP", "GENE_OR_GENE_PRODUCT", 68, 71], ["serum amyloid proteins", "PROTEIN", 21, 43], ["SAA", "PROTEIN", 45, 48], ["SAP", "PROTEIN", 50, 53], ["APP", "PROTEIN", 68, 71], ["serum amyloid proteins", "TEST", 21, 43], ["SAA", "TEST", 45, 48], ["SAP", "TEST", 50, 53], ["viral infection", "PROBLEM", 86, 101], ["viral infection", "OBSERVATION", 86, 101]]], ["3 CRP are the most widely upregulated APP upon antiviral vaccination.", [["CRP", "GENE_OR_GENE_PRODUCT", 2, 5], ["APP", "GENE_OR_GENE_PRODUCT", 38, 41], ["CRP", "PROTEIN", 2, 5], ["APP", "PROTEIN", 38, 41], ["CRP", "TEST", 2, 5], ["antiviral vaccination", "TREATMENT", 47, 68], ["most widely", "OBSERVATION_MODIFIER", 14, 25], ["antiviral vaccination", "OBSERVATION", 47, 68]]], ["4 The antiviral activity of APP in vitro is associated with their virusbinding capacity.", [["APP", "GENE_OR_GENE_PRODUCT", 28, 31], ["APP", "PROTEIN", 28, 31], ["their virusbinding capacity", "PROBLEM", 60, 87], ["antiviral activity", "OBSERVATION", 6, 24]]], ["5 APP use as diagnostic tools is largely dependent on the virus-host situation.", [["APP", "GENE_OR_GENE_PRODUCT", 2, 5], ["APP", "PROTEIN", 2, 5], ["diagnostic tools", "TEST", 13, 29], ["dependent", "OBSERVATION_MODIFIER", 41, 50]]]], "b9150815ccdf8631c77786ab87cdc67833bc4d24": [["IntroductionTurkey coronavirus (TCoV) causes an acute and highly contagious enteric disease affecting turkeys of all ages [ 1 , 2 ] .", [["enteric disease", "DISEASE", 76, 91], ["IntroductionTurkey coronavirus", "ORGANISM", 0, 30], ["TCoV", "ORGANISM", 32, 36], ["turkeys", "ORGANISM", 102, 109], ["coronavirus", "SPECIES", 19, 30], ["turkeys", "SPECIES", 102, 109], ["IntroductionTurkey coronavirus", "SPECIES", 0, 30], ["TCoV", "SPECIES", 32, 36], ["an acute and highly contagious enteric disease", "PROBLEM", 45, 91], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["highly", "OBSERVATION_MODIFIER", 58, 64], ["contagious", "OBSERVATION_MODIFIER", 65, 75], ["enteric disease", "OBSERVATION", 76, 91]]], ["TCoV is an important pathogen and remains as a serious threat to the turkey industry.", [["TCoV", "CHEMICAL", 0, 4], ["TCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["turkey", "ORGANISM", 69, 75], ["turkey", "SPECIES", 69, 75], ["TCoV", "SPECIES", 0, 4], ["turkey", "SPECIES", 69, 75], ["important", "OBSERVATION_MODIFIER", 11, 20], ["pathogen", "OBSERVATION", 21, 29]]], ["There is currently no specifi c treatment or effective vaccine for TCoV infection .", [["TCoV", "CHEMICAL", 67, 71], ["infection", "DISEASE", 72, 81], ["TCoV", "SIMPLE_CHEMICAL", 67, 71], ["TCoV", "SPECIES", 67, 71], ["specifi c treatment", "TREATMENT", 22, 41], ["effective vaccine", "TREATMENT", 45, 62], ["TCoV infection", "PROBLEM", 67, 81], ["no", "UNCERTAINTY", 19, 21], ["infection", "OBSERVATION", 72, 81]]], ["In order to rapidly diagnose and effectively control turkey coronaviral enteritis , serological diagnosis of antibodies to TCoV becomes a critical tool to determine the infectivity of turkeys in the turkey fl ocks.IntroductionImmunofl uorescent antibody assay ( IFA ) for detection of anti-TCoV antibodies has been extensively used for disease outbreaks in the fi elds.", [["coronaviral enteritis", "DISEASE", 60, 81], ["turkey", "ORGANISM", 53, 59], ["TCoV", "GENE_OR_GENE_PRODUCT", 123, 127], ["turkeys", "ORGANISM", 184, 191], ["turkey", "ORGANISM", 199, 205], ["anti-TCoV antibodies", "GENE_OR_GENE_PRODUCT", 285, 305], ["antibodies", "PROTEIN", 109, 119], ["TCoV", "PROTEIN", 123, 127], ["Immunofl uorescent antibody", "PROTEIN", 226, 253], ["anti-TCoV antibodies", "PROTEIN", 285, 305], ["turkey", "SPECIES", 53, 59], ["turkeys", "SPECIES", 184, 191], ["turkey", "SPECIES", 199, 205], ["turkey coronaviral enteritis", "SPECIES", 53, 81], ["TCoV", "SPECIES", 123, 127], ["turkeys", "SPECIES", 184, 191], ["turkey fl ocks", "SPECIES", 199, 213], ["anti-TCoV", "SPECIES", 285, 294], ["coronaviral enteritis", "PROBLEM", 60, 81], ["serological diagnosis", "TEST", 84, 105], ["antibodies to TCoV", "PROBLEM", 109, 127], ["IntroductionImmunofl uorescent antibody assay", "TEST", 214, 259], ["anti-TCoV antibodies", "PROBLEM", 285, 305], ["disease outbreaks", "PROBLEM", 336, 353], ["enteritis", "OBSERVATION", 72, 81]]], ["However, IFA procedures are time consuming and labor intensive for handling large numbers of samples.", [["samples", "ANATOMY", 93, 100], ["samples", "CANCER", 93, 100], ["IFA procedures", "TREATMENT", 9, 23], ["labor", "PROBLEM", 47, 52]]], ["In addition, IFA requires highly trained personnel to prepare frozen sections of turkey or turkey embryo intestines and perform fl uorescent microscopy.IntroductionELISA method has high specifi city and sensitivity and can be applied to large numbers of samples simultaneously.", [["sections", "ANATOMY", 69, 77], ["embryo intestines", "ANATOMY", 98, 115], ["samples", "ANATOMY", 254, 261], ["turkey", "ORGANISM", 81, 87], ["turkey", "ORGANISM", 91, 97], ["embryo intestines", "MULTI-TISSUE_STRUCTURE", 98, 115], ["samples", "CANCER", 254, 261], ["turkey", "SPECIES", 81, 87], ["turkey", "SPECIES", 91, 97], ["turkey", "SPECIES", 81, 87], ["turkey", "SPECIES", 91, 97], ["fl uorescent microscopy", "TEST", 128, 151], ["intestines", "ANATOMY", 105, 115], ["large", "OBSERVATION_MODIFIER", 237, 242]]], ["Two ELISA procedures are highlighted in this chapter.", [["Two ELISA procedures", "TREATMENT", 0, 20]]], ["One ELISA method utilizing infectious bronchitis virus (IBV) as a coating antigen for detection of antibody to TCoV is based on antigenic cross-reactivity between TCoV and IBV [ 3 ] .", [["infectious bronchitis virus", "DISEASE", 27, 54], ["infectious bronchitis virus", "ORGANISM", 27, 54], ["IBV", "ORGANISM", 56, 59], ["TCoV", "GENE_OR_GENE_PRODUCT", 111, 115], ["TCoV", "GENE_OR_GENE_PRODUCT", 163, 167], ["IBV", "ORGANISM", 172, 175], ["TCoV", "PROTEIN", 111, 115], ["infectious bronchitis virus", "SPECIES", 27, 54], ["infectious bronchitis virus", "SPECIES", 27, 54], ["IBV", "SPECIES", 56, 59], ["TCoV", "SPECIES", 111, 115], ["TCoV", "SPECIES", 163, 167], ["IBV", "SPECIES", 172, 175], ["One ELISA method", "TREATMENT", 0, 16], ["infectious bronchitis virus", "PROBLEM", 27, 54], ["a coating antigen", "TEST", 64, 81], ["antibody to TCoV", "TREATMENT", 99, 115], ["antigenic cross-reactivity", "TEST", 128, 154], ["infectious", "OBSERVATION_MODIFIER", 27, 37]]], ["The other antibody-capture ELISA uses a recombinant TCoV nucleocapsid (N) protein as a coating antigen [ 4 , 5 ] .IntroductionNucleocapsid protein appears to be the most abundant viral polypeptide in coronavirus infected cells during all stages of infection .", [["cells", "ANATOMY", 221, 226], ["coronavirus infected", "DISEASE", 200, 220], ["infection", "DISEASE", 248, 257], ["TCoV", "GENE_OR_GENE_PRODUCT", 52, 56], ["Nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 126, 146], ["coronavirus", "ORGANISM", 200, 211], ["cells", "CELL", 221, 226], ["recombinant TCoV nucleocapsid (N) protein", "PROTEIN", 40, 81], ["Nucleocapsid protein", "PROTEIN", 126, 146], ["coronavirus infected cells", "CELL_TYPE", 200, 226], ["coronavirus", "SPECIES", 200, 211], ["TCoV", "SPECIES", 52, 56], ["The other antibody", "TEST", 0, 18], ["capture ELISA", "TEST", 19, 32], ["a coating antigen", "TEST", 85, 102], ["IntroductionNucleocapsid protein", "PROBLEM", 114, 146], ["coronavirus infected cells", "PROBLEM", 200, 226], ["infection", "PROBLEM", 248, 257], ["appears to be", "UNCERTAINTY", 147, 160], ["coronavirus infected cells", "OBSERVATION", 200, 226], ["all stages", "OBSERVATION_MODIFIER", 234, 244], ["infection", "OBSERVATION", 248, 257]]], ["Nucleocapsid protein is detected from 3 to 5 h after infection, at the same time or earlier than the other structural proteins.", [["infection", "DISEASE", 53, 62], ["Nucleocapsid", "GENE_OR_GENE_PRODUCT", 0, 12], ["Nucleocapsid protein", "PROTEIN", 0, 20], ["structural proteins", "PROTEIN", 107, 126], ["Nucleocapsid protein", "TEST", 0, 20], ["infection", "PROBLEM", 53, 62], ["protein", "OBSERVATION", 13, 20], ["infection", "OBSERVATION", 53, 62]]], ["The only known posttranslational modifi cation of coronavirus N proteins is phosphorylation [ 6 ] .", [["coronavirus N proteins", "GENE_OR_GENE_PRODUCT", 50, 72], ["coronavirus N proteins", "PROTEIN", 50, 72], ["known posttranslational modifi cation", "TREATMENT", 9, 46], ["coronavirus N proteins", "TREATMENT", 50, 72]]], ["The coronavirus N protein is immunodominant [ 7 ] .", [["coronavirus", "ORGANISM", 4, 15], ["coronavirus N protein", "PROTEIN", 4, 25], ["The coronavirus N protein", "TEST", 0, 25], ["coronavirus", "OBSERVATION", 4, 15]]], ["Subcloning of the TCoV N gene to a prokaryotic expression system has resulted in a high-level induction of recombinant protein in our laboratory [ 4 ] .", [["TCoV N", "GENE_OR_GENE_PRODUCT", 18, 24], ["TCoV N gene", "DNA", 18, 29], ["recombinant protein", "PROTEIN", 107, 126], ["Subcloning of the TCoV N gene", "TREATMENT", 0, 29], ["a prokaryotic expression system", "PROBLEM", 33, 64]]], ["The recombinant TCoV N protein expressed from the prokaryotic system is expected to maintain its antigenic integrity because it is not glycosylated.Notes1.", [["TCoV N", "GENE_OR_GENE_PRODUCT", 16, 22], ["recombinant TCoV N protein", "PROTEIN", 4, 30], ["Notes1", "PROTEIN", 148, 154], ["TCoV", "SPECIES", 16, 20], ["The recombinant TCoV N protein", "TREATMENT", 0, 30]]], ["Although incubation temperature at 37 \u00b0C is described for steps of blocking buffer, samples, and conjugate, incubation at room temperature can be a viable alternative when incubator with temperature control is not conveniently located.", [["samples", "ANATOMY", 84, 91], ["incubation temperature", "TEST", 9, 31], ["blocking buffer", "TREATMENT", 67, 82], ["temperature control", "TREATMENT", 187, 206]]], ["However, the end results of ELISA value (S/P ratio) as normalized by an appropriate positive control analyzed on the same plate will not be affected.", [["ELISA value", "TEST", 28, 39], ["S/P ratio", "TEST", 41, 50]]], ["It is better to keep a record of room temperature for possible trouble shooting when necessary.Notes2.", [["Notes2", "PROTEIN", 95, 101], ["trouble shooting", "PROBLEM", 63, 79]]], ["In between and in the end of each wash cycle, it is important to tap-dry the plates on a stack of paper towel for lower nonspecifi c background reactivity.ELISA with Recombinant TCoV N Protein as Coating Antigen3.", [["Recombinant TCoV N Protein", "PROTEIN", 166, 192], ["Coating Antigen3", "PROTEIN", 196, 212], ["TCoV", "SPECIES", 178, 182], ["a stack of paper towel", "TREATMENT", 87, 109], ["lower nonspecifi c background reactivity", "PROBLEM", 114, 154], ["ELISA", "TEST", 155, 160], ["Recombinant TCoV N Protein", "TREATMENT", 166, 192]]], ["The commercially available ELISA plate coated with a pool of IBV strains including Massachusetts, JMK, Arkansas, Connecticut, Clone 30, D274, and D1466.ELISA with Recombinant TCoV N Protein as Coating Antigen4.", [["IBV", "ORGANISM", 61, 64], ["Recombinant TCoV N Protein", "PROTEIN", 163, 189], ["Coating Antigen4", "PROTEIN", 193, 209], ["IBV", "SPECIES", 61, 64], ["TCoV", "SPECIES", 175, 179], ["IBV strains", "PROBLEM", 61, 72], ["ELISA", "TEST", 152, 157], ["Recombinant TCoV N Protein", "TREATMENT", 163, 189]]], ["This blocking step is optional because the commercial dry plate is already blocked through the production process of commercial ELISA kits.", [["This blocking step", "TREATMENT", 0, 18], ["the commercial dry plate", "PROBLEM", 39, 63]]], ["The additional blocking step may help rehydrate the coating antigens in the wells before sample incubation step and subsequently enhance assay performance.ELISA with Recombinant TCoV N Protein as Coating Antigen5.", [["sample", "ANATOMY", 89, 95], ["Recombinant TCoV N Protein", "PROTEIN", 166, 192], ["Coating Antigen5", "PROTEIN", 196, 212], ["TCoV", "SPECIES", 178, 182], ["The additional blocking step", "TREATMENT", 0, 28], ["the coating antigens", "TREATMENT", 48, 68], ["assay performance", "TEST", 137, 154], ["ELISA", "TEST", 155, 160], ["Recombinant TCoV N Protein", "TREATMENT", 166, 192]]], ["It is okay to add diluted samples after removal of the blocking buffer and tap dry the plate on a stack of paper towels.", [["samples", "ANATOMY", 26, 33], ["removal", "TREATMENT", 40, 47], ["the blocking buffer", "TREATMENT", 51, 70], ["tap", "TREATMENT", 75, 78], ["a stack of paper towels", "TREATMENT", 96, 119]]], ["The presence of blocking buffer residue has limited effect on the next step for sample incubation.", [["sample", "ANATOMY", 80, 86], ["blocking buffer residue", "PROBLEM", 16, 39], ["sample incubation", "TREATMENT", 80, 97], ["blocking", "OBSERVATION", 16, 24], ["buffer residue", "OBSERVATION", 25, 39]]], ["The components of blocking buffer including PBS buffer and BSA are also parts of the assay buffer in sample dilutions.", [["BSA", "SIMPLE_CHEMICAL", 59, 62], ["blocking buffer", "TREATMENT", 18, 33], ["PBS buffer and BSA", "TREATMENT", 44, 62], ["sample dilutions", "TEST", 101, 117]]], ["This wash step is usually performed in our laboratory to achieve the best possible assay performance.ELISA with Recombinant TCoV N Protein as Coating Antigen6.", [["Recombinant TCoV N Protein", "PROTEIN", 112, 138], ["Coating Antigen6", "PROTEIN", 142, 158], ["TCoV", "SPECIES", 124, 128], ["ELISA", "TEST", 101, 106], ["Recombinant TCoV N Protein", "TREATMENT", 112, 138]]], ["Each sample is analyzed in two wells and the mean ELISA value is reported.", [["sample", "ANATOMY", 5, 11], ["Each sample", "TEST", 0, 11], ["the mean ELISA value", "TEST", 41, 61]]], ["When percentage coeffi cient of variance (%CV) is >20 % and both ELISA values are above cutpoint, the result is not reportable and the sample should be reanalyzed.", [["variance (%CV)", "TEST", 32, 46], ["both ELISA values", "TEST", 60, 77]]], ["When one or both of the two values is below cutpoint, the sample is considered negative.", [["the sample", "TEST", 54, 64], ["negative", "OBSERVATION", 79, 87]]], ["Each control samples (HPC, LPC, and NC) are analyzed in duplicate ( N = 2; 4 wells for two reportable values).ELISA with Recombinant TCoV N Protein as Coating Antigen7.", [["samples", "ANATOMY", 13, 20], ["Recombinant TCoV N Protein", "PROTEIN", 121, 147], ["Coating Antigen7", "PROTEIN", 151, 167], ["TCoV", "SPECIES", 133, 137], ["Each control samples", "TEST", 0, 20], ["HPC", "TEST", 22, 25], ["LPC", "TEST", 27, 30], ["NC", "TREATMENT", 36, 38], ["two reportable values", "TEST", 87, 108], ["ELISA", "TEST", 110, 115], ["Recombinant TCoV N Protein", "TREATMENT", 121, 147]]], ["Pipetting volume below 10 \u03bcl may cause inter-assay variation.", [["Pipetting volume", "TREATMENT", 0, 16], ["inter-assay variation", "OBSERVATION", 39, 60]]], ["Any pipetting volume below 5 \u03bcl is not recommended.", [["Any pipetting volume", "TEST", 0, 20]]], ["To reduce interday variation of dilutions, two steps of dilution may be considered when necessary such as 1:16 and then 1:100 for a fi nal dilution at 1:1600; 1:20 and then 1:40 for a fi nal dilution at 1:800; 1:100 and then 1:100 for a fi nal dilution at 1:10,000.ELISA with Recombinant TCoV N Protein as Coating Antigen8.", [["Recombinant TCoV N Protein", "PROTEIN", 276, 302], ["Coating Antigen8", "PROTEIN", 306, 322], ["TCoV", "SPECIES", 288, 292], ["dilutions", "TREATMENT", 32, 41], ["dilution", "TREATMENT", 56, 64], ["a fi nal dilution", "TREATMENT", 182, 199], ["a fi nal dilution", "TREATMENT", 235, 252], ["ELISA", "TEST", 265, 270], ["Recombinant TCoV N Protein", "TREATMENT", 276, 302]]], ["Color development is a result of HRP enzyme reaction.", [["HRP", "GENE_OR_GENE_PRODUCT", 33, 36], ["HRP enzyme", "PROTEIN", 33, 43], ["HRP enzyme reaction", "PROBLEM", 33, 52]]], ["Laboratory environment such as room temperature may have effect on the reaction rate.", [["room temperature", "TEST", 31, 47], ["the reaction rate", "TEST", 67, 84]]], ["It is recommended to check the color development throughout the incubation of 30 min and stop the reaction with acid to prevent overdevelopment or underdevelopment.", [["acid", "TREATMENT", 112, 116], ["underdevelopment", "PROBLEM", 147, 163], ["underdevelopment", "OBSERVATION", 147, 163]]], ["This may not be easy for the fi rst few runs but not that hard after some experience.", [["may not be", "UNCERTAINTY", 5, 15]]], ["Wash step may be increased a few more times before the addition of TMB substrate if high background of nonspecifi c reactivity is observed.", [["TMB", "CHEMICAL", 67, 70], ["TMB", "SIMPLE_CHEMICAL", 67, 70], ["nonspecifi c", "GENE_OR_GENE_PRODUCT", 103, 115], ["nonspecifi c", "PROTEIN", 103, 115], ["TMB substrate", "TEST", 67, 80], ["nonspecifi c reactivity", "PROBLEM", 103, 126], ["increased", "OBSERVATION_MODIFIER", 17, 26]]], ["Normal turkey sera: reactivity of normal turkey sera is consistently at low background signals in both ELISA methods, suggesting analytical variations.", [["sera", "ANATOMY", 14, 18], ["sera", "ANATOMY", 48, 52], ["turkey", "ORGANISM", 7, 13], ["sera", "ORGANISM_SUBSTANCE", 14, 18], ["turkey", "ORGANISM", 41, 47], ["sera", "ORGANISM_SUBSTANCE", 48, 52], ["turkey", "SPECIES", 7, 13], ["turkey", "SPECIES", 41, 47], ["turkey", "SPECIES", 7, 13], ["turkey", "SPECIES", 41, 47], ["normal", "OBSERVATION", 34, 40], ["analytical variations", "OBSERVATION", 129, 150]]], ["Cutoff point based on normal turkey sera does not refl ect biological variations and therefore is not functional.", [["sera", "ANATOMY", 36, 40], ["turkey", "ORGANISM", 29, 35], ["sera", "ORGANISM_SUBSTANCE", 36, 40], ["turkey", "SPECIES", 29, 35], ["turkey", "SPECIES", 29, 35], ["Cutoff point", "TEST", 0, 12]]], ["ELISA value normalization or cutoff point determination from signals of normal turkey sera is misleading.ELISA with Recombinant TCoV N Protein as Coating AntigenFix OD reading: a fi xed OD reading as cutoff point is not appropriate due to normal reading fl uctuations between batch runs, between analysts, between days, between laboratories.ELISA with Recombinant TCoV N Protein as Coating AntigenData normalization of raw OD readings with a suitable positive control sample is necessary for appropriate interpretation of unknown samples.", [["sera", "ANATOMY", 86, 90], ["samples", "ANATOMY", 530, 537], ["turkey", "ORGANISM", 79, 85], ["sera", "ORGANISM_SUBSTANCE", 86, 90], ["samples", "CANCER", 530, 537], ["Recombinant TCoV N Protein", "PROTEIN", 116, 142], ["Coating AntigenFix OD reading", "DNA", 146, 175], ["Recombinant TCoV N Protein", "PROTEIN", 352, 378], ["turkey", "SPECIES", 79, 85], ["turkey", "SPECIES", 79, 85], ["TCoV", "SPECIES", 364, 368], ["ELISA value normalization", "TEST", 0, 25], ["cutoff point determination", "TEST", 29, 55], ["Recombinant TCoV N Protein", "TREATMENT", 116, 142], ["ELISA", "TEST", 341, 346], ["Recombinant TCoV N Protein", "TREATMENT", 352, 378], ["a suitable positive control sample", "PROBLEM", 440, 474], ["normal", "OBSERVATION", 72, 78]]], ["Comparison of results from different laboratories is diffi cult due to the lack of standardized reagents.", [["different laboratories", "TEST", 27, 49], ["diffi cult", "TEST", 53, 63], ["standardized reagents", "TREATMENT", 83, 104]]], ["Data normalization with a standard source of PC may be a helpful factor to narrow down the comparability of results from different laboratories.ELISA with Recombinant TCoV N Protein as Coating AntigenFor system suitability (batch run acceptance criteria), three controls are recommended in each batch run.", [["PC", "CANCER", 45, 47], ["Recombinant TCoV N Protein", "PROTEIN", 155, 181], ["TCoV", "SPECIES", 167, 171], ["Data normalization", "TEST", 0, 18], ["PC", "TREATMENT", 45, 47], ["ELISA", "TEST", 144, 149], ["Recombinant TCoV N Protein", "TREATMENT", 155, 181]]], ["Each control is analyzed in duplicate ( N = 2; total four wells for two reportable values).", [["two reportable values", "TEST", 68, 89]]], ["Positive control serum is prepared in two levels at high positive control (HPC) and low positive control (LPC) and each analyzed in duplicates.", [["serum", "ANATOMY", 17, 22], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["low positive control (LPC", "PROBLEM", 84, 109], ["control serum", "OBSERVATION_MODIFIER", 9, 22]]], ["Normal turkey serum is analyzed in duplicate as NC.", [["serum", "ANATOMY", 14, 19], ["turkey", "ORGANISM", 7, 13], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["turkey", "SPECIES", 7, 13], ["turkey", "SPECIES", 7, 13]]], ["Wells that contain all reagents except serum samples are nonspecifi c background (blank).", [["serum samples", "ANATOMY", 39, 52], ["serum samples", "ORGANISM_SUBSTANCE", 39, 52], ["all reagents", "TEST", 19, 31], ["serum samples", "TEST", 39, 52]]], ["The general acceptance criteria for these controls in each batch run are based on OD readings.", [["OD readings", "TEST", 82, 93]]], ["At least two-thirds of controls should have readings in the following order: HPC > LPC > NC .ELISA with Recombinant TCoV N Protein as Coating AntigenFor data normalization, the reading of LPC is suggested in the calculation of ELISA value or S/P ratio of each test serum.ELISA with Recombinant TCoV N Protein as Coating AntigenWith a HPC in the calculation of S/P ratio in our laboratory, the optimum cutoff point is 0.18 for antibody-capture ELISA using IBV as the coating antigen , while the optimum cutoff point is 0.2 for ELISA using recombinant TCoV N protein as the coating antigen.", [["serum", "ANATOMY", 265, 270], ["LPC", "CHEMICAL", 188, 191], ["LPC", "CHEMICAL", 188, 191], ["controls", "ORGANISM", 23, 31], ["LPC", "SIMPLE_CHEMICAL", 83, 86], ["serum", "ORGANISM_SUBSTANCE", 265, 270], ["IBV", "ORGANISM", 455, 458], ["TCoV N protein", "GENE_OR_GENE_PRODUCT", 550, 564], ["Recombinant TCoV N Protein", "PROTEIN", 104, 130], ["Recombinant TCoV N Protein", "PROTEIN", 282, 308], ["HPC", "CELL_TYPE", 334, 337], ["recombinant TCoV N protein", "PROTEIN", 538, 564], ["coating antigen", "PROTEIN", 572, 587], ["TCoV", "SPECIES", 294, 298], ["IBV", "SPECIES", 455, 458], ["TCoV", "SPECIES", 550, 554], ["HPC", "TEST", 77, 80], ["LPC", "TEST", 83, 86], ["Recombinant TCoV N Protein", "TREATMENT", 104, 130], ["Coating Antigen", "TEST", 134, 149], ["LPC", "TEST", 188, 191], ["ELISA value", "TEST", 227, 238], ["each test serum", "TEST", 255, 270], ["ELISA", "TEST", 271, 276], ["a HPC", "PROBLEM", 332, 337], ["S/P ratio", "TEST", 360, 369], ["antibody", "TEST", 426, 434], ["IBV", "TREATMENT", 455, 458], ["the coating antigen", "TEST", 462, 481], ["the optimum cutoff point", "TEST", 490, 514], ["ELISA", "TEST", 526, 531], ["recombinant TCoV N protein", "TREATMENT", 538, 564], ["the coating antigen", "TEST", 568, 587]]], ["It is generally noted that incubation up to 5 days does not affect the ELISA results.ELISA with Recombinant TCoV N Protein as Coating Antigen12.", [["Recombinant TCoV N Protein", "PROTEIN", 96, 122], ["Coating Antigen12", "PROTEIN", 126, 143], ["the ELISA", "TEST", 67, 76], ["Recombinant TCoV N Protein", "TREATMENT", 96, 122]]], ["ELISA method with the recombinant TCoV N protein as coating antigen has higher reactivity than that with IBV as coating antigen.", [["TCoV N", "GENE_OR_GENE_PRODUCT", 34, 40], ["IBV", "ORGANISM", 105, 108], ["recombinant TCoV N protein", "PROTEIN", 22, 48], ["coating antigen", "PROTEIN", 52, 67], ["TCoV", "SPECIES", 34, 38], ["IBV", "SPECIES", 105, 108], ["ELISA method", "TEST", 0, 12], ["the recombinant TCoV N protein", "TREATMENT", 18, 48], ["coating antigen", "TEST", 52, 67], ["higher reactivity", "PROBLEM", 72, 89], ["IBV", "PROBLEM", 105, 108], ["higher reactivity", "OBSERVATION_MODIFIER", 72, 89]]], ["The dilution factors for serum samples and conjugates are adjusted accordingly.", [["serum samples", "ANATOMY", 25, 38], ["serum samples", "ORGANISM_SUBSTANCE", 25, 38], ["dilution factors", "PROTEIN", 4, 20], ["The dilution factors", "TREATMENT", 0, 20], ["serum samples", "TEST", 25, 38], ["conjugates", "TREATMENT", 43, 53]]], ["The minimum required dilution of serum samples is 1:800 for the assay with N protein compared to 1:40 for the assay with the IBV.", [["serum samples", "ANATOMY", 33, 46], ["serum samples", "ORGANISM_SUBSTANCE", 33, 46], ["IBV", "ORGANISM", 125, 128], ["N protein", "PROTEIN", 75, 84], ["IBV", "SPECIES", 125, 128], ["serum samples", "TEST", 33, 46], ["the assay", "TEST", 60, 69], ["N protein", "TEST", 75, 84], ["the IBV", "TREATMENT", 121, 128], ["minimum", "OBSERVATION_MODIFIER", 4, 11]]], ["The conjugate dilution factor is 1:10,000 for the assay with N protein compared to 1:1600 for the assay with the IBV.ELISA with Recombinant TCoV N Protein as Coating Antigen13.", [["IBV", "ORGANISM", 113, 116], ["Coating Antigen13", "GENE_OR_GENE_PRODUCT", 158, 175], ["conjugate dilution factor", "PROTEIN", 4, 29], ["N protein", "PROTEIN", 61, 70], ["Recombinant TCoV N Protein", "PROTEIN", 128, 154], ["Coating Antigen13", "PROTEIN", 158, 175], ["IBV", "SPECIES", 113, 116], ["The conjugate dilution factor", "TEST", 0, 29], ["N protein", "TEST", 61, 70], ["the IBV", "TREATMENT", 109, 116], ["Recombinant TCoV N Protein", "TREATMENT", 128, 154]]], ["Prevalence, sensitivity, specifi city, predictive values: The assay sensitivity and specifi city of both ELISA methods relative to IFA are considered comparable.", [["The assay sensitivity", "TEST", 58, 79], ["both ELISA methods", "TEST", 100, 118], ["IFA", "TEST", 131, 134]]], ["With assumptions of relative sensitivity at 90 %, relative specifi city at 95 %, and disease prevalence at 55 %, positive predictive value (PPV) and negative predictive value (NPV) of these two ELISA methods are estimated below:", [["relative sensitivity", "PROBLEM", 20, 40], ["disease prevalence", "TEST", 85, 103], ["PPV", "TEST", 140, 143], ["NPV", "TEST", 176, 179]]]]}